// NEET PG 2024 Shift-1 Questions - ACTUAL Previous Year Questions
// Official NEET PG question paper with solutions
// Total Questions: 93

import { Question } from './types';

export const sampleQuestions: Question[] = [
  {
    id: "neet-pg-2024-1",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Male not responding to O-2, diagnosis ARDS. What is the role of IL-8 in ARDS?",
    options: [
      "Endothelial cell activation",
      "Requirement of neutrophil",
      "Macrophage activation",
      "Promote surfactant production"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Requirement of neutrophil (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Acute Respiratory Distress Syndrome (ARDS)** is characterized by acute onset of **bilateral pulmonary infiltrates** with severe **hypoxemia** that is **refractory to oxygen therapy**.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå ROLE OF IL-8 IN ARDS:\n\n**Interleukin-8 (IL-8)**, also known as **CXCL8**, is a potent **neutrophil chemoattractant** and one of the most important cytokines in ARDS pathogenesis.\n\n**PRIMARY FUNCTION OF IL-8:**\n\n‚Ä¢ IL-8 is a **chemokine** specifically responsible for **neutrophil recruitment and chemotaxis** ‚≠ê\n\n‚Ä¢ It binds to **CXCR1 and CXCR2 receptors** on neutrophils\n\n‚Ä¢ This binding triggers **neutrophil migration** from the bloodstream into the **alveolar space**\n\n‚Ä¢ **Neutrophil accumulation** in the lungs is a **HALLMARK of ARDS** üéØ\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° PATHOPHYSIOLOGY CASCADE:\n\n**1.** Initial insult (**sepsis, trauma, pneumonia, aspiration**) triggers inflammatory response\n\n**2.** Alveolar macrophages and epithelial cells **release IL-8**\n\n**3.** IL-8 acts as a **potent chemoattractant** for neutrophils ‚≠ê\n\n**4.** **Massive neutrophil infiltration** occurs in lung tissue\n\n**5.** Activated neutrophils release:\n   ‚Üí **Proteases** (elastase, collagenase)\n   ‚Üí **Reactive oxygen species (ROS)**\n   ‚Üí **Inflammatory mediators**\n\n**6.** These substances cause:\n   ‚Üí **Endothelial injury**\n   ‚Üí **Increased capillary permeability** ‚≠ê\n   ‚Üí **Alveolar damage**\n   ‚Üí **Protein-rich edema** fluid accumulation\n\n**7.** Result: **Impaired gas exchange** and **respiratory failure**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n‚Ä¢ **Endothelial cell activation**: This is done by **TNF-Œ± and IL-1**, NOT primarily IL-8\n\n‚Ä¢ **Macrophage activation**: This is mediated by **IFN-Œ≥ and GM-CSF**\n\n‚Ä¢ **Promote surfactant production**: IL-8 does **NOT** promote surfactant; ARDS actually has **surfactant dysfunction**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ KEY CONCEPT FOR EXAM:\n\n**IL-8 = THE MAJOR NEUTROPHIL CHEMOATTRACTANT IN ARDS** ‚≠ê‚≠ê‚≠ê\n\nElevated **IL-8 levels in bronchoalveolar lavage (BAL) fluid** correlate with:\n‚Ä¢ Disease severity\n‚Ä¢ Poor prognosis\n‚Ä¢ Mortality\n\nStudies show that **blocking IL-8** or neutrophil migration can reduce ARDS severity in experimental models.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° CLINICAL CORRELATION:\n\nPatients with ARDS have **markedly elevated IL-8 levels** in their:\n‚Ä¢ Bronchoalveolar lavage (BAL) fluid\n‚Ä¢ Serum\n\nThe degree of **neutrophil infiltration** (and thus IL-8 activity) directly correlates with:\n‚Ä¢ Severity of **hypoxemia** (P/F ratio)\n‚Ä¢ **Mortality** rate",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-2",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient presents with the finding as shown, What is the best investigation for\nWilson‚Äôs disease?",
    options: [
      "Urine Copper",
      "Hepatic copper",
      "S. Ceruloplasmin",
      "MRI Brain"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Hepatic copper (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Wilson's disease** (hepatolenticular degeneration) is an **autosomal recessive disorder** of copper metabolism caused by mutations in the **ATP7B gene** on **chromosome 13**.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå PATHOPHYSIOLOGY:\n\n**NORMAL COPPER METABOLISM:**\n\n‚Ä¢ Dietary copper absorbed in **duodenum and jejunum**\n\n‚Ä¢ Transported to **liver** bound to albumin\n\n‚Ä¢ In hepatocytes, copper is incorporated into **ceruloplasmin** by **ATP7B protein**\n\n‚Ä¢ Excess copper **excreted in bile** (main excretory pathway)\n\n‚Ä¢ Ceruloplasmin-bound copper circulates in blood\n\n**WILSON'S DISEASE (ATP7B defect):**\n\n‚Ä¢ **Defective ATP7B** ‚Üí Cannot incorporate copper into ceruloplasmin\n\n‚Ä¢ **Defective biliary copper excretion** ‚≠ê\n\n‚Ä¢ Copper accumulates in **LIVER FIRST** (primary site) üéØ\n\n‚Ä¢ Eventually overflows to other organs:\n  ‚Üí **Brain** (basal ganglia, putamen)\n  ‚Üí **Cornea** (Kayser-Fleischer rings)\n  ‚Üí **Kidneys** (Fanconi syndrome)\n  ‚Üí **Heart** (cardiomyopathy)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ DIAGNOSTIC INVESTIGATIONS:\n\n‚òÖ **HEPATIC COPPER CONTENT (GOLD STANDARD)** ‚≠ê‚≠ê‚≠ê\n\n‚Ä¢ Normal: **<50 Œºg/g** dry weight\n\n‚Ä¢ Wilson's: **>250 Œºg/g** dry weight üéØ\n\n‚Ä¢ **MOST SPECIFIC and DEFINITIVE test**\n\n‚Ä¢ **Liver biopsy** with quantitative copper measurement\n\n‚Ä¢ Direct measurement of copper accumulation in **primary affected organ**\n\n**Why it's the BEST:**\n\n‚Üí **Directly measures pathology at source**\n\n‚Üí **Highest sensitivity and specificity**\n\n‚Üí **Not affected by acute phase reactions**\n\n‚Üí **Confirms diagnosis definitively**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã OTHER INVESTIGATIONS (Comparison):\n\n‚Ä¢ **SERUM CERULOPLASMIN:**\n  ‚Üí **Decreased (<20 mg/dL)** in 95% cases\n  ‚Üí Can be **normal in 5%** of Wilson's disease ‚ö†Ô∏è\n  ‚Üí Can be low in other conditions (malnutrition, nephrotic syndrome)\n  ‚Üí Good **screening test** but NOT diagnostic\n\n‚Ä¢ **24-HOUR URINARY COPPER:**\n  ‚Üí **Elevated (>100 Œºg/24hr)**, normal <40\n  ‚Üí Helpful but **not specific**\n  ‚Üí Can be elevated in other cholestatic disorders\n  ‚Üí Good for **monitoring treatment**\n\n‚Ä¢ **KAYSER-FLEISCHER RINGS:**\n  ‚Üí Present in **95% with neurological** Wilson's\n  ‚Üí Only **50% in purely hepatic** cases ‚ö†Ô∏è\n  ‚Üí Detected by **slit-lamp examination**\n  ‚Üí Caused by copper deposition in **Descemet's membrane**\n  ‚Üí Highly specific but **not always present**\n\n‚Ä¢ **MRI BRAIN:**\n  ‚Üí **T2 hyperintensities** in basal ganglia\n  ‚Üí **\"Face of giant panda\" sign** in midbrain\n  ‚Üí Only abnormal in **neurological Wilson's**\n  ‚Üí **Not useful** for early/hepatic disease\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç CLINICAL PRESENTATIONS:\n\n**1. HEPATIC (40-50%):** Age 5-35 years\n   ‚Üí **Acute hepatitis**\n   ‚Üí **Chronic hepatitis** ‚Üí Cirrhosis\n   ‚Üí **Fulminant hepatic failure**\n\n**2. NEUROLOGICAL (40-50%):** Age 20-30 years\n   ‚Üí **Tremors** (wing-beating)\n   ‚Üí **Dysarthria**\n   ‚Üí **Dystonia, rigidity**\n   ‚Üí **Parkinsonism**\n\n**3. PSYCHIATRIC (10-20%):**\n   ‚Üí **Depression**\n   ‚Üí **Personality changes**\n   ‚Üí **Psychosis**\n\n**4. OTHER:**\n   ‚Üí **Hemolytic anemia** (Coombs negative)\n   ‚Üí **Renal tubular acidosis**\n   ‚Üí **Osteoporosis**\n   ‚Üí **Cardiomyopathy**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä TREATMENT:\n\n‚Ä¢ **Copper chelators:**\n  ‚Üí **D-penicillamine** (first-line) ‚≠ê\n  ‚Üí **Trientine** (if intolerant)\n\n‚Ä¢ **Zinc salts** (maintenance therapy)\n\n‚Ä¢ **Low copper diet** (avoid shellfish, nuts, chocolate)\n\n‚Ä¢ **Liver transplant** (fulminant cases)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**HEPATIC COPPER >250 Œºg/g = GOLD STANDARD** ‚≠ê‚≠ê‚≠ê\n\nWhy? Because it **directly measures the PRIMARY pathology** - copper accumulation in the **LIVER**, which is the **FIRST and MOST affected organ** in Wilson's disease.",
    difficulty: "medium",
    imageUrl: "/images/questions/page2_img4.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-3",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "Which tumor is positive for TTF-1?",
    options: [
      "Squamous Cell Carcinoma (Sq)",
      "Small Cell Carcinoma (Small)",
      "Adenocarcinoma (Adeno Ca)",
      "Carcinoid"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Adenocarcinoma (Option C)**\n\nüî¨ DETAILED EXPLANATION:\n\n**TTF-1 (Thyroid Transcription Factor-1)**, also known as **NKX2-1**, is a **nuclear transcription factor** that serves as a critical **immunohistochemical marker** in the diagnosis of lung tumors.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå TTF-1 EXPRESSION IN LUNG TUMORS:\n\n‚òÖ **ADENOCARCINOMA** ‚≠ê‚≠ê‚≠ê (CORRECT ANSWER)\n  ‚Üí TTF-1 positive in **75-80%** of cases\n  ‚Üí **MOST COMMON TTF-1 positive tumor**\n  ‚Üí Strong nuclear staining pattern\n  ‚Üí Used to differentiate from other primaries\n\n‚Ä¢ **Small Cell Lung Carcinoma (SCLC)**\n  ‚Üí TTF-1 positive in **85-90%** of cases\n  ‚Üí Also strongly positive but less common tumor\n\n‚Ä¢ **Squamous Cell Carcinoma**\n  ‚Üí TTF-1 **NEGATIVE** in >95% of cases\n  ‚Üí Uses **p40/p63** markers instead\n\n‚Ä¢ **Large Cell Carcinoma**\n  ‚Üí TTF-1 positive in only **10-20%**\n  ‚Üí Variable and unreliable\n\n‚Ä¢ **Carcinoid Tumors**\n  ‚Üí TTF-1 **usually NEGATIVE**\n  ‚Üí Rare exceptions\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ IMMUNOHISTOCHEMISTRY PANEL:\n\n**ADENOCARCINOMA Profile:**\n\n‚úÖ **TTF-1 (+)** - Most specific marker ‚≠ê\n‚úÖ **Napsin A (+)** - 80% sensitivity\n‚úÖ **CK7 (+)** - Broad epithelial marker\n‚úÖ **PAS (+)** - Mucin production\n‚ùå **CK20 (‚àí)** - Rules out GI origin\n‚ùå **p40/p63 (‚àí)** - Rules out squamous\n\n**SQUAMOUS CELL CARCINOMA Profile:**\n\n‚ùå **TTF-1 (‚àí)** - Key difference!\n‚úÖ **p40/p63 (+)** - Most specific for squamous ‚≠ê\n‚úÖ **CK5/6 (+)** - Squamous marker\n‚úÖ **p16 (+/‚àí)** - Variable\n‚ùå **Napsin A (‚àí)** - Absent\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL SIGNIFICANCE:\n\n**TTF-1 is POSITIVE in:**\n\n**1. LUNG:**\n‚Ä¢ **Primary lung adenocarcinoma** (75-80%) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Small cell lung cancer** (85-90%)\n‚Ä¢ Expressed in type II pneumocytes\n\n**2. THYROID:**\n‚Ä¢ **Thyroid follicular cells** (normal and neoplastic)\n‚Ä¢ Papillary thyroid carcinoma\n‚Ä¢ Follicular thyroid carcinoma\n\n**Why this matters:**\n‚Üí Helps distinguish **PRIMARY lung adenocarcinoma** from metastases\n‚Üí **Metastatic adenocarcinoma** from breast, colon, pancreas are TTF-1 **NEGATIVE**\n‚Üí If lung mass is TTF-1+, likely **PRIMARY** lung cancer\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ DIFFERENTIAL DIAGNOSIS:\n\n**TTF-1 Positive Lung Mass:**\n‚Ä¢ Primary lung adenocarcinoma ‚≠ê\n‚Ä¢ Small cell lung cancer\n‚Ä¢ Metastatic thyroid cancer (rare)\n\n**TTF-1 Negative Lung Mass:**\n‚Ä¢ Squamous cell carcinoma\n‚Ä¢ Metastatic adenocarcinoma (breast, GI, etc.)\n‚Ä¢ Large cell carcinoma (mostly)\n‚Ä¢ Mesothelioma\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**TTF-1 = ADENOCARCINOMA OF LUNG** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**T**hyroid and **T**horacic (lung) **F**actor-**1**\"\n\n‚Ä¢ Most sensitive and specific marker for **primary lung adenocarcinoma**\n‚Ä¢ Helps differentiate **primary vs metastatic** disease\n‚Ä¢ **Nuclear staining** pattern (transcription factor)\n‚Ä¢ Combined with **Napsin A** for maximum specificity",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-4",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Vitamin to be supplemented after gastrectomy?",
    options: [
      "Vitamin A",
      "Vitamin C",
      "Vitamin B12",
      "Vitamin D"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Vitamin B12 (Option C)**\n\nüî¨ DETAILED EXPLANATION:\n\nAfter **gastrectomy**, **Vitamin B12 supplementation** is **MANDATORY and LIFELONG** due to loss of **intrinsic factor (IF)** production.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL B12 ABSORPTION:\n\n**1. DIETARY B12 (Cobalamin)**\n   ‚Üí Found in meat, fish, dairy, eggs\n\n**2. STOMACH** üéØ\n   ‚Üí **Gastric acid** releases B12 from proteins\n   ‚Üí **Parietal cells** secrete **Intrinsic Factor (IF)** ‚≠ê‚≠ê‚≠ê\n   ‚Üí **IF binds to B12** forming **B12-IF complex**\n\n**3. DUODENUM & JEJUNUM**\n   ‚Üí B12-IF complex remains stable\n\n**4. TERMINAL ILEUM**\n   ‚Üí **Cubam receptors** bind B12-IF complex\n   ‚Üí B12 absorbed into blood\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö†Ô∏è POST-GASTRECTOMY:\n\n**NO STOMACH** ‚Üí ‚ùå **No Parietal Cells**\n\n   ‚Üì\n\n‚ùå **No Intrinsic Factor**\n\n   ‚Üì\n\n‚ùå **No B12 Absorption** (terminal ileum needs B12-IF complex)\n\n   ‚Üì\n\n**MEGALOBLASTIC ANEMIA** (develops in 2-5 years)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä POST-GASTRECTOMY DEFICIENCIES:\n\n**‚òÖ‚òÖ‚òÖ VITAMIN B12** ‚≠ê‚≠ê‚≠ê **(MOST IMPORTANT)**\n\n‚Ä¢ **Mechanism:** No intrinsic factor\n‚Ä¢ **Time:** 2-5 years (after stores deplete)\n‚Ä¢ **Consequences:**\n  ‚Üí **Megaloblastic anemia** (macrocytic)\n  ‚Üí **Neurological:** Subacute combined degeneration\n  ‚Üí **Peripheral neuropathy**\n  ‚Üí **Cognitive impairment**\n‚Ä¢ **Treatment:** **IM B12** 1000 Œºg monthly (lifelong) ‚≠ê\n\n**‚òÖ‚òÖ IRON**\n‚Ä¢ **Mechanism:** ‚Üì Gastric acid, rapid emptying\n‚Ä¢ **Result:** Microcytic anemia\n\n**‚òÖ FOLATE**\n‚Ä¢ Decreased intake\n\n**‚òÖ CALCIUM & VITAMIN D**\n‚Ä¢ Malabsorption ‚Üí Osteoporosis\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ WHY OTHER OPTIONS WRONG:\n\n‚ùå **Vitamin A:** Not specifically affected, liver stores last years\n\n‚ùå **Vitamin C:** Absorbed throughout small intestine, doesn't need stomach\n\n‚ùå **Vitamin D:** While ‚Üì absorption occurs, **B12 is MORE CRITICAL and INEVITABLE**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**POST-GASTRECTOMY = LIFELONG B12 MANDATORY** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**No Stomach, No IF, No B12** ‚Üí Must give **B12 shots forever!**\"\n\n‚Ä¢ **Parietal cells** (stomach) produce **IF**\n‚Ä¢ **IF essential** for B12 absorption in **terminal ileum**\n‚Ä¢ Start supplementation **immediately** (don't wait!)",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-6",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "10-year-old male presents with cervical lymphadenopathy, Surface Ig+, CD34-,\nCD5-, CD23-, Tdt-, CD10+, CD19+:",
    options: [
      "Burkitt‚Äôs Lymphoma",
      "Diffuse Large B-cell Lymphoma (DLBCL)",
      "Anaplastic Large Cell Lymphoma (ALCL)",
      "B-cell Acute Lymphoblastic Leukemia (B-ALL)"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Burkitt's Lymphoma (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Burkitt's Lymphoma** is a **highly aggressive B-cell non-Hodgkin lymphoma** with the **HIGHEST proliferation rate** (Ki-67 >95%) among all lymphomas.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå IMMUNOPHENOTYPING ANALYSIS:\n\n**GIVEN MARKERS:**\n\n‚Ä¢ **Surface Ig (+)** ‚≠ê = MATURE B-cell\n‚Ä¢ **CD34 (‚àí)** ‚≠ê‚≠ê‚≠ê = NOT immature!\n‚Ä¢ **CD5 (‚àí)** = NOT CLL/MCL\n‚Ä¢ **CD23 (‚àí)** = NOT CLL\n‚Ä¢ **TdT (‚àí)** ‚≠ê‚≠ê‚≠ê = NOT lymphoblastic!\n‚Ä¢ **CD10 (+)** ‚≠ê = Germinal center origin\n‚Ä¢ **CD19 (+)** ‚≠ê = B-cell marker\n\n**This = MATURE B-CELL LYMPHOMA** üéØ\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ BURKITT'S LYMPHOMA PROFILE:\n\n**POSITIVE MARKERS:**\n\n‚úÖ **Surface Ig (+)** ‚Üí **MATURE B-cell** (NOT precursor) ‚≠ê‚≠ê‚≠ê\n\n‚úÖ **CD10 (+)** ‚Üí **Germinal center** origin (CALLA antigen)\n\n‚úÖ **CD19 (+), CD20 (+)** ‚Üí Pan B-cell markers\n\n‚úÖ **Ki-67 >95%** ‚Üí **EXTREMELY HIGH proliferation!** ‚≠ê‚≠ê‚≠ê\n\n‚úÖ **BCL-6 (+)** ‚Üí Germinal center marker\n\n**NEGATIVE MARKERS:**\n\n‚ùå **CD34 (‚àí)** ‚Üí **NOT immature/precursor** ‚≠ê‚≠ê‚≠ê\n\n‚ùå **TdT (‚àí)** ‚Üí **NOT lymphoblastic** ‚≠ê‚≠ê‚≠ê\n\n‚ùå **CD5 (‚àí), CD23 (‚àí)** ‚Üí Rules out CLL, MCL\n\n‚ùå **BCL-2 (‚àí)** ‚Üí Unlike follicular lymphoma\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIFFERENTIAL DIAGNOSIS:\n\n**1. BURKITT'S LYMPHOMA** ‚≠ê‚≠ê‚≠ê (CORRECT)\n‚Ä¢ Surface Ig **(+)** - Mature\n‚Ä¢ CD34 **(‚àí)** - Not immature\n‚Ä¢ TdT **(‚àí)** - Not lymphoblastic\n‚Ä¢ **Ki-67 >95%** - Fastest growing!\n‚Ä¢ Age: 10 years old ‚úì\n\n**2. B-ALL (B-cell Acute Lymphoblastic Leukemia)** ‚ùå\n‚Ä¢ Surface Ig **(‚àí)** - Immature ‚ö†Ô∏è\n‚Ä¢ CD34 **(+)** - Precursor marker ‚ö†Ô∏è\n‚Ä¢ TdT **(+)** - Lymphoblastic ‚ö†Ô∏è\n‚Ä¢ Represents **IMMATURE** B-cells\n\n**3. DLBCL** ‚ùå\n‚Ä¢ Similar markers but **Ki-67 60-80%** (lower)\n‚Ä¢ Older age group\n\n**4. ALCL** ‚ùå\n‚Ä¢ **CD30 (+)**, CD19/CD20 **(‚àí)**\n‚Ä¢ T-cell origin\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ MOLECULAR & HISTOLOGY:\n\n**CYTOGENETICS:**\n\n‚Ä¢ **t(8;14)** - **MYC translocation** (80%) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ t(2;8) or t(8;22) variants (20%)\n‚Ä¢ **MYC gene** (chr 8) ‚Üí **IgH** (chr 14)\n‚Ä¢ ‚Üí **MYC overexpression** ‚Üí uncontrolled proliferation\n\n**HISTOLOGY:**\n\n‚Ä¢ **\"Starry sky\" appearance** ‚≠ê‚≠ê‚≠ê\n  ‚Üí \"Sky\" = densely packed lymphoma cells\n  ‚Üí \"Stars\" = tingible body macrophages\n  ‚Üí Macrophages eating apoptotic tumor cells\n‚Ä¢ Medium-sized cells, round nuclei\n‚Ä¢ Basophilic cytoplasm\n‚Ä¢ High mitotic rate\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüåç CLINICAL TYPES:\n\n**1. ENDEMIC (African)**\n‚Ä¢ **EBV positive** (>95%) ‚≠ê\n‚Ä¢ **Jaw/facial bones** involvement\n‚Ä¢ Age: 4-7 years\n‚Ä¢ Malaria belt association\n\n**2. SPORADIC (Western)**\n‚Ä¢ **EBV positive** (15-20%)\n‚Ä¢ **Abdomen** (ileocecal) ‚≠ê\n‚Ä¢ Presents as abdominal mass\n\n**3. IMMUNODEFICIENCY**\n‚Ä¢ HIV/AIDS, post-transplant\n‚Ä¢ **EBV positive** (25-40%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° CLINICAL FEATURES:\n\n‚Ä¢ **Rapidly growing mass** (doubling: 24-48 hrs!)\n‚Ä¢ **B symptoms** (fever, night sweats, weight loss)\n‚Ä¢ **Cervical lymphadenopathy** (as in this case)\n‚Ä¢ **CNS involvement** (25%)\n‚Ä¢ **Tumor lysis syndrome** risk ‚ö†Ô∏è\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**\"BURKITT'S = MATURE, NOT A BABY!\"** ‚≠ê‚≠ê‚≠ê\n\n‚Ä¢ Surface Ig **(+)** = Mature\n‚Ä¢ CD34 **(‚àí)** = NOT immature\n‚Ä¢ TdT **(‚àí)** = NOT lymphoblastic\n‚Ä¢ **Ki-67 >95%** = Fastest lymphoma!\n‚Ä¢ **t(8;14) MYC** = Hallmark\n‚Ä¢ **\"Starry sky\"** = Diagnostic",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-7",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "Most common mutation in Papillary cell carcinoma?",
    options: [
      "BRAF V600E",
      "RET",
      "MET",
      "RAS"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **BRAF V600E (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**BRAF V600E** is the **MOST COMMON genetic mutation** in **Papillary Thyroid Carcinoma (PTC)**, occurring in **40-45%** of cases.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå THYROID CANCER MUTATIONS:\n\n**PAPILLARY THYROID CARCINOMA (PTC):** ‚≠ê\n\n‚Ä¢ **BRAF V600E: 40-45%** ‚≠ê‚≠ê‚≠ê (MOST COMMON - ANSWER!)\n‚Ä¢ **RET/PTC rearrangement: 20-30%** (radiation-induced, children)\n‚Ä¢ **RAS mutation: 10-15%** (follicular variant PTC)\n‚Ä¢ **NTRK fusion: 5-10%** (pediatric)\n\n**FOLLICULAR THYROID CARCINOMA (FTC):**\n\n‚Ä¢ **RAS mutation: 40-50%**\n‚Ä¢ **PAX8/PPARŒ≥ rearrangement: 30-40%**\n\n**MEDULLARY THYROID CARCINOMA (MTC):**\n\n‚Ä¢ **RET mutation: 98%** (hereditary MEN 2)\n\n**ANAPLASTIC THYROID CARCINOMA (ATC):**\n\n‚Ä¢ **p53 mutation** + BRAF/RAS (often evolves from PTC/FTC)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ MAPK/ERK SIGNALING PATHWAY:\n\n**NORMAL CELL:**\n\nGrowth Factor ‚Üí Receptor ‚Üí RAS ‚Üí **RAF (BRAF)** ‚Üí MEK ‚Üí ERK\n                                     ‚Üì\n                        Controlled Cell Growth ‚úì\n\n**BRAF V600E MUTATION:**\n\n‚úó **No Growth Factor needed!**\n         ‚Üì\n**BRAF V600E (CONSTITUTIVELY ACTIVE!)** ‚ö°‚ö°‚ö°\n         ‚Üì\n**MEK** ‚Üë‚Üë‚Üë (Hyperactivated)\n         ‚Üì\n**ERK** ‚Üë‚Üë‚Üë (Hyperactivated)\n         ‚Üì\n**Uncontrolled Cell Proliferation** ‚Üí **CANCER!**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL SIGNIFICANCE OF BRAF V600E:\n\n**WORSE PROGNOSIS INDICATORS:** ‚ö†Ô∏è\n\n‚Ä¢ **More aggressive tumor behavior**\n‚Ä¢ **Higher recurrence rate** (2-3x increased)\n‚Ä¢ **Increased lymph node metastasis**\n‚Ä¢ **Extrathyroidal extension** (invades surrounding tissues)\n‚Ä¢ **Higher stage at presentation**\n‚Ä¢ **Radioiodine resistance** (‚Üì NIS expression)\n‚Ä¢ **Worse disease-free survival**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä THERAPEUTIC IMPLICATIONS:\n\n**TARGETED THERAPY:**\n\n‚Ä¢ **Vemurafenib** - BRAF V600E inhibitor ‚≠ê\n‚Ä¢ **Dabrafenib** - BRAF inhibitor\n‚Ä¢ **Trametinib** - MEK inhibitor (combination therapy)\n\n**Used for:**\n‚Ä¢ **Advanced/metastatic PTC**\n‚Ä¢ **Radioiodine-refractory disease**\n‚Ä¢ **Anaplastic thyroid cancer** with BRAF mutation\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç WHY OTHER OPTIONS ARE WRONG:\n\n‚ùå **RET:**\n‚Ä¢ **2nd most common** in PTC (20-30%)\n‚Ä¢ More common in **radiation-induced** PTC\n‚Ä¢ **Hallmark** of **Medullary thyroid cancer** (98%)\n\n‚ùå **MET:**\n‚Ä¢ Less common in PTC\n‚Ä¢ More associated with **follicular-patterned** tumors\n\n‚ùå **RAS:**\n‚Ä¢ **3rd most common** in PTC (10-15%)\n‚Ä¢ More common in **Follicular thyroid carcinoma** (40-50%)\n‚Ä¢ Associated with **follicular variant PTC**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã PAPILLARY THYROID CARCINOMA FEATURES:\n\n**HISTOLOGY:**\n‚Ä¢ **Orphan Annie eye** nuclei (ground glass)\n‚Ä¢ **Psammoma bodies** (calcifications)\n‚Ä¢ **Nuclear grooves**\n‚Ä¢ **Papillary architecture**\n\n**CLINICAL:**\n‚Ä¢ **Most common** thyroid cancer (80-85%)\n‚Ä¢ **Best prognosis** overall\n‚Ä¢ **Lymph node spread** common (40%)\n‚Ä¢ **Excellent survival** (>95% at 10 years)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**BRAF V600E = MOST COMMON PTC MUTATION** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"BRAF = Bad, Risky, Aggressive, Fast PTC!\"**\n\n‚Ä¢ **40-45%** of all PTC\n‚Ä¢ **V600E** = Valine ‚Üí Glutamic acid at position 600\n‚Ä¢ **Constitutively active** MAPK pathway\n‚Ä¢ **Worse prognosis** but **targetable** with Vemurafenib\n‚Ä¢ **Always think BRAF** in aggressive PTC!",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-8",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Renal mass, haematuria, flank pain:",
    options: [
      "Clear cell",
      "Papillary",
      "Chromophobic",
      "Belini"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Chromophobe RCC (Option C)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Renal Cell Carcinoma (RCC)** presenting with the **CLASSIC TRIAD** (renal mass + hematuria + flank pain) can be of various subtypes. **Chromophobe RCC** is associated with the **BEST PROGNOSIS** among all RCC subtypes, making it the correct answer for favorable outcomes.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå RCC SUBTYPES COMPARISON:\n\n**1. CLEAR CELL RCC** (70-80%) ‚ùå\n\n‚Ä¢ **MOST COMMON** subtype ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Origin:** Proximal convoluted tubule\n‚Ä¢ **Genetics:** **VHL gene** mutation (3p deletion) on chromosome 3\n‚Ä¢ **Histology:**\n  ‚Üí Clear cytoplasm (glycogen, lipid)\n  ‚Üí Delicate vascular network\n  ‚Üí \"Chicken-wire\" capillaries\n‚Ä¢ **Prognosis:** **Intermediate** (worse than chromophobe)\n‚Ä¢ **Metastasis:** Bone, lung, liver, brain\n‚Ä¢ **Associated with:** Von Hippel-Lindau syndrome\n\n**2. PAPILLARY RCC** (10-15%) ‚ùå\n\n‚Ä¢ **2nd most common** subtype\n‚Ä¢ **Origin:** Proximal tubule\n‚Ä¢ **Genetics:** MET proto-oncogene, FH (fumarate hydratase)\n‚Ä¢ **Histology:**\n  ‚Üí Papillary/tubular architecture\n  ‚Üí Foamy macrophages\n  ‚Üí Psammoma bodies (Type 1)\n‚Ä¢ **2 Types:**\n  ‚Üí **Type 1:** Low grade, **BEST prognosis** within papillary\n  ‚Üí **Type 2:** High grade, **worse prognosis**\n‚Ä¢ **Prognosis:** **Better** than clear cell (but not as good as chromophobe)\n‚Ä¢ **Often bilateral** and multifocal\n\n**3. ‚òÖ CHROMOPHOBE RCC** ‚≠ê‚≠ê‚≠ê **(ANSWER - 5% of RCC)**\n\n‚Ä¢ **Origin:** Cortical collecting duct (intercalated cells)\n‚Ä¢ **Genetics:** **Multiple chromosome losses** (1, 2, 6, 10, 13, 17, 21)\n‚Ä¢ **Histology:**\n  ‚Üí **Large pale cells** with abundant cytoplasm\n  ‚Üí **\"Plant-like\" cell borders** ‚≠ê (distinct cell membranes)\n  ‚Üí **Perinuclear halo** (wrinkled raisinoid nuclei)\n  ‚Üí **Binucleation** common\n‚Ä¢ **Special stains:**\n  ‚Üí **Hale's colloidal iron (+)** ‚≠ê‚≠ê‚≠ê (diagnostic!)\n  ‚Üí **CD117 (c-KIT) positive**\n  ‚Üí CK7 diffusely positive\n‚Ä¢ **Prognosis:** **BEST prognosis** of all RCC subtypes! ‚≠ê‚≠ê‚≠ê\n  ‚Üí **5-year survival: 80-90%**\n  ‚Üí **Rarely metastasizes**\n  ‚Üí **Indolent behavior**\n‚Ä¢ **DDx:** Renal oncocytoma (benign, similar Hale's stain)\n\n**4. COLLECTING DUCT (BELLINI) RCC** (1-2%) ‚ùå\n\n‚Ä¢ **RAREST** and **MOST AGGRESSIVE** subtype ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è\n‚Ä¢ **Origin:** Medullary collecting ducts\n‚Ä¢ **Histology:**\n  ‚Üí Tubular/glandular pattern\n  ‚Üí Desmoplastic stroma\n  ‚Üí High-grade cytology\n‚Ä¢ **Location:** **Medullary** (vs others: cortical)\n‚Ä¢ **Prognosis:** **WORST** among all RCC subtypes ‚ö†Ô∏è\n  ‚Üí Often **metastatic at presentation**\n  ‚Üí Very aggressive\n  ‚Üí **5-year survival: <10%**\n‚Ä¢ **Association:** **Sickle cell trait** (medullary carcinoma variant)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLASSIC RCC TRIAD:\n\n**1. FLANK PAIN** (40% of patients)\n‚Ä¢ Dull, constant ache\n‚Ä¢ Due to mass effect/bleeding\n\n**2. HEMATURIA** (40-60% of patients)\n‚Ä¢ Gross or microscopic\n‚Ä¢ **Painless** hematuria\n‚Ä¢ Intermittent\n\n**3. PALPABLE ABDOMINAL/FLANK MASS** (25-45%)\n‚Ä¢ Indicates large tumor\n‚Ä¢ Late sign\n\n**IMPORTANT:** Only **10-15%** of patients present with **ALL 3 together**! ‚ö†Ô∏è\n\nMost patients are **asymptomatic** and diagnosed **incidentally** on imaging (\"incidentaloma\").\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° OTHER CLINICAL FEATURES:\n\n**SYSTEMIC SYMPTOMS:**\n‚Ä¢ **Weight loss**\n‚Ä¢ **Fever** (20%)\n‚Ä¢ **Night sweats**\n‚Ä¢ **Fatigue, anemia**\n‚Ä¢ **Varicocele** (especially left-sided, acute onset - due to renal vein invasion)\n\n**PARANEOPLASTIC SYNDROMES (30%):**\n\n‚Ä¢ **Polycythemia** (5%)\n  ‚Üí **Erythropoietin (EPO) ‚Üë** production\n  ‚Üí Elevated hematocrit\n\n‚Ä¢ **Hypercalcemia** (10-20%)\n  ‚Üí **PTHrP** (parathyroid hormone-related peptide) secretion\n  ‚Üí Bone resorption\n\n‚Ä¢ **Hypertension**\n  ‚Üí **Renin ‚Üë** secretion\n  ‚Üí AV fistulas in tumor\n\n‚Ä¢ **Stauffer Syndrome**\n  ‚Üí **Non-metastatic hepatic dysfunction**\n  ‚Üí ‚Üë Alkaline phosphatase, ‚Üë transaminases\n  ‚Üí Hepatomegaly\n  ‚Üí Resolves after nephrectomy\n\n‚Ä¢ **Cushing syndrome**\n  ‚Üí **ACTH** secretion (rare)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç DIAGNOSIS:\n\n**IMAGING:**\n\n‚Ä¢ **CT abdomen with IV contrast** ‚≠ê (Gold standard)\n  ‚Üí **Heterogeneous enhancing mass**\n  ‚Üí Renal vein/IVC involvement?\n  ‚Üí Staging (T, N, M)\n\n‚Ä¢ **MRI** (if contrast allergy, better for IVC thrombus)\n\n‚Ä¢ **Ultrasound** (initial, often incidental finding)\n  ‚Üí Solid vs cystic\n\n**BIOPSY:**\n‚Ä¢ **Usually NOT needed** if imaging typical\n‚Ä¢ Reserved for:\n  ‚Üí Uncertain diagnosis\n  ‚Üí Small masses (<4 cm)\n  ‚Üí Metastatic disease (to confirm histology)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä STAGING & TREATMENT:\n\n**TNM STAGING:**\n‚Ä¢ **T1:** ‚â§7 cm, confined to kidney\n  ‚Üí T1a: ‚â§4 cm\n  ‚Üí T1b: 4-7 cm\n‚Ä¢ **T2:** >7 cm, confined to kidney\n‚Ä¢ **T3:** Extension into major veins or perinephric tissue\n‚Ä¢ **T4:** Beyond Gerota's fascia\n\n**TREATMENT:**\n\n‚Ä¢ **Localized disease:** **Radical nephrectomy** or **partial nephrectomy** ‚≠ê\n‚Ä¢ **Metastatic disease:**\n  ‚Üí **Targeted therapy:** Sunitinib, pazopanib (VEGF inhibitors)\n  ‚Üí **Immunotherapy:** Nivolumab, pembrolizumab (PD-1 inhibitors)\n  ‚Üí **mTOR inhibitors:** Everolimus, temsirolimus\n‚Ä¢ **RCC is resistant to chemotherapy and radiation!** ‚ö†Ô∏è\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìä PROGNOSIS RANKING (Best ‚Üí Worst):\n\n**1. Chromophobe RCC** ‚≠ê‚≠ê‚≠ê **(BEST - 80-90% 5-yr survival)**\n**2. Papillary RCC Type 1** (Good - 75-85%)\n**3. Clear Cell RCC** (Intermediate - 55-70%)\n**4. Papillary RCC Type 2** (Poor - 40-50%)\n**5. Collecting Duct/Bellini** ‚ö†Ô∏è **(WORST - <10%)**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**CHROMOPHOBE RCC = BEST PROGNOSIS** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"Chromophobe = CHROME = Shiny BEST prognosis!\"**\n\n‚Ä¢ **Chromophobe:** 5%, **BEST prognosis** (80-90% 5-yr survival)\n‚Ä¢ **Hale's colloidal iron (+)** = diagnostic for chromophobe\n‚Ä¢ **\"Plant-like\" cell borders** = chromophobe\n‚Ä¢ **Clear cell:** MOST common (70-80%), VHL gene\n‚Ä¢ **Collecting duct (Bellini):** WORST prognosis (<10%)\n‚Ä¢ **Classic RCC triad:** Mass + Hematuria + Flank pain (only 10% have all 3!)\n‚Ä¢ **Paraneoplastic:** Polycythemia (EPO), Hypercalcemia (PTHrP)\n‚Ä¢ **Treatment:** Surgery for localized; targeted/immuno for metastatic",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-9",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Which disease will show the following mode of inheritance?",
    options: [
      "Wiskott",
      "Wilson",
      "Prader-Willi",
      "Achondroplasia"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Wiskott-Aldrich Syndrome (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Wiskott-Aldrich Syndrome (WAS)** is an **X-LINKED RECESSIVE** disorder. The pedigree pattern shows **affected males only**, **carrier females**, and **NO male-to-male transmission**, which is pathognomonic for **X-linked recessive inheritance**.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå X-LINKED RECESSIVE INHERITANCE PATTERN:\n\n**CARRIER MOTHER (X^W X) √ó NORMAL FATHER (XY)**\n\n**Offspring:**\n\n‚Ä¢ **25%** - X^W X (Carrier daughter) ‚úì\n‚Ä¢ **25%** - XX (Normal daughter) ‚úì\n‚Ä¢ **25%** - X^W Y (**AFFECTED son**) ‚ö†Ô∏è\n‚Ä¢ **25%** - XY (Normal son) ‚úì\n\n**KEY FEATURES OF X-LINKED RECESSIVE:** ‚≠ê‚≠ê‚≠ê\n\n‚úÖ **Affects MALES predominantly** (hemizygous - only 1 X)\n‚úÖ **Females usually carriers** (heterozygous - 2 X chromosomes)\n‚úÖ **NO male-to-male transmission** (fathers give Y to sons, not X)\n‚úÖ **Affected males from carrier mothers**\n‚úÖ **Can skip generations** (carrier females asymptomatic)\n‚úÖ **Maternal uncles/nephews** affected (classic pattern)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ WISKOTT-ALDRICH SYNDROME (WAS):\n\n**GENETICS:**\n‚Ä¢ **X-linked recessive** (Xp11.23)\n‚Ä¢ **WAS gene** mutation ‚≠ê\n  ‚Üí Encodes **WASP (WAS protein)**\n  ‚Üí WASP regulates **actin cytoskeleton** in hematopoietic cells\n  ‚Üí Defect ‚Üí abnormal platelet and lymphocyte function\n\n**CLASSIC TRIAD:** ‚≠ê‚≠ê‚≠ê\n\n**1. THROMBOCYTOPENIA** (low platelets)\n‚Ä¢ **Small platelets** ‚≠ê‚≠ê‚≠ê (‚Üì MPV - mean platelet volume)\n‚Ä¢ **<70,000/ŒºL** (often <20,000)\n‚Ä¢ Petechiae, purpura, bleeding\n‚Ä¢ **Bloody diarrhea** (common in infancy)\n\n**2. ECZEMA**\n‚Ä¢ Severe atopic dermatitis\n‚Ä¢ Similar to atopic eczema\n‚Ä¢ Pruritic, scaling skin lesions\n\n**3. RECURRENT INFECTIONS**\n‚Ä¢ **Combined immunodeficiency** (B + T cell defects)\n‚Ä¢ **Encapsulated bacteria** (‚Üì IgM, poor polysaccharide response)\n‚Ä¢ **Viral, fungal, opportunistic** infections\n\n**Mnemonic: \"WAITER\"** ‚≠ê\n\n**W** - **Wiskott** (X-linked)\n**A** - **Autoimmunity** (hemolytic anemia, vasculitis)\n**I** - **Infections** (recurrent)\n**T** - **Thrombocytopenia** (**SMALL** platelets!) ‚≠ê‚≠ê‚≠ê\n**E** - **Eczema**\n**R** - **Raised IgE**, **decreased IgM** (‚Üì response to polysaccharides)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**HEMATOLOGIC:**\n‚Ä¢ **Thrombocytopenia** with **SMALL platelets** ‚≠ê‚≠ê‚≠ê (key distinguishing feature!)\n‚Ä¢ **Petechiae, purpura** (often at birth)\n‚Ä¢ **Bloody diarrhea** (infancy)\n‚Ä¢ **Intracranial hemorrhage** (life-threatening)\n\n**IMMUNOLOGIC:**\n‚Ä¢ **Recurrent sinopulmonary infections** (Strep pneumoniae, H. influenzae)\n‚Ä¢ **Opportunistic infections** (PCP, CMV, HSV)\n‚Ä¢ **Progressive T-cell dysfunction**\n‚Ä¢ **‚Üì IgM**, **‚Üë IgE**, **‚Üë IgA**, normal/‚Üì IgG\n\n**DERMATOLOGIC:**\n‚Ä¢ **Severe eczema** (face, flexures)\n‚Ä¢ Similar to atopic dermatitis\n\n**AUTOIMMUNE (30-40%):**\n‚Ä¢ **Autoimmune hemolytic anemia** (AIHA)\n‚Ä¢ **Vasculitis** (especially renal)\n‚Ä¢ **Inflammatory bowel disease**\n‚Ä¢ **Arthritis**\n\n**MALIGNANCY (20%):**\n‚Ä¢ **‚Üë Risk of lymphoma** (EBV-associated)\n‚Ä¢ **Leukemia**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç DIAGNOSIS:\n\n**LABORATORY:**\n\n‚Ä¢ **Thrombocytopenia** (<70,000/ŒºL)\n‚Ä¢ **‚Üì Mean Platelet Volume (MPV)** ‚≠ê‚≠ê‚≠ê **(KEY - platelets SMALL!)**\n‚Ä¢ **‚Üì IgM** (poor response to polysaccharides)\n‚Ä¢ **‚Üë IgE, ‚Üë IgA**\n‚Ä¢ **Lymphopenia** (progressive T-cell decline)\n‚Ä¢ **Poor antibody response** to polysaccharide antigens\n\n**GENETIC:**\n‚Ä¢ **WAS gene sequencing** (confirmatory)\n‚Ä¢ **Flow cytometry:** Absent WASP expression\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**CURATIVE:**\n‚Ä¢ **Hematopoietic stem cell transplant (HSCT)** ‚≠ê‚≠ê‚≠ê **(Only cure!)**\n  ‚Üí Best if done early (before age 5)\n  ‚Üí HLA-matched sibling donor ideal\n  ‚Üí **85-90% cure rate** with matched donor\n\n‚Ä¢ **Gene therapy** (experimental, promising)\n\n**SUPPORTIVE:**\n‚Ä¢ **IVIG** (Intravenous immunoglobulin)\n‚Ä¢ **Prophylactic antibiotics** (PCP prophylaxis with TMP-SMX)\n‚Ä¢ **Splenectomy** (if severe thrombocytopenia - but ‚Üë infection risk!)\n‚Ä¢ **Platelet transfusions** (for bleeding)\n‚Ä¢ **Avoid aspirin, NSAIDs** (worsen bleeding)\n‚Ä¢ **Topical steroids** for eczema\n\n**PROGNOSIS:**\n‚Ä¢ **Without HSCT:** Death usually by age 10-15\n‚Ä¢ **Causes of death:** Bleeding (ICH), infection, malignancy\n‚Ä¢ **With HSCT:** Excellent survival (>85%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã DISEASE COMPARISON (Answer options):\n\n**‚òÖ WISKOTT-ALDRICH** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n‚Ä¢ **Inheritance:** **X-linked Recessive** (XLR)\n‚Ä¢ **Gene:** WAS gene (WASP)\n‚Ä¢ **Clinical:** Thrombocytopenia (**SMALL platelets**) + Eczema + Infections\n‚Ä¢ **Immune:** Combined B+T deficiency\n\n**‚Ä¢ WILSON'S DISEASE** ‚ùå\n\n‚Ä¢ **Inheritance:** **Autosomal Recessive** (AR)\n‚Ä¢ **Gene:** ATP7B (copper transporter)\n‚Ä¢ **Clinical:** Liver disease + neurological (Kayser-Fleischer rings)\n‚Ä¢ **NOT X-linked!**\n\n**‚Ä¢ PRADER-WILLI SYNDROME** ‚ùå\n\n‚Ä¢ **Inheritance:** **Genomic imprinting** (NOT Mendelian)\n‚Ä¢ **Genetics:** **Paternal deletion 15q11-q13** (or maternal UPD 15)\n‚Ä¢ **Clinical:** Hyperphagia, obesity, intellectual disability, hypogonadism\n‚Ä¢ **NOT X-linked!**\n\n**‚Ä¢ ACHONDROPLASIA** ‚ùå\n\n‚Ä¢ **Inheritance:** **Autosomal Dominant** (AD)\n‚Ä¢ **Gene:** **FGFR3** mutation (chromosome 4)\n‚Ä¢ **Clinical:** Short-limb dwarfism, rhizomelic shortening\n‚Ä¢ **NOT X-linked!** (affects both males and females equally)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ OTHER X-LINKED RECESSIVE DISORDERS:\n\n**IMMUNODEFICIENCY:**\n‚Ä¢ **X-linked agammaglobulinemia (Bruton's)** - BTK gene\n‚Ä¢ **X-linked SCID** - IL2RG gene\n‚Ä¢ **Chronic granulomatous disease** (X-linked form) - CYBB gene\n‚Ä¢ **Wiskott-Aldrich** - WAS gene ‚≠ê\n\n**HEMATOLOGIC:**\n‚Ä¢ **Hemophilia A** (Factor VIII deficiency)\n‚Ä¢ **Hemophilia B** (Factor IX deficiency)\n‚Ä¢ **G6PD deficiency**\n\n**NEUROMUSCULAR:**\n‚Ä¢ **Duchenne/Becker muscular dystrophy**\n‚Ä¢ **Fragile X syndrome**\n\n**OTHER:**\n‚Ä¢ **Color blindness** (red-green)\n‚Ä¢ **Hunter syndrome** (MPS II)\n‚Ä¢ **Fabry disease**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**WISKOTT-ALDRICH = X-LINKED RECESSIVE** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"WAS on X: Boys get WASted!\"**\n\n**\"WAITER\" mnemonic:**\n‚Ä¢ **W** - Wiskott (**X-linked**)\n‚Ä¢ **A** - Autoimmunity\n‚Ä¢ **I** - Infections\n‚Ä¢ **T** - **Thrombocytopenia (SMALL platelets!)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **E** - Eczema\n‚Ä¢ **R** - Raised IgE, ‚Üì IgM\n\n**X-linked recessive pattern:**\n‚Ä¢ Affects **MALES** only\n‚Ä¢ **NO male-to-male** transmission\n‚Ä¢ **Carrier females**\n‚Ä¢ **Maternal uncles** affected\n\n**Treatment:** **HSCT = ONLY CURE!**",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-10",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "Young male died during exercise. History of similar deaths in sibling, On gross\nmorphology: septal thickening was seen. Most common cause of death?",
    options: [
      "Dilated Cardiomyopathy (DCM)",
      "Restrictive Cardiomyopathy (RCM)",
      "Hypertrophic Obstructive Cardiomyopathy (HOCM)",
      "Viral Myocarditis"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Hypertrophic Obstructive Cardiomyopathy (HOCM) - Option C**\n\nüî¨ DETAILED EXPLANATION:\n\n**HOCM** is the **#1 CAUSE** of **sudden cardiac death in YOUNG ATHLETES** and individuals <35 years old. The case describes classic findings: **young male**, **sudden death during exercise**, **family history**, and **septal thickening** on gross morphology.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå CARDIOMYOPATHY COMPARISON:\n\n**‚òÖ HOCM (HCM)** ‚≠ê‚≠ê‚≠ê **(ANSWER!)**\n\n‚Ä¢ **Septum:** ‚Üë‚Üë‚Üë **THICK** (>15mm) - **Asymmetric Septal Hypertrophy (ASH)**\n‚Ä¢ **EF:** ‚Üë or Normal **(>60-70%)** - Hyperdynamic!\n‚Ä¢ **LV Cavity:** ‚Üì **SMALL** (\"Banana-shaped\")\n‚Ä¢ **LV Wall:** Thick\n‚Ä¢ **Genetics:** **Autosomal Dominant** (MYH7, MYBPC3)\n‚Ä¢ **Key finding:** **LVOT obstruction**\n\n**‚Ä¢ DCM (Dilated Cardiomyopathy)** ‚ùå\n\n‚Ä¢ Septum: Normal thickness\n‚Ä¢ EF: ‚Üì‚Üì **<40%** (systolic dysfunction)\n‚Ä¢ LV Cavity: ‚Üë‚Üë **LARGE** (dilated)\n‚Ä¢ Causes: Alcohol, viral, idiopathic\n‚Ä¢ Presents with **heart failure** (not sudden death)\n\n**‚Ä¢ RCM (Restrictive Cardiomyopathy)** ‚ùå\n\n‚Ä¢ Septum: Normal\n‚Ä¢ EF: Normal\n‚Ä¢ LV Cavity: Normal size but **RIGID** (stiff)\n‚Ä¢ **Diastolic dysfunction** (filling problem)\n‚Ä¢ Rare; causes: Amyloidosis, sarcoidosis\n\n**‚Ä¢ Viral Myocarditis** ‚ùå\n\n‚Ä¢ **Acute inflammation** of myocardium\n‚Ä¢ Can cause sudden death but **NO familial pattern**\n‚Ä¢ **NO septal thickening** on gross exam\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nü´Ä PATHOPHYSIOLOGY:\n\n**HOCM Heart Anatomy:**\n\n‚Ä¢ **Asymmetric Septal Hypertrophy (ASH)** ‚≠ê‚≠ê‚≠ê\n  ‚Üí Septum >15mm (normal: 7-11mm)\n  ‚Üí **Interventricular septum** >> LV free wall\n  ‚Üí Creates **\"Banana-shaped\" LV cavity**\n\n‚Ä¢ **LVOT Obstruction** (Left Ventricular Outflow Tract)\n  ‚Üí Thick septum **narrows** outflow path\n  ‚Üí Blood has difficulty exiting LV\n\n‚Ä¢ **SAM (Systolic Anterior Motion)** ‚≠ê\n  ‚Üí Mitral valve **sucked forward** by Venturi effect\n  ‚Üí Worsens LVOT obstruction\n  ‚Üí Causes mitral regurgitation\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° SUDDEN DEATH MECHANISM:\n\n**Normal State:**\n‚Ä¢ Some LVOT obstruction at rest\n‚Ä¢ Can be asymptomatic\n\n**During EXERCISE:** ‚ö†Ô∏è\n\n**1. Increased Contractility**\n   ‚Üí Septum contracts harder\n   ‚Üì\n\n**2. Decreased LV Volume**\n   ‚Üí Less blood in chamber\n   ‚Üì\n\n**3. WORSE LVOT Obstruction**\n   ‚Üí Outflow path even narrower!\n   ‚Üì\n\n**4. Decreased Cardiac Output**\n   ‚Üí Brain hypoperfusion\n   ‚Üì\n\n**5. Ventricular Arrhythmias**\n   ‚Üí **VT/VF** (myocardial disarray creates substrate)\n   ‚Üì\n\n**SUDDEN CARDIAC DEATH** ‚ö°‚ö°‚ö°\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**TRIAD:**\n\n1. **Family history** of sudden death (AD inheritance)\n2. **Syncope with exercise** (LVOT obstruction worsens)\n3. **Systolic murmur** that ‚Üë with Valsalva\n\n**SYMPTOMS:**\n\n‚Ä¢ **Dyspnea** (exertional)\n‚Ä¢ **Angina** (despite normal coronaries - supply-demand mismatch)\n‚Ä¢ **Palpitations**\n‚Ä¢ **Syncope** (especially with exercise)\n‚Ä¢ **Sudden cardiac death** (often FIRST presentation!) ‚ö†Ô∏è\n\n**PHYSICAL EXAM:**\n\n‚Ä¢ **Harsh systolic murmur** at LLSB\n‚Ä¢ **‚Üë with Valsalva, standing** (‚Üì preload ‚Üí ‚Üë obstruction)\n‚Ä¢ **‚Üì with squatting, handgrip** (‚Üë afterload ‚Üí ‚Üì obstruction)\n‚Ä¢ **Double apical impulse** (presystolic impulse)\n‚Ä¢ **Jerky carotid pulse** (\"spike and dome\")\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ HISTOPATHOLOGY:\n\n‚Ä¢ **Myocardial disarray** ‚≠ê‚≠ê‚≠ê (Hallmark!)\n  ‚Üí Disorganized myocyte arrangement\n  ‚Üí Creates arrhythmia substrate\n\n‚Ä¢ **Myocyte hypertrophy**\n‚Ä¢ **Interstitial fibrosis**\n‚Ä¢ **Thickened intramural coronaries**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç DIAGNOSIS:\n\n**ECHO (Gold Standard):**\n‚Ä¢ **Septal thickness >15mm** (or >13mm with family history)\n‚Ä¢ **SAM of mitral valve**\n‚Ä¢ **LVOT gradient** >30 mmHg\n‚Ä¢ Small LV cavity\n\n**ECG:**\n‚Ä¢ **LVH** with strain\n‚Ä¢ **Deep Q waves** (septal)\n‚Ä¢ **T wave inversion**\n\n**Genetic Testing:**\n‚Ä¢ **MYH7** (Œ≤-myosin heavy chain) - 40%\n‚Ä¢ **MYBPC3** (myosin-binding protein C) - 40%\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**AVOID:**\n‚Ä¢ **Competitive sports** ‚ö†Ô∏è\n‚Ä¢ **Dehydration**\n‚Ä¢ **Vasodilators** (nitroglycerin - worsens obstruction!)\n‚Ä¢ **Digoxin** (‚Üë contractility ‚Üí worse)\n\n**MEDICATIONS:**\n‚Ä¢ **Beta-blockers** (metoprolol) - 1st line ‚≠ê\n‚Ä¢ **Calcium channel blockers** (verapamil)\n‚Ä¢ **Disopyramide** (antiarrhythmic)\n\n**INTERVENTIONS:**\n‚Ä¢ **ICD** (Implantable Cardioverter-Defibrillator) - High-risk patients ‚≠ê\n‚Ä¢ **Septal myectomy** (surgery)\n‚Ä¢ **Alcohol septal ablation**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**HOCM = #1 CAUSE OF SUDDEN DEATH IN YOUNG ATHLETES** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"HOCM Hits Obstructing Cardiac Marathon runners\"**\n\n‚Ä¢ **Asymmetric Septal Hypertrophy** (>15mm)\n‚Ä¢ **Autosomal Dominant** (MYH7, MYBPC3)\n‚Ä¢ **Worse with exercise** (‚Üë obstruction)\n‚Ä¢ **Myocardial disarray** = arrhythmia substrate\n‚Ä¢ **SAM** = Systolic Anterior Motion\n‚Ä¢ Murmur **‚Üë with Valsalva/standing**\n‚Ä¢ **Beta-blockers** = Treatment\n‚Ä¢ **ICD** for high-risk patients",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-11",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Which is not true?",
    options: [
      "VWD type 1 is mostly severe in children",
      "VWD type 3 is mostly severe in children",
      "VWD type 2 is more related to activity rather than levels",
      "VWD type 3 has severely low VWD"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **\"VWD type 1 is mostly severe in children\" - This is INCORRECT (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Von Willebrand Disease (VWD)** is the **MOST COMMON inherited bleeding disorder** (1-2% of population). The statement \"VWD type 1 is mostly severe\" is **FALSE** - **Type 1 is MILD to MODERATE**, NOT severe!\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå VWD TYPE CLASSIFICATION:\n\n**‚òÖ TYPE 1 (70-80% of VWD)** ‚≠ê‚≠ê‚≠ê **MOST COMMON**\n\n‚Ä¢ **Defect:** **Quantitative** (‚Üì amount, normal function)\n‚Ä¢ **VWF Level:** ‚Üì **30-50%** of normal\n‚Ä¢ **VWF Function:** NORMAL\n‚Ä¢ **Severity:** **MILD to MODERATE** ‚úì (NOT SEVERE! ‚ùå)\n‚Ä¢ **Inheritance:** **Autosomal Dominant** (AD)\n‚Ä¢ **Factor VIII:** Mildly ‚Üì (parallels VWF)\n‚Ä¢ **Clinical:** Mild mucocutaneous bleeding\n‚Ä¢ **Treatment:** **DDAVP** (desmopressin)\n\n**‚Ä¢ TYPE 2 (15-20% of VWD)** - MODERATE\n\n‚Ä¢ **Defect:** **Qualitative** (abnormal function) ‚≠ê\n‚Ä¢ **VWF Level:** Normal or mildly ‚Üì\n‚Ä¢ **VWF Function:** ABNORMAL/DYSFUNCTIONAL\n‚Ä¢ **Key point:** **\"Activity > Levels\"** issue ‚úì (Option C is TRUE!)\n‚Ä¢ **Inheritance:** AD (most subtypes)\n‚Ä¢ **4 Subtypes:**\n  **2A** - ‚Üì high molecular weight multimers\n  **2B** - ‚Üë affinity for GPIb (gain of function)\n  **2M** - ‚Üì platelet binding\n  **2N** - ‚Üì Factor VIII binding (\"Normandy\")\n\n**‚Ä¢ TYPE 3 (1-5% of VWD)** - SEVERE ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è\n\n‚Ä¢ **Defect:** **Complete absence** of VWF\n‚Ä¢ **VWF Level:** **<5%** (virtually absent) ‚úì (Option D is TRUE!)\n‚Ä¢ **Severity:** **SEVERE** in children ‚úì (Option B is TRUE!)\n‚Ä¢ **Inheritance:** **Autosomal Recessive** (AR)\n‚Ä¢ **Factor VIII:** Very LOW (<10%)\n‚Ä¢ **Clinical:** \n  ‚Üí Severe mucocutaneous bleeding\n  ‚Üí **Hemarthrosis** (joint bleeding like hemophilia!)\n  ‚Üí Muscle hematomas\n  ‚Üí Life-threatening bleeding\n‚Ä¢ **Treatment:** VWF/Factor VIII concentrates (DDAVP doesn't work!)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ ANALYSIS OF ALL OPTIONS:\n\n‚ùå **Option A: \"VWD type 1 is mostly severe in children\"**\n\n**INCORRECT! Type 1 is MILD to MODERATE, NOT severe!**\n\n‚Ä¢ Type 1 has **30-50% VWF** (not absent)\n‚Ä¢ Causes **mild mucocutaneous bleeding**\n‚Ä¢ Many patients have **minimal symptoms**\n‚Ä¢ Can go **undiagnosed** for years\n‚Ä¢ **NOT life-threatening** in children\n\n‚úÖ **Option B: \"VWD type 3 is mostly severe in children\"**\n\n**CORRECT!** Type 3 is indeed **SEVERE** in children!\n\n‚Ä¢ **<5% VWF** (virtually absent)\n‚Ä¢ **Early onset** severe bleeding in infancy/childhood\n‚Ä¢ **Life-threatening bleeding** episodes\n‚Ä¢ Requires **prophylactic treatment**\n\n‚úÖ **Option C: \"VWD type 2 is more related to activity rather than levels\"**\n\n**CORRECT!** Type 2 is a **QUALITATIVE defect**!\n\n‚Ä¢ VWF **levels** may be **normal**\n‚Ä¢ VWF **activity** is **decreased** (dysfunctional)\n‚Ä¢ **VWF:RCo/VWF:Ag ratio <0.6** (key diagnostic finding)\n‚Ä¢ The protein is there, but it **doesn't work properly**\n\n‚úÖ **Option D: \"VWD type 3 has severely low VWD\"**\n\n**CORRECT!** Type 3 has **severely low (<5%) or absent VWF**!\n\n‚Ä¢ **Complete or near-complete deficiency**\n‚Ä¢ Both VWF antigen and activity virtually absent\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ VON WILLEBRAND FACTOR (VWF) - FUNCTIONS:\n\n**VWF has 2 CRITICAL roles:**\n\n**1. PRIMARY HEMOSTASIS** ‚≠ê\n\n‚Ä¢ **Platelet ADHESION** to injured endothelium\n‚Ä¢ VWF binds:\n  ‚Üí **Collagen** (exposed on damaged vessel)\n  ‚Üí **GPIb** (glycoprotein Ib on platelets)\n‚Ä¢ Creates **bridge** for platelet plug formation\n\n**2. SECONDARY HEMOSTASIS** ‚≠ê\n\n‚Ä¢ **Carrier protein** for **Factor VIII**\n‚Ä¢ **Protects Factor VIII** from rapid degradation\n‚Ä¢ Increases Factor VIII **half-life** from minutes ‚Üí hours\n‚Ä¢ Without VWF ‚Üí Factor VIII ‚Üì‚Üì‚Üì\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíâ LABORATORY FINDINGS:\n\n**TYPE 1:**\n‚Ä¢ **VWF:Ag:** ‚Üì (30-50%)\n‚Ä¢ **VWF:RCo:** ‚Üì (parallel to antigen)\n‚Ä¢ **Factor VIII:** Mildly ‚Üì\n‚Ä¢ **aPTT:** Normal or mildly ‚Üë\n‚Ä¢ **Bleeding time:** Prolonged\n‚Ä¢ **Platelet count:** Normal\n\n**TYPE 2:**\n‚Ä¢ VWF:Ag: Normal or mildly ‚Üì\n‚Ä¢ **VWF:RCo: ‚Üì‚Üì** (disproportionately low)\n‚Ä¢ **VWF:RCo/VWF:Ag <0.6** ‚≠ê (key finding!)\n‚Ä¢ Multimer analysis: Abnormal pattern\n\n**TYPE 3:**\n‚Ä¢ VWF:Ag: **<5%** (absent)\n‚Ä¢ VWF:RCo: Absent\n‚Ä¢ **Factor VIII: <10%** (very low)\n‚Ä¢ **aPTT:** Markedly prolonged\n‚Ä¢ Bleeding time: Very prolonged\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES BY TYPE:\n\n**TYPE 1 (MILD):**\n‚Ä¢ **Epistaxis** (nosebleeds)\n‚Ä¢ **Easy bruising**\n‚Ä¢ **Menorrhagia** (heavy periods)\n‚Ä¢ Bleeding after dental procedures\n‚Ä¢ **NO hemarthrosis** (joint bleeding)\n‚Ä¢ **PTT:** Normal or slightly ‚Üë\n\n**TYPE 2 (MODERATE):**\n‚Ä¢ **Moderate mucocutaneous bleeding**\n‚Ä¢ **Epistaxis** (++)\n‚Ä¢ **GI bleeding** (can occur)\n‚Ä¢ **Rarely hemarthrosis**\n‚Ä¢ **PTT:** Mildly ‚Üë\n\n**TYPE 3 (SEVERE):**\n‚Ä¢ **Severe mucocutaneous bleeding** (+++)\n‚Ä¢ **Hemarthrosis** ‚≠ê (like hemophilia A/B!)\n‚Ä¢ **Muscle hematomas**\n‚Ä¢ **ICH risk** (intracranial hemorrhage)\n‚Ä¢ **Life-threatening bleeding**\n‚Ä¢ **PTT:** Markedly ‚Üë (Factor VIII ‚Üì‚Üì‚Üì)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**TYPE 1:**\n‚Ä¢ **DDAVP (Desmopressin)** ‚≠ê‚≠ê‚≠ê (1st line)\n  ‚Üí Releases VWF from endothelial stores\n  ‚Üí ‚Üë VWF & Factor VIII by 2-5x\n‚Ä¢ **Tranexamic acid** (antifibrinolytic)\n\n**TYPE 2:**\n‚Ä¢ **DDAVP** (for 2A, 2M, 2N)\n‚Ä¢ **AVOID DDAVP in Type 2B** ‚ö†Ô∏è (causes thrombocytopenia!)\n‚Ä¢ VWF/Factor VIII concentrates\n\n**TYPE 3:**\n‚Ä¢ **VWF/Factor VIII concentrate** (DDAVP doesn't work)\n‚Ä¢ **Prophylaxis** may be needed\n‚Ä¢ Manage like severe hemophilia\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**TYPE 1 = MILD, NOT SEVERE!** ‚≠ê‚≠ê‚≠ê (This is the answer!)\n\n**Remember: \"Type 1 = 1 problem (‚Üì quantity), Type 2 = 2nd problem (‚Üì quality), Type 3 = 3x SEVERE!\"**\n\n‚Ä¢ **Type 1:** 70-80%, **MILD**, Quantitative, AD\n‚Ä¢ **Type 2:** 15-20%, Moderate, **Qualitative (activity issue)**, AD\n‚Ä¢ **Type 3:** 1-5%, **SEVERE**, Absent VWF, AR\n‚Ä¢ **VWF:** Platelet adhesion + Factor VIII carrier",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-12",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Child presents with sunlight causing eruptions, diagnosed with a DNA repair\ndefect. Which defect could it be?",
    options: [
      "Nucleotide excision",
      "Base excision repair",
      "Mismatch repair defect",
      "Recombination defect"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Nucleotide Excision Repair (NER) defect (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Xeroderma Pigmentosum (XP)** is a **rare autosomal recessive** disorder caused by defective **Nucleotide Excision Repair (NER)**. Patients cannot repair **UV-induced DNA damage**, leading to **extreme photosensitivity** and **1000x increased risk** of skin cancers. They are called **\"Children of the Night\"** because they must avoid sunlight.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå DNA REPAIR MECHANISMS:\n\n**‚òÖ NUCLEOTIDE EXCISION REPAIR (NER)** ‚≠ê‚≠ê‚≠ê **(ANSWER!)**\n\n‚Ä¢ **Repairs:** **UV-induced damage** (pyrimidine dimers), bulky DNA lesions\n‚Ä¢ **Defect causes:** **Xeroderma Pigmentosum (XP)** ‚≠ê\n‚Ä¢ **Mechanism:**\n  ‚Üí Recognizes **bulky DNA adducts** (thymine dimers from UV)\n  ‚Üí Excises **20-30 nucleotides** around damage\n  ‚Üí DNA polymerase fills the gap\n  ‚Üí Ligase seals the nick\n‚Ä¢ **Genes involved:** XPA-XPG (7 complementation groups)\n‚Ä¢ **Key feature:** Repairs **UV damage specifically**\n\n**‚Ä¢ BASE EXCISION REPAIR (BER)** ‚ùå\n\n‚Ä¢ **Repairs:** **Oxidative damage**, deamination, alkylation\n‚Ä¢ **Removes:** **Single damaged base** (not bulky lesions)\n‚Ä¢ **Enzyme:** DNA glycosylase\n‚Ä¢ **Defect causes:** MYH-associated polyposis (MAP)\n‚Ä¢ **Does NOT repair UV damage**\n\n**‚Ä¢ MISMATCH REPAIR (MMR)** ‚ùå\n\n‚Ä¢ **Repairs:** **Replication errors** (base-base mismatches)\n‚Ä¢ **Corrects:** Wrong nucleotide insertion during DNA replication\n‚Ä¢ **Genes:** MLH1, MSH2, MSH6, PMS2\n‚Ä¢ **Defect causes:** **Lynch syndrome (HNPCC)** - hereditary colorectal cancer\n‚Ä¢ **Clinical:** Colorectal, endometrial cancers (NOT photosensitivity)\n‚Ä¢ **Does NOT repair UV damage**\n\n**‚Ä¢ RECOMBINATION REPAIR (Homologous Recombination/NHEJ)** ‚ùå\n\n‚Ä¢ **Repairs:** **Double-strand breaks (DSBs)**\n‚Ä¢ **Genes:** BRCA1, BRCA2, ATM, RAD51\n‚Ä¢ **Defect causes:**\n  ‚Üí **Ataxia-telangiectasia** (ATM defect)\n  ‚Üí **Bloom syndrome** (BLM helicase defect)\n  ‚Üí **BRCA mutations** (breast/ovarian cancer)\n‚Ä¢ **Does NOT repair UV damage**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚òÄÔ∏è PATHOPHYSIOLOGY:\n\n**NORMAL SKIN:**\n\n‚òÄÔ∏è **UV exposure** (UVB especially)\n  ‚Üì\n**Pyrimidine dimers** form (thymine-thymine bonds)\n  ‚Üì\n**NER system** recognizes damage ‚úì\n  ‚Üì\n**Excises 20-30 nucleotides** around dimer\n  ‚Üì\n**DNA polymerase fills gap**\n  ‚Üì\n**DNA REPAIRED!** ‚úì ‚Üí Normal skin\n\n**XERODERMA PIGMENTOSUM (NER DEFECT):**\n\n‚òÄÔ∏è **UV exposure**\n  ‚Üì\n**Pyrimidine dimers** form\n  ‚Üì\n**NER system DEFECTIVE** ‚úó (XP genes mutated)\n  ‚Üì\n**Cannot remove dimers!**\n  ‚Üì\n**DNA damage accumulates** with each sun exposure ‚ö†Ô∏è\n  ‚Üì\n‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê\n‚Üì                           ‚Üì\n**MUTATIONS**          **CELL APOPTOSIS**\n‚Üì                           ‚Üì\n**p53, oncogenes**    **Photosensitivity**\n‚Üì                     **Skin atrophy**\n**SKIN CANCERS!** ‚ö°‚ö°‚ö°\n‚Ä¢ BCC, SCC, Melanoma\n‚Ä¢ **1000x ‚Üë risk!**\n‚Ä¢ **Median age: 8-10 years** (vs 60+ normally)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**\"CHILDREN OF THE NIGHT\"** ‚≠ê‚≠ê‚≠ê\n\n**CUTANEOUS (Skin):**\n\n‚Ä¢ **Extreme photosensitivity** ‚≠ê (exaggerated sunburn with minimal UV)\n‚Ä¢ **Freckling** on sun-exposed areas (by age 1-2)\n‚Ä¢ **Dry, parchment-like skin** (\"xeroderma\" = dry skin)\n‚Ä¢ **Hyperpigmentation & hypopigmentation** (poikiloderma)\n‚Ä¢ **Actinic keratoses** (pre-malignant)\n‚Ä¢ **Skin atrophy**\n\n**MALIGNANCIES:** ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è\n\n‚Ä¢ **Basal Cell Carcinoma (BCC)** - Most common\n‚Ä¢ **Squamous Cell Carcinoma (SCC)**\n‚Ä¢ **Melanoma** - 2000x ‚Üë risk!\n‚Ä¢ **Median age of 1st skin cancer: 8-10 years** (vs 60+ in general population)\n‚Ä¢ **1000x overall ‚Üë cancer risk**\n\n**OCULAR (Eye):**\n\n‚Ä¢ **Photophobia** (painful light sensitivity)\n‚Ä¢ **Conjunctivitis, keratitis**\n‚Ä¢ **Corneal opacification**\n‚Ä¢ **Eyelid tumors** (BCC, SCC)\n‚Ä¢ **Progressive vision loss**\n\n**NEUROLOGICAL (20-30% of cases):**\n\n‚Ä¢ **De Sanctis-Cacchione syndrome** (XP + neurodegeneration)\n‚Ä¢ **Progressive neurodegeneration**\n‚Ä¢ **Intellectual disability**\n‚Ä¢ **Sensorineural hearing loss**\n‚Ä¢ **Ataxia, spasticity**\n‚Ä¢ **Peripheral neuropathy**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIAGNOSIS:\n\n**CLINICAL:**\n‚Ä¢ History of **severe sunburn** with minimal UV exposure\n‚Ä¢ **Freckling <2 years** of age on face\n‚Ä¢ **Multiple skin cancers** in childhood\n\n**LABORATORY:**\n‚Ä¢ **UV sensitivity test** on fibroblasts\n‚Ä¢ **Reduced unscheduled DNA synthesis (UDS)** after UV exposure\n‚Ä¢ **Complementation analysis** (identify which XP gene)\n‚Ä¢ **Genetic testing** (XPA-XPG genes)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**PRIMARY PREVENTION (MOST IMPORTANT!):**\n\n‚Ä¢ **STRICT sun avoidance** ‚≠ê‚≠ê‚≠ê\n  ‚Üí Stay indoors during daylight\n  ‚Üí **\"Children of the Night\"** - active only after sunset\n\n‚Ä¢ **UV-protective measures:**\n  ‚Üí **Broad-spectrum sunscreen SPF 50+** (reapply q2h)\n  ‚Üí **UV-blocking clothing** (long sleeves, pants, hats)\n  ‚Üí **UV-filtering windows** at home/school/car\n  ‚Üí **UV-blocking goggles**\n\n**SURVEILLANCE:**\n\n‚Ä¢ **Monthly full-body skin exams**\n‚Ä¢ **Early detection** of skin cancers\n‚Ä¢ **Ophthalmology exams** every 3-6 months\n‚Ä¢ **Neurological assessment** if indicated\n\n**TREATMENT:**\n\n‚Ä¢ **Early excision** of all suspicious lesions\n‚Ä¢ **High-dose oral retinoids** (isotretinoin) - may reduce new cancers\n‚Ä¢ **5-FU, imiquimod** (topical for actinic keratoses)\n‚Ä¢ **Dermabrasion** for severe actinic damage\n‚Ä¢ **Gene therapy** (experimental)\n\n**PROGNOSIS:**\n\n‚Ä¢ **Without sun protection:** Life expectancy ~30 years\n‚Ä¢ **With strict protection:** Near-normal lifespan possible\n‚Ä¢ Death usually from **metastatic melanoma or SCC**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**XERODERMA PIGMENTOSUM = NER DEFECT** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"NER fixes UV ‚Üí XP can't fix UV ‚Üí Sunlight = Cancer!\"**\n\n**\"Children of the Night\"** - must avoid ALL sunlight!\n\n‚Ä¢ **NER defect** (XPA-XPG genes)\n‚Ä¢ **Cannot repair UV damage** (pyrimidine dimers)\n‚Ä¢ **Extreme photosensitivity** + freckling\n‚Ä¢ **1000x ‚Üë skin cancer risk**\n‚Ä¢ **Median age 1st cancer: 8-10 years**\n‚Ä¢ **Autosomal recessive**\n‚Ä¢ **Treatment:** STRICT sun avoidance",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-13",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "18-year-old male with hepatosplenomegaly, Hb 7 gm percent, LN+, WBC 50K,\nplatelets 30, petechiae, purpura, and fatigue: what is the most appropriate\nmanagement?\n7",
    options: [
      "Cytarabine + Iso?",
      "IVIG x 2 days",
      "Prednisolone + Vinblastine",
      "Radiotherapy to LN"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Prednisolone + Vinblastine (Option C)**\n\nüî¨ DETAILED EXPLANATION:\n\nThis **18-year-old male** presents with classic features of **Acute Lymphoblastic Leukemia (ALL)** or **Lymphoblastic Lymphoma**:\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå CLINICAL PRESENTATION ANALYSIS:\n\n**SYSTEMIC FEATURES:**\n\n‚Ä¢ **Hepatosplenomegaly** ‚≠ê ‚Üí Leukemic infiltration\n‚Ä¢ **Lymphadenopathy (LN+)** ‚≠ê ‚Üí Lymphoid organ involvement\n‚Ä¢ **Fatigue** ‚Üí Anemia, systemic disease\n\n**HEMATOLOGICAL FEATURES:**\n\n‚Ä¢ **Hemoglobin: 7 g/dL** ‚Üí Severe **anemia** (marrow infiltration)\n‚Ä¢ **WBC: 50,000/ŒºL** ‚Üí **Leukocytosis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Platelets: 30,000/ŒºL** ‚Üí **Thrombocytopenia** ‚≠ê\n‚Ä¢ **Petechiae & purpura** ‚Üí Bleeding due to low platelets\n\n**This triad = PANCYTOPENIA + LEUKOCYTOSIS = LEUKEMIA** üéØ\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ DIAGNOSIS: **ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)**\n\n**Why ALL (not CML/CLL)?**\n\n‚Ä¢ **Young age (18 years)** ‚Üí ALL peak: 2-5 years, 2nd peak: adolescence ‚≠ê\n‚Ä¢ **Acute presentation** ‚Üí Fatigue, bleeding, organomegaly\n‚Ä¢ **Lymphadenopathy + organomegaly** ‚Üí Lymphoblastic origin\n‚Ä¢ **High WBC with pancytopenia** ‚Üí Marrow replacement\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT: **Prednisolone + Vinblastine**\n\n**HODGKIN LYMPHOMA Treatment Protocol** (this presentation fits):\n\n**ABVD Regimen** ‚≠ê‚≠ê‚≠ê (First-line for Hodgkin)\n\n‚Ä¢ **A** - **Adriamycin** (Doxorubicin)\n‚Ä¢ **B** - **Bleomycin**\n‚Ä¢ **V** - **Vinblastine** ‚≠ê (in this question)\n‚Ä¢ **D** - **Dacarbazine**\n\n**+ Prednisolone** (Steroid) ‚≠ê\n\n‚Ä¢ Reduces tumor bulk\n‚Ä¢ Decreases inflammation\n‚Ä¢ Improves symptoms rapidly\n‚Ä¢ Used in both ALL and lymphoma protocols\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Cytarabine + Iso? (Isoretinoin?)** ‚ùå\n\n‚Ä¢ **Cytarabine** used in **AML** (not ALL/Lymphoma)\n‚Ä¢ AML typically affects **older adults (>60 years)**\n‚Ä¢ Presentation doesn't fit AML (no Auer rods mentioned)\n\n**B. IVIG √ó 2 days** ‚ùå\n\n‚Ä¢ Used for **Immune Thrombocytopenic Purpura (ITP)**\n‚Ä¢ ITP: isolated thrombocytopenia, **normal WBC/Hb**\n‚Ä¢ This patient has **pancytopenia + high WBC** ‚Üí Not ITP\n\n**D. Radiotherapy to LN** ‚ùå\n\n‚Ä¢ **NOT first-line** for systemic disease\n‚Ä¢ Radiotherapy: **localized disease** or **consolidation**\n‚Ä¢ This is **systemic disease** ‚Üí needs systemic chemotherapy\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã ALL vs HODGKIN LYMPHOMA:\n\n**ACUTE LYMPHOBLASTIC LEUKEMIA (ALL):**\n\n‚Ä¢ **Bone marrow:** >20% lymphoblasts ‚≠ê\n‚Ä¢ **Blood:** Circulating blasts\n‚Ä¢ **Treatment:** **Induction** (Vincristine, Prednisone, Asparaginase, Daunorubicin)\n\n**HODGKIN LYMPHOMA:**\n\n‚Ä¢ **Lymph nodes:** Reed-Sternberg cells ‚≠ê\n‚Ä¢ **Treatment:** **ABVD** (Adriamycin, Bleomycin, **Vinblastine**, Dacarbazine) + Steroids\n\n**Both use Steroids + Vinca alkaloids** (Vinblastine/Vincristine)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Young patient + Lymphadenopathy + Hepatosplenomegaly + Pancytopenia = Lymphoproliferative disorder**\n\n**Treatment = Steroid (Prednisolone) + Chemotherapy (Vinblastine)** ‚≠ê‚≠ê‚≠ê\n\n‚Ä¢ **Prednisolone:** Reduces tumor burden, anti-inflammatory\n‚Ä¢ **Vinblastine:** Vinca alkaloid, disrupts microtubules, stops cell division\n‚Ä¢ Used in **ABVD** regimen for Hodgkin and some ALL protocols",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-14",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A baby failed to pass meconium. The structures absent in the disease are absent in\nwhich layer?",
    options: [
      "Epithelial",
      "Submucosa",
      "Muscular",
      "Serosa"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Submucosa (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Hirschsprung Disease (Congenital Aganglionic Megacolon)** is caused by **absence of ganglion cells** in **BOTH** the **submucosal (Meissner's) plexus** and **myenteric (Auerbach's) plexus**. However, since the question asks which **layer** contains the absent structures, the **submucosa** is the best answer as it's a distinct layer, while the myenteric plexus is located between muscle layers.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå INTESTINAL WALL LAYERS (Inside ‚Üí Outside):\n\n**1. MUCOSA** ‚ùå\n\n‚Ä¢ **Epithelium** (absorptive cells)\n‚Ä¢ **Lamina propria** (connective tissue)\n‚Ä¢ **Muscularis mucosae** (thin smooth muscle)\n‚Ä¢ **In Hirschsprung:** Normal epithelium, NO ganglion cells here\n\n**2. SUBMUCOSA** ‚≠ê‚≠ê‚≠ê **(ANSWER!)**\n\n‚Ä¢ **Connective tissue**\n‚Ä¢ **Blood vessels, lymphatics**\n‚Ä¢ **Meissner's plexus (submucosal plexus)** ‚≠ê‚≠ê‚≠ê\n  ‚Üí **Controls secretion, blood flow**\n  ‚Üí **ABSENT in Hirschsprung!** ‚úó\n  ‚Üí Contains **ganglion cells** normally\n\n**3. MUSCULARIS PROPRIA** ‚ùå\n\n‚Ä¢ **Inner circular muscle layer**\n‚Ä¢ **Auerbach's plexus (myenteric plexus)** ‚≠ê‚≠ê‚≠ê\n  ‚Üí Located **BETWEEN** the muscle layers (not within submucosa)\n  ‚Üí **Controls motility, peristalsis**\n  ‚Üí **ABSENT in Hirschsprung!** ‚úó\n‚Ä¢ **Outer longitudinal muscle layer**\n‚Ä¢ Note: Plexus is between layers, not in \"muscular\" layer itself\n\n**4. SUBSEROSA/SEROSA** ‚ùå\n\n‚Ä¢ **Connective tissue** (subserosa)\n‚Ä¢ **Mesothelium** (serosa)\n‚Ä¢ **In Hirschsprung:** Normal, no ganglion cells here\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ PATHOPHYSIOLOGY:\n\n**EMBRYOLOGY:**\n\n‚Ä¢ **Neural crest cells** migrate from esophagus ‚Üí rectum (5-12 weeks)\n‚Ä¢ Migration is **craniocaudal** (head ‚Üí tail direction)\n‚Ä¢ **Failure of migration** ‚Üí No ganglion cells in distal bowel\n‚Ä¢ **RET proto-oncogene mutation** (most common) ‚≠ê\n\n**NORMAL COLON:**\n\n**Ganglion cells present** ‚úì\n  ‚Üì\n**Coordinated peristalsis**\n  ‚Üì\n**Proximal segment contracts**\n  ‚Üì\n**Distal segment RELAXES** ‚úì\n  ‚Üì\n**Stool passes normally**\n\n**HIRSCHSPRUNG SEGMENT:**\n\n**NO ganglion cells** ‚úó (**Aganglionosis**)\n  ‚Üì\n**Loss of inhibitory innervation**\n  ‚Üì\n**Unopposed sympathetic tone**\n  ‚Üì\n**Distal segment SPASTIC** (always contracted) ‚ö†Ô∏è\n  ‚Üì\n**NO relaxation!** ‚úó\n  ‚Üì\n**Functional obstruction**\n  ‚Üì\n**Proximal colon dilates** (Megacolon)\n  ‚Üì\n**Cannot pass stool!**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**NEONATAL PRESENTATION (Most common):**\n\n‚Ä¢ **Delayed meconium passage >48 hours** ‚≠ê‚≠ê‚≠ê (RED FLAG!)\n  ‚Üí 95% of normal babies pass meconium <48 hrs\n  ‚Üí **90% of Hirschsprung: delayed >48 hrs**\n\n‚Ä¢ **Bilious vomiting**\n‚Ä¢ **Abdominal distension**\n‚Ä¢ **Explosive stool** after rectal exam (relief of obstruction)\n‚Ä¢ **Failure to thrive**\n\n**HIRSCHSPRUNG-ASSOCIATED ENTEROCOLITIS (HAEC):** ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è\n\n‚Ä¢ **Life-threatening complication** (30% of cases)\n‚Ä¢ **Bacterial overgrowth** + ischemia\n‚Ä¢ Presents with:\n  ‚Üí **Explosive, foul-smelling diarrhea**\n  ‚Üí **Fever, toxic appearance**\n  ‚Üí **Abdominal distension, pain**\n  ‚Üí **Sepsis, shock**\n‚Ä¢ **Leading cause of death** in Hirschsprung\n‚Ä¢ **Emergency:** Requires immediate decompression + antibiotics\n\n**OLDER CHILDREN:**\n\n‚Ä¢ **Chronic severe constipation** (from birth)\n‚Ä¢ **Abdominal distension**\n‚Ä¢ **Ribbon-like stools**\n‚Ä¢ **Failure to thrive**\n‚Ä¢ **NO fecal soiling** (vs functional constipation)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìç EXTENT OF INVOLVEMENT:\n\n**SHORT SEGMENT (80%):**\n‚Ä¢ **Rectosigmoid only** (most common) ‚≠ê\n‚Ä¢ Better prognosis\n\n**LONG SEGMENT (15-20%):**\n‚Ä¢ **Beyond sigmoid colon**\n‚Ä¢ More complex surgery\n\n**TOTAL COLONIC (5%):**\n‚Ä¢ **Entire colon** affected\n‚Ä¢ May involve terminal ileum\n‚Ä¢ Worst prognosis\n\n**KEY POINT:** \n‚Ä¢ **ALWAYS involves rectum** (starts distally) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Never \"skips\" rectum (unlike Crohn's)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç DIAGNOSIS:\n\n**1. RECTAL BIOPSY** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD)**\n\n‚Ä¢ **Suction rectal biopsy** (2-3 cm above dentate line)\n\n**Findings:**\n‚Ä¢ **Absence of ganglion cells** in submucosa & myenteric plexus ‚úì\n‚Ä¢ **Hypertrophic nerve fibers**\n‚Ä¢ **‚Üë Acetylcholinesterase (AChE) staining** ‚≠ê (diagnostic!)\n  ‚Üí Positive AChE stain = Hirschsprung confirmed\n\n**2. CONTRAST ENEMA** (Barium enema)\n\n‚Ä¢ **Transition zone** visible ‚≠ê\n  ‚Üí **Narrow distal segment** (aganglionic)\n  ‚Üí **Dilated proximal segment** (normal ganglion cells)\n‚Ä¢ May see **saw-tooth\" irregular mucosa**\n‚Ä¢ **Late films (24h):** Retained contrast in colon\n\n**3. ANORECTAL MANOMETRY**\n\n‚Ä¢ **Absence of rectoanal inhibitory reflex (RAIR)** ‚≠ê\n‚Ä¢ Normal: Rectal distension ‚Üí internal sphincter relaxes\n‚Ä¢ Hirschsprung: **NO relaxation!** (no ganglion cells)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ GENETICS & ASSOCIATIONS:\n\n**GENETICS:**\n‚Ä¢ **RET proto-oncogene** (chromosome 10) - Most common mutation ‚≠ê\n‚Ä¢ **EDNRB** (endothelin receptor B)\n‚Ä¢ **Male:Female = 4:1**\n‚Ä¢ **Familial risk:** ~4% sibling recurrence\n\n**ASSOCIATED CONDITIONS:**\n‚Ä¢ **Down syndrome (Trisomy 21)** ‚≠ê (10-15% of HD patients)\n‚Ä¢ **MEN 2A, MEN 2B** (RET mutations)\n‚Ä¢ **Waardenburg syndrome** (hearing loss, heterochromia)\n‚Ä¢ **Congenital central hypoventilation (Ondine's curse)**\n‚Ä¢ **Cardiac defects** (VSD, ASD)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**INITIAL MANAGEMENT:**\n\n‚Ä¢ **NPO** (nothing by mouth)\n‚Ä¢ **NG tube decompression**\n‚Ä¢ **IV fluids**\n‚Ä¢ **Rectal irrigations** (decompress bowel)\n‚Ä¢ **Antibiotics** (if enterocolitis suspected)\n\n**DEFINITIVE TREATMENT:** **SURGERY** ‚≠ê\n\n‚Ä¢ **Pull-through procedures:**\n  ‚Üí **Swenson** (original)\n  ‚Üí **Duhamel** (most common)\n  ‚Üí **Soave** (endorectal)\n\n‚Ä¢ **Principle:** Resect aganglionic segment + anastomose normal bowel to anus\n\n‚Ä¢ **Timing:** \n  ‚Üí Can be done in **infancy** (single-stage)\n  ‚Üí Or **delayed** with temporary colostomy\n\n**PROGNOSIS:**\n‚Ä¢ **85-90%** have good bowel function\n‚Ä¢ **Persistent constipation** (25%)\n‚Ä¢ **Fecal incontinence** (10-15%)\n‚Ä¢ **Recurrent enterocolitis** (5-10%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**HIRSCHSPRUNG = NO GANGLION IN SUBMUCOSA** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"HD = Hasn't Defecated (>48hrs)\"**\n\n‚Ä¢ **Delayed meconium >48 hrs** = RED FLAG!\n‚Ä¢ **Absence of ganglion cells** in **Meissner's (submucosa)** + **Auerbach's (myenteric) plexus**\n‚Ä¢ **ALWAYS involves rectum** (starts distally)\n‚Ä¢ **Diagnosis:** Rectal biopsy (‚Üë AChE stain, no ganglion cells)\n‚Ä¢ **Contrast enema:** Transition zone\n‚Ä¢ **Anorectal manometry:** No RAIR\n‚Ä¢ **RET gene mutation** (most common)\n‚Ä¢ **Association:** Down syndrome (10-15%)\n‚Ä¢ **Complication:** HAEC (enterocolitis) - life-threatening!\n‚Ä¢ **Treatment:** Surgical pull-through",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-15",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "Muscle responsible for ptosis in Horner syndrome:",
    options: [
      "Orbicularis oculi",
      "Levator palpebrae",
      "Horner muscle",
      "Muller‚Äôs muscle"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **M√ºller's muscle (Option D)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Horner's syndrome** results from **disruption of the sympathetic pathway** to the eye. The **mild ptosis (2-3mm)** seen in Horner's is caused by paralysis of **M√ºller's muscle** (superior tarsal muscle), NOT levator palpebrae superioris.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå EYELID ELEVATION MUSCLES:\n\n**LEVATOR PALPEBRAE SUPERIORIS:** ‚ùå\n\n‚Ä¢ **Innervation:** **CN III (Oculomotor nerve)** ‚≠ê\n‚Ä¢ **Type:** MAJOR eyelid elevator\n‚Ä¢ **Elevation:** **10-12mm** (most of eyelid opening)\n‚Ä¢ **Control:** Voluntary (somatic)\n‚Ä¢ **Origin:** Lesser wing of sphenoid\n‚Ä¢ **Insertion:** Tarsal plate, skin of upper lid\n‚Ä¢ **If paralyzed:** **SEVERE ptosis** (complete lid droop) - **CN III palsy**\n\n**‚òÖ M√úLLER'S MUSCLE (Superior Tarsal Muscle)** ‚≠ê‚≠ê‚≠ê **(ANSWER!)**\n\n‚Ä¢ **Innervation:** **SYMPATHETIC** nerves ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Type:** MINOR eyelid elevator (smooth muscle)\n‚Ä¢ **Elevation:** **2-3mm only** (subtle lift)\n‚Ä¢ **Control:** **Involuntary** (autonomic)\n‚Ä¢ **Origin:** Undersurface of levator palpebrae\n‚Ä¢ **Insertion:** Superior tarsal border\n‚Ä¢ **If paralyzed:** **MILD ptosis (2-3mm)** - **Horner's syndrome** ‚≠ê\n\n**ORBICULARIS OCULI:** ‚ùå\n\n‚Ä¢ **Function:** **CLOSES** eyelid (NOT opens!)\n‚Ä¢ **Innervation:** CN VII (Facial nerve)\n‚Ä¢ **If paralyzed:** Cannot close eye (Bell's palsy)\n\n**\"HORNER MUSCLE\":** ‚ùå\n\n‚Ä¢ **Does NOT exist!** (Trick option)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ HORNER'S SYNDROME - CLASSIC TRIAD:\n\n**Disruption of Sympathetic Pathway to Eye**\n\n**1. PTOSIS** ‚≠ê (Mild - **2-3mm drop**)\n‚Ä¢ **M√ºller's muscle** paralyzed\n‚Ä¢ Upper lid droops slightly\n‚Ä¢ **MILD** ptosis (vs CN III = severe)\n\n**2. MIOSIS** ‚≠ê (Small pupil)\n‚Ä¢ **Dilator pupillae** muscle paralyzed\n‚Ä¢ Unopposed **constriction** by parasympathetics\n‚Ä¢ Pupil appears **smaller** on affected side\n‚Ä¢ **Still reactive to light!** (CN III intact)\n\n**3. ANHIDROSIS** ‚≠ê (Decreased sweating)\n‚Ä¢ **Facial sweat glands** affected\n‚Ä¢ **Distribution depends on lesion location:**\n  ‚Üí Central/Preganglionic: **Entire face** anhidrosis\n  ‚Üí Postganglionic: **NO anhidrosis** (fibers separate)\n\n**ADDITIONAL SIGNS:**\n\n‚Ä¢ **Enophthalmos** (sunken eye - apparent, not true)\n‚Ä¢ **Loss of ciliospinal reflex**\n‚Ä¢ **Facial flushing** (vasodilation)\n‚Ä¢ **Conjunctival injection**\n‚Ä¢ **Heterochromia** (if congenital - lighter iris)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìç SYMPATHETIC PATHWAY (3-Neuron Chain):\n\n**1ST ORDER NEURON (Central):**\n\n‚Ä¢ **Origin:** **Hypothalamus** (posterolateral)\n‚Ä¢ **Course:** Brainstem ‚Üí Cervical spinal cord\n‚Ä¢ **Ends:** **C8-T2** (ciliospinal center of Budge)\n\n**Lesion causes:**\n‚Ä¢ **Stroke** (lateral medullary - Wallenberg)\n‚Ä¢ **MS** (multiple sclerosis)\n‚Ä¢ **Brainstem tumor**\n‚Ä¢ **Syringomyelia**\n\n**2ND ORDER NEURON (Preganglionic):**\n\n‚Ä¢ **Origin:** C8-T2 spinal cord\n‚Ä¢ **Course:** \n  ‚Üí Exits spinal cord\n  ‚Üí Over **lung apex** ‚ö†Ô∏è (vulnerable!)\n  ‚Üí Passes **stellate ganglion** (sympathetic chain)\n‚Ä¢ **Ends:** **Superior cervical ganglion** (neck)\n\n**Lesion causes:**\n‚Ä¢ **Pancoast tumor** ‚≠ê‚≠ê‚≠ê (lung apex tumor) - Most common!\n‚Ä¢ **Thyroid surgery**\n‚Ä¢ **Neck trauma/surgery**\n‚Ä¢ **Cervical rib**\n‚Ä¢ **Thoracic outlet syndrome**\n\n**3RD ORDER NEURON (Postganglionic):**\n\n‚Ä¢ **Origin:** Superior cervical ganglion\n‚Ä¢ **Course:**\n  ‚Üí Along **internal carotid artery** ‚ö†Ô∏è\n  ‚Üí Forms **carotid plexus**\n  ‚Üí Through **cavernous sinus**\n  ‚Üí To eye via **CN V1** (ophthalmic)\n‚Ä¢ **Ends:** Eye structures\n\n**Lesion causes:**\n‚Ä¢ **Carotid artery dissection** ‚≠ê‚≠ê‚≠ê (Most common 3rd order!)\n‚Ä¢ **Cavernous sinus thrombosis**\n‚Ä¢ **Cluster headache** (transient)\n‚Ä¢ **Internal carotid aneurysm**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç CLINICAL LOCALIZATION:\n\n**ANHIDROSIS PATTERN helps localize!**\n\n‚Ä¢ **1st or 2nd order lesion:** Anhidrosis of **ENTIRE FACE** ‚úì\n‚Ä¢ **3rd order lesion:** **NO anhidrosis** (sudomotor fibers separate early)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ COMMON CAUSES BY AGE:\n\n**ADULTS:**\n‚Ä¢ **Carotid artery dissection** ‚≠ê (3rd order) - sudden onset with neck/head pain\n‚Ä¢ **Pancoast tumor** ‚≠ê (2nd order) - lung apex, shoulder pain\n‚Ä¢ **Iatrogenic** (thyroid/neck surgery)\n‚Ä¢ **Cluster headache** (transient)\n\n**CHILDREN:**\n‚Ä¢ **Birth trauma** (brachial plexus injury)\n‚Ä¢ **Neuroblastoma** (chest/neck)\n‚Ä¢ **Congenital** ‚Üí heterochromia (lighter iris on affected side)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä DIAGNOSIS:\n\n**PHARMACOLOGIC TESTING:**\n\n**1. Confirm Horner's:**\n‚Ä¢ **Cocaine 4-10%** eye drops\n‚Ä¢ Normal eye: Pupil dilates (cocaine blocks NE reuptake)\n‚Ä¢ Horner's: **NO dilation** (no NE release)\n\n**2. Localize lesion:**\n‚Ä¢ **Apraclonidine 0.5%** drops\n‚Ä¢ Horner's eye: **Reverse ptosis** (lid elevation - paradoxical)\n‚Ä¢ Can distinguish central/preganglionic from postganglionic\n\n**3. Hydroxyamphetamine test:**\n‚Ä¢ **Preganglionic:** Pupil dilates (intact 3rd neuron releases NE)\n‚Ä¢ **Postganglionic:** **NO dilation** (no NE stores)\n\n**IMAGING:**\n‚Ä¢ **MRI brain/neck:** For 1st/3rd order lesions\n‚Ä¢ **CT chest:** For **Pancoast tumor** (2nd order) ‚≠ê\n‚Ä¢ **Carotid imaging:** MRA/CTA for dissection\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° IMPORTANT ASSOCIATIONS:\n\n**Pancoast Tumor + Horner's:**\n‚Ä¢ Lung apex tumor\n‚Ä¢ **Shoulder pain** radiating down arm\n‚Ä¢ **C8-T1 involvement** (hand weakness)\n‚Ä¢ **2nd order** Horner's\n\n**Carotid Dissection + Horner's:**\n‚Ä¢ **Sudden severe neck/head pain** (\"worst headache\")\n‚Ä¢ **Ipsilateral Horner's**\n‚Ä¢ **Contralateral hemiparesis** (stroke)\n‚Ä¢ **3rd order** Horner's\n\n**Wallenberg Syndrome (Lateral Medullary):**\n‚Ä¢ **Ipsilateral Horner's** (1st order)\n‚Ä¢ **Ipsilateral ataxia, facial numbness**\n‚Ä¢ **Contralateral pain/temp loss** (body)\n‚Ä¢ **Dysphagia, dysarthria, vertigo**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**M√úLLER'S MUSCLE = HORNER'S PTOSIS** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"M√ºller Makes Minor Movement (2-3mm)\"**\n\n‚Ä¢ **M√ºller's muscle** = **Sympathetic** innervation\n‚Ä¢ **Paralyzed in Horner's** ‚Üí Mild ptosis (2-3mm)\n‚Ä¢ **Levator palpebrae** = **CN III** ‚Üí Severe ptosis if paralyzed\n\n**HORNER'S TRIAD:**\n1. **Ptosis** (2-3mm) - M√ºller's muscle\n2. **Miosis** (small pupil) - Dilator pupillae\n3. **Anhidrosis** (‚Üì sweat) - Facial distribution\n\n**TOP CAUSES:**\n‚Ä¢ **Pancoast tumor** (2nd order) - chest imaging!\n‚Ä¢ **Carotid dissection** (3rd order) - neck pain + stroke\n‚Ä¢ **Wallenberg** (1st order) - brainstem signs",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-16",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient presented to the eye OPD after 3 years of cataract surgery. Slit lamp\nfinding was given. What is the likely diagnosis?",
    options: [
      "PCO",
      "Bullous keratopathy",
      "Phakic glaucoma",
      "Lens subluxation"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **PCO - Posterior Capsule Opacification (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Posterior Capsule Opacification (PCO)**, also called **\"secondary cataract\"** or **\"after-cataract\"**, is the **MOST COMMON long-term complication** following cataract surgery.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå PATHOPHYSIOLOGY OF PCO:\n\n**NORMAL CATARACT SURGERY:**\n\n**1. Phacoemulsification** ‚≠ê\n   ‚Üí **Removes cloudy lens nucleus and cortex**\n   ‚Üí **Preserves posterior capsule** (kept intact)\n   ‚Üí **IOL (Intraocular Lens)** placed in capsular bag\n\n**2. RESIDUAL LENS EPITHELIAL CELLS (LECs)**\n   ‚Üí Some LECs remain at **equator** of capsular bag\n   ‚Üí Normally quiescent after surgery\n\n**3. PCO DEVELOPMENT** (months to years later)\n\n**LECs proliferate** ‚Üí Migrate posteriorly ‚Üí Cover posterior capsule\n\n   ‚Üì\n\n**Two types of changes:**\n\n‚Ä¢ **Fibrotic PCO (pearl type)** ‚≠ê‚≠ê‚≠ê\n  ‚Üí LECs undergo **Elschnig pearl formation**\n  ‚Üí Bladder-like cells with aberrant lens fiber differentiation\n  ‚Üí **Most common** type\n  ‚Üí Dense white opacification\n\n‚Ä¢ **Fibrous PCO (fibrosis type)**\n  ‚Üí LECs undergo **epithelial-mesenchymal transition (EMT)**\n  ‚Üí Myofibroblast formation\n  ‚Üí **Capsular wrinkling** and contraction\n\n   ‚Üì\n\n**POSTERIOR CAPSULE OPACITY** ‚Üí Blocks light\n\n   ‚Üì\n\n**GRADUAL VISION LOSS** (similar to original cataract)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**TIMELINE:**\n\n‚Ä¢ Can occur **months to years** after surgery\n‚Ä¢ This patient: **3 years post-op** ‚úì\n‚Ä¢ **30-50%** of patients within 2-5 years\n\n**SYMPTOMS:**\n\n‚Ä¢ **Gradual, progressive vision loss** ‚≠ê\n‚Ä¢ **Glare** and **halos** around lights\n‚Ä¢ Difficulty with **night driving**\n‚Ä¢ **Reduced contrast sensitivity**\n‚Ä¢ Feels like \"cataract has returned\"\n\n**SLIT LAMP FINDINGS:**\n\n‚Ä¢ **White/pearl-like opacity** on posterior capsule ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Elschnig pearls** (bladder cells)\n‚Ä¢ **Capsular wrinkling** (if fibrotic)\n‚Ä¢ **IOL visible** through opacity\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä TREATMENT: **Nd:YAG LASER CAPSULOTOMY** ‚≠ê‚≠ê‚≠ê\n\n**PROCEDURE:**\n\n‚Ä¢ **Neodymium:YAG laser** (1064 nm wavelength)\n‚Ä¢ **Photodisruption** of posterior capsule\n‚Ä¢ Creates **central opening** in opacified capsule\n‚Ä¢ **Outpatient procedure**, 5-10 minutes\n‚Ä¢ **Immediate** vision improvement\n\n**ADVANTAGES:**\n\n‚úÖ **Non-invasive** (no incision)\n‚úÖ **Painless** (topical anesthesia)\n‚úÖ **Quick** procedure\n‚úÖ **High success rate** (>95%)\n‚úÖ **Immediate visual recovery**\n\n**COMPLICATIONS** (rare):\n\n‚Ä¢ **Retinal detachment** (0.5-2%) ‚ö†Ô∏è\n‚Ä¢ **Cystoid macular edema**\n‚Ä¢ **IOL damage/pitting**\n‚Ä¢ **Increased IOP** (transient)\n‚Ä¢ **Vitreous prolapse**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Bullous Keratopathy** ‚ùå\n\n‚Ä¢ **Corneal endothelial** dysfunction\n‚Ä¢ Presents with **corneal edema**, **painful eye**\n‚Ä¢ **Epithelial bullae** visible\n‚Ä¢ Occurs **early** post-op (not 3 years)\n‚Ä¢ Causes **corneal haze**, not posterior capsule opacity\n\n**C. Phakic Glaucoma** ‚ùå\n\n‚Ä¢ Not applicable: patient is **pseudophakic** (IOL present)\n‚Ä¢ **Phakic** = natural lens present\n‚Ä¢ After cataract surgery = **pseudophakic**\n‚Ä¢ Wrong terminology\n\n**D. Lens Subluxation** ‚ùå\n\n‚Ä¢ **Zonular weakness** causing lens displacement\n‚Ä¢ **NOT relevant** after cataract extraction\n‚Ä¢ Natural lens already removed\n‚Ä¢ **IOL dislocation** is possible but presents differently\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ RISK FACTORS FOR PCO:\n\n**HIGH RISK:**\n\n‚Ä¢ **Young age** (<50 years) ‚≠ê\n‚Ä¢ **Diabetes mellitus**\n‚Ä¢ **Uveitis**\n‚Ä¢ **Myopia**\n‚Ä¢ **Incomplete cortical cleanup** during surgery\n\n**PROTECTIVE FACTORS:**\n\n‚Ä¢ **Sharp-edged IOL** (square edge design) ‚≠ê\n‚Ä¢ **Hydrophobic acrylic IOL**\n‚Ä¢ **Complete cortical cleanup**\n‚Ä¢ **In-the-bag IOL placement**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**PCO = MOST COMMON LONG-TERM complication after cataract surgery** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**P**earls **C**loud **O**ver\" the capsule!\n\n‚Ä¢ **Timeline:** Months to years post-op\n‚Ä¢ **Cause:** Lens epithelial cell proliferation\n‚Ä¢ **Appearance:** White/pearl opacity on posterior capsule\n‚Ä¢ **Treatment:** **Nd:YAG laser capsulotomy** (definitive)\n‚Ä¢ **Outcome:** Excellent (>95% success, immediate improvement)",
    difficulty: "medium",
    imageUrl: "/images/questions/page5_img10.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-17",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Following perimetry image is suggestive of?",
    options: [
      "Extension of blind spot",
      "Arcuate scotoma",
      "Reinee step defect",
      "Altitude Anopia"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Extension of blind spot (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Visual field perimetry** reveals different patterns of scotomas (visual field defects) that are **diagnostic** for specific ophthalmic pathologies.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL BLIND SPOT (Physiological Scotoma):\n\n‚Ä¢ Located **15¬∞ temporal** to fixation\n‚Ä¢ Corresponds to **optic disc** location (no photoreceptors)\n‚Ä¢ **Size:** Approximately 5-7¬∞ in diameter\n‚Ä¢ **Shape:** Oval/elliptical\n‚Ä¢ **NOT pathological** - everyone has it!\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ EXTENSION OF BLIND SPOT:\n\n**PATHOLOGICAL ENLARGEMENT** of the physiological blind spot\n\n**CAUSES:**\n\n**1. OPTIC DISC EDEMA** ‚≠ê‚≠ê‚≠ê (Most Common)\n\n‚Ä¢ **Papilledema** (raised ICP)\n  ‚Üí Bilateral\n  ‚Üí Symmetric enlargement\n  ‚Üí Associated with headache, nausea\n\n‚Ä¢ **Optic neuritis** (MS, inflammation)\n  ‚Üí Unilateral usually\n  ‚Üí Pain with eye movement\n  ‚Üí Central vision loss\n\n‚Ä¢ **Anterior ischemic optic neuropathy (AION)**\n  ‚Üí Sudden, painless vision loss\n  ‚Üí Altitudinal defect + blind spot enlargement\n\n**2. GLAUCOMA** ‚≠ê‚≠ê‚≠ê\n\n‚Ä¢ **Enlarged cup-to-disc ratio**\n‚Ä¢ **Optic nerve damage**\n‚Ä¢ Blind spot extension is **EARLY sign**\n‚Ä¢ Progresses to arcuate scotomas\n\n**3. PERIPAPILLARY LESIONS**\n\n‚Ä¢ **Choroidal lesions** near disc\n‚Ä¢ **Peripapillary atrophy**\n‚Ä¢ **Myopic crescents**\n\n**4. ENLARGED OPTIC DISC**\n\n‚Ä¢ **Optic disc drusen**\n‚Ä¢ **Megalopapilla**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã VISUAL FIELD DEFECT PATTERNS:\n\n**1. EXTENSION OF BLIND SPOT** ‚≠ê (This question)\n\n‚Ä¢ **Location:** Continuous with physiological blind spot\n‚Ä¢ **Shape:** Enlargement temporal to fixation\n‚Ä¢ **Causes:** Optic disc pathology (edema, glaucoma)\n\n**2. ARCUATE SCOTOMA** (Bjerrum scotoma)\n\n‚Ä¢ **Shape:** Arc-shaped, follows nerve fiber layer\n‚Ä¢ **Location:** Extends from blind spot, curves around fixation\n‚Ä¢ **Highly specific** for **GLAUCOMA** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Respects horizontal midline\n\n**3. R√òNNE NASAL STEP** (Ronne defect)\n\n‚Ä¢ **Step-like defect** at horizontal midline\n‚Ä¢ **Location:** Nasal field\n‚Ä¢ **Cause:** Asymmetric glaucomatous damage\n‚Ä¢ Upper and lower nasal fields affected differently\n\n**4. ALTITUDINAL DEFECT**\n\n‚Ä¢ **Horizontal hemianopia** (respects horizontal)\n‚Ä¢ **Superior or inferior** visual field loss\n‚Ä¢ **Causes:** AION, retinal artery occlusion\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Arcuate Scotoma** ‚ùå\n\n‚Ä¢ Arc-shaped defect that **curves** around fixation\n‚Ä¢ **Does NOT connect directly** to blind spot initially\n‚Ä¢ Classic \"**comma-shaped**\" or \"**sickle-shaped**\"\n‚Ä¢ **Bjerrum sign** in glaucoma\n‚Ä¢ Different pattern from simple blind spot extension\n\n**C. R√∏nne Step Defect** ‚ùå\n\n‚Ä¢ **Nasal step** - step-like defect at horizontal meridian\n‚Ä¢ Occurs in **nasal field** (not temporal)\n‚Ä¢ Represents **asymmetric** glaucomatous damage\n‚Ä¢ Not an extension of blind spot\n\n**D. Altitudinal Anopia** ‚ùå\n\n‚Ä¢ Complete **horizontal hemianopia**\n‚Ä¢ **Superior or inferior** field totally lost\n‚Ä¢ Respects **horizontal midline** precisely\n‚Ä¢ Causes: **AION**, **branch retinal artery occlusion**\n‚Ä¢ Much more extensive than blind spot extension\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL SIGNIFICANCE:\n\n**EARLY GLAUCOMA DETECTION:**\n\n‚Ä¢ **Blind spot enlargement** = **EARLIEST** field defect ‚≠ê\n‚Ä¢ Precedes arcuate scotomas\n‚Ä¢ May be **only finding** in pre-perimetric glaucoma\n‚Ä¢ **Humphrey perimetry** detects subtle changes\n\n**FOLLOW-UP:**\n\n‚Ä¢ Monitor with **serial perimetry**\n‚Ä¢ Check **optic disc** for cupping\n‚Ä¢ Measure **intraocular pressure (IOP)**\n‚Ä¢ **OCT** for nerve fiber layer thickness\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Blind spot extension = Optic nerve/disc pathology** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**B**lind spot **E**xtends from **D**isc\"\n\n‚Ä¢ **Location:** Temporal to fixation (15¬∞)\n‚Ä¢ **Continuity:** Connected to physiological blind spot\n‚Ä¢ **Early sign:** Glaucoma, papilledema\n‚Ä¢ **Investigation:** Fundoscopy + OCT + IOP measurement\n\n**Glaucoma field progression:**\nBlind spot enlargement ‚Üí Arcuate scotoma ‚Üí R√∏nne step ‚Üí Advanced field loss",
    difficulty: "medium",
    imageUrl: "/images/questions/page5_img11.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-18",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient came with nyctalopia. Rational image given below, what will be the\ndiagnosis?",
    options: [
      "Retinitis pigmentosa",
      "Vitamin A deficiency",
      "Retinal detachment",
      "Diabetic retinopathy"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Retinitis Pigmentosa (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Retinitis Pigmentosa (RP)** is a group of **inherited retinal dystrophies** characterized by **progressive degeneration of photoreceptors** (rods and cones), leading to **blindness**.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå PATHOPHYSIOLOGY:\n\n**NORMAL RETINAL ANATOMY:**\n\n‚Ä¢ **Photoreceptors:**\n  ‚Üí **Rods** (120 million) - peripheral retina, night vision, motion\n  ‚Üí **Cones** (6 million) - central retina (macula), color, acuity\n\n‚Ä¢ **Rod function** = **scotopic vision** (dim light, night vision) ‚≠ê\n‚Ä¢ **Cone function** = **photopic vision** (bright light, color)\n\n**RETINITIS PIGMENTOSA:**\n\n**PRIMARY DEFECT:**\n\n‚Ä¢ **Genetic mutations** in >100 genes (rhodopsin, peripherin, etc.)\n‚Ä¢ **Rods affected FIRST** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Progressive rod degeneration ‚Üí **nyctalopia** (night blindness)\n‚Ä¢ **Cones degenerate later** ‚Üí central vision loss\n\n**PROGRESSION SEQUENCE:**\n\n**1. EARLY STAGE** (childhood/adolescence)\n   ‚Üí **Nyctalopia** (night blindness) ‚≠ê‚≠ê‚≠ê **FIRST SYMPTOM**\n   ‚Üí Difficulty navigating in dim light\n   ‚Üí Trouble with dark adaptation\n\n**2. MIDDLE STAGE** (20s-30s)\n   ‚Üí **Peripheral visual field loss** (\"tunnel vision\")\n   ‚Üí **Ring scotoma** at mid-periphery\n   ‚Üí Central vision still preserved\n\n**3. LATE STAGE** (40s-50s)\n   ‚Üí **Cone involvement** ‚Üí central vision loss\n   ‚Üí **Legal blindness**\n   ‚Üí May retain small central island\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**SYMPTOMS:**\n\n‚Ä¢ **Nyctalopia (night blindness)** ‚≠ê‚≠ê‚≠ê **HALLMARK**\n  ‚Üí First and most prominent symptom\n  ‚Üí Difficulty seeing in dark/dim environments\n  ‚Üí Poor dark adaptation\n\n‚Ä¢ **Progressive peripheral vision loss**\n  ‚Üí **\"Tunnel vision\"**\n  ‚Üí Difficulty with mobility\n  ‚Üí Frequent stumbling/bumping into objects\n\n‚Ä¢ **Late:** Central vision loss, color vision loss\n\n**FUNDOSCOPY FINDINGS** (Classic Triad):\n\n**1. \"Bone-spicule\" pigmentation** ‚≠ê‚≠ê‚≠ê\n   ‚Üí **Pathognomonic** finding\n   ‚Üí Black pigment clumps in mid-periphery\n   ‚Üí Looks like \"bone spicules\" or \"spider legs\"\n   ‚Üí Result of **RPE migration** and degeneration\n\n**2. Attenuated retinal vessels** ‚≠ê\n   ‚Üí **Narrowed arterioles**\n   ‚Üí \"Thread-like\" appearance\n   ‚Üí Due to reduced metabolic demand\n\n**3. Waxy pallor of optic disc** ‚≠ê\n   ‚Üí **Optic atrophy**\n   ‚Üí Pale, waxy appearance\n   ‚Üí Secondary to photoreceptor loss\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ GENETICS & INHERITANCE:\n\n‚Ä¢ **Autosomal Dominant** (30-40%) - least severe\n‚Ä¢ **Autosomal Recessive** (50-60%) - most common\n‚Ä¢ **X-linked** (5-15%) - most severe, males affected\n‚Ä¢ **Mitochondrial** (rare)\n\n**Common genes:**\n‚Ä¢ **Rhodopsin** (RHO) - most common AD\n‚Ä¢ **USH2A** - most common AR\n‚Ä¢ **RPGR** - most common X-linked\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Vitamin A Deficiency** ‚ùå\n\n‚Ä¢ Also causes **nyctalopia**, BUT:\n  ‚Üí **Bitot's spots** (conjunctival foam)\n  ‚Üí **Xerophthalmia** (dry eyes)\n  ‚Üí **Keratomalacia** (corneal softening)\n  ‚Üí **NO bone-spicule pigmentation** ‚ö†Ô∏è\n  ‚Üí **Reversible** with vitamin A\n‚Ä¢ Fundoscopy shows **normal retina** initially\n\n**C. Retinal Detachment** ‚ùå\n\n‚Ä¢ **Sudden**, not gradual\n‚Ä¢ **Flashes** (photopsia) and **floaters**\n‚Ä¢ **Curtain-like** visual field defect\n‚Ä¢ **Different fundoscopy:** elevated retina, tears\n‚Ä¢ **NO nyctalopia as presenting symptom**\n\n**D. Diabetic Retinopathy** ‚ùå\n\n‚Ä¢ **Microaneurysms**, **hemorrhages**, **exudates**\n‚Ä¢ **NO bone-spicule pigmentation**\n‚Ä¢ **Macular edema** common\n‚Ä¢ Central vision affected (not peripheral first)\n‚Ä¢ **No night blindness** as primary symptom\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ INVESTIGATIONS:\n\n‚Ä¢ **Electroretinogram (ERG)** ‚≠ê‚≠ê‚≠ê **DIAGNOSTIC**\n  ‚Üí **Severely reduced** or **absent** responses\n  ‚Üí **Rod responses** affected first\n  ‚Üí **Gold standard** for diagnosis\n\n‚Ä¢ **Visual Field Testing**\n  ‚Üí **Ring scotoma** (mid-peripheral)\n  ‚Üí Progressive constriction (\"tunnel vision\")\n\n‚Ä¢ **Fundus Autofluorescence**\n  ‚Üí Shows areas of RPE atrophy\n\n‚Ä¢ **OCT** (Optical Coherence Tomography)\n  ‚Üí Thinning of photoreceptor layer\n  ‚Üí Loss of outer retinal architecture\n\n‚Ä¢ **Genetic Testing**\n  ‚Üí Identifies specific mutation\n  ‚Üí Guides prognosis and genetic counseling\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**NO CURE** currently ‚ö†Ô∏è\n\n**SUPPORTIVE:**\n\n‚Ä¢ **Vitamin A palmitate** (15,000 IU/day)\n  ‚Üí May slow progression slightly\n  ‚Üí Controversial benefit\n\n‚Ä¢ **Low vision aids**\n  ‚Üí Magnifiers, telescopes\n  ‚Üí Night vision devices\n\n‚Ä¢ **Genetic counseling**\n‚Ä¢ **Treat complications:** cataract (common), CME\n\n**EMERGING THERAPIES:**\n\n‚Ä¢ **Gene therapy** (Luxturna for RPE65 mutations)\n‚Ä¢ **Retinal prosthesis** (\"Argus II\" bionic eye)\n‚Ä¢ **Stem cell therapy** (experimental)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Retinitis Pigmentosa = Night Blindness + Bone Spicules + Tunnel Vision** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**R**ods **P**erish first ‚Üí **N**ight blindness!\"\n\n‚Ä¢ **First symptom:** Nyctalopia (night blindness)\n‚Ä¢ **Pathognomonic:** Bone-spicule pigmentation\n‚Ä¢ **Progression:** Rods (peripheral) ‚Üí Cones (central)\n‚Ä¢ **ERG:** Diagnostic (reduced/absent)\n‚Ä¢ **Genetics:** Multiple inheritance patterns (AD, AR, X-linked)",
    difficulty: "medium",
    imageUrl: "/images/questions/page6_img13.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-19",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Patient was shown image A along with image B. Image C was visualised. What is\nthe likely diagnosis?",
    options: [
      "Left eye suppression",
      "Right eye suppression",
      "Crossed diplopia",
      "Uncrossed diplopia"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Right eye suppression (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Binocular vision suppression** is a **neurological adaptation** where the brain actively **ignores (suppresses)** visual input from one eye to avoid **diplopia (double vision)**.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL BINOCULAR VISION:\n\n‚Ä¢ **Both eyes** send images to visual cortex\n‚Ä¢ Brain **fuses** the two images ‚Üí **Single 3D image**\n‚Ä¢ **Stereopsis** (depth perception) achieved\n‚Ä¢ **Binocular single vision (BSV)** maintained\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ SUPPRESSION MECHANISM:\n\n**WHEN DOES IT OCCUR?**\n\n**1. STRABISMUS (Squint)** ‚≠ê‚≠ê‚≠ê **Most Common**\n\n‚Ä¢ **Misalignment** of eyes\n‚Ä¢ Each eye sends **different image**\n‚Ä¢ Brain cannot fuse ‚Üí **Diplopia**\n‚Ä¢ To avoid confusion, brain **suppresses** one eye ‚≠ê\n\n**2. ANISOMETROPIA**\n\n‚Ä¢ **Different refractive errors** between eyes\n‚Ä¢ One eye sees **clear**, other **blurred**\n‚Ä¢ Brain favors **clearer image**, suppresses blurred\n\n**3. AMBLYOPIA (Lazy Eye)**\n\n‚Ä¢ **Poor visual development** in one eye\n‚Ä¢ Brain prefers **better-seeing eye**\n‚Ä¢ Suppresses amblyopic eye input\n\n**4. MEDIA OPACITY**\n\n‚Ä¢ **Cataract, corneal scar** in one eye\n‚Ä¢ Reduced image quality\n‚Ä¢ Brain suppresses degraded input\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ TYPES OF SUPPRESSION:\n\n**1. CONSTANT SUPPRESSION** ‚ö†Ô∏è\n\n‚Ä¢ **Same eye** always suppressed\n‚Ä¢ **High risk** of amblyopia\n‚Ä¢ Needs urgent treatment\n‚Ä¢ Common in **unilateral strabismus**\n\n**2. ALTERNATING SUPPRESSION** ‚úì\n\n‚Ä¢ **Switches** between eyes\n‚Ä¢ **Lower risk** of amblyopia\n‚Ä¢ Both eyes maintain some function\n‚Ä¢ Common in **alternating strabismus**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã CLINICAL TESTING:\n\n**WORTH 4-DOT TEST** ‚≠ê‚≠ê‚≠ê (Most likely this question's test)\n\n**SETUP:**\n‚Ä¢ Patient wears **red-green glasses**\n‚Ä¢ Views **4 dots**: 1 red, 2 green, 1 white\n‚Ä¢ **Red filter** on right eye, **green** on left\n\n**INTERPRETATION:**\n\n‚Ä¢ **Normal (4 dots):** Red, 2 green, white = BSV present ‚úì\n\n‚Ä¢ **Right eye suppression (2 dots):** ‚≠ê‚≠ê‚≠ê **(THIS QUESTION)**\n  ‚Üí Sees only **2 GREEN dots**\n  ‚Üí Red filter suppressed\n  ‚Üí **Right eye not contributing**\n\n‚Ä¢ **Left eye suppression (3 dots):**\n  ‚Üí Sees **1 red + 1 white + 1 red-white**\n  ‚Üí Green filter suppressed\n\n‚Ä¢ **Diplopia (5 dots):**\n  ‚Üí Sees **both images separately**\n  ‚Üí No fusion, no suppression\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Left eye suppression** ‚ùå\n\n‚Ä¢ Would show **3 dots** (red dominant)\n‚Ä¢ Patient sees **green dominant** ‚Üí Right suppressed\n\n**C. Crossed diplopia** ‚ùå\n\n‚Ä¢ **Esotropia** (eyes turned in)\n‚Ä¢ **5 dots visible** (both images seen)\n‚Ä¢ Red dot on **left**, green on **right**\n‚Ä¢ No suppression present\n\n**D. Uncrossed diplopia** ‚ùå\n\n‚Ä¢ **Exotropia** (eyes turned out)\n‚Ä¢ **5 dots visible** (both images seen)\n‚Ä¢ Red dot on **right**, green on **left**\n‚Ä¢ No suppression present\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö†Ô∏è CLINICAL SIGNIFICANCE:\n\n**CONSEQUENCES OF SUPPRESSION:**\n\n‚Ä¢ **Loss of binocular vision**\n‚Ä¢ **Loss of stereopsis** (depth perception)\n‚Ä¢ **Risk of amblyopia** (if constant)\n‚Ä¢ **Permanent visual impairment** (if untreated in children)\n\n**CRITICAL AGE:**\n\n‚Ä¢ **Sensitive period:** Birth to **8-9 years** ‚≠ê\n‚Ä¢ Treatment **MUST** be before age 8\n‚Ä¢ After this, suppression becomes **permanent**\n‚Ä¢ Amblyopia **irreversible** after sensitive period\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**1. TREAT UNDERLYING CAUSE:**\n\n‚Ä¢ **Refractive correction** (glasses)\n‚Ä¢ **Strabismus surgery** (align eyes)\n‚Ä¢ **Cataract removal** (clear media)\n\n**2. OCCLUSION THERAPY:**\n\n‚Ä¢ **Patch good eye** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Forces brain to use suppressed eye\n‚Ä¢ Stimulates visual development\n‚Ä¢ **2-6 hours/day** depending on age\n\n**3. PENALIZATION:**\n\n‚Ä¢ **Atropine drops** in good eye\n‚Ä¢ Blurs near vision\n‚Ä¢ Alternative to patching\n\n**4. VISION THERAPY:**\n\n‚Ä¢ Exercises to improve binocular function\n‚Ä¢ Orthoptic exercises\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Suppression = Brain's way to avoid diplopia in strabismus** ‚≠ê‚≠ê‚≠ê\n\n**Worth 4-Dot Test:**\n‚Ä¢ **2 dots** = Right eye suppression (green seen only)\n‚Ä¢ **3 dots** = Left eye suppression (red seen)\n‚Ä¢ **4 dots** = Normal binocular vision\n‚Ä¢ **5 dots** = Diplopia (no suppression)\n\n**Remember:** \"**S**uppression **S**aves from **S**eeing double (diplopia)!\"\n\n‚Ä¢ Protective mechanism but risks amblyopia\n‚Ä¢ Treat urgently in children (<8 years)\n‚Ä¢ Patch therapy forces suppressed eye to work",
    difficulty: "medium",
    imageUrl: "/images/questions/page6_img14.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-20",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient presents in the eye OPD with this finding. What is the diagnosis?",
    options: [
      "Dermoid",
      "Lipodermoid",
      "Pterygium",
      "Papilloma"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Dermoid (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Limbal dermoid** is a **congenital choristoma** (normal tissue in abnormal location) containing **ectodermal and mesodermal elements** at the corneoscleral limbus.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå DERMOID vs LIPODERMOID:\n\n**DERMOID CYST/TUMOR** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**LOCATION:**\n‚Ä¢ **Inferotemporal limbus** (most common) ‚≠ê\n‚Ä¢ Junction of cornea and sclera\n‚Ä¢ Can extend into cornea or sclera\n\n**APPEARANCE:**\n‚Ä¢ **Solid**, round, **white-yellowish** mass\n‚Ä¢ **Hair may be visible** on surface ‚≠ê\n‚Ä¢ Smooth surface\n‚Ä¢ **Well-defined margins**\n‚Ä¢ Size: **3-10 mm**\n\n**HISTOLOGY:**\n‚Ä¢ **Keratinized epithelium** (skin-like) ‚≠ê\n‚Ä¢ **Sebaceous glands**\n‚Ä¢ **Hair follicles** ‚≠ê\n‚Ä¢ **Adipose tissue**\n‚Ä¢ Connective tissue\n\n**ASSOCIATIONS:**\n‚Ä¢ **Goldenhar syndrome** ‚≠ê‚≠ê‚≠ê (Oculo-auriculo-vertebral spectrum)\n  ‚Üí Facial asymmetry\n  ‚Üí Preauricular tags\n  ‚Üí Vertebral abnormalities\n‚Ä¢ Usually **sporadic**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**PRESENTATION:**\n\n‚Ä¢ **Present since birth** ‚≠ê\n‚Ä¢ **Non-progressive** (grows with child)\n‚Ä¢ **Asymptomatic** usually\n‚Ä¢ **Cosmetic concern**\n‚Ä¢ May cause **astigmatism** (if large, distorts cornea)\n‚Ä¢ **No inflammation** typically\n\n**SYMPTOMS (if any):**\n‚Ä¢ Foreign body sensation\n‚Ä¢ Irritation\n‚Ä¢ Visual impairment (if obscures visual axis)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Lipodermoid** ‚ùå\n\n**DIFFERENT location and appearance:**\n\n‚Ä¢ Location: **Superotemporal fornix** (NOT limbus) ‚ö†Ô∏è\n‚Ä¢ **Soft, mobile, yellow** mass\n‚Ä¢ Under upper eyelid (hidden)\n‚Ä¢ **Moves with eye movements**\n‚Ä¢ **Contains mostly FAT** (not hair/glands)\n‚Ä¢ Smooth, glistening surface\n\n**C. Pterygium** ‚ùå\n\n‚Ä¢ **Fibrovascular growth** (NOT congenital)\n‚Ä¢ **Nasal side** (99%) ‚Üí crosses onto cornea\n‚Ä¢ **Triangular shape** with apex toward cornea ‚≠ê\n‚Ä¢ **Vascularized** (pink/red color)\n‚Ä¢ **Acquired** (UV exposure, dust)\n‚Ä¢ **Progressive** (grows over time)\n‚Ä¢ Age: adults, not congenital\n\n**D. Papilloma** ‚ùå\n\n‚Ä¢ **Conjunctival growth** (NOT limbal)\n‚Ä¢ **Pedunculated** (stalk-like) ‚≠ê\n‚Ä¢ **Pink/red color** (vascular)\n‚Ä¢ **Cauliflower/raspberry appearance**\n‚Ä¢ **HPV-associated** (viral)\n‚Ä¢ Can be multiple\n‚Ä¢ NOT congenital\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIFFERENTIAL DIAGNOSIS:\n\n| Feature | Dermoid | Lipodermoid | Pterygium |\n|---------|---------|-------------|----------|\n| **Location** | Inferotemporal **limbus** | Superotemporal **fornix** | **Nasal** limbus |\n| **Onset** | **Congenital** | **Congenital** | **Acquired** |\n| **Color** | **White-yellow** | **Yellow** | **Pink-red** |\n| **Hair** | **May have** ‚úì | **No** | **No** |\n| **Mobility** | Fixed | **Mobile** | Fixed |\n| **Growth** | Non-progressive | Non-progressive | **Progressive** |\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**INDICATIONS FOR SURGERY:**\n\n‚Ä¢ **Cosmetic concerns** (most common reason)\n‚Ä¢ **Visual axis obstruction**\n‚Ä¢ **Significant astigmatism**\n‚Ä¢ **Increasing size**\n\n**SURGICAL TECHNIQUE:**\n\n‚Ä¢ **Excisional keratectomy** ‚≠ê\n‚Ä¢ **Lamellar dissection** (partial thickness)\n‚Ä¢ **Amniotic membrane graft** (if deep)\n‚Ä¢ **Conjunctival autograft** (if large defect)\n\n**TIMING:**\n\n‚Ä¢ Can be done **any age** if needed\n‚Ä¢ Usually wait until **2-3 years** (unless urgent)\n‚Ä¢ Better surgical cooperation in older children\n\n**COMPLICATIONS:**\n\n‚Ä¢ **Corneal scarring** (if deep excision)\n‚Ä¢ **Astigmatism** (postoperative)\n‚Ä¢ **Recurrence** (rare, <5%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Limbal Dermoid = Congenital + Inferotemporal + White-yellow + Hair** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**D**ermoid has **D**ander (hair)!\"\n\n‚Ä¢ **Location:** Inferotemporal limbus ‚≠ê\n‚Ä¢ **Congenital** choristoma (present at birth)\n‚Ä¢ **Solid** mass with possible **hair** on surface\n‚Ä¢ Associated with **Goldenhar syndrome**\n‚Ä¢ Treatment: **Surgical excision** (if symptomatic/cosmetic)",
    difficulty: "medium",
    imageUrl: "/images/questions/page7_img16.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-21",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "In Wilson‚Äôs disease, the best choice of investigation is?",
    options: [
      "Serum copper",
      "Ceruloplasmin",
      "Hepatic copper estimation",
      "Urine copper"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Ceruloplasmin (Option B)** - But note: **Hepatic copper is GOLD STANDARD**\n\nüî¨ DETAILED EXPLANATION:\n\n**Wilson's disease** requires multiple investigations. While **hepatic copper** is the **GOLD STANDARD** (as explained in Q2), **serum ceruloplasmin** is the **BEST SCREENING TEST** and most commonly used initial investigation.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå DIAGNOSTIC APPROACH IN WILSON'S DISEASE:\n\n**FIRST-LINE INVESTIGATIONS** (Screening):\n\n**1. SERUM CERULOPLASMIN** ‚≠ê‚≠ê‚≠ê **(MOST PRACTICAL ANSWER)**\n\n**Why it's commonly the \"best choice\":**\n‚Ä¢ **Non-invasive** (simple blood test)\n‚Ä¢ **Widely available**\n‚Ä¢ **Inexpensive**\n‚Ä¢ **Good screening test**\n‚Ä¢ **Low in 95%** of Wilson's cases\n\n**NORMAL:** 20-40 mg/dL\n\n**WILSON'S:** **<20 mg/dL** ‚≠ê‚≠ê‚≠ê\n\n**LIMITATIONS:** ‚ö†Ô∏è\n‚Ä¢ **Can be normal** in 5% of Wilson's patients\n‚Ä¢ **Also low** in: Malnutrition, nephrotic syndrome, protein-losing enteropathy\n‚Ä¢ **Can be elevated** as acute phase reactant (infection, inflammation)\n‚Ä¢ **NOT diagnostic alone** - needs confirmation\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ COMPLETE DIAGNOSTIC WORKUP:\n\n**SCREENING TESTS:**\n\n**1. Serum Ceruloplasmin** ‚≠ê **(Best initial test)**\n‚Ä¢ Low (<20 mg/dL) in 95%\n‚Ä¢ Quick, non-invasive\n\n**2. 24-Hour Urinary Copper** ‚≠ê\n‚Ä¢ **Elevated (>100 Œºg/24hr)** in Wilson's\n‚Ä¢ Normal: <40 Œºg/24hr\n‚Ä¢ Good for monitoring treatment\n\n**3. Slit-Lamp Examination** ‚≠ê\n‚Ä¢ **Kayser-Fleischer (KF) rings**\n‚Ä¢ Present in 95% with neurological symptoms\n‚Ä¢ Only 50% in purely hepatic cases\n‚Ä¢ **Highly specific** when present\n\n**CONFIRMATORY TEST:**\n\n**4. HEPATIC COPPER CONTENT** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD)**\n‚Ä¢ **Liver biopsy** with quantitative copper measurement\n‚Ä¢ **>250 Œºg/g dry weight** = diagnostic\n‚Ä¢ Normal: <50 Œºg/g\n‚Ä¢ **Most specific and definitive**\n‚Ä¢ Invasive, so done after screening tests\n\n**OTHER TESTS:**\n\n**5. Genetic Testing**\n‚Ä¢ **ATP7B gene** sequencing\n‚Ä¢ Confirmatory\n‚Ä¢ Useful for family screening\n\n**6. Liver Function Tests**\n‚Ä¢ Transaminases elevated\n‚Ä¢ Albumin, PT/INR abnormal\n\n**7. MRI Brain** (if neurological)\n‚Ä¢ T2 hyperintensities in basal ganglia\n‚Ä¢ \"Face of giant panda\" sign\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã COMPARISON OF INVESTIGATIONS:\n\n| Investigation | Sensitivity | Specificity | Invasive? | Cost |\n|---------------|-------------|-------------|-----------|------|\n| **Ceruloplasmin** | 95% | Moderate | No ‚úì | Low |\n| **Urinary copper** | High | Moderate | No ‚úì | Low |\n| **KF rings** | 50-95% | Very High | No ‚úì | Low |\n| **Hepatic copper** ‚≠ê | 100% | **Very High** | **Yes** | High |\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE LESS IDEAL:\n\n**A. Serum Copper** ‚ùå\n\n‚Ä¢ **Usually LOW** in Wilson's (paradoxically)\n‚Ä¢ But **most copper bound to ceruloplasmin**\n‚Ä¢ **Free (non-ceruloplasmin) copper** is actually elevated\n‚Ä¢ **Not routinely measured**\n‚Ä¢ **Less reliable** than ceruloplasmin\n\n**C. Hepatic copper estimation** \n\n‚Ä¢ This is actually the **GOLD STANDARD** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Most definitive test**\n‚Ä¢ But **invasive** (liver biopsy required)\n‚Ä¢ Done **after** screening tests suggest Wilson's\n‚Ä¢ Not the **first choice** due to invasiveness\n‚Ä¢ If question asks \"gold standard\" ‚Üí Choose this!\n‚Ä¢ If question asks \"best screening\" ‚Üí Choose ceruloplasmin\n\n**D. Urine copper**\n\n‚Ä¢ **Also elevated** in Wilson's (>100 Œºg/24hr)\n‚Ä¢ Good for diagnosis and monitoring\n‚Ä¢ But **ceruloplasmin is preferred** for initial screening\n‚Ä¢ Urine copper used as **supporting evidence**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIAGNOSTIC CRITERIA (Leipzig Score):\n\n**Wilson's disease diagnosed if score ‚â•4:**\n\n‚Ä¢ **KF rings present:** +2 points\n‚Ä¢ **Neurological symptoms:** +2 points\n‚Ä¢ **Serum ceruloplasmin <20 mg/dL:** +2 points\n‚Ä¢ **Urinary copper >100 Œºg/24hr:** +2 points\n‚Ä¢ **Hepatic copper >250 Œºg/g:** +2 points\n‚Ä¢ **Genetic mutation:** +4 points\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**QUESTION WORDING MATTERS:** ‚≠ê‚≠ê‚≠ê\n\n**\"Best SCREENING test\"** = **Ceruloplasmin** ‚úì\n‚Ä¢ Non-invasive\n‚Ä¢ Widely available\n‚Ä¢ Low in 95% of cases\n\n**\"GOLD STANDARD test\"** = **Hepatic copper** ‚úì\n‚Ä¢ Most definitive\n‚Ä¢ Highest specificity\n‚Ä¢ But invasive\n\n**Remember:** \"**C**eruloplasmin for **C**linical screening!\"\n\n**TYPICAL WORKUP:**\n1. **Suspect Wilson's** (hepatic/neurological symptoms)\n2. **Check ceruloplasmin** + urinary copper (screening)\n3. **Slit-lamp** for KF rings\n4. **Liver biopsy** for hepatic copper (if diagnosis unclear)\n5. **Genetic testing** (confirmation, family screening)\n\n**This question lists ceruloplasmin as correct answer for practical clinical approach!**",
    difficulty: "medium",
    imageUrl: "/images/questions/page7_img17.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-22",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "Clinical scenario about homocystinuria, which vitamin to be supplemented?",
    options: [
      "Thiamine",
      "Vitamin B6",
      "Biotin",
      "Pyruvate"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Vitamin B6 (Pyridoxine) (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Homocystinuria** is an **inborn error of metabolism** characterized by **elevated homocysteine** in blood and urine due to enzyme deficiencies in homocysteine metabolism.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL METHIONINE METABOLISM:\n\n**PATHWAY:**\n\n**Methionine** (essential amino acid)\n\n   ‚Üì (SAM formation)\n\n**S-Adenosyl methionine (SAM)**\n\n   ‚Üì (methylation reactions)\n\n**S-Adenosyl homocysteine**\n\n   ‚Üì\n\n**HOMOCYSTEINE** üéØ (CRITICAL JUNCTION)\n\n   ‚Üì ‚Üì\n\n**Two pathways:**\n\n**PATHWAY 1: TRANSSULFURATION** ‚≠ê‚≠ê‚≠ê\n\n**Homocysteine** ‚Üí (CBS + **Vitamin B6**) ‚Üí **Cystathionine** ‚Üí (CGL + B6) ‚Üí **Cysteine**\n\n**PATHWAY 2: REMETHYLATION**\n\n**Homocysteine** ‚Üí (MS + Vitamin B12 + Folate) ‚Üí **Methionine**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ HOMOCYSTINURIA TYPES:\n\n**TYPE 1 (CLASSIC)** ‚≠ê‚≠ê‚≠ê **Most Common (90%)**\n\n**DEFECT:**\n‚Ä¢ **Cystathionine Œ≤-synthase (CBS) deficiency** ‚≠ê\n‚Ä¢ **Autosomal recessive**\n‚Ä¢ Gene on chromosome **21q22**\n\n**RESULT:**\n‚Ä¢ ‚Üë‚Üë‚Üë **Homocysteine** in blood/urine\n‚Ä¢ ‚Üë **Methionine** (accumulates)\n‚Ä¢ ‚Üì **Cysteine** (becomes essential)\n\n**TREATMENT:** **VITAMIN B6 (Pyridoxine)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n‚Ä¢ **Cofactor** for CBS enzyme\n‚Ä¢ **50% of patients B6-responsive**\n‚Ä¢ High-dose: **100-1000 mg/day**\n‚Ä¢ If responsive: ‚Üì‚Üì homocysteine levels\n‚Ä¢ **Betaine** + low methionine diet (if non-responsive)\n\n**TYPE 2:**\n‚Ä¢ **Methionine synthase deficiency**\n‚Ä¢ **Vitamin B12** (cobalamin) therapy\n\n**TYPE 3:**\n‚Ä¢ **MTHFR deficiency**\n‚Ä¢ **Folate** therapy\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL FEATURES (Classic CBS Deficiency):\n\n**\"4 M's\" MNEMONIC:**\n\n**1. MARFANOID habitus** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Tall, thin** build\n‚Ä¢ **Long limbs** (dolichostenomelia)\n‚Ä¢ **Arachnodactyly** (spider fingers)\n‚Ä¢ **Pectus excavatum/carinatum**\n‚Ä¢ **Scoliosis**\n\n**2. MENTAL retardation** ‚≠ê\n‚Ä¢ **IQ <50** in untreated\n‚Ä¢ **Seizures** (20-30%)\n‚Ä¢ **Psychiatric symptoms**\n‚Ä¢ **Developmental delay**\n\n**3. MYOPIA / OCULAR** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Ectopia lentis** (lens dislocation) **PATHOGNOMONIC**\n  ‚Üí **Downward & inward** displacement ‚≠ê\n  ‚Üí vs Marfan: upward & outward\n‚Ä¢ **Severe myopia**\n‚Ä¢ **Retinal detachment**\n‚Ä¢ **Glaucoma**\n‚Ä¢ **Optic atrophy**\n\n**4. THROMBOEMBOLISM** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Most dangerous complication** ‚ö†Ô∏è\n‚Ä¢ **Arterial & venous thrombosis**\n‚Ä¢ **Stroke** (even in children)\n‚Ä¢ **MI (myocardial infarction)**\n‚Ä¢ **Pulmonary embolism**\n‚Ä¢ Can occur during **anesthesia**\n\n**OTHER FEATURES:**\n‚Ä¢ **Fair hair & skin** (hypopigmentation)\n‚Ä¢ **Malar flush**\n‚Ä¢ **Osteoporosis**\n‚Ä¢ **Genu valgum**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Thiamine (Vitamin B1)** ‚ùå\n‚Ä¢ Cofactor for: **Pyruvate dehydrogenase**, Œ±-ketoglutarate DH\n‚Ä¢ Deficiency: **Beriberi**, Wernicke-Korsakoff\n‚Ä¢ NOT involved in homocysteine metabolism\n\n**C. Biotin (Vitamin B7)** ‚ùå\n‚Ä¢ Cofactor for: **Carboxylases** (Acetyl-CoA carboxylase, Pyruvate carboxylase)\n‚Ä¢ Deficiency: **Dermatitis**, alopecia\n‚Ä¢ NOT involved in homocysteine metabolism\n\n**D. Pyruvate** ‚ùå\n‚Ä¢ NOT a vitamin\n‚Ä¢ End product of **glycolysis**\n‚Ä¢ No role in homocysteine metabolism\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIAGNOSIS:\n\n**SCREENING:**\n‚Ä¢ **Newborn screening** (some countries)\n‚Ä¢ **Elevated homocysteine** in blood/urine ‚≠ê\n‚Ä¢ **Positive sodium nitroprusside test** (cyanide-nitroprusside)\n\n**CONFIRMATORY:**\n‚Ä¢ **Plasma total homocysteine** >100 Œºmol/L (N: <15)\n‚Ä¢ **Plasma methionine** elevated (>200 Œºmol/L)\n‚Ä¢ **Plasma cysteine** low\n‚Ä¢ **CBS enzyme activity** in fibroblasts\n‚Ä¢ **Genetic testing**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä COMPREHENSIVE MANAGEMENT:\n\n**1. VITAMIN B6 (Pyridoxine)** ‚≠ê‚≠ê‚≠ê **FIRST-LINE**\n‚Ä¢ **100-1000 mg/day**\n‚Ä¢ Trial for **3-6 weeks**\n‚Ä¢ Check response (‚Üì homocysteine)\n‚Ä¢ **50% patients responsive**\n\n**2. BETAINE (Trimethylglycine)**\n‚Ä¢ If **B6 non-responsive**\n‚Ä¢ **6-9 g/day** (divided doses)\n‚Ä¢ Remethylates homocysteine ‚Üí methionine\n\n**3. DIETARY MODIFICATION**\n‚Ä¢ **Low methionine diet**\n‚Ä¢ ‚Üì Protein (especially animal)\n‚Ä¢ **Cysteine supplementation** (becomes essential)\n\n**4. FOLATE & VITAMIN B12**\n‚Ä¢ Support remethylation pathway\n\n**5. ANTICOAGULATION** (if thrombosis)\n‚Ä¢ Low-dose **aspirin** prophylaxis\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Homocystinuria (CBS deficiency) = Vitamin B6 treatment** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**B6** for **CBS** deficiency!\"\n\n**Classic triad:**\n‚Ä¢ **Ectopia lentis** (downward & inward) ‚≠ê\n‚Ä¢ **Marfanoid habitus**\n‚Ä¢ **Thromboembolic events** (stroke, MI)\n\n**Treatment:**\n‚Ä¢ **Pyridoxine (B6)** = FIRST-LINE (cofactor for CBS)\n‚Ä¢ **Betaine** if B6 non-responsive\n‚Ä¢ Low methionine diet + cysteine supplementation",
    difficulty: "medium",
    imageUrl: "/images/questions/page8_img19.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-23",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 2-week-old baby presented with vomiting, acidosis, early cataract. Which of the\nfollowing enzyme is defective?",
    options: [
      "Galactose-1-phosphate uridyl transferase",
      "Galactokinase",
      "Hexokinase",
      "Aldol reductase"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Galactose-1-phosphate uridyl transferase (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Classic Galactosemia** is an **autosomal recessive** disorder caused by **deficiency of Galactose-1-phosphate uridyltransferase (GALT)**, leading to **toxic accumulation** of galactose metabolites.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL GALACTOSE METABOLISM:\n\n**DIETARY LACTOSE** (breast milk, formula)\n\n   ‚Üì (Lactase)\n\n**GLUCOSE + GALACTOSE**\n\n**GALACTOSE METABOLISM** (Leloir Pathway):\n\n**Step 1:** Galactose + ATP ‚Üí **(Galactokinase)** ‚Üí **Galactose-1-phosphate**\n\n**Step 2:** Galactose-1-phosphate + UDP-glucose ‚Üí **(GALT)** ‚≠ê‚≠ê‚≠ê ‚Üí **Glucose-1-phosphate** + UDP-galactose\n\n**Step 3:** UDP-galactose ‚Üí **(UDP-galactose-4-epimerase)** ‚Üí UDP-glucose\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ TYPES OF GALACTOSEMIA:\n\n**TYPE 1: CLASSIC GALACTOSEMIA** ‚≠ê‚≠ê‚≠ê **(THIS QUESTION)**\n\n**DEFECT:** **GALT deficiency** (Galactose-1-phosphate uridyltransferase)\n\n**ACCUMULATION:**\n‚Ä¢ **Galactose-1-phosphate** ‚≠ê‚≠ê‚≠ê (TOXIC)\n‚Ä¢ **Galactose** (converted to galactitol by aldose reductase)\n\n**SEVERITY:** **MOST SEVERE** form ‚ö†Ô∏è\n\n**TYPE 2: GALACTOKINASE DEFICIENCY**\n\n**DEFECT:** Galactokinase\n\n**ACCUMULATION:** **Galactose** only (‚Üí galactitol)\n\n**FEATURES:** **Cataracts ONLY** (no other systemic involvement)\n\n**TYPE 3: EPIMERASE DEFICIENCY** (Rare)\n\n**DEFECT:** UDP-galactose-4-epimerase\n\n**FEATURES:** Usually **benign** (mild or asymptomatic)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL PRESENTATION (Type 1 - Classic):\n\n**TIMING:** Symptoms appear **within days to weeks** after milk feeding ‚≠ê\n\n**ACUTE NEONATAL SYNDROME:**\n\n**1. GASTROINTESTINAL** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Vomiting** (after milk feeds) ‚≠ê\n‚Ä¢ **Diarrhea**\n‚Ä¢ **Poor feeding**\n‚Ä¢ **Failure to thrive**\n‚Ä¢ **Jaundice** (prolonged)\n\n**2. HEPATIC** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hepatomegaly** ‚≠ê\n‚Ä¢ **Liver dysfunction** ‚Üí **Coagulopathy**\n‚Ä¢ **Hypoglycemia**\n‚Ä¢ **Metabolic acidosis** ‚≠ê\n‚Ä¢ Can progress to **cirrhosis**\n\n**3. RENAL**\n‚Ä¢ **Renal tubular dysfunction** (Fanconi syndrome)\n‚Ä¢ **Aminoaciduria**\n‚Ä¢ **Proteinuria**\n\n**4. OCULAR** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Early infantile cataracts** ‚≠ê (\"oil-drop\" cataract)\n‚Ä¢ Due to **galactitol** accumulation in lens\n‚Ä¢ Can appear **within days** of milk feeding\n‚Ä¢ **Reversible** if diet started early\n\n**5. NEUROLOGICAL**\n‚Ä¢ **Lethargy**, **hypotonia**\n‚Ä¢ Risk of **E. coli sepsis** ‚ö†Ô∏è (neonatal period)\n‚Ä¢ **Intellectual disability** (if untreated)\n‚Ä¢ **Developmental delay**\n\n**6. OVARIAN FAILURE** (females)\n‚Ä¢ **Primary ovarian insufficiency** (POI)\n‚Ä¢ **Hypergonadotropic hypogonadism**\n‚Ä¢ Occurs despite treatment ‚ö†Ô∏è\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° PATHOPHYSIOLOGY OF TOXICITY:\n\n**GALACTOSE-1-PHOSPHATE ACCUMULATION:**\n‚Ä¢ **Inhibits** glucokinase, phosphoglucomutase\n‚Ä¢ ‚Üí **Hypoglycemia**\n‚Ä¢ **Hepatotoxicity** (direct toxic effect)\n‚Ä¢ **Renal tubular damage**\n\n**GALACTITOL ACCUMULATION:**\n‚Ä¢ **Aldose reductase** converts galactose ‚Üí **galactitol**\n‚Ä¢ Galactitol **accumulates in lens** (polyol pathway)\n‚Ä¢ **Osmotic stress** ‚Üí lens swelling\n‚Ä¢ ‚Üí **Cataracts** ‚≠ê\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Galactokinase** ‚ùå\n‚Ä¢ Deficiency causes **Type 2** galactosemia\n‚Ä¢ **ONLY cataracts**, no systemic involvement ‚ö†Ô∏è\n‚Ä¢ **NO vomiting, acidosis, hepatomegaly**\n‚Ä¢ **Milder** presentation\n\n**C. Hexokinase** ‚ùå\n‚Ä¢ **NOT involved** in galactose metabolism\n‚Ä¢ Phosphorylates **glucose** ‚Üí glucose-6-phosphate\n‚Ä¢ Part of **glycolysis**, not galactose pathway\n\n**D. Aldose reductase** ‚ùå\n‚Ä¢ **NOT deficient** in galactosemia\n‚Ä¢ Actually **INCREASED** activity\n‚Ä¢ Converts galactose ‚Üí galactitol (worsens cataracts)\n‚Ä¢ **Not the primary defect**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIAGNOSIS:\n\n**NEWBORN SCREENING** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Guthrie test** (bacterial inhibition assay)\n‚Ä¢ **Elevated galactose** in blood\n‚Ä¢ **Elevated Gal-1-P** in RBCs\n\n**CONFIRMATORY TESTS:**\n‚Ä¢ **GALT enzyme activity** in RBCs ‚≠ê (absent or <5% normal)\n‚Ä¢ **Genetic testing** (GALT gene mutations)\n‚Ä¢ **Urinary reducing substances** positive (Clinitest +, glucose oxidase ‚àí)\n\n**ADDITIONAL:**\n‚Ä¢ **Liver function tests** (elevated transaminases)\n‚Ä¢ **Coagulation profile** (prolonged PT/INR)\n‚Ä¢ **Blood glucose** (hypoglycemia)\n‚Ä¢ **Amino acids** in urine\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**IMMEDIATE:**\n\n‚Ä¢ **Stop ALL lactose/galactose** ‚≠ê‚≠ê‚≠ê **LIFELONG**\n‚Ä¢ **Stop breastfeeding** immediately\n‚Ä¢ **Soy-based formula** or lactose-free formula\n\n**DIETARY RESTRICTIONS:**\n\n‚Ä¢ **NO milk, dairy products** (lactose)\n‚Ä¢ **NO legumes** (raffinose, stachyose contain galactose)\n‚Ä¢ **Avoid** certain vegetables (peas, beans)\n‚Ä¢ **Read labels** carefully (hidden galactose)\n\n**MONITORING:**\n\n‚Ä¢ **Galactose-1-phosphate levels** in RBCs\n‚Ä¢ **Growth & development**\n‚Ä¢ **Liver function**\n‚Ä¢ **Ophthalmology** (cataracts)\n‚Ä¢ **Ovarian function** (females)\n\n**PROGNOSIS:**\n\n‚Ä¢ **Early treatment** (within 10 days): ‚úì Good outcome\n‚Ä¢ **Cataracts** may reverse if caught very early\n‚Ä¢ **Ovarian failure** occurs despite treatment ‚ö†Ô∏è\n‚Ä¢ **Learning difficulties** may persist (10-50%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Classic Galactosemia = GALT deficiency** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**GALT** causes **GAL**actose to **HALT**!\"\n\n**Triad:** \n‚Ä¢ **Vomiting** (after milk) + **Acidosis** + **Early cataracts** ‚≠ê\n‚Ä¢ Hepatomegaly + Hypoglycemia\n‚Ä¢ E. coli sepsis risk (neonate)\n\n**Treatment:**\n‚Ä¢ **Lifelong galactose-free diet** (no milk/dairy)\n‚Ä¢ **Soy-based formula**\n‚Ä¢ Early diagnosis crucial (newborn screening)\n\n**Key difference from Galactokinase deficiency:**\n‚Ä¢ Galactokinase = **Cataracts ONLY** (no systemic symptoms)\n‚Ä¢ GALT = **Multi-system** (hepatic, renal, neurological + cataracts)",
    difficulty: "medium",
    imageUrl: "/images/questions/page9_img21.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-24",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Diagnosis of MRI image:",
    options: [
      "Arnold-Chiari malformation",
      "Corpus callosal agenesis",
      "Vein of Galen malformation",
      "Dandy-Walker malformation"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Arnold-Chiari malformation (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Arnold-Chiari malformations** (now called **Chiari malformations**) are a group of **congenital hindbrain abnormalities** involving **herniation of cerebellar structures** through the foramen magnum into the spinal canal.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå TYPES OF CHIARI MALFORMATIONS:\n\n**CHIARI TYPE I** ‚≠ê‚≠ê‚≠ê **(MOST COMMON in adults)**\n\n**ANATOMY:**\n‚Ä¢ **Cerebellar tonsils herniate** >5 mm below foramen magnum ‚≠ê\n‚Ä¢ **No brainstem** involvement\n‚Ä¢ Often **asymptomatic** until adulthood\n\n**AGE:** Adolescence/young adults (20s-30s)\n\n**ASSOCIATIONS:**\n‚Ä¢ **Syringomyelia** (50-70%) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hydrocephalus** (rare)\n‚Ä¢ **Scoliosis**\n\n**SYMPTOMS:**\n‚Ä¢ **Headache** (occipital, worse with Valsalva) ‚≠ê\n‚Ä¢ **Neck pain**\n‚Ä¢ **Ataxia, dizziness**\n‚Ä¢ **Syringomyelia symptoms:**\n  ‚Üí **Cape-like** sensory loss (pain/temperature)\n  ‚Üí **Motor weakness** (hands)\n  ‚Üí **Charcot joints**\n\n**CHIARI TYPE II** (Arnold-Chiari) ‚≠ê‚≠ê‚≠ê **CLASSIC**\n\n**ANATOMY:**\n‚Ä¢ **Cerebellar vermis + tonsils + medulla** herniate ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Small posterior fossa**\n‚Ä¢ **Tectal beaking** (tectum deformed)\n‚Ä¢ **Elongated 4th ventricle**\n\n**ALWAYS associated with:**\n‚Ä¢ **Myelomeningocele** (lumbosacral) ‚≠ê‚≠ê‚≠ê **100%**\n‚Ä¢ **Hydrocephalus** (90%)\n‚Ä¢ **Syringomyelia** (50-90%)\n\n**AGE:** **Infancy/childhood**\n\n**SYMPTOMS:**\n‚Ä¢ **Feeding difficulties**, weak cry\n‚Ä¢ **Stridor** (vocal cord paralysis)\n‚Ä¢ **Apnea** (brainstem compression)\n‚Ä¢ **Developmental delay**\n‚Ä¢ **Lower cranial nerve palsies** (IX, X, XI, XII)\n\n**CHIARI TYPE III** (Rare, severe)\n‚Ä¢ **Cerebellar herniation** into **occipital encephalocele**\n‚Ä¢ **High mortality**\n\n**CHIARI TYPE IV** (Rare)\n‚Ä¢ **Cerebellar hypoplasia** (no herniation)\n‚Ä¢ **Incompatible with life**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ MRI FINDINGS (Chiari I & II):\n\n**CHIARI TYPE I:**\n‚Ä¢ **Cerebellar tonsils >5 mm** below foramen magnum ‚≠ê\n‚Ä¢ **\"Peg-like\" tonsils**\n‚Ä¢ **Crowding** at craniocervical junction\n‚Ä¢ May have **syrinx** in spinal cord\n\n**CHIARI TYPE II:**\n‚Ä¢ **Vermis + tonsils + medulla** herniate ‚≠ê\n‚Ä¢ **Small posterior fossa**\n‚Ä¢ **\"Banana\" sign** (curved cerebellum) on fetal US\n‚Ä¢ **\"Lemon\" sign** (frontal bossing) on fetal US\n‚Ä¢ **Enlarged foramen magnum**\n‚Ä¢ **Beaked tectum**\n‚Ä¢ **Cervical syringomyelia**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Corpus callosal agenesis** ‚ùå\n\n‚Ä¢ **Absence/underdevelopment** of corpus callosum\n‚Ä¢ MRI shows:\n  ‚Üí **\"Moose antler\" ventricles** (lateral ventricles widely separated)\n  ‚Üí **Absent corpus callosum**\n  ‚Üí **High-riding 3rd ventricle**\n‚Ä¢ **NO cerebellar herniation**\n‚Ä¢ Different malformation\n\n**C. Vein of Galen malformation** ‚ùå\n\n‚Ä¢ **Arteriovenous malformation** (AVM)\n‚Ä¢ **Dilated vein of Galen** (aneurysmal)\n‚Ä¢ MRI/angiography shows:\n  ‚Üí **Large midline vascular mass**\n  ‚Üí **Flow voids** (high-flow vessel)\n‚Ä¢ Presents with:\n  ‚Üí **High-output cardiac failure** (neonates)\n  ‚Üí **Hydrocephalus** (venous congestion)\n‚Ä¢ **NOT a hindbrain malformation**\n\n**D. Dandy-Walker malformation** ‚ùå\n\n‚Ä¢ **Posterior fossa cyst** + **cerebellar vermis hypoplasia** ‚≠ê\n‚Ä¢ MRI shows:\n  ‚Üí **Large posterior fossa cyst**\n  ‚Üí **Absent/hypoplastic cerebellar vermis**\n  ‚Üí **Elevated tentorium**\n  ‚Üí **Enlarged 4th ventricle**\n‚Ä¢ **NO cerebellar herniation** ‚ö†Ô∏è\n‚Ä¢ Key difference: **Vermis absent** (Chiari: vermis herniates)\n‚Ä¢ Associated with **hydrocephalus** (80%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ COMPARISON:\n\n| Feature | Chiari I | Chiari II | Dandy-Walker |\n|---------|----------|-----------|-------------|\n| **Tonsils** | Herniate >5mm | Herniate | Normal position |\n| **Vermis** | Normal | **Herniates** | **Absent/hypoplastic** |\n| **Myelomeningocele** | No | **Yes (100%)** ‚≠ê | No |\n| **Hydrocephalus** | Rare | **Common (90%)** | Common (80%) |\n| **Age** | Adults | **Infants** | Infants |\n| **Posterior fossa** | Normal size | **Small** | **Enlarged (cyst)** |\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**INDICATIONS FOR SURGERY:**\n‚Ä¢ **Symptomatic** patients\n‚Ä¢ **Progressive symptoms**\n‚Ä¢ **Syringomyelia** (enlarging)\n\n**SURGICAL OPTIONS:**\n\n**1. POSTERIOR FOSSA DECOMPRESSION** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Suboccipital craniectomy**\n‚Ä¢ **C1 laminectomy**\n‚Ä¢ **Duraplasty** (enlarge dura)\n‚Ä¢ Relieves compression\n\n**2. VP SHUNT** (if hydrocephalus)\n\n**3. SYRINX DRAINAGE** (if large)\n\n**OUTCOMES:**\n‚Ä¢ **Headache** improves in 80%\n‚Ä¢ **Syrinx** stabilizes/reduces\n‚Ä¢ **Motor symptoms** may improve\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Chiari Malformation = Cerebellar herniation through foramen magnum** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**C**hiari **H**erniates, **D**andy-Walker **D**eficient (absent vermis)!\"\n\n**Type I:**\n‚Ä¢ **Tonsils only** herniate\n‚Ä¢ **Adults**, headache\n‚Ä¢ Associated with **syringomyelia**\n\n**Type II (Arnold-Chiari):**\n‚Ä¢ **Tonsils + vermis + medulla** herniate ‚≠ê\n‚Ä¢ **Infants**, always with **myelomeningocele**\n‚Ä¢ **Hydrocephalus** common\n\n**MRI:** Diagnostic - shows herniation below foramen magnum",
    difficulty: "medium",
    imageUrl: "/images/questions/page10_img23.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-25",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2024",
    question: "A 76-year-old elderly patient presents in a confused state. He is on antihypertensive\nmedication and on aspirin due to a previous heart attack. There is a minor trauma due\nto fall from a chair 3 weeks back. NCCT is done and shows the following. Diagnosis?",
    options: [
      "SAH (Subarachnoid Hemorrhage)",
      "EDH (Epidural Hematoma)",
      "Normal Study",
      "Chronic SDH (Subdural Hematoma)"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Chronic Subdural Hematoma (SDH) (Option D)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Chronic Subdural Hematoma (SDH)** is a collection of **old blood** in the **subdural space** (between dura and arachnoid), occurring **weeks to months** after minor head trauma, most commonly in **elderly** patients.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå TYPES OF INTRACRANIAL HEMORRHAGE:\n\n**ACUTE SDH** (0-3 days):\n‚Ä¢ **Hyperdense** (bright) on CT\n‚Ä¢ **Crescent-shaped** ‚≠ê\n‚Ä¢ Crosses suture lines\n‚Ä¢ Severe trauma usually\n\n**SUBACUTE SDH** (3-21 days):\n‚Ä¢ **Isodense** (same as brain)\n‚Ä¢ May be missed on CT\n\n**CHRONIC SDH** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **Hypodense** (dark) on CT ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **>3 weeks** after trauma\n‚Ä¢ **Crescent-shaped**\n‚Ä¢ **Elderly**, **alcoholics**, **anticoagulated** patients\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ RISK FACTORS FOR CHRONIC SDH:\n\n**HIGH RISK:**\n\n‚Ä¢ **Age >65 years** ‚≠ê‚≠ê‚≠ê (brain atrophy ‚Üí bridging veins stretched)\n‚Ä¢ **Anticoagulation** (aspirin, warfarin, NOACs) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Antiplatelet therapy** (aspirin, clopidogrel) ‚≠ê\n‚Ä¢ **Alcohol abuse** (brain atrophy, coagulopathy)\n‚Ä¢ **Dementia** (brain atrophy)\n‚Ä¢ **Falls** (minor trauma sufficient)\n\n**MECHANISM:**\n‚Ä¢ **Brain atrophy** ‚Üí ‚Üë subdural space\n‚Ä¢ **Bridging veins** stretched and fragile\n‚Ä¢ **Minor trauma** tears vein\n‚Ä¢ **Slow bleeding** into subdural space\n‚Ä¢ Blood **liquefies** over weeks (fibrinolysis)\n‚Ä¢ ‚Üí **Hypodense** appearance\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL PRESENTATION:\n\n**TIMELINE:** Symptoms **weeks to months** after trauma ‚≠ê\n\n**CLASSIC TRIAD** (often incomplete):\n‚Ä¢ **Confusion/altered mental status** ‚≠ê‚≠ê‚≠ê (most common)\n‚Ä¢ **Headache** (gradual onset)\n‚Ä¢ **Gait disturbance/ataxia**\n\n**OTHER SYMPTOMS:**\n‚Ä¢ **Cognitive decline** (mimics dementia)\n‚Ä¢ **Hemiparesis** (focal weakness)\n‚Ä¢ **Seizures**\n‚Ä¢ **Speech difficulties**\n‚Ä¢ **Personality changes**\n‚Ä¢ **Urinary incontinence**\n\n**PRESENTATION IN THIS CASE:**\n‚Ä¢ **76-year-old** ‚úì (elderly)\n‚Ä¢ **Antihypertensive + aspirin** ‚úì (antiplatelet)\n‚Ä¢ **Minor trauma 3 weeks ago** ‚úì (chronic timeframe)\n‚Ä¢ **Confusion** ‚úì (classic symptom)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã CT FINDINGS:\n\n**CHRONIC SDH:**\n‚Ä¢ **Hypodense** (darker than brain) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Crescent-shaped** (follows brain contour)\n‚Ä¢ **Crosses suture lines** (unlike epidural)\n‚Ä¢ May have **fluid-fluid level** (rebleeding)\n‚Ä¢ **Mass effect** (midline shift)\n‚Ä¢ **Bilateral** in 25%\n\n**vs ACUTE SDH:**\n‚Ä¢ **Hyperdense** (brighter than brain)\n‚Ä¢ Recent trauma\n\n**vs SUBDURAL HYGROMA:**\n‚Ä¢ **CSF-density** (very hypodense)\n‚Ä¢ No blood products\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Subarachnoid Hemorrhage (SAH)** ‚ùå\n\n‚Ä¢ **Sudden severe headache** (\"thunderclap\") ‚≠ê\n‚Ä¢ \"**Worst headache of life**\"\n‚Ä¢ CT shows:\n  ‚Üí **Blood in subarachnoid spaces** (sulci, cisterns)\n  ‚Üí **Star-shaped** around brain\n  ‚Üí **NOT crescent-shaped**\n‚Ä¢ Acute onset (not 3 weeks)\n‚Ä¢ Usually from **aneurysm rupture**\n\n**B. Epidural Hematoma (EDH)** ‚ùå\n\n‚Ä¢ **Biconvex/lens-shaped** ‚≠ê‚≠ê‚≠ê (NOT crescent)\n‚Ä¢ **Does NOT cross suture lines** ‚ö†Ô∏è\n‚Ä¢ **High-impact trauma** (usually)\n‚Ä¢ **Middle meningeal artery** tear\n‚Ä¢ **Lucid interval** classic (but not always)\n‚Ä¢ **Hyperdense** (acute blood)\n‚Ä¢ Younger patients typically\n\n**C. Normal Study** ‚ùå\n\n‚Ä¢ Patient is **confused** with **trauma history**\n‚Ä¢ **Anticoagulated** (aspirin)\n‚Ä¢ **Must have pathology** to explain symptoms\n‚Ä¢ Chronic SDH would show **hypodense crescent**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**INDICATIONS FOR SURGERY:**\n‚Ä¢ **Symptomatic** (confusion, weakness)\n‚Ä¢ **>10 mm thickness**\n‚Ä¢ **Midline shift >5 mm**\n‚Ä¢ **Mass effect**\n\n**SURGICAL OPTIONS:**\n\n**1. BURR HOLE DRAINAGE** ‚≠ê‚≠ê‚≠ê (Most common)\n‚Ä¢ Simple, quick procedure\n‚Ä¢ Drill burr hole(s)\n‚Ä¢ Drain liquefied blood\n‚Ä¢ **Subdural drain** left 24-48 hrs\n‚Ä¢ **Success rate 70-90%**\n\n**2. CRANIOTOMY** (if organized/septated)\n‚Ä¢ Larger opening\n‚Ä¢ Remove membranes\n‚Ä¢ For complex/recurrent cases\n\n**MEDICAL MANAGEMENT:**\n‚Ä¢ **Stop anticoagulation** (if safe)\n‚Ä¢ **Reverse coagulopathy**\n‚Ä¢ **Monitor** (if small, asymptomatic)\n\n**RECURRENCE:**\n‚Ä¢ **10-30%** recurrence rate\n‚Ä¢ May need repeat drainage\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Chronic SDH = Elderly + Minor trauma + Weeks later + Confusion + Hypodense crescent** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**C**hronic SDH is **D**ark (**H**ypodense) on CT!\"\n\n**Classic scenario:**\n‚Ä¢ **Elderly patient** (brain atrophy)\n‚Ä¢ **Anticoagulation/antiplatelet** (aspirin) ‚≠ê\n‚Ä¢ **Minor trauma** (even trivial/forgotten)\n‚Ä¢ **Delayed presentation** (3 weeks in this case) ‚≠ê\n‚Ä¢ **Gradual confusion** (not acute)\n\n**CT:** **Hypodense crescent** (darker than brain)\n\n**Treatment:** **Burr hole drainage** (simple, effective)",
    difficulty: "medium",
    imageUrl: "/images/questions/page10_img24.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-26",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "Diagnosis of MRCP image:",
    options: [
      "GB Stone (Gallbladder Stone)",
      "Cholangiocarcinoma",
      "Choledochal Cyst",
      "Gall and Blood Cancer"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Cholangiocarcinoma (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Cholangiocarcinoma (CCA)** is a **malignant tumor** arising from **bile duct epithelium**, presenting as a **stricture or mass** on MRCP imaging.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå CLASSIFICATION BY LOCATION:\n\n**INTRAHEPATIC CCA** (10-20%)\n‚Ä¢ Within liver parenchyma\n‚Ä¢ Mass lesion\n‚Ä¢ Better prognosis\n\n**PERIHILAR (Klatskin tumor)** ‚≠ê‚≠ê‚≠ê (50-60%) **MOST COMMON**\n‚Ä¢ **Confluence of right & left hepatic ducts**\n‚Ä¢ **Stricture** appearance on MRCP ‚≠ê\n‚Ä¢ Worst prognosis\n‚Ä¢ Named after Gerald Klatskin\n\n**DISTAL (Extrahepatic)** (20-30%)\n‚Ä¢ Common bile duct\n‚Ä¢ Presents like pancreatic head cancer\n‚Ä¢ Jaundice early\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ MRCP FINDINGS:\n\n**CHOLANGIOCARCINOMA:**\n‚Ä¢ **Irregular stricture** ‚≠ê‚≠ê‚≠ê (abrupt, asymmetric)\n‚Ä¢ **Bile duct cutoff** (sudden termination)\n‚Ä¢ **Upstream dilatation** (dilated ducts proximal to stricture)\n‚Ä¢ **Mass** (if intrahepatic)\n‚Ä¢ **\"Pruned tree\" appearance** (peripheral ducts not filling)\n‚Ä¢ May show **vascular encasement**\n\n**MRCP = Magnetic Resonance Cholangiopancreatography:**\n‚Ä¢ **Non-invasive** visualization of biliary tree\n‚Ä¢ **Gold standard** for biliary imaging ‚≠ê\n‚Ä¢ Shows anatomy without contrast\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ RISK FACTORS:\n\n**HIGH RISK:**\n‚Ä¢ **Primary Sclerosing Cholangitis (PSC)** ‚≠ê‚≠ê‚≠ê (10-15% lifetime risk)\n‚Ä¢ **Liver flukes** (*Clonorchis sinensis*, *Opisthorchis viverrini*) - Asia\n‚Ä¢ **Choledochal cysts**\n‚Ä¢ **Hepatolithiasis** (intrahepatic stones)\n‚Ä¢ **Thorotrast exposure** (old contrast agent)\n‚Ä¢ **Chronic hepatitis B/C**\n\n**ASSOCIATIONS:**\n‚Ä¢ **Ulcerative colitis** (via PSC)\n‚Ä¢ **Caroli disease**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Gallbladder Stone** ‚ùå\n‚Ä¢ **Filling defect** in GB (not bile duct stricture)\n‚Ä¢ **Mobile** (changes position)\n‚Ä¢ **Round/oval** shape\n‚Ä¢ **Acoustic shadow** on ultrasound\n‚Ä¢ **No bile duct stricture** ‚ö†Ô∏è\n‚Ä¢ May cause **secondary** CBD obstruction but different appearance\n\n**C. Choledochal Cyst** ‚ùå\n‚Ä¢ **Congenital dilatation** of bile ducts ‚≠ê\n‚Ä¢ **Smooth, fusiform** dilatation (NOT stricture) ‚ö†Ô∏è\n‚Ä¢ **Todani classification** (Type I-V)\n‚Ä¢ MRCP shows **cystic dilatation**, not stricture\n‚Ä¢ Presents in **children** usually\n‚Ä¢ **Increased risk** of cholangiocarcinoma (10-15%)\n\n**D. Gall and Blood Cancer** ‚ùå\n‚Ä¢ Not a recognized medical term\n‚Ä¢ Possibly referring to **gallbladder carcinoma**?\n‚Ä¢ GB carcinoma:\n  ‚Üí **Thickened GB wall** (>3mm)\n  ‚Üí **Mass** replacing GB\n  ‚Üí **NOT bile duct stricture**\n  ‚Üí Different imaging appearance\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL PRESENTATION:\n\n**SYMPTOMS:**\n‚Ä¢ **Painless progressive jaundice** ‚≠ê‚≠ê‚≠ê (most common)\n‚Ä¢ **Pruritus** (itching from bile salts)\n‚Ä¢ **Weight loss** (malignancy)\n‚Ä¢ **Clay-colored stools** (acholic)\n‚Ä¢ **Dark urine** (tea-colored)\n‚Ä¢ **Hepatomegaly**\n‚Ä¢ **Courvoisier sign** (palpable, non-tender GB) - if distal\n\n**LABS:**\n‚Ä¢ **‚Üë‚Üë Alkaline phosphatase** ‚≠ê‚≠ê‚≠ê (cholestatic pattern)\n‚Ä¢ **‚Üë‚Üë Direct bilirubin** (conjugated)\n‚Ä¢ **‚Üë GGT**\n‚Ä¢ **CA 19-9** elevated (tumor marker, not specific)\n‚Ä¢ **CEA** may be elevated\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã DIAGNOSTIC WORKUP:\n\n**IMAGING:**\n\n**1. MRCP** ‚≠ê‚≠ê‚≠ê **BEST non-invasive**\n‚Ä¢ Shows stricture, level of obstruction\n‚Ä¢ Assesses resectability\n\n**2. CT Abdomen with contrast**\n‚Ä¢ Staging (metastases, vascular involvement)\n‚Ä¢ Lymph nodes\n\n**3. ERCP** (Endoscopic Retrograde Cholangiopancreatography)\n‚Ä¢ **Diagnostic + therapeutic**\n‚Ä¢ Can obtain **brush cytology/biopsy**\n‚Ä¢ Can place **stent** for drainage\n\n**4. PET-CT** (staging)\n\n**BIOPSY:**\n‚Ä¢ Often **not needed** preoperatively if resectable\n‚Ä¢ Risk of **peritoneal seeding**\n‚Ä¢ ERCP brushings (low sensitivity ~30%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**CURATIVE:**\n\n**SURGERY** (only curative option) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Resectable** in only 20-30% at diagnosis ‚ö†Ô∏è\n\n**Perihilar (Klatskin):**\n‚Ä¢ **Hepatic resection + bile duct excision**\n‚Ä¢ Very complex surgery\n‚Ä¢ 5-year survival: 20-40%\n\n**Distal:**\n‚Ä¢ **Whipple procedure** (pancreaticoduodenectomy)\n‚Ä¢ Better outcomes than perihilar\n\n**Intrahepatic:**\n‚Ä¢ **Hepatectomy** (liver resection)\n\n**PALLIATIVE:**\n\n**1. BILIARY DRAINAGE** ‚≠ê\n‚Ä¢ **ERCP with stenting** (plastic or metal)\n‚Ä¢ **Percutaneous transhepatic drainage (PTD)**\n‚Ä¢ Relieves jaundice, pruritus\n\n**2. CHEMOTHERAPY**\n‚Ä¢ **Gemcitabine + Cisplatin** (standard)\n‚Ä¢ Modest survival benefit\n\n**PROGNOSIS:**\n‚Ä¢ **Poor** overall (5-year survival <10% for unresectable)\n‚Ä¢ **Late diagnosis** (usually advanced at presentation)\n‚Ä¢ **Perihilar worst** prognosis\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Cholangiocarcinoma on MRCP = Irregular stricture + Upstream dilatation** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**C**holangiocarcinoma **C**auses **C**utoff (stricture)!\"\n\n**Classic presentation:**\n‚Ä¢ **Painless progressive jaundice**\n‚Ä¢ **‚Üë‚Üë Alkaline phosphatase** (cholestatic)\n‚Ä¢ **MRCP:** Irregular bile duct stricture\n‚Ä¢ **Most common site:** Perihilar (Klatskin tumor)\n\n**Risk factors:** **PSC** (primary sclerosing cholangitis) ‚≠ê‚≠ê‚≠ê\n\n**Treatment:** Surgery only if resectable (minority), otherwise palliative drainage + chemo",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-27",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A 35-year-old nullipara female presented with dull aching pain with exacerbation\nduring the menstrual cycle. USG reveals a heterogeneous mass in the right adnexa.\nMRI reveals a 4 x 5 cm T1 hyperintense mass with no suppression on fat-saturated\nimages. T2-weighted images show low signal with dark shading. Diagnosis?",
    options: [
      "Dermoid cyst",
      "Endometrioma",
      "Ovarian cancer",
      "Para-Ovarian Cyst"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Endometrioma (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Endometrioma** (\"chocolate cyst\") is an **ovarian cyst** containing **old hemorrhagic blood** from **ectopic endometrial tissue**. It's a manifestation of **endometriosis** affecting the ovaries.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå ENDOMETRIOSIS OVERVIEW:\n\n**DEFINITION:** **Endometrial tissue outside uterus** ‚≠ê\n\n**COMMON SITES:**\n‚Ä¢ **Ovaries** ‚≠ê‚≠ê‚≠ê (most common - endometrioma)\n‚Ä¢ **Pouch of Douglas** (rectovaginal septum)\n‚Ä¢ **Uterosacral ligaments**\n‚Ä¢ **Peritoneum**\n‚Ä¢ Rare: lungs, brain, surgical scars\n\n**ENDOMETRIOMA:**\n‚Ä¢ **Ovarian endometriosis** specifically\n‚Ä¢ **Size:** 3-10 cm typically\n‚Ä¢ Contains **thick, dark blood** ‚Üí \"**Chocolate cyst**\" ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bilateral** in 50%\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL PRESENTATION:\n\n**THIS CASE:**\n‚Ä¢ **35-year-old nullipara** ‚úì (peak age 25-35)\n‚Ä¢ **Dull aching pain** ‚úì\n‚Ä¢ **Exacerbation during menstrual cycle** ‚úì‚≠ê‚≠ê‚≠ê (KEY!)\n‚Ä¢ **Right adnexal mass** on USG\n\n**CLASSIC TRIAD:**\n‚Ä¢ **Dysmenorrhea** ‚≠ê‚≠ê‚≠ê (painful periods) **PROGRESSIVE**\n‚Ä¢ **Dyspareunia** (painful intercourse)\n‚Ä¢ **Infertility** ‚≠ê‚≠ê‚≠ê (25-50% of infertile women have endometriosis)\n\n**OTHER SYMPTOMS:**\n‚Ä¢ **Chronic pelvic pain** (cyclical or constant)\n‚Ä¢ **Dyschezia** (painful defecation) - if rectovaginal\n‚Ä¢ **Dysuria** (painful urination) - if bladder involvement\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã MRI FINDINGS (PATHOGNOMONIC):\n\n**ENDOMETRIOMA** ‚≠ê‚≠ê‚≠ê:\n\n**T1-weighted:**\n‚Ä¢ **Hyperintense** (bright) ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **No suppression** on fat-saturated images ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n  ‚Üí Key: differentiates from dermoid (fat suppresses)\n\n**T2-weighted:**\n‚Ä¢ **Low signal** (dark) ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **\"Dark shading\" sign** ‚≠ê‚≠ê‚≠ê **PATHOGNOMONIC**\n  ‚Üí Due to **methemoglobin** (breakdown product)\n  ‚Üí Layering effect from repeated hemorrhages\n\n**\"CHOCOLATE CYST\" appearance:**\n‚Ä¢ T1 bright + T2 dark = **old blood** with high protein/methemoglobin content\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Dermoid cyst (Mature cystic teratoma)** ‚ùå\n\n**MRI:**\n‚Ä¢ **T1 hyperintense** (due to **FAT**) ‚ö†Ô∏è\n‚Ä¢ **SUPPRESSES** on fat-saturated images ‚≠ê‚≠ê‚≠ê **KEY DIFFERENCE!**\n‚Ä¢ **T2 variable** signal\n‚Ä¢ **\"Fat-fluid level\"**\n‚Ä¢ May have **Rokitansky nodule** (mural nodule)\n\n**Clinical:**\n‚Ä¢ **Asymptomatic** usually\n‚Ä¢ **NO cyclical pain** ‚ö†Ô∏è\n‚Ä¢ **Young women** (20s-30s)\n‚Ä¢ **NO infertility** association\n\n**C. Ovarian cancer** ‚ùå\n\n**MRI:**\n‚Ä¢ **Complex mass** with solid + cystic components\n‚Ä¢ **Irregular thick septations**\n‚Ä¢ **Papillary projections**\n‚Ä¢ **Contrast enhancement**\n‚Ä¢ **Ascites**, **peritoneal nodules**\n‚Ä¢ **NOT uniform** T1/T2 pattern\n\n**Clinical:**\n‚Ä¢ **Older age** (>50 years) typically\n‚Ä¢ **Weight loss**, bloating, **ascites**\n‚Ä¢ **CA-125 markedly elevated**\n‚Ä¢ **NO cyclical pain**\n\n**D. Para-Ovarian Cyst** ‚ùå\n\n**MRI:**\n‚Ä¢ **Simple cyst** (thin-walled)\n‚Ä¢ **T1 hypointense** (dark) ‚ö†Ô∏è\n‚Ä¢ **T2 hyperintense** (bright) - simple fluid\n‚Ä¢ **NO dark shading**\n‚Ä¢ Located **separate from ovary** (broad ligament)\n\n**Clinical:**\n‚Ä¢ **Asymptomatic** usually\n‚Ä¢ **NO cyclical symptoms** ‚ö†Ô∏è\n‚Ä¢ **Incidental finding**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIAGNOSIS:\n\n**IMAGING:**\n‚Ä¢ **Transvaginal ultrasound** (first-line)\n  ‚Üí **\"Ground glass\"** echotexture\n‚Ä¢ **MRI** ‚≠ê‚≠ê‚≠ê (best for characterization)\n  ‚Üí T1 bright + T2 dark shading\n\n**LABS:**\n‚Ä¢ **CA-125** may be elevated (not specific)\n\n**GOLD STANDARD:**\n‚Ä¢ **Laparoscopy with histology** ‚≠ê\n‚Ä¢ But MRI findings are highly characteristic\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**MEDICAL** (suppress endometriosis):\n\n‚Ä¢ **NSAIDs** (pain relief)\n‚Ä¢ **OCPs** (continuous) ‚≠ê\n‚Ä¢ **GnRH agonists** (leuprolide) - temporary menopause\n‚Ä¢ **Progestins** (dienogest)\n\n**SURGICAL** (definitive):\n\n**Indications:**\n‚Ä¢ **Large** (>4 cm)\n‚Ä¢ **Symptomatic** (pain, infertility)\n‚Ä¢ **Suspicious** features\n\n**Procedure:**\n‚Ä¢ **Laparoscopic cystectomy** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Preserve ovarian tissue** (fertility)\n‚Ä¢ **Avoid cyst rupture** (spill can worsen endometriosis)\n‚Ä¢ **Recurrence** 10-40%\n\n**FERTILITY:**\n‚Ä¢ Surgery may **improve fertility**\n‚Ä¢ IVF if persistent infertility\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Endometrioma MRI = T1 bright + T2 dark (\"shading\") + No fat suppression** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**E**ndometrioma = **C**yclical pain + **C**hocolate cyst!\"\n\n**Classic case:**\n‚Ä¢ **Nulliparous woman** (20s-30s)\n‚Ä¢ **Cyclical pelvic pain** ‚≠ê‚≠ê‚≠ê (worse during menses)\n‚Ä¢ **Infertility**\n‚Ä¢ **MRI:** T1 bright + T2 dark shading + **NO fat suppression**\n\n**vs Dermoid:** Dermoid **suppresses** on fat-sat (has fat)\n**vs Simple cyst:** Simple cyst is T1 dark + T2 bright (water signal)",
    difficulty: "medium",
    imageUrl: "/images/questions/page11_img26.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-28",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Diagnosis of following Plain X-ray of abdomen:",
    options: [
      "Enterolith in jejunum",
      "Calcific mediastinal lymph nodes",
      "Horse shoe kidney with calculi",
      "Chronic calcific pancreatitis"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Chronic calcific pancreatitis (Option D)**\n\nüî¨ **Chronic pancreatitis** is **progressive inflammatory disease** causing **irreversible damage** to pancreatic parenchyma with **fibrosis** and **calcifications** ‚≠ê‚≠ê‚≠ê.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **CAUSES:**\n‚Ä¢ **Alcohol** (70-80%) ‚≠ê‚≠ê‚≠ê - most common\n‚Ä¢ **Idiopathic** (10-20%)\n‚Ä¢ **Genetic** (PRSS1, CFTR mutations)\n‚Ä¢ **Tropical pancreatitis**\n‚Ä¢ **Autoimmune**\n‚Ä¢ **Hypercalcemia, hyperlipidemia**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **IMAGING - PLAIN X-RAY ABDOMEN:**\n‚Ä¢ **Scattered pancreatic calcifications** ‚≠ê‚≠ê‚≠ê **DIAGNOSTIC**\n‚Ä¢ **Head, body, tail** distribution\n‚Ä¢ **Radio-opaque** stones (calcium carbonate)\n‚Ä¢ Seen in **50% of chronic pancreatitis**\n\n**WHY CALCIFICATIONS?**\n‚Ä¢ **Protein plugs** in ducts\n‚Ä¢ **Calcium deposition** on plugs\n‚Ä¢ **Ductal obstruction** ‚Üí stones\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä **CLINICAL:**\n‚Ä¢ **Recurrent epigastric pain** ‚≠ê\n‚Ä¢ **Steatorrhea** (fatty stools) - exocrine insufficiency\n‚Ä¢ **Diabetes** - endocrine insufficiency\n‚Ä¢ **Weight loss**\n\nüí° **KEY:** Plain X-ray showing **pancreatic calcifications** = **Chronic calcific pancreatitis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-29",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient has Proteus infection and now plain X-ray of abdomen was done and a\nlarge stone was shown in the urinary bladder. The stone is made up of:",
    options: [
      "Calcium Phosphate",
      "Cysteine",
      "Calcium Oxalate",
      "Xanthine"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Calcium Phosphate (Option A)** - Actually, this should be **STRUVITE (Magnesium Ammonium Phosphate)**\n\nüî¨ **PROTEUS INFECTION** ‚Üí **STRUVITE (STAGHORN) CALCULI** ‚≠ê‚≠ê‚≠ê\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **MECHANISM:**\n\n**Proteus** (urease-positive bacteria) ‚≠ê‚≠ê‚≠ê\n\n   ‚Üì (produces **UREASE** enzyme)\n\n**Urea ‚Üí Ammonia + CO‚ÇÇ**\n\n   ‚Üì\n\n**‚Üë‚Üë Urine pH** (alkaline, >7.2) ‚≠ê‚≠ê‚≠ê\n\n   ‚Üì\n\n**Precipitation of:**\n‚Ä¢ **Magnesium Ammonium Phosphate (STRUVITE)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Calcium Phosphate (Carbonate Apatite)**\n\n   ‚Üì\n\n**STAGHORN CALCULUS** (fills renal pelvis)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **STRUVITE STONES (\"Infection stones\"):**\n‚Ä¢ **Composition:** **MgNH‚ÇÑPO‚ÇÑ¬∑6H‚ÇÇO** (Triple phosphate) ‚≠ê\n‚Ä¢ **Large, branching** (staghorn)\n‚Ä¢ **Radio-opaque** (visible on X-ray)\n‚Ä¢ **Alkaline urine** (pH >7.2)\n‚Ä¢ **Urease-positive organisms:**\n  ‚Üí **Proteus** ‚≠ê‚≠ê‚≠ê (most common)\n  ‚Üí Klebsiella, Pseudomonas, Staphylococcus\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä **TREATMENT:**\n‚Ä¢ **Surgical removal** (PCNL, nephrolithotomy)\n‚Ä¢ **Antibiotics** (treat infection)\n‚Ä¢ **Acidify urine** (vitamin C)\n‚Ä¢ **Urease inhibitors** (acetohydroxamic acid)\n\nüí° **KEY:** **Proteus + Large stone = STRUVITE (Magnesium Ammonium Phosphate)** ‚≠ê‚≠ê‚≠ê\n\n**Note:** Question answer says Calcium Phosphate, but medically, **Proteus specifically causes STRUVITE stones**. Both precipitate together in alkaline urine from Proteus infection.",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-30",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Correct statement regarding esophageal foreign body (FB):",
    options: [
      "Right main bronchus is one of the sites of constriction",
      "Most common site of impaction is cricopharyngeus",
      "Commonly seen in adults",
      "Can‚Äôt cause mediastinitis"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Most common site of impaction is cricopharyngeus (Option B)**\n\nüî¨ **ESOPHAGEAL FOREIGN BODY** impaction occurs at **anatomical narrowings** ‚≠ê\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **3 SITES OF ESOPHAGEAL CONSTRICTION:**\n\n**1. CRICOPHARYNGEUS (Upper Esophageal Sphincter)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **C6 level** (15 cm from incisors)\n‚Ä¢ **MOST COMMON site** (70%) ‚≠ê‚≠ê‚≠ê **ANSWER**\n‚Ä¢ **Physiological sphincter**\n‚Ä¢ Especially in **children** (coins, toys)\n\n**2. AORTIC ARCH (Middle)**\n‚Ä¢ **T4 level** (22-23 cm from incisors)\n‚Ä¢ **Aorta crosses** esophagus\n‚Ä¢ **Left main bronchus** also crosses here\n\n**3. LOWER ESOPHAGEAL SPHINCTER (Gastroesophageal junction)**\n‚Ä¢ **T10-T11** (38-40 cm from incisors)\n‚Ä¢ **Diaphragmatic hiatus**\n‚Ä¢ Food bolus impaction in adults\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **COMPLICATIONS:**\n‚Ä¢ **Perforation** ‚Üí **Mediastinitis** ‚ö†Ô∏è (can cause!)\n‚Ä¢ **Retropharyngeal abscess**\n‚Ä¢ **Tracheoesophageal fistula**\n‚Ä¢ **Aortoesophageal fistula** (rare, fatal)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå **WHY OTHER OPTIONS WRONG:**\n‚Ä¢ **A. Right main bronchus** - NOT esophageal site\n‚Ä¢ **C. Adults** - More common in **CHILDREN** ‚ö†Ô∏è\n‚Ä¢ **D. Can't cause mediastinitis** - FALSE! **CAN cause** if perforation occurs\n\nüí° **KEY:** **Cricopharyngeus = Most common FB impaction site** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-31",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Gastrectomy patient needs supplemental: (PART A)",
    options: [
      "Vitamin C",
      "Vitamin D",
      "Vitamin B12",
      "Vitamin A"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Vitamin B12 (Option C)**\n\nüî¨ DETAILED EXPLANATION:\n\nAfter **gastrectomy**, **Vitamin B12 supplementation** is **MANDATORY and LIFELONG** due to loss of **intrinsic factor (IF)** production.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL B12 ABSORPTION:\n\n**1. DIETARY B12 (Cobalamin)**\n   ‚Üí Found in meat, fish, dairy, eggs\n\n**2. STOMACH** üéØ\n   ‚Üí **Gastric acid** releases B12 from proteins\n   ‚Üí **Parietal cells** secrete **Intrinsic Factor (IF)** ‚≠ê‚≠ê‚≠ê\n   ‚Üí **IF binds to B12** forming **B12-IF complex**\n\n**3. DUODENUM & JEJUNUM**\n   ‚Üí B12-IF complex remains stable\n\n**4. TERMINAL ILEUM**\n   ‚Üí **Cubam receptors** bind B12-IF complex\n   ‚Üí B12 absorbed into blood\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö†Ô∏è POST-GASTRECTOMY:\n\n**NO STOMACH** ‚Üí ‚ùå **No Parietal Cells**\n\n   ‚Üì\n\n‚ùå **No Intrinsic Factor**\n\n   ‚Üì\n\n‚ùå **No B12 Absorption** (terminal ileum needs B12-IF complex)\n\n   ‚Üì\n\n**MEGALOBLASTIC ANEMIA** (develops in 2-5 years)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä POST-GASTRECTOMY DEFICIENCIES:\n\n**‚òÖ‚òÖ‚òÖ VITAMIN B12** ‚≠ê‚≠ê‚≠ê **(MOST IMPORTANT)**\n\n‚Ä¢ **Mechanism:** No intrinsic factor\n‚Ä¢ **Time:** 2-5 years (after stores deplete)\n‚Ä¢ **Consequences:**\n  ‚Üí **Megaloblastic anemia** (macrocytic)\n  ‚Üí **Neurological:** Subacute combined degeneration\n  ‚Üí **Peripheral neuropathy**\n  ‚Üí **Cognitive impairment**\n‚Ä¢ **Treatment:** **IM B12** 1000 Œºg monthly (lifelong) ‚≠ê\n\n**‚òÖ‚òÖ IRON**\n‚Ä¢ **Mechanism:** ‚Üì Gastric acid, rapid emptying\n‚Ä¢ **Result:** Microcytic anemia\n\n**‚òÖ FOLATE**\n‚Ä¢ Decreased intake\n\n**‚òÖ CALCIUM & VITAMIN D**\n‚Ä¢ Malabsorption ‚Üí Osteoporosis\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ WHY OTHER OPTIONS WRONG:\n\n‚ùå **Vitamin A:** Not specifically affected, liver stores last years\n\n‚ùå **Vitamin C:** Absorbed throughout small intestine, doesn't need stomach\n\n‚ùå **Vitamin D:** While ‚Üì absorption occurs, **B12 is MORE CRITICAL and INEVITABLE**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**POST-GASTRECTOMY = LIFELONG B12 MANDATORY** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**No Stomach, No IF, No B12** ‚Üí Must give **B12 shots forever!**\"\n\n‚Ä¢ **Parietal cells** (stomach) produce **IF**\n‚Ä¢ **IF essential** for B12 absorption in **terminal ileum**\n‚Ä¢ Start supplementation **immediately** (don't wait!)",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-32",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "After a right limb amputation, the patient is experiencing severe phantom limb\npain. What is the mechanism behind this?",
    options: [
      "Projection of adjacent fibers to overlap to right sensory cortex",
      "Projection of adjacent fibers to overlap to left sensory cortex",
      "Expansion of right sensory cortex",
      "Expansion of left sensory cortex"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Projection of adjacent fibers to overlap to left sensory cortex (Option B)**\n\nüî¨ **PHANTOM LIMB PAIN** - Pain sensation from **amputated/missing limb** due to **cortical reorganization** ‚≠ê‚≠ê‚≠ê\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **MECHANISM (Cortical Remapping):**\n\n**NORMAL:** Right limb ‚Üí **Left sensory cortex** (contralateral)\n\n**AFTER RIGHT LIMB AMPUTATION:**\n\n**Step 1:** **Deafferentation** (no input from right limb)\n\n   ‚Üì\n\n**Step 2:** **Adjacent cortical areas** (face, trunk) ‚≠ê‚≠ê‚≠ê\n\n   ‚Üì **EXPAND and INVADE**\n\n**Step 3:** **Overlap onto LEFT sensory cortex** area previously for right limb ‚≠ê\n\n   ‚Üì\n\n**Result:** Touching **face** ‚Üí Brain interprets as **right limb** sensation!\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **KEY CONCEPTS:**\n‚Ä¢ **Right limb amputation** ‚Üí **LEFT cortex** affected (contralateral) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Adjacent fibers** (face, arm) **project** to limb area\n‚Ä¢ **Maladaptive plasticity** = reorganization causes pain\n‚Ä¢ **Penfield homunculus** - face adjacent to hand in cortex\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä **TREATMENT:**\n‚Ä¢ **Mirror therapy** ‚≠ê\n‚Ä¢ **Gabapentin, pregabalin**\n‚Ä¢ **Amitriptyline**\n‚Ä¢ **Transcutaneous nerve stimulation (TENS)**\n\nüí° **KEY:** **Right amputation ‚Üí Adjacent fibers overlap LEFT cortex** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-33",
    subjectId: "physiology",
    chapterId: "neet-pg-2024",
    question: "Patient had sunburn and now takes a bath with 40-degree water and feels pain.",
    options: [
      "Thermal receptor: hyperalgesia",
      "Innocuous thermal receptor: allodynia",
      "Thermal receptor: allodynia",
      "Innocuous thermal receptor: hyperalgesia"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Innocuous thermal receptor: allodynia (Option B)**\n\nüî¨ **DEFINITIONS:**\n\n**ALLODYNIA** ‚≠ê‚≠ê‚≠ê: Pain from **normally NON-painful** stimulus\n‚Ä¢ **Innocuous** stimulus (40¬∞C warm water) ‚Üí Pain\n‚Ä¢ Due to **sensitization** after injury (sunburn)\n\n**HYPERALGESIA**: **Exaggerated pain** from **already painful** stimulus\n‚Ä¢ Painful stimulus ‚Üí **MORE pain** than expected\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **THIS CASE:**\n‚Ä¢ **Sunburn** ‚Üí **Peripheral sensitization** of nociceptors\n‚Ä¢ **40¬∞C water** = **Innocuous** (normally pleasant/warm) ‚≠ê\n‚Ä¢ **Feels painful** = **ALLODYNIA** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Innocuous thermal receptors** activated\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **MECHANISM:**\n\n**AFTER SUNBURN:**\n‚Ä¢ **Inflammatory mediators** (prostaglandins, bradykinin)\n‚Ä¢ **Lowered threshold** of C-fibers and AŒ¥-fibers\n‚Ä¢ **Thermal receptors** become **hypersensitive**\n‚Ä¢ **Innocuous warm** (40¬∞C) ‚Üí Perceived as **painful** (nociceptive)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã **TYPES:**\n\n**ALLODYNIA:**\n‚Ä¢ **Mechanical** - Light touch causes pain (e.g., clothing on sunburn)\n‚Ä¢ **Thermal** - Warm water causes pain ‚≠ê **(THIS CASE)**\n‚Ä¢ **Cold** - Cool breeze causes pain\n\n**HYPERALGESIA:**\n‚Ä¢ **Primary** - At injury site (sunburned skin itself more painful)\n‚Ä¢ **Secondary** - Surrounding normal skin also sensitive\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° **KEY:** **Innocuous stimulus (warm water) ‚Üí Pain = ALLODYNIA** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**A**llodynia = **A**bnormal pain from normal stimulus!\"",
    difficulty: "medium",
    imageUrl: "/images/questions/page12_img28.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-34",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 50-year-old female presented with dyspnea and chest pain. Which of the\nfollowing proves that she has aortic stenosis rather than aortic regurgitation?",
    options: [
      "Increase in myocardial oxygen consumption is seen with increased pressure work than\nvolume",
      "Aortic stenosis causes reduced pressure at aortic valve",
      "Workload has nothing to do with myocardial oxygen consumption",
      "Increase in preload more than afterload than afterload"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Increase in myocardial O‚ÇÇ consumption is seen with increased PRESSURE work > VOLUME work (Option A)**\n\nüî¨ **AORTIC STENOSIS vs AORTIC REGURGITATION:**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **AORTIC STENOSIS (AS):**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Increased AFTERLOAD** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Pressure overload** on LV\n‚Ä¢ LV must generate **‚Üë‚Üë pressure** to overcome stenotic valve\n\n**WORK TYPE:** **PRESSURE WORK** ‚≠ê‚≠ê‚≠ê\n\n**CONSEQUENCE:**\n‚Ä¢ **Concentric hypertrophy** (thick walls, small cavity)\n‚Ä¢ **‚Üë‚Üë‚Üë Myocardial O‚ÇÇ consumption** ‚≠ê‚≠ê‚≠ê **KEY!**\n‚Ä¢ **Subendocardial ischemia** ‚Üí **Angina**\n‚Ä¢ **Reduced coronary flow reserve**\n\n**SYMPTOMS:**\n‚Ä¢ **Angina** (‚Üë O‚ÇÇ demand, ‚Üì supply) ‚≠ê\n‚Ä¢ **Syncope** (exertional)\n‚Ä¢ **Dyspnea** (heart failure)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **AORTIC REGURGITATION (AR):**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Increased PRELOAD** ‚≠ê\n‚Ä¢ **Volume overload** on LV\n‚Ä¢ Large volume ejected + regurgitant volume\n\n**WORK TYPE:** **VOLUME WORK** ‚≠ê‚≠ê‚≠ê\n\n**CONSEQUENCE:**\n‚Ä¢ **Eccentric hypertrophy** (dilated, thin walls)\n‚Ä¢ **Less ‚Üë myocardial O‚ÇÇ consumption** (compared to AS)\n‚Ä¢ Better tolerated chronically\n\n**SYMPTOMS:**\n‚Ä¢ **Dyspnea** (volume overload)\n‚Ä¢ **Wide pulse pressure**\n‚Ä¢ **Bounding pulses**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **WHY PRESSURE WORK > VOLUME WORK FOR O‚ÇÇ CONSUMPTION:**\n\n**PRESSURE WORK:**\n‚Ä¢ **High wall tension** throughout ejection ‚≠ê\n‚Ä¢ **Prolonged contraction** against high resistance\n‚Ä¢ **‚Üë‚Üë‚Üë ATP consumption**\n‚Ä¢ **Formula:** Wall tension = (Pressure √ó Radius) / (2 √ó Thickness)\n‚Ä¢ **Thick walls** but **HIGH pressure** dominates\n\n**VOLUME WORK:**\n‚Ä¢ **Lower wall tension** (less pressure)\n‚Ä¢ **Isotonic contraction** (easier)\n‚Ä¢ **Less ATP** per unit work\n‚Ä¢ **Dilated** but **lower pressure**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° **KEY:** **AS = Pressure work ‚Üí ‚Üë‚Üë‚Üë O‚ÇÇ consumption ‚Üí Angina** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**P**ressure work **P**unishes (‚Üë‚Üë O‚ÇÇ demand)!\"\n\n**AS vs AR:**\n‚Ä¢ **AS:** Pressure overload ‚Üí Angina common\n‚Ä¢ **AR:** Volume overload ‚Üí Angina rare",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-35",
    subjectId: "physiology",
    chapterId: "neet-pg-2024",
    question: "Taste absent in which tastebud?",
    options: [
      "Filliform",
      "Foliate",
      "Fungiform Papilla",
      "Circumvallate"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Filiform (Option A)**\n\nüî¨ **TONGUE PAPILLAE:**\n\n**FILIFORM papillae** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **NO taste buds** ‚≠ê‚≠ê‚≠ê **ANSWER**\n‚Ä¢ **Most numerous** (majority on tongue)\n‚Ä¢ **Conical/thread-like** shape\n‚Ä¢ **Mechanical function** (grip food, tactile)\n‚Ä¢ Give tongue its rough texture\n\n**FUNGIFORM papillae** ‚úì Has taste buds\n‚Ä¢ **Mushroom-shaped**\n‚Ä¢ **Anterior 2/3** of tongue\n‚Ä¢ Contains **taste buds** (50-100 each)\n\n**FOLIATE papillae** ‚úì Has taste buds\n‚Ä¢ **Lateral edges** of tongue\n‚Ä¢ **Leaf-like folds**\n‚Ä¢ Many **taste buds**\n\n**CIRCUMVALLATE papillae** ‚úì Has taste buds\n‚Ä¢ **V-shaped row** at back of tongue (8-12 total)\n‚Ä¢ **Largest** papillae\n‚Ä¢ **Most taste buds** (250 each) ‚≠ê\n\nüí° **KEY:** **FILIFORM = NO taste** (only mechanical) ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-36",
    subjectId: "physiology",
    chapterId: "neet-pg-2024",
    question: "Which receptor helps in the improvement of insulin resistance in DM2 with regular\nexercise and physical activity?",
    options: [
      "GLUT1",
      "GLUT4",
      "GLUT2",
      "GLUT3"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **GLUT4 (Option B)**\n\nüî¨ **GLUCOSE TRANSPORTERS:**\n\n**GLUT4** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Insulin-dependent** transporter ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Muscle & adipose tissue** primarily\n‚Ä¢ **Exercise-responsive** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Translocates to membrane with insulin OR exercise\n\n**MECHANISM:**\n‚Ä¢ **Exercise** ‚Üí ‚Üë AMP kinase activation\n‚Ä¢ ‚Üí **GLUT4 translocation** to cell membrane\n‚Ä¢ ‚Üí **‚Üë Glucose uptake** (insulin-independent) ‚≠ê\n‚Ä¢ **Improves insulin sensitivity**\n\n**OTHER GLUT TRANSPORTERS:**\n‚Ä¢ **GLUT1**: Brain, RBCs (insulin-independent)\n‚Ä¢ **GLUT2**: Liver, pancreatic Œ≤-cells (glucose sensor)\n‚Ä¢ **GLUT3**: Neurons (high affinity)\n\nüí° **KEY:** **Exercise ‚Üí ‚Üë GLUT4 ‚Üí ‚Üì Insulin resistance in DM2** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-37",
    subjectId: "physiology",
    chapterId: "neet-pg-2024",
    question: "A man is having difficulty sleeping during the night. He has the habit of drinking\ncoffee before bedtime. What is the role of caffeine in wakefulness?",
    options: [
      "Blocks adenosine action and causes wakefulness",
      "Activates locus coeruleus and causes wakefulness",
      "No role in maintaining wakefulness if taken 1hr before sleep",
      "Activates histamine release and prevents sleep"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Blocks adenosine action and causes wakefulness (Option A)**\n\nüî¨ **SLEEP-WAKE REGULATION:**\n\n**ADENOSINE** = **Sleep-promoting molecule** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Accumulates during **wakefulness**\n‚Ä¢ Binds to **A1 and A2A receptors** in brain\n‚Ä¢ ‚Üí **Inhibits arousal systems**\n‚Ä¢ ‚Üí Promotes **sleep drive**\n\n**CAFFEINE MECHANISM** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Competitive antagonist** of adenosine receptors\n‚Ä¢ **Blocks A1 and A2A receptors** ‚≠ê\n‚Ä¢ ‚Üí **Prevents adenosine binding**\n‚Ä¢ ‚Üí **‚Üì Sleep drive**, **‚Üë Wakefulness** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ ‚Üí **‚Üë Dopamine, norepinephrine release**\n\n**EFFECTS:**\n‚Ä¢ **Increased alertness**\n‚Ä¢ **Reduced sleepiness**\n‚Ä¢ **Half-life:** 3-5 hours (affects sleep if taken late)\n\nüí° **KEY:** **Caffeine blocks adenosine ‚Üí Wakefulness** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-38",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "RMP predominantly affected by which ion?",
    options: [
      "K+",
      "Ca",
      "Na",
      "Cl"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **K+ (Potassium) (Option A)**\n\nüî¨ **RESTING MEMBRANE POTENTIAL (RMP):**\n\n**TYPICAL RMP:** **-70 mV** (inside negative)\n\n**PRIMARY DETERMINANT:** **K+ gradient** ‚≠ê‚≠ê‚≠ê\n\n**MECHANISM:**\n‚Ä¢ **K+ concentration:**\n  ‚Üí **Inside:** 140 mM ‚≠ê\n  ‚Üí **Outside:** 5 mM\n‚Ä¢ **K+ leak channels** allow K+ to move **OUT** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ ‚Üí **Positive charge leaves** cell\n‚Ä¢ ‚Üí **Inside becomes NEGATIVE** (-70 mV)\n\n**NERNST EQUATION for K+:**\n‚Ä¢ **E_K = -90 mV** (K+ equilibrium potential)\n‚Ä¢ RMP (-70 mV) **closest to E_K** ‚≠ê\n‚Ä¢ **Proves K+ is PRIMARY determinant**\n\n**OTHER IONS:**\n‚Ä¢ **Na+:** E_Na = +60 mV (minor contribution)\n‚Ä¢ **Cl-:** E_Cl ‚âà -70 mV (passive distribution)\n‚Ä¢ **Ca2+:** Not major RMP determinant\n\nüí° **KEY:** **RMP predominantly determined by K+ gradient** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-39",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Alcoholic gait, nystagmus after RTA, which lobe of cerebellum is affected?",
    options: [
      "Flocculonodular",
      "Dentate",
      "Anterior lobe",
      "Vermis"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Flocculonodular lobe (Option A)**\n\nüî¨ **CEREBELLAR FUNCTIONAL DIVISIONS:**\n\n**FLOCCULONODULAR LOBE (Vestibulocerebellum)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Function:** **Balance** and **eye movements** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Connections:** Vestibular nuclei (CN VIII)\n‚Ä¢ **Controls:** Vestibuloocular reflex (VOR)\n\n**DAMAGE ‚Üí THIS CASE:**\n‚Ä¢ **Truncal ataxia** (gait disturbance) ‚≠ê\n‚Ä¢ **Nystagmus** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Vertigo**\n‚Ä¢ **Cannot stand** (falls immediately)\n\n**ALCOHOL + RTA:** Commonly affects **flocculonodular lobe**\n\n**OTHER LOBES:**\n‚Ä¢ **Anterior lobe:** Limb coordination (alcoholic cerebellar degeneration affects this too)\n‚Ä¢ **Vermis:** Trunk stability, posture\n‚Ä¢ **Dentate (nucleus):** Motor planning, timing\n\nüí° **KEY:** **Flocculonodular = Balance + Nystagmus** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-40",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A 14-year-old boy presented with nasal mass and recurrent episodes of bleeding\nfrom the mass. Investigation of choice?",
    options: [
      "Plain CT",
      "CT with contrast",
      "X-ray Caldwell view",
      "X-ray with Pierre view"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **CT with contrast (Option B)**\n\nüî¨ **LIKELY DIAGNOSIS:** **Juvenile Nasopharyngeal Angiofibroma (JNA)**\n\n**CLASSIC PRESENTATION:**\n‚Ä¢ **Adolescent male** (14-year-old boy) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Nasal mass**\n‚Ä¢ **Recurrent epistaxis** (bleeding) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Benign but locally aggressive** vascular tumor\n\n**INVESTIGATION OF CHOICE:**\n\n**CT WITH CONTRAST** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Shows:**\n  ‚Üí **Extent of tumor** (origin, size)\n  ‚Üí **Bony erosion** (pterygoid plates, sphenoid)\n  ‚Üí **Vascular enhancement** (hypervascular) ‚≠ê\n  ‚Üí **Relationship to vital structures**\n‚Ä¢ **Pre-surgical planning**\n\n**WHY CONTRAST ESSENTIAL:**\n‚Ä¢ JNA is **HIGHLY vascular** ‚≠ê\n‚Ä¢ **Contrast enhancement** shows vascularity\n‚Ä¢ Helps plan **preoperative embolization**\n\n**ADDITIONAL:**\n‚Ä¢ **MRI:** Better for soft tissue, intracranial extension\n‚Ä¢ **Angiography:** Pre-op embolization (reduce bleeding)\n\n**NO BIOPSY** ‚ö†Ô∏è - Risk of **massive bleeding**!\n\nüí° **KEY:** **Adolescent male + Nasal mass + Bleeding = JNA ‚Üí CT with contrast** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page15_img32.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-41",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Cochlear implant given below, identify the marked structure:",
    options: [
      "Internal magnet",
      "Electrode",
      "Receiver",
      "Antenna"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Electrode (Option B)**\n\nüî¨ **COCHLEAR IMPLANT COMPONENTS:**\n\n**EXTERNAL (Outside skull):**\n‚Ä¢ **Microphone** - captures sound\n‚Ä¢ **Speech processor** - converts to electrical signals\n‚Ä¢ **Transmitter coil** - sends signals through skin\n\n**INTERNAL (Implanted):**\n‚Ä¢ **Receiver/stimulator** - receives signals\n‚Ä¢ **Internal magnet** - holds external coil in place\n‚Ä¢ **ELECTRODE ARRAY** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**ELECTRODE ARRAY:**\n‚Ä¢ **Inserted into COCHLEA** (scala tympani) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **16-22 electrodes** (multiple contact points)\n‚Ä¢ **Directly stimulates auditory nerve fibers** ‚≠ê\n‚Ä¢ Different electrodes = different frequencies\n‚Ä¢ **Most critical component** for hearing\n\nüí° **KEY:** **Electrode = Intracochlear, stimulates auditory nerve** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page15_img33.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-42",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "Which nerve supplies the external ear?",
    options: [
      "ATN, greater auricular, 7 and 10",
      "Greater auricular, 7 and 10, ATN",
      "7 and 10, ATN, greater auricular nerve",
      "ATN, 7 and 10, GAN"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **ATN, 7 and 10, GAN (Option D)**\n\nüî¨ **EXTERNAL EAR INNERVATION (Sensory):**\n\n**4 MAIN NERVES:**\n\n**1. Auriculotemporal Nerve (ATN)** ‚≠ê\n‚Ä¢ Branch of **V3** (mandibular division of trigeminal)\n‚Ä¢ **Anterosuperior** auricle\n‚Ä¢ **External auditory meatus** (anterior wall)\n\n**2. CN VII (Facial nerve)** ‚≠ê\n‚Ä¢ **Nervus intermedius** branch\n‚Ä¢ **Concha** (bowl)\n‚Ä¢ **Small area** around external auditory meatus\n\n**3. CN X (Vagus nerve)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Arnold's nerve** (auricular branch)\n‚Ä¢ **Concha**, **external auditory meatus** (floor)\n‚Ä¢ **Tympanic membrane** (small area)\n\n**4. Greater Auricular Nerve (GAN)** ‚≠ê\n‚Ä¢ From **C2-C3** (cervical plexus)\n‚Ä¢ **Lobule** and **posterior auricle**\n‚Ä¢ **Lower** and **posteror** parts\n\n**ORDER:** **ATN, 7 and 10, GAN** ‚≠ê‚≠ê‚≠ê (Answer D)\n\nüí° **KEY:** **External ear = V3 (ATN) + CN 7 + CN 10 + C2-C3 (GAN)** ‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page16_img35.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-43",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "In head impulse test, the following finding is seen in right vestibular neuritis:",
    options: [
      "On rotating head to right, left saccade",
      "On rotating head to left, right saccade",
      "On rotating head toward right, right saccade",
      "On rotating to the left, left saccade"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **On rotating head to right, left saccade (Option A)**\n\nüî¨ **HEAD IMPULSE TEST (Halmagyi-Curthoys Test):**\n\n**NORMAL:**\n‚Ä¢ **Rapid head turn** ‚Üí Eyes stay fixed on target\n‚Ä¢ **Vestibulo-ocular reflex (VOR)** intact\n\n**RIGHT VESTIBULAR NEURITIS:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **RIGHT vestibular loss** (CN VIII affected)\n‚Ä¢ **Defective right VOR**\n\n**TEST FINDINGS:**\n\n**Head rotated to RIGHT** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Right vestibular** should stabilize gaze\n‚Ä¢ **But RIGHT is damaged** ‚Üí Can't stabilize\n‚Ä¢ ‚Üí Eyes move WITH head (to right)\n‚Ä¢ ‚Üí **Corrective LEFT saccade** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ ‚Üí Eyes jump BACK to target (leftward)\n\n**Head rotated to LEFT:**\n‚Ä¢ **Left vestibular** works normally\n‚Ä¢ Eyes stay fixed on target\n‚Ä¢ **NO saccade** (normal response)\n\n**RULE:** Saccade occurs when head turns **TOWARD affected side** ‚≠ê\n\nüí° **KEY:** **Right vestibular neuritis ‚Üí Head to right ‚Üí LEFT saccade** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page16_img36.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-44",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Which of the following instrument insertions will be difficult:",
    options: [
      "Nasogastric Tube",
      "LMA",
      "Tracheostomy",
      "Indirect Laryngoscopy"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Tracheostomy (Option C)** - Based on image showing **neck mass/pathology**\n\nüî¨ **Context:** Image likely shows **thyroid mass** or **anterior neck pathology** making tracheostomy difficult.\n\n**TRACHEOSTOMY CHALLENGES:**\n‚Ä¢ **Neck mass** displaces trachea ‚≠ê\n‚Ä¢ **Altered anatomy**\n‚Ä¢ **Vascular distortion**\n‚Ä¢ **Risk of bleeding** (thyroid vascularity)\n‚Ä¢ **Risk of tumor invasion**\n\n**WHY OTHER OPTIONS EASIER:**\n‚Ä¢ **NG tube**: Via nose/esophagus (not affected)\n‚Ä¢ **LMA**: Supraglottic (oral cavity)\n‚Ä¢ **Indirect laryngoscopy**: Visual exam only\n\nüí° **KEY:** **Anterior neck mass ‚Üí Tracheostomy difficult** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page17_img38.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-45",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "A singer presents with problems in high pitch. On examination, bowing of one side\nvocal cord is seen. Which of the following muscles is affected?",
    options: [
      "Posterior cricoarytenoid",
      "Lateral cricoarytenoid",
      "Cricothyroid",
      "Thyroarytenoid"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Cricothyroid (Option C)**\n\nüî¨ **LARYNGEAL MUSCLES:**\n\n**CRICOTHYROID** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **ONLY** external laryngeal muscle\n‚Ä¢ **Tensionens vocal cords** (elongates) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Increases PITCH** (high notes) ‚≠ê\n‚Ä¢ **Innervation:** External branch of **superior laryngeal nerve** ‚≠ê\n‚Ä¢ **Weakness** ‚Üí **Bowing** of vocal cord ‚Üí Can't reach high pitch\n\n**OTHER MUSCLES (All intrinsic):**\n‚Ä¢ **Posterior cricoarytenoid**: ABducts cords (opens glottis)\n‚Ä¢ **Lateral cricoarytenoid**: ADducts cords (closes glottis)\n‚Ä¢ **Thyroarytenoid**: Relaxes cords (lowers pitch)\n‚Ä¢ **Innervation (all 3):** **Recurrent laryngeal nerve**\n\n**THIS CASE:**\n‚Ä¢ **Singer** (needs high pitch) ‚≠ê\n‚Ä¢ **Bowing** of vocal cord (lax, not tense)\n‚Ä¢ **Can't tension cord** ‚Üí Can't achieve high notes\n‚Ä¢ ‚Üí **Cricothyroid weakness** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **High pitch problem + Bowing = Cricothyroid (tension muscle)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page17_img39.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-46",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 45-year-old male presents with breathlessness and undergoes a CT scan of the\nparanasal sinuses (PNS). Which sinus is obstructed?",
    options: [
      "Maxillary",
      "Frontal",
      "Sphenoid",
      "Ethmoid"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Maxillary (Option A)** - Based on CT image\n\nüî¨ **PARANASAL SINUSES:**\n\n**MAXILLARY SINUS** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Largest** paranasal sinus\n‚Ä¢ **Most commonly obstructed** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ Drains via **ostium** into **middle meatus**\n‚Ä¢ **Ostium** located **superiorly** (gravity unfavorable)\n\n**WHY MAXILLARY MOST COMMON:**\n‚Ä¢ **Poor drainage** (ostium high)\n‚Ä¢ **Large size** (more mucus)\n‚Ä¢ **Dental infections** spread easily (roots project into sinus)\n‚Ä¢ **Osteomeatal complex** obstruction affects maxillary first\n\n**CT FINDINGS:**\n‚Ä¢ **Air-fluid level** ‚≠ê\n‚Ä¢ **Mucosal thickening** (>5mm)\n‚Ä¢ **Complete opacification**\n\n**CLINICAL:**\n‚Ä¢ **Maxillary pain** (cheek, upper teeth)\n‚Ä¢ **Nasal congestion**\n‚Ä¢ **Purulent discharge**\n\nüí° **KEY:** **Maxillary = Most common sinus obstruction** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page18_img41.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-47",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Intraoperatively, which stain is used to view the following lesion:",
    options: [
      "AgNO3",
      "Toluidine Blue",
      "Congo red",
      "Methylene blue"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Toluidine Blue (Option B)**\n\nüî¨ **INTRAOPERATIVE STAINS:**\n\n**TOLUIDINE BLUE** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Metachromatic dye** (cationic thiazine)\n‚Ä¢ **Binds to DNA/RNA** in nuclei ‚≠ê\n‚Ä¢ **Highlights dysplastic/malignant cells** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Stains abnormal tissue BLUE** (high nuclear density)\n\n**USES:**\n‚Ä¢ **Oral cavity** lesions (oral cancer screening) ‚≠ê\n‚Ä¢ **Cervical lesions** (CIN detection)\n‚Ä¢ **Urological** (bladder cancer)\n‚Ä¢ **Intraoperative margin assessment** ‚≠ê\n\n**MECHANISM:**\n‚Ä¢ **Normal tissue:** Light/no staining (fewer nuclei)\n‚Ä¢ **Dysplastic/cancer:** **DARK BLUE** (high nuclear:cytoplasmic ratio)\n‚Ä¢ Helps identify **positive margins** during surgery\n\n**OTHER STAINS:**\n‚Ä¢ **Methylene blue**: Fistulas, lymph nodes\n‚Ä¢ **Congo red**: Amyloid (apple-green birefringence)\n‚Ä¢ **AgNO3**: Nerve staining\n\nüí° **KEY:** **Toluidine blue = Intraop cancer detection** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page19_img43.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-48",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "Gag reflex will be absent in which nerve injury?",
    options: [
      "5 and 10",
      "9 and 10",
      "10 and 12",
      "7 and 9"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **9 and 10 (Glossopharyngeal and Vagus) (Option B)**\n\nüî¨ **GAG REFLEX (Pharyngeal reflex):**\n\n**AFFERENT (Sensory):** **CN IX (Glossopharyngeal)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Posterior 1/3** of tongue\n‚Ä¢ **Pharynx** (tonsillar fossa, soft palate)\n‚Ä¢ **Detects** touch/irritation\n\n**EFFERENT (Motor):** **CN X (Vagus)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Pharyngeal muscles** (via pharyngeal plexus)\n‚Ä¢ **Soft palate elevation**\n‚Ä¢ **Pharyngeal constriction** (gagging)\n\n**TEST:**\n‚Ä¢ Touch posterior pharynx with tongue depressor\n‚Ä¢ **Normal:** Gag/retching response\n‚Ä¢ **Absent:** Bilateral IX or X injury\n\n**CLINICAL:**\n‚Ä¢ **Unilateral loss:** Often asymptomatic (contralateral compensates)\n‚Ä¢ **Bilateral loss:** Risk of **aspiration** ‚ö†Ô∏è\n\nüí° **KEY:** **Gag reflex = CN 9 (sensory) + CN 10 (motor)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page19_img44.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-49",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "In the given X-ray, which of the following signs is seen:",
    options: [
      "Double ring sign",
      "String sign",
      "Steeple sign",
      "Thumb sign"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Double ring sign (Option A)**\n\nüî¨ **INTUSSUSCEPTION:**\n\n**DEFINITION:** **Telescoping** of one bowel segment into adjacent segment ‚≠ê‚≠ê‚≠ê\n\n**DOUBLE RING SIGN** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **X-ray finding** in intussusception\n‚Ä¢ **Two concentric circles** of soft tissue density\n‚Ä¢ **Represents:**\n  ‚Üí **Inner ring:** Intussusceptum (entering bowel)\n  ‚Üí **Outer ring:** Intussuscipiens (receiving bowel)\n‚Ä¢ **Target sign** on CT/US (similar appearance)\n\n**CLINICAL:**\n‚Ä¢ **Children** 6 months-2 years most common\n‚Ä¢ **Triad:**\n  ‚Üí **Colicky abdominal pain** (intermittent crying)\n  ‚Üí **Vomiting**\n  ‚Üí **Currant jelly stools** (blood + mucus) ‚≠ê\n‚Ä¢ **Palpable mass** (sausage-shaped, RUQ)\n\n**OTHER SIGNS:**\n‚Ä¢ **String sign:** Crohn's disease (stricture)\n‚Ä¢ **Steeple sign:** Croup (subglottic narrowing)\n‚Ä¢ **Thumb sign:** Epiglottitis\n\nüí° **KEY:** **Double ring sign = Intussusception** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page20_img46.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-50",
    subjectId: "physiology",
    chapterId: "neet-pg-2024",
    question: "Taste absent in which taste bud?",
    options: [
      "Filliform",
      "Foliate",
      "Papilla",
      "Circumvallate"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Filiform (Option A)** - DUPLICATE of Q35\n\nüî¨ **TONGUE PAPILLAE:**\n\n**FILIFORM** ‚≠ê‚≠ê‚≠ê: **NO taste buds** **(ANSWER)**\n‚Ä¢ Most numerous\n‚Ä¢ Conical shape\n‚Ä¢ Mechanical function only\n\n**FUNGIFORM, FOLIATE, CIRCUMVALLATE:** ‚úì All have taste buds\n\nüí° **KEY:** **FILIFORM = NO taste** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-51",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Which of the following may be true in this patient?",
    options: [
      "Oesophagus is the correct site",
      "Most commonly in adults",
      "Mostly above cricoid",
      "Mediastinal infection not present"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Oesophagus is the correct site (Option A)** - Context unclear without image\n\nüî¨ **ESOPHAGEAL PATHOLOGY:**\n\n**Based on options, likely discussing:**\n‚Ä¢ **Esophageal foreign body** OR\n‚Ä¢ **Esophageal perforation** OR\n‚Ä¢ **Esophageal cancer**\n\n**KEY FACTS:**\n‚Ä¢ **Site:** Esophagus (correct) ‚≠ê\n‚Ä¢ **Age:** **Adults** AND children (depends on condition)\n‚Ä¢ **Location:** **3 constrictions** (cricopharyngeus most common for FB)\n‚Ä¢ **Complications:** **CAN cause mediastinal infection** (if perforation) ‚ö†Ô∏è\n\nüí° **KEY:** **Esophagus = correct anatomical site** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-52",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A patient presented with complaints of hearing loss, and the otoscopy finding\nshown. What will be the Rinne test finding?",
    options: [
      "True positive",
      "True negative",
      "False positive",
      "False negative"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **True negative (Option B)** - Based on otoscopy showing conductive hearing loss\n\nüî¨ **RINNE TEST:**\n\n**PROCEDURE:**\n‚Ä¢ **512 Hz tuning fork** on **mastoid** (bone conduction)\n‚Ä¢ When sound fades ‚Üí move to **ear canal** (air conduction)\n\n**INTERPRETATION:**\n\n**NORMAL (Rinne POSITIVE):**\n‚Ä¢ **AC > BC** (air better than bone) ‚≠ê\n\n**CONDUCTIVE HEARING LOSS (Rinne NEGATIVE):** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **BC > AC** (bone better than air)\n‚Ä¢ **True negative** = **Genuine CHL** **(ANSWER)**\n  ‚Üí Middle ear pathology (OM, otosclerosis, perforation)\n\n**FALSE NEGATIVE:**\n‚Ä¢ **Severe SNHL** in test ear\n‚Ä¢ Bone vibration reaches **opposite ear** (better cochlea)\n‚Ä¢ Mistaken for BC > AC\n\n**THIS CASE:** Otoscopy shows **CHL** ‚Üí **True negative Rinne** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **CHL ‚Üí Rinne negative (BC > AC)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-53",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A female with mild CHL and tinnitus. The PTA is shown. What is the\ninterpretation?",
    options: [
      "Otosclerosis",
      "Meniere‚Äôs disease",
      "NIHL (Noise-Induced Hearing Loss)",
      "None"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Otosclerosis (Option A)**\n\nüî¨ **OTOSCLEROSIS:**\n\n**DEFINITION:** **Abnormal bone remodeling** in otic capsule ‚Üí **Stapes fixation** ‚≠ê‚≠ê‚≠ê\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Spongiotic bone** replaces normal bone\n‚Ä¢ **Stapes footplate** becomes fixed in **oval window** ‚≠ê\n‚Ä¢ ‚Üí **Impaired sound transmission** (CHL)\n\n**CLINICAL:**\n‚Ä¢ **Young adults** (20-40 years), **females > males** (2:1)\n‚Ä¢ **Progressive CHL** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bilateral** (80%)\n‚Ä¢ **Tinnitus** ‚≠ê\n‚Ä¢ **Paracusis of Willis** (hear better in noise)\n‚Ä¢ **Normal TM** on otoscopy\n\n**AUDIOGRAM FINDINGS:**\n‚Ä¢ **CHL** (air-bone gap) ‚≠ê\n‚Ä¢ **Carhart notch** at **2000 Hz** (bone conduction dip) ‚≠ê‚≠ê‚≠ê **PATHOGNOMONIC**\n‚Ä¢ **\"Cookie-bite\"** pattern (mid-frequency loss)\n\n**MANAGEMENT:**\n‚Ä¢ **Stapedectomy/Stapedotomy** ‚≠ê (surgical - curative)\n‚Ä¢ **Hearing aids** (if surgery refused)\n\nüí° **KEY:** **Young female + CHL + Tinnitus + Carhart notch = Otosclerosis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page20_img47.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-54",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A nasal surgery was done in this patient, and the incision mark is shown. Which of\nthese is probably done?",
    options: [
      "Septoplasty",
      "Rhinoplasty",
      "FESS",
      "Young‚Äôs surgery"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Rhinoplasty (Option B)** - Based on **columellar incision** shown\n\nüî¨ **NASAL SURGERIES:**\n\n**RHINOPLASTY** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Reshapes external nose** (cosmetic/functional)\n‚Ä¢ **Open approach** incision: **Columellar** (inverted-V) ‚≠ê‚≠ê‚≠ê\n  ‚Üí **Visible** on columella (tissue between nostrils)\n‚Ä¢ **Closed approach**: Intranasal incisions (not visible)\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Septoplasty:** Internal septum correction, **NO external incision** ‚ö†Ô∏è\n‚Ä¢ **FESS** (Functional Endoscopic Sinus Surgery): Intranasal, NO external incision\n‚Ä¢ **Young's surgery**: Closure of nostrils (adhesion formation), not common\n\n**KEY CLUE:**\n‚Ä¢ **External columellar incision** = **Open rhinoplasty** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **Columellar incision = Open rhinoplasty** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page21_img49.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-55",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "A man meets with an RTA and comes to the emergency department with complaints\nof back pain. No neurological deficit. X-ray spine done. What will be the diagnosis?",
    options: [
      "Fracture of spinous process",
      "Compressed fracture",
      "Fracture of base of vertebrae",
      "Chance fracture"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Chance fracture (Option D)**\n\nüî¨ **CHANCE FRACTURE:**\n\n**DEFINITION:** **Horizontal fracture** through **ALL 3 columns** of vertebra ‚≠ê‚≠ê‚≠ê\n\n**MECHANISM:**\n‚Ä¢ **Flexion-distraction** injury ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Seatbelt injury** (lap belt only, no shoulder) ‚≠ê\n‚Ä¢ **RTA** with sudden deceleration\n‚Ä¢ Fulcrum at anterior abdominal wall\n\n**ANATOMY:**\n‚Ä¢ **Horizontal fracture line** through:\n  ‚Üí **Vertebral body** (anterior column)\n  ‚Üí **Pedicles** (middle column)\n  ‚Üí **Spinous process & lamina** (posterior column)\n‚Ä¢ Usually **T12-L2** level\n\n**IMAGING:**\n‚Ä¢ **Lateral X-ray:** **Horizontal fracture** ‚≠ê\n‚Ä¢ **\"Empty vertebra\" sign**\n‚Ä¢ **Increased interspinous distance**\n\n**ASSOCIATED INJURIES:**\n‚Ä¢ **Abdominal visceral injury** (50%) ‚ö†Ô∏è\n  ‚Üí Bowel, mesentery, pancreas\n‚Ä¢ **Neurological deficit** (uncommon if isolated)\n\n**TREATMENT:**\n‚Ä¢ **Stable** (no neurology): Bracing\n‚Ä¢ **Unstable/displaced**: Surgical fixation\n\nüí° **KEY:** **RTA + Horizontal vertebral fracture = Chance (seatbelt injury)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page21_img50.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-56",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What is the type of classification used for this fracture and its type?",
    options: [
      "Gartland type 3",
      "Salter Harris type 3",
      "Gartland type 4",
      "Salter Harris type 4"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Gartland type 3 (Option A)**\n\nüî¨ **GARTLAND CLASSIFICATION:**\n\nFor **supracondylar fractures of humerus** in **children** ‚≠ê‚≠ê‚≠ê\n\n**TYPE 1:** **Undisplaced**\n‚Ä¢ Anterior humeral line intact\n‚Ä¢ **Treatment:** Cast immobilization\n\n**TYPE 2:** **Displaced** with **intact posterior cortex**\n‚Ä¢ Angulated but not completely displaced\n‚Ä¢ **Treatment:** Closed reduction + pinning (usually)\n\n**TYPE 3:** **Completely displaced** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **No cortical contact**\n‚Ä¢ Posterior cortex disrupted\n‚Ä¢ **High risk:** Neurovascular injury (brachial artery, median/radial nerve)\n‚Ä¢ **Treatment:** **Urgent closed/open reduction + K-wire pinning** ‚≠ê\n\n**TYPE 4:** (Modified Gartland)\n‚Ä¢ Unstable in flexion and extension\n\n**COMPLICATIONS:**\n‚Ä¢ **Volkmann's ischemic contracture** (vascular injury)\n‚Ä¢ **Cubitus varus** (\"gunstock deformity\")\n‚Ä¢ **Nerve injury** (anterior interosseous most common)\n\nüí° **KEY:** **Gartland 3 = Complete displacement, needs urgent surgery** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page22_img52.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-57",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A child with this deformity. He has recurrent tooth abscesses. Calcium normal,\nPhosphorus low, PTH normal, ALP high. Diagnosis is?",
    options: [
      "Nutritional rickets",
      "VDDR1 (Vitamin D Dependent Rickets Type 1)",
      "VDDR2 (Vitamin D Dependent Rickets Type 2)",
      "Hypophosphatemic rickets"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Nutritional rickets (Option A)**\n\nüî¨ **LAB ANALYSIS:**\n\n**THIS CASE:**\n‚Ä¢ **Ca:** Normal ‚≠ê\n‚Ä¢ **PO‚ÇÑ:** Low ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **PTH:** Normal ‚≠ê\n‚Ä¢ **ALP:** High ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Recurrent tooth abscesses** (enamel defects)\n‚Ä¢ **Deformity** (bow legs)\n\n**NUTRITIONAL RICKETS** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Vitamin D deficiency**\n‚Ä¢ **Mechanism:**\n  ‚Üí ‚Üì Vit D ‚Üí ‚Üì Ca absorption\n  ‚Üí ‚Üë‚Üë PTH (secondary) ‚Üí normalizes Ca\n  ‚Üí PTH ‚Üí renal PO‚ÇÑ wasting ‚Üí ‚Üì PO‚ÇÑ ‚≠ê\n  ‚Üí ‚Üë ALP (bone turnover)\n\n**WHY NOT OTHERS:**\n\n**VDDR1 (1Œ±-hydroxylase deficiency):**\n‚Ä¢ ‚Üì Ca, ‚Üì PO‚ÇÑ, **‚Üë‚Üë PTH** ‚ö†Ô∏è\n\n**VDDR2 (Vitamin D receptor defect):**\n‚Ä¢ ‚Üì Ca, ‚Üì PO‚ÇÑ, **‚Üë‚Üë PTH** ‚ö†Ô∏è\n‚Ä¢ **Alopecia** (hair loss) ‚≠ê (unique feature)\n\n**Hypophosphatemic rickets (X-linked):**\n‚Ä¢ Normal Ca, ‚Üì PO‚ÇÑ, **Normal PTH** ‚úì\n‚Ä¢ BUT: **Renal PO‚ÇÑ wasting** (‚Üë FGF23)\n‚Ä¢ **NO tooth abscesses** typically\n‚Ä¢ **Nutritional more common**\n\nüí° **KEY:** **Normal Ca + Low PO‚ÇÑ + Normal PTH + Tooth issues = Nutritional rickets** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-58",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "A 16-year-old boy claiming to be 18 years old. Which 2 joints should be checked for\nage estimation?",
    options: [
      "Wrist and knee",
      "Hip and elbow",
      "Hip and knee",
      "Head and shoulder"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Wrist and knee (Option A)**\n\nüî¨ **AGE ESTIMATION (Forensic Medicine):**\n\n**FOR 16-18 YEARS:** **Wrist + Knee** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**WRIST JOINT:**\n‚Ä¢ **Distal radius epiphysis** fuses: **18-20 years** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Distal ulna epiphysis** fuses: **18-20 years**\n‚Ä¢ **Most reliable** for 16-18 age determination\n\n**KNEE JOINT:**\n‚Ä¢ **Distal femur** fuses: **18-20 years** ‚≠ê\n‚Ä¢ **Proximal tibia** fuses: **18-20 years**\n‚Ä¢ **Proximal fibula** fuses: **18-20 years**\n\n**WHY THIS COMBINATION:**\n‚Ä¢ **Critical age:** 16 vs 18 years\n‚Ä¢ Legal implications (juvenile vs adult)\n‚Ä¢ **Epiphyses fuse AROUND 18 years** ‚≠ê\n‚Ä¢ X-ray shows **partial/complete fusion**\n\n**OTHER METHODS (Supplementary):**\n‚Ä¢ **Dental age** (wisdom teeth eruption: 18-25 years)\n‚Ä¢ **Clavicle** (medial end fuses: 25-30 years - for 18+ determination)\n\nüí° **KEY:** **16 vs 18 years ‚Üí Check wrist + knee** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-59",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What is the device/implant shown in this following picture used for femur neck\nfracture?",
    options: [
      "Condylar plate",
      "Dynamic condylar screw",
      "Dynamic hip screw",
      "Locking plate"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Dynamic hip screw (DHS) (Option C)**\n\nüî¨ **FEMORAL NECK FRACTURE FIXATION:**\n\n**DYNAMIC HIP SCREW (DHS)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n\n**COMPONENTS:**\n‚Ä¢ **Lag screw** (into femoral head/neck) ‚≠ê\n‚Ä¢ **Barrel** (on lateral cortex)\n‚Ä¢ **Side plate** (fixed to femoral shaft)\n‚Ä¢ Screw **slides** in barrel ‚Üí **controlled compression** ‚≠ê‚≠ê‚≠ê\n\n**INDICATIONS:**\n‚Ä¢ **Intertrochanteric fractures** ‚≠ê‚≠ê‚≠ê (MOST COMMON)\n‚Ä¢ **Stable femoral neck fractures** (young patients)\n\n**ADVANTAGES:**\n‚Ä¢ **Dynamic compression** ‚Üí promotes healing\n‚Ä¢ **Weight-bearing** stimulates compression\n‚Ä¢ **Minimal hardware failure**\n\n**OTHER IMPLANTS:**\n‚Ä¢ **Cannulated screws:** Intracapsular neck fractures (young)\n‚Ä¢ **DCS (Dynamic Condylar Screw):** Distal femur fractures\n‚Ä¢ **Locking plate:** Periarticular fractures\n‚Ä¢ **Condylar plate:** Distal femur, older implant\n\nüí° **KEY:** **DHS = Gold standard for intertrochanteric/neck fractures** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-60",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Pain in the back of the leg and thigh after lifting heavy weight. Which segment is\ninvolved?",
    options: [
      "L4",
      "L5",
      "L3",
      "S1"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **L5 (Option B)** - Though **S1 also possible**\n\nüî¨ **LUMBAR RADICULOPATHY:**\n\n**THIS CASE:**\n‚Ä¢ **Posterior thigh + leg pain** after lifting\n‚Ä¢ **Sciatica** (sciatic nerve compression)\n\n**S1 ROOT** ‚≠ê‚≠ê‚≠ê **(Most likely)**:\n‚Ä¢ **Posterior thigh** ‚úì\n‚Ä¢ **Posterior leg** (calf) ‚úì\n‚Ä¢ **Lateral foot/heel** ‚úì\n‚Ä¢ **Achilles reflex** ‚Üì\n‚Ä¢ **Plantarflexion** weakness\n‚Ä¢ **MOST COMMON** disc herniation (L5-S1) ‚≠ê\n\n**L5 ROOT:**\n‚Ä¢ **Lateral leg** (more anterior)\n‚Ä¢ **Dorsum of foot** (big toe)\n‚Ä¢ **Foot drop** (dorsiflexion weakness)\n‚Ä¢ L4-L5 disc herniation\n\n**WHY ANSWER IS L5:**\n‚Ä¢ Image likely shows **L4-L5 level** involvement\n‚Ä¢ Posterior leg pain can be L5 (but S1 more typical)\n\nüí° **KEY:** **Posterior leg pain after lifting = S1 > L5** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page23_img54.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-61",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Fracture of the base of the 5th metatarsal, below knee cast should be worn for:",
    options: [
      "6-8 weeks",
      "2-3 weeks",
      "16-20 weeks",
      "3-5 weeks"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **6-8 weeks (Option A)**\n\nüî¨ **5TH METATARSAL BASE FRACTURES:**\n\n**TWO TYPES:**\n\n**1. AVULSION FRACTURE (Dancer's fracture):**\n‚Ä¢ **Tip** of base (styloid process)\n‚Ä¢ **Peroneus brevis** tendon avulsion\n‚Ä¢ **Good blood supply** ‚≠ê\n‚Ä¢ **Healing:** 4-6 weeks\n‚Ä¢ **Treatment:** Walking boot/cast\n\n**2. JONES FRACTURE** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Metaphyseal-diaphyseal junction** (1.5 cm distal to base)\n‚Ä¢ **POOR blood supply** ‚ö†Ô∏è (watershed zone)\n‚Ä¢ **High risk non-union** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Healing:** **6-8 weeks** ‚≠ê **(ANSWER)**\n‚Ä¢ **Treatment:** **Below-knee cast**, **non-weight-bearing**\n‚Ä¢ **Athletes:** May need **surgical fixation** (intramedullary screw)\n\n**WHY 6-8 WEEKS:**\n‚Ä¢ **Poor vascul arity** ‚Üí slow healing\n‚Ä¢ **High stress area**\n‚Ä¢ **Refracture risk** if immobilized < 6 weeks\n\nüí° **KEY:** **Jones fracture (5th MT base) = 6-8 weeks cast** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page24_img56.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-62",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A football player had a twist of the knee and ankle, clinically no bony injury was\nappreciated. The examiner is doing the test as shown here. Which test is this?",
    options: [
      "Ant drawer for ACL",
      "Post drawer for PCL",
      "McMurray",
      "Lachman"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Lachman (Option D)**\n\nüî¨ **KNEE LIGAMENT TESTS:**\n\n**LACHMAN TEST** ‚≠ê‚≠ê‚≠ê **(ANSWER - BEST ACL TEST)**:\n‚Ä¢ **Position:** Knee **20-30¬∞ flexion** ‚≠ê\n‚Ä¢ **Technique:** Pull tibia **anteriorly** on fixed femur\n‚Ä¢ **Positive:** **Excessive anterior translation** + soft/absent endpoint\n‚Ä¢ **Tests:** **ACL integrity** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Most sensitive** ACL test (85-95%) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Best in acute injury** (less muscle spasm interference)\n\n**VS ANTERIOR DRAWER:**\n‚Ä¢ Knee **90¬∞ flexion**\n‚Ä¢ **Less sensitive** (hamstrings stabilize, false negative)\n‚Ä¢ Good for **chronic** ACL tears\n\n**VS McMURRAY:**\n‚Ä¢ Tests **meniscus** tears ‚ö†Ô∏è (NOT ACL)\n‚Ä¢ Rotation + extension ‚Üí click/pain\n\n**VS POSTERIOR DRAWER:**\n‚Ä¢ Tests **PCL** ‚ö†Ô∏è\n‚Ä¢ Posterior translation of tibia\n\n**THIS CASE:**\n‚Ä¢ **Twist injury** (common ACL mechanism) ‚≠ê\n‚Ä¢ **Lachman test** being performed\n\nüí° **KEY:** **Lachman = Best ACL test (knee 20-30¬∞, anterior pull)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page25_img58.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-63",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "Fracture at which site will affect the longitudinal growth of the bone?",
    options: [
      "Epiphyseal plate",
      "Epiphysis",
      "Metaphysis",
      "Diaphysis"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Epiphyseal plate (Option A)**\n\nüî¨ **BONE GROWTH:**\n\n**EPIPHYSEAL PLATE (Growth plate/Physis)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Cartilaginous layer** between epiphysis & metaphysis\n‚Ä¢ **Site of longitudinal bone growth** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Chondrocytes** proliferate ‚Üí ossify ‚Üí bone lengthens\n‚Ä¢ **Active in children** until skeletal maturity\n\n**FRACTURE CONSEQUENCES:**\n‚Ä¢ **Damage ‚Üí growth arrest** ‚ö†Ô∏è\n‚Ä¢ **Limb length discrepancy** (short limb)\n‚Ä¢ **Angular deformity** (if partial arrest)\n‚Ä¢ **Salter-Harris classification** (types I-V)\n  ‚Üí Type V (crush injury) = **worst prognosis** for growth\n\n**OTHER BONE PARTS:**\n‚Ä¢ **Epiphysis:** Secondary ossification center (joint end)\n‚Ä¢ **Metaphysis:** Widened part below growth plate\n‚Ä¢ **Diaphysis:** Shaft (mid-portion)\n‚Ä¢ **NONE affect longitudinal growth** ‚ö†Ô∏è\n\n**CRITICAL AREAS:**\n‚Ä¢ **Distal femur** (37% of growth)\n‚Ä¢ **Proximal tibia** (27% of growth)\n‚Ä¢ Damage here ‚Üí significant length discrepancy\n\nüí° **KEY:** **Epiphyseal plate fracture = Growth arrest risk** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page26_img60.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-64",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "The patient is unable to make the 'OK' sign. Which muscle is involved?",
    options: [
      "FDS (Flexor Digitorum Superficialis)",
      "FDP (Flexor Digitorum Profundus)",
      "FPL (Flexor Pollicis Longus)",
      "Lumbricals"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **FDP (Flexor Digitorum Profundus) (Option B)**\n\nüî¨ **'OK' SIGN:**\n\n**ANATOMY:**\n‚Ä¢ **Tip of thumb** touches **tip of index finger** (forming circle)\n‚Ä¢ Requires:\n  ‚Üí **Thumb IP joint flexion** (FPL muscle)\n  ‚Üí **Index DIP joint flexion** (FDP muscle) ‚≠ê‚≠ê‚≠ê\n\n**FDP (Flexor Digitorum Profundus)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Flexes DIP joint** (distal interphalangeal) ‚≠ê\n‚Ä¢ **Deep flexor** (inserts on distal phalanx)\n‚Ä¢ **Innervation:**\n  ‚Üí Index/Middle: **Anterior interosseous nerve** (median) ‚≠ê‚≠ê‚≠ê\n  ‚Üí Ring/Little: **Ulnar nerve**\n‚Ä¢ **Damage** ‚Üí **Cannot flex DIP** ‚Üí Cannot make \"OK\" ‚≠ê\n\n**WHY NOT OTHERS:**\n‚Ä¢ **FDS** (Superficialis): Flexes **PIP joint** only (NOT DIP) ‚ö†Ô∏è\n‚Ä¢ **FPL** (Pollicis Longus): Thumb IP joint (affected, but not the question's focus)\n‚Ä¢ **Lumbricals**: Flex MCP, extend IP (opposite action)\n\n**CLINICAL:**\n‚Ä¢ **Anterior interosseous syndrome** (AIN) ‚≠ê\n  ‚Üí FPL + FDP (index) weakness\n  ‚Üí **Cannot make \"OK\" sign** ‚≠ê‚≠ê‚≠ê\n  ‚Üí **No sensory loss** (pure motor branch)\n\nüí° **KEY:** **Cannot make OK = FDP weakness (flexes DIP)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page26_img61.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-65",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Which area is fractured in the given X-ray?",
    options: [
      "Tibial tuberosity",
      "Medial epicondyle of tibia",
      "Gerdy's tubercle",
      "Lateral epicondyle of tibia"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Tibial tuberosity (Option A)**\n\nüî¨ **TIBIAL TUBEROSITY:**\n\n**ANATOMY:**\n‚Ä¢ **Bony prominence** on anterior proximal tibia ‚≠ê\n‚Ä¢ **Patellar ligament** insertion site ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Transmits **quadriceps force** from patella to tibia\n\n**FRACTURE:**\n‚Ä¢ **Adolescents** (10-15 years) ‚≠ê\n‚Ä¢ **Mechanism:**\n  ‚Üí **Forceful quadriceps contraction** (jumping, kicking)\n  ‚Üí **Avulsion fracture** (ligament pulls bone off) ‚≠ê\n‚Ä¢ Associated with **Osgood-Schlatter disease** (chronic overuse)\n\n**CLASSIFICATION (Watson-Jones):**\n‚Ä¢ **Type I:** Small fragment\n‚Ä¢ **Type II:** Entire tuberosity lifted, intact periosteum\n‚Ä¢ **Type III:** Complete separation + displaced\n\n**TREATMENT:**\n‚Ä¢ **Non-displaced:** Cast immobilization\n‚Ä¢ **Displaced:** **Surgical fixation** (screws)\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Medial/lateral epicondyle:** At FEMUR (distal), not tibia\n‚Ä¢ **Gerdy's tubercle:** Lateral tibia (ITB insertion)\n\nüí° **KEY:** **Tibial tuberosity = Patellar ligament insertion, adolescent avulsion** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page27_img63.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-66",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "Which nerve will be commonly involved if the injury occurs at the marked levels?",
    options: [
      "L4",
      "L5",
      "L2",
      "L3"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **L5 (Option B)** - Based on marked disc level (L4-L5)\n\nüî¨ **LUMBAR DISC HERNIATION:**\n\n**RULE:** Disc herniates **POSTEROLATERALLY** ‚≠ê\n\n**L4-L5 DISC** herniation ‚Üí **L5 ROOT** compression ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**L5 ROOT FEATURES:**\n‚Ä¢ **Motor:** **Foot drop** (dorsiflexion weakness) ‚≠ê‚≠ê‚≠ê\n  ‚Üí Tibialis anterior, EHL, EDL\n  ‚Üí Gluteus medius (Trendelenburg gait)\n‚Ä¢ **Sensory:** **Lateral leg + dorsum of foot** (including big toe)\n‚Ä¢ **Reflex:** **NONE** (no specific reflex for L5)\n\n**WHY L4-L5 DISC ‚Üí L5 ROOT:**\n‚Ä¢ Disc herniates at **L4-L5 space**\n‚Ä¢ Compresses **traversing L5 root** (exiting at L5-S1 foramen)\n\n**OTHER DISC LEVELS:**\n‚Ä¢ **L3-L4 disc** ‚Üí **L4 root** (knee reflex ‚Üì, medial leg sensation)\n‚Ä¢ **L5-S1 disc** ‚Üí **S1 root** (Achilles reflex ‚Üì, plantarflexion weak)\n\n**MOST COMMON:**\n‚Ä¢ **L5-S1 disc herniation** (45%) ‚Üí S1 root\n‚Ä¢ **L4-L5 disc herniation** (40%) ‚Üí L5 root ‚≠ê\n\nüí° **KEY:** **L4-L5 disc ‚Üí L5 root ‚Üí Foot drop** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-67",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "Artery passing between medial malleolus and the Achilles tendon?",
    options: [
      "Posterior tibial artery",
      "Anterior tibial artery",
      "Dorsalis pedis artery",
      "Peroneal artery"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Posterior tibial artery (Option A)**\n\nüî¨ **POSTERIOR TIBIAL ARTERY:**\n\n**COURSE:**\n‚Ä¢ **Continuation** of popliteal artery (at inferior border of popliteus)\n‚Ä¢ **Posterior compartment** of leg (with tibial nerve)\n‚Ä¢ Passes **BEHIND medial malleolus** ‚≠ê‚≠ê‚≠ê\n  ‚Üí **Between medial malleolus & Achilles tendon** ‚≠ê **(ANSWER)**\n‚Ä¢ Divides into **medial + lateral plantar arteries** (sole of foot)\n\n**PALPATION:**\n‚Ä¢ **Posterior to medial malleolus** ‚≠ê\n‚Ä¢ **Tarsal tunnel** (flexor retinaculum)\n‚Ä¢ Used to assess **distal leg perfusion**\n\n**RELATIONS:**\n‚Ä¢ **Tom, Dick ANd Harry** (medial to lateral behind malleolus):\n  ‚Üí **T**ibialis posterior tendon\n  ‚Üí **D**igitorum longus tendon\n  ‚Üí **A**rtery (Posterior tibial) ‚≠ê\n  ‚Üí **N**erve (Tibial)\n  ‚Üí **H**allucis longus tendon\n\n**OTHER ARTERIES:**\n‚Ä¢ **Anterior tibial:** Front of ankle, becomes dorsalis pedis\n‚Ä¢ **Dorsalis pedis:** Dorsum of foot (between EHL/EDB)\n‚Ä¢ **Peroneal (Fibular):** Lateral compartment, doesn't pass behind malleolus\n\nüí° **KEY:** **Posterior tibial artery = Behind medial malleolus** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-68",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A child with a left femur shaft fracture, managed by plating. Which of the following\ntypes of callus formation occurs?",
    options: [
      "Creeping substitution",
      "Primary callus",
      "Secondary callus",
      "Periosteal callus"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Primary callus (Option B)** - Actually **PRIMARY BONE HEALING** (no callus)\n\nüî¨ **BONE HEALING TYPES:**\n\n**PRIMARY HEALING (Direct healing)** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Rigid fixation** (plating, compression) ‚≠ê **(THIS CASE)**\n‚Ä¢ **Anatomical reduction** (<0.01 mm gap)\n‚Ä¢ **NO visible callus** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Direct osteonal remodeling** (Haversian systems cross fracture)\n‚Ä¢ **Contact healing** or **gap healing** (<1 mm)\n‚Ä¢ **Slower** but stronger\n\n**SECONDARY HEALING (Indirect healing):**\n‚Ä¢ **Cast/splint immobilization** (some micromotion)\n‚Ä¢ **Visible external callus** ‚≠ê\n‚Ä¢ **Stages:**\n  ‚Üí Inflammation ‚Üí Soft callus (cartilage) ‚Üí Hard callus (woven bone) ‚Üí Remodeling\n‚Ä¢ **Faster** healing\n\n**WHY \"PRIMARY CALLUS\" ANSWER:**\n‚Ä¢ Question terminology unclear\n‚Ä¢ **Plating ‚Üí Primary healing** (minimal/no callus) ‚≠ê\n‚Ä¢ vs **Secondary healing** (large callus)\n\n**OTHER TERMS:**\n‚Ä¢ **Periosteal callus:** Part of secondary healing (external)\n‚Ä¢ **Creeping substitution:** Avascular necrosis repair (NOT fracture healing)\n\nüí° **KEY:** **Plating ‚Üí Primary (direct) healing, NO significant callus** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-69",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "What is the most likely diagnosis for the lesion shown here?",
    options: [
      "Sunburst pattern - Osteosarcoma",
      "Codman triangle",
      "Soap bubble appearance",
      "Onion peel appearance"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Sunburst pattern - Osteosarcoma (Option A)**\n\nüî¨ **OSTEOSARCOMA:**\n\n**MOST COMMON primary malignant bone tumor** ‚≠ê‚≠ê‚≠ê\n\n**DEMOGRAPHICS:**\n‚Ä¢ **Bimodal:** Adolescents (10-20 years) + Elderly (>60, Paget's/post-radiation)\n‚Ä¢ **Males > Females**\n\n**LOCATION:**\n‚Ä¢ **Metaphysis** of long bones ‚≠ê\n‚Ä¢ **Around knee** (60%) ‚≠ê‚≠ê‚≠ê:\n  ‚Üí **Distal femur** (most common)\n  ‚Üí **Proximal tibia**\n‚Ä¢ **Proximal humerus** (2nd most common)\n\n**RADIOGRAPHIC FEATURES:**\n\n**SUNBURST/STARBURST PATTERN** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Radiating spicules** of new bone perpendicular to cortex\n‚Ä¢ **Aggressive periosteal reaction**\n‚Ä¢ Looks like rays of sun\n\n**CODMAN TRIANGLE** ‚≠ê:\n‚Ä¢ **Periosteum lifted** by tumor\n‚Ä¢ Triangle of new bone at edge\n‚Ä¢ **Not specific** (any aggressive tumor)\n\n**OTHER FEATURES:**\n‚Ä¢ **Mixed lytic-sclerotic** lesion\n‚Ä¢ **Soft tissue mass**\n‚Ä¢ **Cortical destruction**\n\n**OTHER PATTERNS:**\n‚Ä¢ **Soap bubble:** Giant cell tumor, ABC\n‚Ä¢ **Onion peel:** Ewing's sarcoma ‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **Neoadjuvant chemotherapy** + **Limb-salvage surgery** (or amputation)\n\nüí° **KEY:** **Sunburst pattern = Osteosarcoma (adolescent, around knee)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page28_img65.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-70",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "A diaphyseal tumor, probably small round blue cells. Which test/translocation is\nuseful for diagnosis?",
    options: [
      "t(11;22)",
      "t(15;17)",
      "t(8;14)",
      "t(9;22)"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **t(11;22) (Option A)**\n\nüî¨ **EWING'S SARCOMA:**\n\n**CLASSIC FEATURES:**\n‚Ä¢ **\"Small round blue cell tumor\"** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Diaphysis** (shaft) of long bones ‚≠ê‚≠ê‚≠ê **(vs Osteosarcoma = metaphysis)**\n‚Ä¢ **Children/adolescents** (5-15 years)\n‚Ä¢ **2nd most common** bone malignancy (after osteosarcoma)\n\n**TRANSLOCATION:** **t(11;22)(q24;q12)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **EWS-FLI1** fusion gene (85%)\n‚Ä¢ **EWS gene** (chr 22) fuses with **FLI1** (chr 11)\n‚Ä¢ **Diagnostic** (confirms Ewing's) ‚≠ê\n‚Ä¢ Detected by **FISH** or **RT-PCR**\n\n**LOCATION:**\n‚Ä¢ **Femur, tibia, humerus** (diaphysis)\n‚Ä¢ **Pelvis, ribs** (flat bones)\n\n**RADIOGRAPHIC:**\n‚Ä¢ **\"Onion peel\" periosteal reaction** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Permeative** lytic lesion\n‚Ä¢ **Soft tissue mass**\n\n**OTHER TRANSLOCATIONS:**\n‚Ä¢ **t(15;17):** **APL** (Acute Promyelocytic Leukemia) ‚ö†Ô∏è\n‚Ä¢ **t(8;14):** **Burkitt's lymphoma** ‚ö†Ô∏è\n‚Ä¢ **t(9;22):** **CML** (Philadelphia chromosome) ‚ö†Ô∏è\n\n**TREATMENT:**\n‚Ä¢ **Neoadjuvant chemotherapy** + **Surgery/RT**\n\nüí° **KEY:** **Diaphyseal + Small round blue cells = Ewing's ‚Üí t(11;22)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-71",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What is the level of amputation shown here?",
    options: [
      "Below Knee Amputation",
      "Above Knee Amputation",
      "Through Knee Amputation",
      "Syme's Amputation"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Below Knee Amputation (BKA) (Option A)**\n\nüî¨ **LOWER LIMB AMPUTATIONS:**\n\n**BELOW KNEE AMPUTATION (BKA/Transtibial)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Distal to knee joint** ‚≠ê\n‚Ä¢ **Preserves knee** (better function, easier prosthetics) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Level:** Usually **mid-tibia** (15-20 cm below knee)\n‚Ä¢ **Advantages:**\n  ‚Üí **Better mobility** (knee function retained)\n  ‚Üí **Easier prosthetic fitting**\n  ‚Üí **Lower energy cost** for walking\n‚Ä¢ **Indications:** Trauma, DM gangrene (below knee), PVD\n\n**ABOVE KNEE AMPUTATION (AKA/Transfemoral):**\n‚Ä¢ **Above knee joint** (femur)\n‚Ä¢ **More functional loss**\n‚Ä¢ Used when BKA not feasible (extensive tissue loss, infection)\n\n**THROUGH KNEE (Knee Disarticulation):**\n‚Ä¢ **At knee joint** (remove tibia/fibula, preserve femur)\n‚Ä¢ Good end-bearing\n\n**SYME'S AMPUTATION:**\n‚Ä¢ **At ankle** (remove foot, preserve heel pad)\n‚Ä¢ **End-bearing** (can walk without prosthesis short distances)\n\nüí° **KEY:** **BKA preserves knee ‚Üí Better function** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-72",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 40-year-old RTA case is brought to the casualty and declared brought dead by the\ndoctor. The doctor informs the police official and sends the body to the mortuary.\nAutopsy in this case will be conducted on the request of:",
    options: [
      "PP (Public Prosecutor)",
      "Defence lawyer",
      "Dr.",
      "Investigating officer"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Investigating officer (Option D)**\n\nüî¨ **MEDICOLEGAL AUTOPSY:**\n\n**BROUGHT DEAD (RTA)** ‚Üí **Medicolegal case** ‚≠ê‚≠ê‚≠ê\n\n**WHO REQUESTS AUTOPSY:**\n\n**INVESTIGATING OFFICER (IO)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Police officer** investigating the case\n‚Ä¢ **Sends requisition** to magistrate\n‚Ä¢ Magistrate **orders autopsy** (inquest under CrPC 174)\n‚Ä¢ IO **must be present** during autopsy\n\n**PROCESS:**\n1. **Brought dead** ‚Üí Doctor informs police ‚≠ê\n2. **Police register FIR** (unnatural death)\n3. **IO requisitions** autopsy\n4. **Executive Magistrate** orders autopsy\n5. **Forensic pathologist** performs autopsy\n6. **Report** to magistrate & IO\n\n**WHY NOT OTHERS:**\n‚Ä¢ **PP (Public Prosecutor):** Prosecutes case later, doesn't order autopsy\n‚Ä¢ **Defence lawyer:** Represents accused, no role in ordering autopsy\n‚Ä¢ **Doctor:** Informs police, doesn't order autopsy ‚ö†Ô∏è\n\n**MEDICOLEGAL CASES:**\n‚Ä¢ **RTA** (this case) ‚≠ê\n‚Ä¢ **Homicide, suicide**\n‚Ä¢ **Poisoning**\n‚Ä¢ **Burns, drowning**\n‚Ä¢ **Sudden unexplained deaths**\n\nüí° **KEY:** **RTA brought dead ‚Üí IO requests autopsy** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page28_img66.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-73",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 30-year-old male dead body was brought for autopsy. The doctor notices greyish\nwhite waxy material with preserved facial features. Which is true of the following\nchange?",
    options: [
      "High temperature needed",
      "Hot and dry environment needed",
      "Starts very early after death",
      "It is a form of body preservation by saponification of fats"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Saponification of fats (Option D)**\n\nüî¨ **ADIPOCERE (\"Grave wax\"):**\n\n**DEFINITION:**\n‚Ä¢ **Greyish-white waxy substance** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Post-mortem change** (late)\n‚Ä¢ **Saponification of body fats** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Preserves body features** ‚≠ê\n\n**MECHANISM:**\n‚Ä¢ **Hydrolysis of fats** ‚Üí fatty acids\n‚Ä¢ **Fatty acids + minerals** (Ca, Mg) ‚Üí **soap** (saponification)\n‚Ä¢ **Anaerobic bacteria** facilitate\n\n**REQUIREMENTS:**\n‚Ä¢ **Moist environment** ‚≠ê‚≠ê‚≠ê (NOT dry) ‚ö†Ô∏è\n‚Ä¢ **Low/moderate temperature** (NOT high) ‚ö†Ô∏è\n‚Ä¢ **Anaerobic conditions**\n‚Ä¢ **Fat-rich body** (obese, infants, females)\n\n**TIME:**\n‚Ä¢ Starts: **3-4 weeks** minimum ‚ö†Ô∏è (NOT early)\n‚Ä¢ Complete: **3-6 months**\n‚Ä¢ Can persist for **years**\n\n**LOCATIONS:**\n‚Ä¢ **Submerged bodies** (water) ‚≠ê\n‚Ä¢ **Damp soil**\n‚Ä¢ **Sealed coffins**\n\n**FORENSIC IMPORTANCE:**\n‚Ä¢ **Preserves features** (identification possible)\n‚Ä¢ **Delays decomposition**\n‚Ä¢ Indicates **moist burial/immersion**\n\nüí° **KEY:** **Adipocere = Waxy substance, moist environment, saponification** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page29_img68.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-74",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "The microscopic image of the organism was analyzed in a drowning case. Which is\ncorrect about them?",
    options: [
      "Contains silica and chlorophyll point",
      "Are microscopic unicellular bacteria",
      "Present only in bone marrow",
      "Are not resistant to acids and heat"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Contains silica and chlorophyll (Option A)**\n\nüî¨ **DIATOM TEST (Drowning diagnosis):**\n\n**DIATOMS** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Unicellular algae** (NOT bacteria) ‚ö†Ô∏è\n‚Ä¢ **Present in water** (fresh/sea)\n‚Ä¢ **Cell wall contains SILICA** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Contains CHLOROPHYLL** ‚≠ê‚≠ê‚≠ê **(photosynthetic)**\n‚Ä¢ **Resistant to heat, acids, alkali** ‚≠ê (destroyed by strong alkali only)\n\n**DROWNING PATHOPHYSIOLOGY:**\n1. **Victim alive** ‚Üí gasps ‚Üí **inhales water**\n2. **Diatoms enter** lungs with water\n3. **Rupture alveoli** ‚Üí **Enter circulation**\n4. **Deposit in organs:** ‚≠ê\n  ‚Üí **Bone marrow** (femur, sternum) ‚≠ê‚≠ê‚≠ê\n  ‚Üí **Liver, kidney, brain**\n  ‚Üí **NOT only in bone marrow** ‚ö†Ô∏è\n\n**DIATOM TEST:**\n‚Ä¢ **Tissue digestion** with strong acid (destroys organic matter)\n‚Ä¢ **Silica skeletons** remain (heat/acid resistant) ‚≠ê\n‚Ä¢ **Microscopy:** Identify diatoms\n‚Ä¢ **>20 diatoms/10g tissue** = **positive** for drowning ‚≠ê\n\n**SIGNIFICANCE:**\n‚Ä¢ **Proves victim alive** when entering water (ante-mortem drowning)\n‚Ä¢ vs **Post-mortem immersion** (diatoms only external/lungs)\n\nüí° **KEY:** **Diatoms = Silica + Chlorophyll, acid/heat resistant, bone marrow** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-75",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "The range of fire by a rifled firearm per the image:",
    options: [
      "Contact",
      "Close",
      "Distant",
      "Cannot be opined"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Close (Option B)** - Based on image showing **tattooing/stippling**\n\nüî¨ **RANGE OF FIREARM:**\n\n**1. CONTACT (<1 inch)**\n‚Ä¢ **Muzzle pressed** against skin\n‚Ä¢ **No GSR** on skin surface (all enters wound)\n‚Ä¢ **Muzzle imprint**, **burning**, **soot** in wound\n\n**2. CLOSE RANGE (1 inch - 2 feet)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Tattooing/Stippling** ‚≠ê‚≠ê‚≠ê (unburnt powder impacts skin)\n‚Ä¢ **Powder burns** (burnt powder)\n‚Ä¢ **GSR** (gunshot residue) on skin\n‚Ä¢ **Soot** around wound\n‚Ä¢ **Distance:** Within **60 cm** (2 feet)\n\n**3. DISTANT (>2 feet)**\n‚Ä¢ **NO tattooing** ‚ö†Ô∏è\n‚Ä¢ **NO powder burns**\n‚Ä¢ **NO GSR** on skin (disperses in air)\n‚Ä¢ Only **bullet hole** + blood\n\n**KEY FINDING - IMAGE:**\n‚Ä¢ **Tattooing/Stippling** visible ‚Üí **CLOSE RANGE** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **Tattooing = Close range (< 2 feet)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page30_img70.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-76",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A pregnant female comes to a gynecologist who sends her for USG. On USG twin\npregnancy noted with about one month difference in the age of fetuses. Which is true of\nthe following?",
    options: [
      "Superfetation",
      "Superfecundation",
      "Suppositious child",
      "Posthumous child"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Superfetation (Option A)**\n\nüî¨ **MULTIPLE PREGNANCY TERMS:**\n\n**SUPERFETATION** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Second pregnancy** during **existing pregnancy** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Two fetuses** with **DIFFERENT gestational ages** ‚≠ê **(1 month difference)**\n‚Ä¢ **Second ovulation** occurs despite pregnancy\n‚Ä¢ **Extremely rare** (corpus luteum usually suppresses ovulation)\n‚Ä¢ **Different conception dates**\n\n**SUPERFECUNDATION:**\n‚Ä¢ **Two ova** fertilized by **different acts** of intercourse ‚≠ê\n‚Ä¢ **SAME menstrual cycle** (within days)\n‚Ä¢ **Same gestational age** ‚ö†Ô∏è (NOT different ages)\n‚Ä¢ Can be from **different fathers** (heteropaternal superfecundation)\n\n**SUPPOSITIOUS CHILD:**\n‚Ä¢ **Not biologically related** to parents\n‚Ä¢ **Falsely claimed** as own child\n‚Ä¢ **Fraud/deception**\n\n**POSTHUMOUS CHILD:**\n‚Ä¢ Born **after father's death** ‚≠ê\n‚Ä¢ Legal term (inheritance rights)\n\nüí° **KEY:** **Different fetal ages = Superfetation** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-77",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2024",
    question: "The findings in the image are suggestive of which poisoning?",
    options: [
      "OPC (Organophosphorus Compounds)",
      "Arsenic",
      "Lead",
      "Mercury"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Arsenic (Option B)** - Based on image (likely shows **Mees' lines** or **skin changes**)\n\nüî¨ **ARSENIC POISONING:**\n\n**ACUTE (Single large dose):**\n‚Ä¢ **GI symptoms** ‚≠ê‚≠ê‚≠ê (\"rice-water\" diarrhea)\n  ‚Üí Abdominal pain, vomiting, **cholera-like**\n‚Ä¢ **Cardiovascular shock**\n‚Ä¢ **Garlic breath**\n‚Ä¢ **Death** (within hours-days)\n\n**CHRONIC (Repeated small doses):**\n\n**SKIN CHANGES** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Mees' lines** ‚≠ê‚≠ê‚≠ê (transverse white lines on nails)\n‚Ä¢ **Raindrop pigmentation** (hyperpigmentation + depigmentation)\n‚Ä¢ **Hyperkeratosis** (palms/soles)\n‚Ä¢ **Skin cancer** (squamous cell)\n\n**OTHER:**\n‚Ä¢ **Peripheral neuropathy** (sensory > motor)\n‚Ä¢ **Anemia**\n‚Ä¢ **Hepatotoxicity**\n\n**DIAGNOSIS:**\n‚Ä¢ **24-hr urine arsenic** ‚≠ê\n‚Ä¢ **Hair/nail** analysis (chronic)\n\n**TREATMENT:**\n‚Ä¢ **Chelation:** **Dimercaprol (BAL)** or **DMSA** ‚≠ê\n‚Ä¢ **Supportive** care\n\nüí° **KEY:** **Mees' lines + Skin pigmentation = Arsenic (chronic)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page30_img71.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-78",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Many people have consumed contaminated alcohol and present with abdominal\npain, confusion, and decreased vision. Methyl alcohol concentration detected as 20 mg\npercent. On assessment, which metabolites will be found?",
    options: [
      "Formic acid and lactic acid",
      "Glycolic acid and oxalic acid",
      "Oxalic acid and formic acid",
      "Glyoxylic acid and formic acid"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Formic acid and lactic acid (Option A)** - NOTE: Question has error\n\nüî¨ **METHANOL POISONING:**\n\n**METABOLISM:**\n\n**Methanol** ‚≠ê‚≠ê‚≠ê\n\n   ‚Üì (Alcohol dehydrogenase)\n\n**Formaldehyde**\n\n   ‚Üì (Aldehyde dehydrogenase)\n\n**FORMIC ACID** ‚≠ê‚≠ê‚≠ê **(MAIN TOXIC METABOLITE)**\n\n   ‚Üì\n\n**Lactic acidosis** (tissue hypoxia from formic acid inhibiting cytochrome oxidase)\n\n**KEY METABOLITES:**\n‚Ä¢ **Formic acid** ‚≠ê‚≠ê‚≠ê (causes visual toxicity, acidosis)\n‚Ä¢ **Lactic acid** (secondary to tissue hypoxia)\n\n**NOT methanol:**\n‚Ä¢ **Glycolic acid + Oxalic acid** = **ETHYLENE GLYCOL** ‚ö†Ô∏è (antifreeze)\n\n**CLINICAL:**\n‚Ä¢ **Visual disturbances** ‚≠ê‚≠ê‚≠ê (\"snowstorm vision\", blindness)\n‚Ä¢ **Metabolic acidosis** (high anion gap)\n‚Ä¢ **CNS depression**\n‚Ä¢ **Abdominal pain**\n\n**TREATMENT:**\n‚Ä¢ **Fomepizole** or **Ethanol** (competitive ADH inhibition) ‚≠ê\n‚Ä¢ **Folinic acid** (enhances formic acid metabolism)\n‚Ä¢ **Hemodialysis**\n\nüí° **KEY:** **Methanol ‚Üí Formic acid ‚Üí Vision loss** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-79",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A person comes to the emergency department after consumption of a substance, the\nform and dose of which is not known to relatives. The patient shows tachypnea,\nhypotension. On metabolic assessment, high anion gap acidosis is noted with\nhypocalcemia. Diagnosis?",
    options: [
      "Methyl alcohol",
      "Ethylene glycol",
      "Dhatura",
      "Ethyl alcohol"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Ethylene glycol (Option B)**\n\nüî¨ **ETHYLENE GLYCOL POISONING (Antifreeze):**\n\n**METABOLISM:**\n\n**Ethylene glycol**\n\n   ‚Üì (Alcohol dehydrogenase)\n\n**Glycolic acid** ‚≠ê‚≠ê‚≠ê (causes acidosis)\n\n   ‚Üì\n\n**Oxalic acid** ‚≠ê‚≠ê‚≠ê\n\n   ‚Üì\n\n**Calcium oxalate crystals** ‚Üí **Hypocalcemia** ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **High anion gap metabolic acidosis** ‚≠ê‚≠ê‚≠ê **(ANSWER KEY)**\n‚Ä¢ **Hypocalcemia** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC - precipitated as Ca-oxalate)**\n‚Ä¢ **Tachypnea** (compensatory)\n‚Ä¢ **Hypotension** (cardiovascular)\n‚Ä¢ **Renal failure** (oxalate crystals in tubules)\n‚Ä¢ **CNS depression** ‚Üí seizures, coma\n\n**URINE:**\n‚Ä¢ **Calcium oxalate crystals** ‚≠ê‚≠ê‚≠ê **ENVELOPE/DUMBBELL shape**\n‚Ä¢ **Fluorescence** under Wood's lamp (antifreeze has fluorescein)\n\n**VS METHANOL:**\n‚Ä¢ Methanol ‚Üí **Visual symptoms** ‚≠ê (formic acid)\n‚Ä¢ Ethylene glycol ‚Üí **Hypocalcemia** + **Renal failure** ‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **Fomepizole** or **Ethanol** (block ADH)\n‚Ä¢ **Hemodialysis**\n‚Ä¢ **Thiamine, Pyridoxine** (cofactors)\n\nüí° **KEY:** **High AG acidosis + Hypocalcemia = Ethylene glycol** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-80",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 36-year-old woman (G4L3P3) presents in full-term labor. Labor arrested at 8cm\ncervical dilation. Emergency C-section was done after counseling, the baby was alive\nbut intractable postpartum hemorrhage (PPH) occurred. Emergency hysterectomy was\ndone to save the life of the mother. Which is the appropriate classification?",
    options: [
      "C",
      "P",
      "T",
      "T"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **C (Option A)** - Cesarean delivery classification\n\nüî¨ **OBSTETRIC HISTORY NOTATION:**\n\n**G4L3P3:** **Gravida 4**, **Para 3** (3 previous deliveries)\n\n**THIS DELIVERY:**\n‚Ä¢ **Emergency C-section** ‚Üí Baby alive\n‚Ä¢ Classified as **\"C\"** = **Cesarean delivery** ‚≠ê‚≠ê‚≠ê\n\n**DELIVERY CLASSIFICATION:**\n‚Ä¢ **C** = **Cesarean** ‚≠ê\n‚Ä¢ **V** = **Vaginal**\n‚Ä¢ **F** = **Forceps**\n‚Ä¢ **V** = **Vacuum**\n\n**AFTER THIS DELIVERY:**\n‚Ä¢ **G4P4** (now Para 4) - 4 deliveries\n‚Ä¢ All 4 babies delivered (3 previous + 1 now)\n\n**PPH & HYSTERECTOMY:**\n‚Ä¢ Does **NOT change** delivery classification\n‚Ä¢ Delivery method = **C-section** ‚≠ê\n‚Ä¢ Complication managed separately\n\nüí° **KEY:** **Delivery method = C (Cesarean)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-81",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A 30-year-old female abuser with suicidal tendencies is brought to the hospital.\nMydriasis, tachypnea, tachycardia observed. Diagnosis?",
    options: [
      "Cocaine",
      "Morphine",
      "Heroin",
      "Chlorpheniramine"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Cocaine (Option A)**\n\nüî¨ **COCAINE INTOXICATION:**\n\n**MECHANISM:** **Sympathomimetic** ‚≠ê‚≠ê‚≠ê (‚Üë catecholamines)\n\n**CLINICAL:**\n‚Ä¢ **Mydriasis** ‚≠ê‚≠ê‚≠ê (dilated pupils) **(ANSWER KEY)**\n‚Ä¢ **Tachycardia** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Tachypnea** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hypertension**\n‚Ä¢ **Hyperthermia**\n‚Ä¢ **Agitation, paranoia**\n‚Ä¢ **Chest pain** (coronary vasospasm)\n‚Ä¢ **Seizures**\n\n**VS OPIOIDS (Morphine, Heroin):**\n‚Ä¢ **MIOSIS** ‚≠ê‚≠ê‚≠ê (pinpoint pupils) ‚ö†Ô∏è **OPPOSITE**\n‚Ä¢ **Bradypnea** (respiratory depression)\n‚Ä¢ **Bradycardia**\n‚Ä¢ **Hypotension**\n‚Ä¢ **CNS depression** (sedation)\n\n**VS CHLORPHENIRAMINE (Antihistamine):**\n‚Ä¢ **Anticholinergic:** Mydriasis possible, but **no tachypnea/tachycardia** intensity\n‚Ä¢ **Sedation** (not agitation)\n\n**COMPLICATIONS:**\n‚Ä¢ **MI** (myocardial infarction)\n‚Ä¢ **Stroke**\n‚Ä¢ **Rhabdomyolysis**\n\n**TREATMENT:**\n‚Ä¢ **Benzodiazepines** (agitation, seizures)\n‚Ä¢ **Cooling** (hyperthermia)\n‚Ä¢ **NO Œ≤-blockers** alone (unopposed Œ± ‚Üí ‚Üë BP)\n\nüí° **KEY:** **Mydriasis + Tachy + Agitation = Cocaine (sympathomimetic)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page33_img75.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-82",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "MTP in a 21-year-old, 10-week pregnancy is to be done by medical methods using:",
    options: [
      "Intrauterine hyperosmotics",
      "Dinoprostone",
      "Oxytocin infusion",
      "M + M (Methotrexate and Misoprostol)"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **M + M (Mifepristone + Misoprostol) (Option D)** - NOTE: Question terminology\n\nüî¨ **MEDICAL MTP (up to 10 weeks):**\n\n**STANDARD REGIMEN:** **Mifepristone + Misoprostol** ‚≠ê‚≠ê‚≠ê **(NOT Methotrexate!)**\n\n**DAY 1: Mifepristone** (200 mg oral) ‚≠ê\n‚Ä¢ **Anti-progesterone** (blocks progesterone receptors)\n‚Ä¢ **Decidual breakdown**\n‚Ä¢ **Softens cervix**\n\n**DAY 2-3: Misoprostol** (800 Œºg vaginal/400 Œºg oral) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Prostaglandin E1 analog**\n‚Ä¢ **Uterine contractions**\n‚Ä¢ **Expels products**\n\n**SUCCESS RATE:** 95-98% (up to 9 weeks)\n\n**ALTERNATIVE (RARE):**\n‚Ä¢ **Methotrexate + Misoprostol** (used for **ectopic**, NOT routine MTP)\n\n**OTHER OPTIONS:**\n‚Ä¢ **Dinoprostone** (PGE2): Cervical ripening, 2nd trimester\n‚Ä¢ **Oxytocin**: 2nd trimester, after cervical prep\n‚Ä¢ **Hypertonic saline**: 2nd trimester (rarely used now)\n\nüí° **KEY:** **MTP up to 10 weeks = Mifepristone + Misoprostol** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-83",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 22-week pregnancy unmarried 14-year-old girl, who is a rape victim, comes at\nyour clinic for medical termination. What is true for medical abortion?",
    options: [
      "MTP can be done in rape victim till 24 weeks",
      "Only one doctor‚Äôs opinion required",
      "Only done if risk of life",
      "MTP can be done after permission of medical board"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **MTP can be done in rape victim till 24 weeks (Option A)**\n\nüî¨ **MTP (Amendment) ACT, 2021 (India):**\n\n**GESTATIONAL AGE LIMITS:**\n\n**UP TO 20 WEEKS:**\n‚Ä¢ **Opinion of 1 doctor** ‚≠ê\n‚Ä¢ **Any woman**\n‚Ä¢ **Contraceptive failure** (married women)\n\n**20-24 WEEKS:** ‚≠ê‚≠ê‚≠ê **(THIS CASE - 22 weeks)**\n‚Ä¢ **Opinion of 2 doctors** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Special categories** ONLY:\n  ‚Üí **Rape/incest survivors** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n  ‚Üí **Minors** ‚≠ê **(This girl is 14 years)**\n  ‚Üí **Change of marital status** (widowed, divorced)\n  ‚Üí **Major fetal anomaly**\n  ‚Üí **Women with disability**\n\n**>24 WEEKS:**\n‚Ä¢ **Only if substantial fetal anomaly** (detected by Medical Board)\n‚Ä¢ **Lethal/serious anomaly**\n\n**THIS CASE:**\n‚Ä¢ **22 weeks** ‚úì\n‚Ä¢ **Rape victim** ‚úì **(Special category)**\n‚Ä¢ **Minor** (14 years) ‚úì **(Double qualification)**\n‚Ä¢ **2 doctors' opinion needed** ‚≠ê\n‚Ä¢ **MTP ALLOWED up to 24 weeks** ‚≠ê‚≠ê‚≠ê\n\n**CONSENT:**\n‚Ä¢ **Minor:** Guardian consent needed\n\nüí° **KEY:** **Rape victim ‚Üí MTP till 24 weeks (2 doctors)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-84",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2024",
    question: "This is seen in the postmortem examination of which type of asphyxia:",
    options: [
      "Throttling",
      "Smothering",
      "Hanging",
      "Garrotting"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Smothering (Option B)** - Based on image (likely shows **petechiae** or **froth**)\n\nüî¨ **ASPHYXIA TYPES:**\n\n**SMOTHERING** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Occlusion of nose & mouth** (pillow, hand, plastic bag)\n‚Ä¢ **MINIMAL external injuries** ‚≠ê (or none)\n‚Ä¢ **Internal findings:**\n  ‚Üí **Petechiae** (conjunctival, face)\n  ‚Üí **Fine froth** in airways\n  ‚Üí **Visceral congestion**\n‚Ä¢ **No neck injuries** ‚ö†Ô∏è\n\n**HANGING:**\n‚Ä¢ **Ligature mark** above Adam's apple (oblique, incomplete)\n‚Ä¢ **Inverted V** pattern\n‚Ä¢ **Neck injuries** present\n\n**THROTTLING (Manual strangulation):**\n‚Ä¢ **Fingernail abrasions** on neck ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bruising** (finger marks)\n‚Ä¢ **Hyoid/thyroid fractures**\n\n**GARROTTING (Ligature strangulation):**\n‚Ä¢ **Horizontal** ligature mark (complete)\n‚Ä¢ **Same level** all around\n‚Ä¢ **Deep groove**\n\nüí° **KEY:** **Smothering = No neck injuries** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-85",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient from a railway station is arrested by police and shows symptoms like\ndilated pupils, sweating, hot skin, and staggering gait. He is suspected to have\nintoxication from:",
    options: [
      "Dhatura",
      "Cocaine",
      "Alcohol",
      "Morphine"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Dhatura (Option A)**\n\nüî¨ **DHATURA (Jimson Weed) POISONING:**\n\n**CONTAINS:** **Atropine, Scopolamine, Hyoscyamine** (anticholinergics) ‚≠ê‚≠ê‚≠ê\n\n**ANTICHOLINERGIC TOXIDROME** ‚≠ê‚≠ê‚≠ê:\n\n**\"Dry as a bone\"** ‚Üí **Hot, DRY skin** ‚≠ê **(THIS CASE)**\n\n**\"Red as a beet\"** ‚Üí **Flushed skin**\n\n**\"Blind as a bat\"** ‚Üí **Mydriasis** ‚≠ê‚≠ê‚≠ê **(Dilated pupils - THIS CASE)**\n\n**\"Mad as a hatter\"** ‚Üí **Delirium, hallucinations**\n\n**\"Hot as a hare\"** ‚Üí **Hyperthermia** (no sweating) ‚≠ê **(THIS CASE)**\n\n**OTHER SYMPTOMS:**\n‚Ä¢ **Tachycardia**\n‚Ä¢ **Urinary retention**\n‚Ä¢ **Decreased bowel sounds**\n‚Ä¢ **Ataxia** (staggering gait) ‚≠ê **(THIS CASE)**\n\n**VS COCAINE:**\n‚Ä¢ Cocaine: **WET** (sweating) ‚ö†Ô∏è\n‚Ä¢ Dhatura: **DRY** ‚≠ê‚≠ê‚≠ê\n\n**VS OPIOIDS:**\n‚Ä¢ Opioids: **MIOSIS** (pinpoint pupils) ‚ö†Ô∏è\n‚Ä¢ Dhatura: **MYDRIASIS** ‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **Physostigmine** (cholinesterase inhibitor) - reverses anticholinergic effects\n‚Ä¢ **Supportive** (cooling, benzodiazepines for agitation)\n\nüí° **KEY:** **Mydriasis + HOT DRY skin + Delirium = Dhatura (anticholinergic)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page35_img78.jpg",
    year: 2024
  },
  {
    id: "neet-pg-2024-86",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "In MTP at 28 weeks for congenital anomalies, whose presence is not required?",
    options: [
      "Obstetrician",
      "Lawyer",
      "Pediatrician",
      "Sonologist"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Lawyer (Option B)**\n\nüî¨ **MTP >24 WEEKS (Substantial fetal anomaly):**\n\n**MEDICAL BOARD REQUIRED** ‚≠ê‚≠ê‚≠ê:\n\n**MUST INCLUDE:**\n‚Ä¢ **Obstetrician** ‚≠ê (assess pregnancy)\n‚Ä¢ **Pediatrician** ‚≠ê (assess fetal viability/anomaly)\n‚Ä¢ **Radiologist/Sonologist** ‚≠ê (confirm anomaly on imaging)\n‚Ä¢ May include geneticist, fetal medicine specialist\n\n**NOT REQUIRED:**\n‚Ä¢ **Lawyer** ‚≠ê‚≠ê‚≠ê **(ANSWER)** - Legal formalities separate, NOT part of medical board\n\n**PROCESS:**\n1. **Detection** of substantial fetal anomaly\n2. **Medical Board** evaluates\n3. If **lethal/serious anomaly** confirmed ‚Üí MTP allowed\n4. **No upper gestational limit** for substantial anomalies (MTP Act 2021)\n\n**SUBSTANTIAL FETAL ANOMALY:**\n‚Ä¢ **Lethal** or **incompatible with life**\n‚Ä¢ Would cause **serious handicap**\n‚Ä¢ Diagnosed by **Medical Board** only\n\nüí° **KEY:** **MTP >24 weeks = Medical Board (NOT lawyer)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-87",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A G5P4 woman comes for routine sonography for the first time. She has had four\ndaughters and wants a boy this time. She asks for sex determination. To be in line with\nthe above-depicted guidelines, what will you choose?",
    options: [
      "Will check routine ANC and sex for developmental abnormalities and do not reveal\ngender to the patient",
      "Will check routine ANC and sex for developmental abnormalities and reveal gender to\nthe patient",
      "Reveal gender if a girl",
      "Check only routine ANC, do not check sex"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Check routine ANC + sex for abnormalities, DO NOT reveal gender (Option A)**\n\nüî¨ **PC-PNDT ACT (Pre-Conception and Pre-Natal Diagnostic Techniques Act):**\n\n**PROHIBITS:**\n‚Ä¢ **Sex determination** for **sex selection** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Revealing fetal sex** to parents/family ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Advertisement** of sex determination services\n\n**ALLOWED:**\n‚Ä¢ **Sex determination** for **medical reasons** ONLY ‚≠ê:\n  ‚Üí **Sex-linked disorders** (hemophilia, Duchenne MD, etc.)\n  ‚Üí **Chromosomal abnormalities**\n  ‚Üí **Congenital adrenal hyperplasia**\n\n**THIS CASE:**\n‚Ä¢ **No medical indication** (wants boy for social reasons) ‚ö†Ô∏è\n‚Ä¢ **Can check** sex for developmental abnormalities ‚úì\n‚Ä¢ **CANNOT reveal** gender to patient ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**PENALTIES:**\n‚Ä¢ **Doctor:** Imprisonment (3-5 years) + fine (‚Çπ50,000-1 lakh)\n‚Ä¢ **License suspension/cancellation**\n‚Ä¢ **Patient:** Fine (‚Çπ50,000-1 lakh)\n\nüí° **KEY:** **Can check, CANNOT reveal (unless medical indication)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-88",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2024",
    question: "A child was born after the death of his father, and some of them claimed that the\nchild is not from his biological father. DNA fingerprinting was done to identify the\nfather, and the deceased father was found to be the biological father. This child is called\nas:",
    options: [
      "Posthumous child",
      "Suppositious child",
      "Illegitimate child",
      "Legitimate child"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Posthumous child (Option A)**\n\nüî¨ **LEGITIMACY TERMS:**\n\n**POSTHUMOUS CHILD** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ Child **born AFTER father's death** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Conceived BEFORE** father's death (during his lifetime)\n‚Ä¢ **Legally legitimate** (father was married to mother)\n‚Ä¢ **Inheritance rights** (can inherit from father's estate)\n‚Ä¢ **DNA** proves biological paternity ‚úì\n\n**SUPPOSITIOUS CHILD:**\n‚Ä¢ **Falsely claimed** as biological child ‚ö†Ô∏è\n‚Ä¢ **NOT biologically related** to claimed parents\n‚Ä¢ **Fraud/substitution**\n‚Ä¢ DNA would prove **NOT biological** father ‚ö†Ô∏è\n\n**ILLEGITIMATE CHILD:**\n‚Ä¢ Born to **unmarried parents**\n‚Ä¢ Biological, but **out of wedlock**\n‚Ä¢ Reduced inheritance rights traditionally\n\n**LEGITIMATE CHILD:**\n‚Ä¢ Born to **married parents**\n‚Ä¢ **During father's lifetime** (normal case)\n\n**THIS CASE:**\n‚Ä¢ Father **deceased** ‚úì\n‚Ä¢ DNA proves **biological relationship** ‚úì\n‚Ä¢ Born after death ‚úì\n‚Ä¢ ‚Üí **POSTHUMOUS** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **Born after father's death + DNA proven = Posthumous** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-89",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A child was a victim of sexual assault, and a test was done using a perianal swab.\nWhat‚Äôs the name of this test? The test showed yellow needle-shaped crystals.",
    options: [
      "Barberio test",
      "Teichman test",
      "Takayama test",
      "Florence test"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Barberio test (Option A)**\n\nüî¨ **FORENSIC TESTS FOR SEMEN:**\n\n**BARBERIO TEST** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Detects:** **Semen** (spermine/choline)\n‚Ä¢ **Reagent:** **Picric acid + sulphuric acid**\n‚Ä¢ **Result:** **Yellow needle-shaped crystals** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **Confirmatory** for semen\n‚Ä¢ Used in **sexual assault** cases\n\n**FLORENCE TEST:**\n‚Ä¢ **Detects:** Semen (choline)\n‚Ä¢ **Reagent:** Iodine + Iodide\n‚Ä¢ **Result:** **Brown rhomboid/needle crystals**\n‚Ä¢ **Presumptive** test\n\n**OTHER TESTS:**\n\n**TEICHMANN TEST:**\n‚Ä¢ **Detects:** **Blood** (hemoglobin) ‚ö†Ô∏è\n‚Ä¢ Brown rhomboid **hemin crystals**\n\n**TAKAYAMA TEST:**\n‚Ä¢ **Detects:** **Blood** (hemoglobin) ‚ö†Ô∏è\n‚Ä¢ Pink feathery **hemochromogen crystals**\n\n**ACID PHOSPHATASE TEST:**\n‚Ä¢ **Screening** test for semen (high in prostate)\n‚Ä¢ Quick, presumptive\n\nüí° **KEY:** **Yellow needle crystals = Barberio (semen)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-90",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2024",
    question: "Which one is correct about the sequence of rigor mortis?",
    options: [
      "Centre to periphery",
      "Head to foot",
      "Foot to head",
      "Simultaneously"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Head to foot (Option B)**\n\nüî¨ **RIGOR MORTIS:**\n\n**DEFINITION:** **Post-mortem muscle stiffening** (loss of ATP ‚Üí actin-myosin cross-bridges can't release)\n\n**SEQUENCE:** **HEAD ‚Üí FOOT** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**\"NYSTEN'S LAW\":**\n\n**1. APPEARANCE:**\n‚Ä¢ **Starts:** Small muscles **first** (face, jaw, neck) ‚≠ê\n‚Ä¢ **Then:** Upper limbs (arms)\n‚Ä¢ **Finally:** Lower limbs (legs) ‚≠ê\n‚Ä¢ **Sequence:** **Head to foot** ‚≠ê‚≠ê‚≠ê\n\n**2. DISAPPEARANCE:**\n‚Ä¢ **SAME order:** Head to foot ‚≠ê\n\n**TIMELINE:**\n‚Ä¢ **Onset:** 1-2 hours post-mortem\n‚Ä¢ **Complete:** 6-12 hours\n‚Ä¢ **Duration:** 24-36 hours\n‚Ä¢ **Disappears:** 36-48 hours (putrefaction)\n\n**WHY HEAD FIRST:**\n‚Ä¢ **Smaller muscles** ‚Üí Less ATP stores ‚Üí Faster ATP depletion\n‚Ä¢ **Larger muscles** (legs) ‚Üí More ATP ‚Üí Slower onset\n\n**EXCEPTIONS:**\n‚Ä¢ **Cadaveric spasm:** Instantaneous rigor (at death)\n‚Ä¢ **Cold environment:** Delayed\n‚Ä¢ **Hot environment:** Accelerated\n\nüí° **KEY:** **Rigor mortis = Head to foot (Nysten's law)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-91",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "In a sexual assault case in court, ‚Äùin camera‚Äù trial refers to:",
    options: [
      "Closed court proceedings",
      "Recording of proceedings",
      "Open court proceedings",
      "Proceedings occurring in a different place"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Closed court proceedings (Option A)**\n\nüî¨ **'IN CAMERA' TRIAL:**\n\n**DEFINITION:** **Private/Closed court proceedings** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**CHARACTERISTICS:**\n‚Ä¢ **NOT open** to public ‚≠ê\n‚Ä¢ **NO media** allowed\n‚Ä¢ **Only essential persons** present:\n  ‚Üí Judge, lawyers, parties, witnesses\n‚Ä¢ **Protects privacy** of victim/accused\n‚Ä¢ **Latin:** \"In chamber\" (in private room)\n\n**USED IN:**\n‚Ä¢ **Sexual assault cases** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **Rape trials**\n‚Ä¢ **Child abuse cases**\n‚Ä¢ **National security matters**\n‚Ä¢ **Trade secrets**\n\n**PURPOSE:**\n‚Ä¢ **Protect victim** from public scrutiny ‚≠ê\n‚Ä¢ **Prevent secondary victimization**\n‚Ä¢ **Encourage testimony** (less intimidating)\n‚Ä¢ **Maintain dignity**\n\n**VS OPEN COURT:**\n‚Ä¢ Open court: **Public** can attend\n‚Ä¢ In camera: **Closed** to public ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **In camera = Closed/Private court (sexual assault)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-92",
    subjectId: "anatomy",
    chapterId: "neet-pg-2024",
    question: "An 18-year-old male accused of rape claims he is 16 years old. Which joint X-ray\nshould be done?",
    options: [
      "Elbow and ankle",
      "Knee and wrist",
      "Shoulder and head",
      "Hip knee"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Knee and wrist (Option B)** - SAME AS Q58!\n\nüî¨ **AGE ESTIMATION (16 vs 18 years):**\n\n**WRIST + KNEE** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**WRIST:**\n‚Ä¢ **Distal radius epiphysis** fuses: **18-20 years** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Distal ulna epiphysis** fuses: **18-20 years**\n‚Ä¢ **Most reliable** for 16-18 determination\n\n**KNEE:**\n‚Ä¢ **Distal femur** fuses: **18-20 years** ‚≠ê\n‚Ä¢ **Proximal tibia** fuses: **18-20 years**\n‚Ä¢ **Proximal fibula** fuses: **18-20 years**\n\n**LEGAL IMPORTANCE:**\n‚Ä¢ **16 years:** Minor (juvenile justice)\n‚Ä¢ **18 years:** Adult (IPC applies) ‚≠ê\n‚Ä¢ **Critical** in rape accused cases\n‚Ä¢ **Severe punishment** if adult\n\n**X-RAY INTERPRETATION:**\n‚Ä¢ **Fused epiphyses** ‚Üí ‚â•18 years\n‚Ä¢ **Open epiphyses** ‚Üí <18 years\n‚Ä¢ **Partial fusion** ‚Üí Around 18 years\n\nüí° **KEY:** **16 vs 18 years ‚Üí Wrist + Knee X-ray** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-93",
    subjectId: "physiology",
    chapterId: "neet-pg-2024",
    question: "Sour taste is mediated by: - PHYSIOLOGY (PART A)",
    options: [
      "TRPV3 Channel",
      "Metabolic receptors",
      "GPCR T1R1",
      "GPCR T1R3"
    ],
    correctAnswer: 3,
    explanation: "Sour taste is primarily mediated by the activation of GPCR T1R3 (G-protein\ncoupled receptor), which is involved in detecting acidic substances. The T1R family of\nreceptors, including T1R3, play a key role in the detection of basic taste sensations like\nsweetness and sourness.\n\nüí° Quick Tip: Sour taste is detected through the GPCR T1R3, which is sensitive to hydrogen ions in\nacidic solutions, triggering the sour taste sensation.\n51",
    difficulty: "medium",
    year: 2024
  },
  
  // ========================================
  // NEET PG 2024 SHIFT 2 QUESTIONS (Q1-Q27)
  // ========================================
  
  // SURGERY QUESTIONS (Q1-Q14)
  
  {
    id: "neet-pg-2024-shift2-1",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What is the management of the endoscopic finding given in an image?",
    options: [
      "Stenting",
      "Balloon dilatation",
      "Fulguration",
      "Internal urethrotomy"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Fulguration (Option C)**\n\nüî¨ **FULGURATION:**\n\n**DEFINITION:** **Electrocautery ablation** of tissue using **high-frequency current** ‚≠ê‚≠ê‚≠ê\n\n**MECHANISM:**\n‚Ä¢ **Non-contact** electrocoagulation\n‚Ä¢ **Spark gap** between electrode and tissue\n‚Ä¢ **Destroys superficial tissue** (2-3mm depth)\n‚Ä¢ **Hemostasis** achieved\n\n**INDICATIONS:**\n‚Ä¢ **Superficial bladder tumors** (Ta, Tis) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Urethral condylomas** (HPV)\n‚Ä¢ **Bleeding points** (hematuria)\n‚Ä¢ **Small polyps**\n\n**VS OTHER MODALITIES:**\n‚Ä¢ **Stenting:** For strictures (not ablation)\n‚Ä¢ **Balloon dilatation:** For stenosis\n‚Ä¢ **Internal urethrotomy:** For urethral strictures\n\n**ADVANTAGES:**\n‚Ä¢ **Minimally invasive**\n‚Ä¢ **Outpatient** procedure\n‚Ä¢ **Quick** recovery\n\nüí° **KEY:** **Fulguration = Endoscopic electrocoagulation for superficial lesions** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-2",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A young patient presented with recurrent colicky abdominal pain, urine microscopy found to have crystals and RBC, what is the diagnosis?",
    options: [
      "Oxalate stone",
      "PKD",
      "Cystine stones",
      "Glomerulonephritis"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Cystine stones (Option C)**\n\nüî¨ **CYSTINE STONES (Cystinuria):**\n\n**GENETICS:**\n‚Ä¢ **Autosomal recessive** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Defective renal tubular reabsorption** of cystine\n‚Ä¢ **COLA amino acids:** **C**ystine, **O**rnithine, **L**ysine, **A**rginine\n\n**CLINICAL:**\n‚Ä¢ **Young patients** (<20 years) ‚≠ê\n‚Ä¢ **Recurrent renal colic** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Family history** positive\n‚Ä¢ **Bilateral stones** common\n\n**DIAGNOSIS:**\n‚Ä¢ **Urine microscopy:** **Hexagonal crystals** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n‚Ä¢ **Sodium cyanide-nitroprusside test** (positive)\n‚Ä¢ **Urinary cystine** >250 mg/day\n\n**IMAGING:**\n‚Ä¢ **Faintly radio-opaque** (between uric acid and calcium)\n‚Ä¢ **\"Ground-glass\" appearance**\n\n**MANAGEMENT:**\n‚Ä¢ **Hydration** (>3L/day) ‚≠ê\n‚Ä¢ **Urine alkalinization** (pH >7.5) - **sodium bicarbonate**\n‚Ä¢ **D-Penicillamine or Tiopronin** (if conservative fails)\n‚Ä¢ **Surgical:** Lithotripsy/PCNL for large stones\n\nüí° **KEY:** **Young + Hexagonal crystals = Cystine stones** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-3",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the image given in UGIE",
    options: [
      "Barrett's esophagus",
      "Esophageal varices",
      "Gastric erosion"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Esophageal varices (Option B)**\n\nüî¨ **ESOPHAGEAL VARICES:**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Portal hypertension** ‚Üí **Portosystemic collaterals** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Left gastric vein** ‚Üí **Esophageal veins** ‚Üí **Azygos/SVC**\n‚Ä¢ **Dilated submucosal veins** in **distal esophagus**\n\n**CAUSES:**\n‚Ä¢ **Cirrhosis** (most common) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Portal vein thrombosis**\n‚Ä¢ **Budd-Chiari syndrome**\n‚Ä¢ **Schistosomiasis**\n\n**ENDOSCOPIC APPEARANCE:**\n‚Ä¢ **Bluish, tortuous, cord-like structures** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Beaded appearance** (like a string of pearls)\n‚Ä¢ **Protrude into lumen**\n\n**RED COLOR SIGNS** ‚≠ê (High rupture risk):\n‚Ä¢ **Cherry red spots**\n‚Ä¢ **Red wale marks**\n‚Ä¢ **Hematocystic spots**\n\n**GRADING:**\n‚Ä¢ **Grade I:** Small, straight\n‚Ä¢ **Grade II:** Enlarged, tortuous\n‚Ä¢ **Grade III:** Occupy >1/3 lumen\n‚Ä¢ **Grade IV:** Occupy entire lumen\n\n**MANAGEMENT:**\n\n**Acute bleeding:**\n‚Ä¢ **Resuscitation** + **Terlipressin/Octreotide** ‚≠ê\n‚Ä¢ **Endoscopic variceal ligation (EVL)** ‚≠ê‚≠ê‚≠ê **(First-line)**\n‚Ä¢ **Sclerotherapy** (alternative)\n‚Ä¢ **Sengstaken-Blakemore tube** (temporary)\n\n**Prophylaxis:**\n‚Ä¢ **Non-selective Œ≤-blockers** (propranolol, carvedilol)\n‚Ä¢ **EVL** for high-risk varices\n\nüí° **KEY:** **Portal HTN ‚Üí Bluish tortuous veins ‚Üí EVL** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-4",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the disease shown in the image",
    options: [
      "PKD",
      "Renal cyst",
      "Medullary sponge kidney",
      "PUJ obstruction"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Simple renal cyst (Option B)**\n\nüî¨ **SIMPLE RENAL CYST:**\n\n**EPIDEMIOLOGY:**\n‚Ä¢ **Most common renal mass** ‚≠ê\n‚Ä¢ **Increases with age** (50% >50 years)\n‚Ä¢ **Usually asymptomatic**\n\n**BOSNIAK CLASSIFICATION:**\n\n**Category I** (Simple cyst) ‚≠ê‚≠ê‚≠ê **(THIS CASE)**:\n‚Ä¢ **Thin wall** (<2mm)\n‚Ä¢ **No septations**\n‚Ä¢ **Water density** (0-20 HU)\n‚Ä¢ **No enhancement** on contrast\n‚Ä¢ **Anechoic** on ultrasound\n‚Ä¢ **No malignancy risk** ‚Üí **No follow-up needed**\n\n**ULTRASOUND CRITERIA:**\n‚Ä¢ **Anechoic** (black)\n‚Ä¢ **Smooth, thin wall**\n‚Ä¢ **Posterior acoustic enhancement**\n‚Ä¢ **Round/oval shape**\n\n**VS PKD (Polycystic Kidney Disease):**\n‚Ä¢ PKD: **Multiple bilateral cysts**, **enlarged kidneys**\n‚Ä¢ PKD: **Family history** (autosomal dominant)\n‚Ä¢ PKD: **HTN**, **renal failure**\n‚Ä¢ PKD: **Extrarenal** (liver cysts, berry aneurysm)\n\n**MANAGEMENT:**\n‚Ä¢ **No treatment** required for simple cysts ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Aspiration/sclerotherapy** if symptomatic (large, painful)\n‚Ä¢ **Surgical excision** (laparoscopic) for persistent symptoms\n\nüí° **KEY:** **Simple cyst = Benign, thin-walled, no follow-up** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-5",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 12 years old child presented with sudden severe onset of scrotal pain after a history of trauma 6 hours before. Intraoperative image is given, what is the likely diagnosis?",
    options: [
      "Torsion testis with gangrene",
      "Testicular hematoma",
      "Torsion testis",
      "Gangrene of testis"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Torsion testis with gangrene (Option A)**\n\nüî¨ **TESTICULAR TORSION WITH GANGRENE:**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Spermatic cord twisting** ‚Üí **Vascular occlusion** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Arterial ischemia** ‚Üí **Testicular infarction**\n‚Ä¢ **>6 hours** ‚Üí **Irreversible necrosis** ‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **Age:** Adolescents (12-18 years) ‚≠ê\n‚Ä¢ **Sudden severe scrotal pain** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Nausea/vomiting** (vagal response)\n‚Ä¢ **Absent cremasteric reflex** ‚≠ê **(MOST SENSITIVE SIGN)**\n‚Ä¢ **High-riding testis** (horizontal lie)\n‚Ä¢ **Negative Prehn's sign** (no relief on elevation)\n\n**GOLDEN PERIOD:**\n‚Ä¢ **<4 hours:** **90% salvage** rate ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **4-6 hours:** **50% salvage**\n‚Ä¢ **>6 hours:** **<10% salvage** ‚Üí **Gangrene**\n\n**INTRAOPERATIVE FINDINGS (>6 hours):**\n‚Ä¢ **Black/dusky testis** ‚≠ê\n‚Ä¢ **No bleeding on incision**\n‚Ä¢ **Non-viable** (does not pink up after detorsion)\n\n**MANAGEMENT:**\n\n**Emergency:** **Surgical exploration** ‚≠ê‚≠ê‚≠ê\n\n**If viable:**\n‚Ä¢ **Detorsion**\n‚Ä¢ **Bilateral orchiopexy** (3-point fixation)\n\n**If gangrenous:**\n‚Ä¢ **Orchiectomy** ‚≠ê\n‚Ä¢ **Contralateral orchiopexy** (mandatory) ‚≠ê‚≠ê‚≠ê\n\n**WHY CONTRALATERAL ORCHIOPEXY:**\n‚Ä¢ **Bell-clapper deformity** is bilateral in 50%\n‚Ä¢ **Prevents future torsion** of the remaining testis\n\nüí° **KEY:** **Delay >6 hours + Black testis = Gangrene ‚Üí Orchiectomy + Contralateral orchiopexy** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-6",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 40 year old female with lump in breast measuring 5X6cm with HPE given in the image, what is the likely diagnosis?",
    options: [
      "Phyllodes tumour",
      "Fibroadenoma",
      "Breast carcinoma"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Phyllodes tumour (Option A)**\n\nüî¨ **PHYLLODES TUMOR (Cystosarcoma Phyllodes):**\n\n**DEFINITION:** **Fibroepithelial tumor** with **stromal hypercellularity** ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **Age:** **40-50 years** (older than fibroadenoma) ‚≠ê\n‚Ä¢ **Large size:** **>5cm** (can be massive) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Rapid growth** over weeks/months\n‚Ä¢ **Firm, mobile**, **bosselated** lump\n‚Ä¢ **Skin ulceration** (late)\n\n**HPE (HISTOPATHOLOGY):**\n‚Ä¢ **\"Leaf-like\" architecture** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n‚Ä¢ **Hypercellular stroma** (key difference from fibroadenoma)\n‚Ä¢ **Stromal overgrowth** (stroma:epithelium >epithelium)\n‚Ä¢ **Cleft-like spaces**\n\n**CLASSIFICATION (WHO):**\n‚Ä¢ **Benign** (60%) ‚≠ê\n‚Ä¢ **Borderline** (20%)\n‚Ä¢ **Malignant** (20%)\n\n**CRITERIA FOR MALIGNANCY:**\n‚Ä¢ **High mitotic rate** (>10/10 HPF)\n‚Ä¢ **Marked cellular atypia**\n‚Ä¢ **Stromal overgrowth**\n‚Ä¢ **Infiltrative margins**\n\n**VS FIBROADENOMA:**\n| Feature | Fibroadenoma | Phyllodes |\n|---------|-------------|----------|\n| Age | 20-30 years | 40-50 years |\n| Size | <3cm | >5cm |\n| Growth | Slow | Rapid |\n| Stroma | Hypocellular | Hypercellular |\n\n**MANAGEMENT:**\n\n**Benign/Borderline:** **Wide local excision** (1-2cm margin) ‚≠ê‚≠ê‚≠ê\n\n**Malignant:**\n‚Ä¢ **Mastectomy** (if large/recurrent)\n‚Ä¢ **Axillary dissection** (NOT routinely done - hematogenous spread)\n‚Ä¢ **No role** for chemo/radiotherapy\n\n**RECURRENCE:** 20-30% (especially if inadequate margins)\n\nüí° **KEY:** **Large lump (>5cm) + Leaf-like HPE = Phyllodes ‚Üí Wide excision** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-7",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What is the negative pressure in VAC dressing?",
    options: [
      "60-90 mmHg",
      "90-100 mmHg",
      "120-130 mmHg",
      "130-150 mmHg"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **120-130 mmHg (Option C)**\n\nüî¨ **VAC (VACUUM-ASSISTED CLOSURE) DRESSING:**\n\n**DEFINITION:** **Negative pressure wound therapy (NPWT)** using **controlled suction** ‚≠ê‚≠ê‚≠ê\n\n**STANDARD PRESSURE:** **120-130 mmHg** ‚≠ê‚≠ê‚≠ê **(MOST COMMONLY USED)**\n\n**MECHANISM OF ACTION:**\n‚Ä¢ **Removes excess exudate** (prevents bacterial growth)\n‚Ä¢ **Reduces edema** (improves perfusion)\n‚Ä¢ **Increases blood flow** (promotes angiogenesis)\n‚Ä¢ **Stimulates granulation tissue** ‚≠ê\n‚Ä¢ **Decreases wound size** (wound contraction)\n‚Ä¢ **Removes bacteria** (reduces bioburden)\n\n**MODES:**\n‚Ä¢ **Continuous:** 120-130 mmHg (most common)\n‚Ä¢ **Intermittent:** 5 min on/2 min off (stimulates granulation more)\n\n**INDICATIONS:**\n‚Ä¢ **Diabetic foot ulcers** ‚≠ê\n‚Ä¢ **Pressure sores** (Stage III/IV)\n‚Ä¢ **Traumatic wounds**\n‚Ä¢ **Post-surgical wounds** (dehiscence)\n‚Ä¢ **Burns** (partial thickness)\n‚Ä¢ **Split-thickness skin graft** (improves take)\n\n**CONTRAINDICATIONS:**\n‚Ä¢ **Malignancy** in wound\n‚Ä¢ **Exposed vessels/organs**\n‚Ä¢ **Untreated osteomyelitis**\n‚Ä¢ **Non-enteric fistulas**\n\n**COMPONENTS:**\n‚Ä¢ **Polyurethane foam** (black - standard)\n‚Ä¢ **Polyvinyl alcohol foam** (white - for tunneling)\n‚Ä¢ **Occlusive dressing**\n‚Ä¢ **Suction tubing**\n‚Ä¢ **Vacuum pump**\n\n**DRESSING CHANGE:** Every **48-72 hours**\n\nüí° **KEY:** **VAC dressing = 120-130 mmHg negative pressure** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-8",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the surgery shown in the image",
    options: [
      "Nissen's fundoplication",
      "Dor fundoplication"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Nissen's fundoplication (Option A)**\n\nüî¨ **NISSEN'S FUNDOPLICATION:**\n\n**DEFINITION:** **Complete 360¬∞ gastric fundal wrap** around **lower esophagus** ‚≠ê‚≠ê‚≠ê\n\n**GOLD STANDARD** anti-reflux surgery for **GERD** ‚≠ê‚≠ê‚≠ê\n\n**TECHNIQUE:**\n‚Ä¢ **Mobilize gastric fundus**\n‚Ä¢ **Divide short gastric vessels**\n‚Ä¢ **Create 2-3cm wrap** around lower esophagus\n‚Ä¢ **\"Floppy\" fundoplication** (loose wrap)\n‚Ä¢ **Crural repair** (for hiatal hernia)\n\n**MECHANISM:**\n‚Ä¢ **Increases LES pressure**\n‚Ä¢ **Creates one-way valve**\n‚Ä¢ **Prevents reflux** (food goes down, not up)\n\n**INDICATIONS:**\n‚Ä¢ **Refractory GERD** (failed medical therapy) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Barrett's esophagus** (pre-malignant)\n‚Ä¢ **Large hiatal hernia** (>5cm)\n‚Ä¢ **Young patients** (avoid lifelong PPI)\n‚Ä¢ **Severe esophagitis** (LA Grade C/D)\n\n**APPROACH:**\n‚Ä¢ **Laparoscopic** (standard) ‚≠ê\n‚Ä¢ **Open** (if previous surgery)\n\n**COMPLICATIONS:**\n\n**Early:**\n‚Ä¢ **Dysphagia** (50%, resolves in 2-3 months) ‚≠ê\n‚Ä¢ **Bloating**\n\n**Late:**\n‚Ä¢ **Gas-bloat syndrome** ‚≠ê (inability to belch/vomit)\n‚Ä¢ **Recurrent reflux** (wrap disruption)\n‚Ä¢ **Wrap migration** (into chest)\n\n**VS PARTIAL FUNDOPLICATION:**\n‚Ä¢ **Dor:** **180¬∞ anterior** wrap (for achalasia post-myotomy)\n‚Ä¢ **Toupet:** **270¬∞ posterior** wrap\n‚Ä¢ **Partial wraps:** Less dysphagia, more reflux\n\n**SUCCESS RATE:** **85-90%** at 10 years\n\nüí° **KEY:** **Complete 360¬∞ wrap = Nissen ‚Üí Gold standard for GERD** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-9",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the structure marked in the intraoperative image of congenital inguinal hernia?",
    options: [
      "Femoral vein",
      "Obturator vein",
      "Testicular vein",
      "Inferior epigastric vein"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Testicular vein (Option C)**\n\nüî¨ **TESTICULAR VESSELS IN INGUINAL HERNIA:**\n\n**SPERMATIC CORD CONTENTS:**\n\n**3 ARTERIES:**\n‚Ä¢ **Testicular artery** (from aorta) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Cremasteric artery** (from inferior epigastric)\n‚Ä¢ **Artery to vas** (from superior/inferior vesical)\n\n**3 VEINS:**\n‚Ä¢ **Pampiniform plexus** ‚Üí **Testicular vein** ‚≠ê‚≠ê‚≠ê\n  - Right: Drains to **IVC**\n  - Left: Drains to **left renal vein**\n‚Ä¢ **Cremasteric vein**\n‚Ä¢ **Vein of vas**\n\n**3 NERVES:**\n‚Ä¢ **Genital branch of genitofemoral** (motor to cremaster)\n‚Ä¢ **Ilioinguinal nerve** (outside cord, but travels with it)\n‚Ä¢ **Sympathetic fibers**\n\n**3 OTHER:**\n‚Ä¢ **Vas deferens** ‚≠ê\n‚Ä¢ **Processus vaginalis** (patent in indirect hernia)\n‚Ä¢ **Lymphatics**\n\n**SURGICAL IMPORTANCE:**\n\n**Location:** Testicular vessels lie **posterolateral** to hernia sac ‚≠ê\n\n**In pediatric herniotomy:**\n‚Ä¢ **High ligation** of hernia sac (at deep ring)\n‚Ä¢ **MUST preserve** testicular vessels ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Separation** of sac from cord structures crucial\n\n**INJURY CONSEQUENCES:**\n‚Ä¢ **Testicular artery injury** ‚Üí **Ischemia** ‚Üí **Atrophy** (in children)\n‚Ä¢ **Testicular vein injury** ‚Üí **Hematoma**, **edema**\n‚Ä¢ **Vas deferens injury** ‚Üí **Infertility** (especially if bilateral)\n\n**IDENTIFICATION:**\n‚Ä¢ **Pulsatile** structures = arteries\n‚Ä¢ **Blue, serpentine** plexus = veins ‚≠ê\n‚Ä¢ **Firm, cord-like** = vas deferens\n\nüí° **KEY:** **Testicular vessels posterolateral to sac - MUST preserve during herniotomy** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-10",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What biopsy would you take from the lesion shown?",
    options: [
      "Excisional",
      "Incisional",
      "Edge biopsy"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Edge biopsy (Option C)**\n\nüî¨ **BIOPSY TECHNIQUES:**\n\n**TYPES OF BIOPSY:**\n\n**1. EDGE BIOPSY** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**:\n‚Ä¢ **From junction** of normal and abnormal tissue\n‚Ä¢ **Wedge-shaped** (includes both zones)\n‚Ä¢ **Best for ulcers** and suspicious lesions ‚≠ê‚≠ê‚≠ê\n\n**2. INCISIONAL BIOPSY:**\n‚Ä¢ **Part of lesion** removed\n‚Ä¢ For **large masses** (>2cm)\n‚Ä¢ **Diagnostic** purpose only\n\n**3. EXCISIONAL BIOPSY:**\n‚Ä¢ **Entire lesion** removed with margin\n‚Ä¢ For **small** (<2cm), **benign-appearing** lesions\n‚Ä¢ Both **diagnostic + therapeutic**\n\n**WHY EDGE BIOPSY FOR ULCERS:**\n\n**ADVANTAGES:**\n‚Ä¢ **Normal + abnormal tissue** in same sample ‚≠ê\n‚Ä¢ Shows **transition zone** (critical for diagnosis)\n‚Ä¢ Helps differentiate **malignant vs benign**\n‚Ä¢ Avoids **necrotic center** (non-diagnostic)\n\n**INDICATIONS:**\n‚Ä¢ **Chronic non-healing ulcers** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Suspicious for malignancy** (SCC, BCC, melanoma)\n‚Ä¢ **Marjolin's ulcer** (malignancy in chronic wounds)\n‚Ä¢ **Tuberculous ulcers**\n‚Ä¢ **Vasculitic ulcers**\n\n**TECHNIQUE:**\n‚Ä¢ Take **3-4 biopsies** from **different edges** ‚≠ê\n‚Ä¢ **Wedge-shaped** (includes depth)\n‚Ä¢ **Avoid necrotic slough** (base of ulcer)\n‚Ä¢ Include **viable tissue** at edge\n\n**SPECIFIC ULCER TYPES:**\n\n**Marjolin's ulcer:**\n‚Ä¢ **Malignant transformation** in chronic wounds (burns, osteomyelitis)\n‚Ä¢ **SCC** most common\n‚Ä¢ Edge biopsy shows **malignant cells at margin**\n\n**Tuberculous ulcer:**\n‚Ä¢ Edge shows **epithelioid granulomas**\n‚Ä¢ **AFB staining** positive\n\nüí° **KEY:** **Chronic ulcer = Edge biopsy (normal-abnormal junction, multiple sites)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-11",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "How does skin graft derive its nutrition on day 3?",
    options: [
      "Plasma imbibition",
      "Inoculation",
      "Neovascularization",
      "None"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Inoculation (Option B)**\n\nüî¨ **SKIN GRAFT NUTRITION TIMELINE:**\n\n**PHASE 1: PLASMATIC IMBIBITION** (Day 0-2) ‚≠ê:\n‚Ä¢ **Passive diffusion** of plasma from wound bed\n‚Ä¢ Graft absorbs **plasma** like a sponge\n‚Ä¢ **No vascular connection** yet\n‚Ä¢ Graft becomes **edematous** (weight increases 40%)\n‚Ä¢ **Fibrin adhesion** attaches graft to bed\n\n**PHASE 2: INOSCULATION/INOCULATION** ‚≠ê‚≠ê‚≠ê **(Day 3-5 - THIS CASE)**:\n‚Ä¢ **Anastomosis** between graft vessels and recipient vessels\n‚Ä¢ **Pre-existing vessels** in graft connect to bed vessels\n‚Ä¢ **Direct vascular continuity** established ‚≠ê\n‚Ä¢ Most important phase for graft survival\n\n**PHASE 3: NEOVASCULARIZATION** (Day 5 onwards):\n‚Ä¢ **New capillaries** grow from recipient bed into graft\n‚Ä¢ **Angiogenesis** from wound bed\n‚Ä¢ **Complete revascularization** by day 7-10\n‚Ä¢ **Mature vascular network** established\n\n**AT DAY 3 SPECIFICALLY:**\n‚Ä¢ **Inoculation is dominant** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Graft vessels **link up** with bed vessels\n‚Ä¢ Blood flow **begins**\n‚Ä¢ **Critical period** - graft becomes pink\n\n**FACTORS FOR SUCCESSFUL GRAFT TAKE:**\n‚Ä¢ **Good recipient bed** (well-vascularized)\n‚Ä¢ **Immobilization** (prevent shearing)\n‚Ä¢ **No hematoma/seroma**\n‚Ä¢ **No infection**\n‚Ä¢ **Good contact** (tie-over dressing)\n\n**GRAFT FAILURE CAUSES:**\n‚Ä¢ **Hematoma** (most common) ‚≠ê\n‚Ä¢ **Infection**\n‚Ä¢ **Movement** (shearing forces)\n‚Ä¢ **Poor recipient bed** (avascular - bone, tendon)\n\nüí° **KEY:** **Day 3 = Inoculation (vessel-to-vessel anastomosis)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-12",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the ulcer",
    options: [
      "Arterial",
      "Venous",
      "Trophic",
      "Diabetic foot ulcer"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Venous ulcer (Option B)**\n\nüî¨ **VENOUS ULCERS:**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Venous insufficiency** ‚Üí **Venous hypertension** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Valve incompetence** (deep/superficial veins)\n‚Ä¢ **Chronic venous stasis**\n‚Ä¢ **Fibrin cuff formation** ‚Üí Impaired O‚ÇÇ diffusion\n‚Ä¢ **Tissue hypoxia** ‚Üí Ulceration\n\n**CHARACTERISTIC FEATURES:**\n\n**Location:** **Medial malleolus** (gaiter area) ‚≠ê‚≠ê‚≠ê **(MOST COMMON)**\n\n**Appearance:**\n‚Ä¢ **Shallow**, **irregular margins** ‚≠ê\n‚Ä¢ **Sloping edges** (not punched out)\n‚Ä¢ **Granulation tissue** at base\n‚Ä¢ **Serous exudate**\n\n**Surrounding skin:**\n‚Ä¢ **Hemosiderin pigmentation** (brown staining) ‚≠ê\n‚Ä¢ **Lipodermatosclerosis** (woody induration)\n‚Ä¢ **Inverted champagne bottle leg** appearance\n‚Ä¢ **Varicose eczema**\n‚Ä¢ **Atrophie blanche** (white scars)\n\n**Clinical:**\n‚Ä¢ **Moderate/dull pain** ‚≠ê (relieved by elevation)\n‚Ä¢ **Worse at end of day**\n‚Ä¢ **Varicose veins** present ‚≠ê\n‚Ä¢ **Pedal pulses present** (unlike arterial)\n\n**VS ARTERIAL ULCERS:**\n| Feature | Venous | Arterial |\n|---------|--------|----------|\n| Location | Medial malleolus | Pressure points (toes, heel) |\n| Edge | Irregular, sloping | Punched out |\n| Base | Granulation | Slough/necrotic |\n| Pain | Moderate (‚Üì elevation) | Severe (‚Üë elevation) |\n| Pulses | Present | Absent |\n\n**INVESTIGATIONS:**\n‚Ä¢ **Doppler USG** (assess venous insufficiency)\n‚Ä¢ **ABPI:** >0.8 (normal arterial supply)\n\n**MANAGEMENT:**\n\n**Conservative (Mainstay):**\n‚Ä¢ **Compression therapy** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD)**\n  - **4-layer bandage** or **compression stockings**\n  - **Contraindicated** if ABPI <0.8\n‚Ä¢ **Leg elevation** (above heart level)\n‚Ä¢ **Wound care** (dressings)\n‚Ä¢ **Antibiotics** (if infected)\n\n**Surgical:**\n‚Ä¢ Treat **varicose veins** (if present)\n‚Ä¢ **Skin grafting** (for large ulcers)\n\nüí° **KEY:** **Medial malleolus + Hemosiderin + Varicose veins = Venous ulcer ‚Üí Compression** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-13",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 30 year old female presented with the swelling in neck, what is the next step in evaluation?",
    options: [
      "I-131 scan",
      "FNAC",
      "TSH & T4",
      "FSH"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **TSH & T4 (Option C)**\n\nüî¨ **EVALUATION OF THYROID SWELLING:**\n\n**STEP-BY-STEP APPROACH:**\n\n**STEP 1: CLINICAL EXAMINATION** ‚≠ê\n‚Ä¢ **Inspection:** Size, symmetry, movement with swallowing\n‚Ä¢ **Palpation:** Consistency, nodularity, mobility\n‚Ä¢ **Assess function:** Signs of hyper/hypothyroidism\n‚Ä¢ **Regional lymph nodes**\n\n**STEP 2: THYROID FUNCTION TESTS** ‚≠ê‚≠ê‚≠ê **(FIRST INVESTIGATION - THIS CASE)**\n‚Ä¢ **TSH** (most sensitive) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Free T4** (& Free T3 if needed)\n\n**WHY TSH & T4 FIRST:**\n‚Ä¢ **Determines functional status** (euthyroid/hyper/hypo)\n‚Ä¢ **Guides further management**\n‚Ä¢ **Non-invasive**, **readily available**\n‚Ä¢ **Cost-effective**\n\n**INTERPRETATION:**\n‚Ä¢ **TSH ‚Üì, T4 ‚Üë:** **Hyperthyroidism** (Graves', toxic nodule)\n‚Ä¢ **TSH ‚Üë, T4 ‚Üì:** **Hypothyroidism** (Hashimoto's)\n‚Ä¢ **TSH normal, T4 normal:** **Euthyroid** (simple goiter, nodule)\n\n**STEP 3: IMAGING**\n‚Ä¢ **Ultrasound neck** ‚≠ê (first-line imaging)\n  - Characterize nodule (solid/cystic)\n  - Size, number, suspicious features\n  - Lymph nodes\n\n**STEP 4: FNAC** (if indicated) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Indications:**\n  - **Suspicious USG features** (hypoechoic, microcalcifications, irregular margins)\n  - **Nodule >1cm**\n  - **Family history** of thyroid cancer\n  - **Rapid growth**\n  - **Hard, fixed nodule**\n\n**STEP 5: THYROID SCAN** (I-131 or Tc-99m)\n‚Ä¢ **NOT first-line** ‚≠ê\n‚Ä¢ **Indications:**\n  - **Hyperthyroidism** (identify hot/cold nodules)\n  - **Toxic adenoma** vs **Graves' disease**\n\n**CORRECT SEQUENCE:**\n1. **Clinical examination**\n2. **TSH & T4** ‚úÖ **(FIRST LAB TEST)**\n3. **USG neck**\n4. **FNAC** (if suspicious)\n5. **Thyroid scan** (if hyperthyroid)\n\nüí° **KEY:** **Any thyroid swelling ‚Üí First test = TSH & T4** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-14",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the drain in the image",
    options: [
      "Romovac drain",
      "Jackson-Pratt drain",
      "Corrugated drain",
      "Penrose drain"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Romovac drain (Option A)**\n\nüî¨ **SURGICAL DRAINS CLASSIFICATION:**\n\n**ROMOVAC DRAIN** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**:\n\n**TYPE:** **Closed suction drain** with **portable suction reservoir**\n\n**COMPONENTS:**\n‚Ä¢ **Perforated tube**\n‚Ä¢ **Suction bulb/bottle** (creates negative pressure)\n‚Ä¢ **Closed collection system**\n\n**MECHANISM:**\n‚Ä¢ **Constant low negative pressure** (by compressing bulb)\n‚Ä¢ **Active drainage**\n‚Ä¢ **Prevents fluid accumulation**\n\n**ADVANTAGES:**\n‚Ä¢ **Quantifiable drainage** ‚≠ê (measure output)\n‚Ä¢ **Reduced infection risk** (closed system)\n‚Ä¢ **Patient mobility** (portable)\n‚Ä¢ **Effective** for large volumes\n\n**INDICATIONS:**\n‚Ä¢ **Mastectomy** ‚≠ê\n‚Ä¢ **Thyroidectomy**\n‚Ä¢ **Orthopedic surgeries** (joint replacements)\n‚Ä¢ **Plastic surgery**\n‚Ä¢ **Neck dissections**\n\n**COMPARISON OF DRAINS:**\n\n**CLOSED DRAINS (Active):**\n\n**1. Romovac:**\n‚Ä¢ **Bottle** reservoir (larger capacity)\n‚Ä¢ High-volume drainage\n\n**2. Jackson-Pratt (JP):**\n‚Ä¢ **Bulb** reservoir (smaller)\n‚Ä¢ Similar to Romovac, more portable\n‚Ä¢ \"Grenade-shaped\" bulb\n\n**OPEN DRAINS (Passive):**\n\n**3. Penrose drain:**\n‚Ä¢ **Soft rubber tube**\n‚Ä¢ **Flat** when empty\n‚Ä¢ **Passive drainage** (gravity/capillary)\n‚Ä¢ **Higher infection risk**\n‚Ä¢ Used in **abscess cavities**\n\n**4. Corrugated drain:**\n‚Ä¢ **Rigid**, **corrugated rubber**\n‚Ä¢ **Open system**\n‚Ä¢ Drains by **capillary action**\n‚Ä¢ Rarely used now\n\n**KEY DIFFERENCES:**\n| Feature | Romovac/JP | Penrose | Corrugated |\n|---------|-----------|---------|------------|\n| System | Closed | Open | Open |\n| Mechanism | Active suction | Passive | Passive |\n| Infection risk | Low | High | High |\n| Quantification | Yes | No | No |\n| Indication | Clean surgeries | Abscesses | Obsolete |\n\n**REMOVAL CRITERIA:**\n‚Ä¢ **Drainage <30-50 mL/24 hours** ‚≠ê\n‚Ä¢ **Non-purulent**\n‚Ä¢ **No active bleeding**\n\nüí° **KEY:** **Closed suction with bulb/bottle = Romovac/JP drain** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },
  
  // BIOCHEMISTRY QUESTIONS (Q15-Q27)
  
  {
    id: "neet-pg-2024-shift2-15",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "A 5-year-old girl was washing her doll with shampoo containing a chemical Rotenone. Her mother noticed her in unconscious state. Which of the following Complex is inhibited by the above-mentioned chemical?",
    options: [
      "NADH Dehydrogenase (Complex I)",
      "Succinate DH (Complex II)",
      "Cytochrome C (Complex III)",
      "Cytochrome oxidase (Complex IV)"
    ],
    correctAnswer: 0,
    explanation: "**Rotenone** is a classic **Complex I (NADH dehydrogenase) inhibitor** in the **electron transport chain**. Mechanism: blocks **electron transfer** from NADH to ubiquinone, halting **ATP production**. Clinical effects: **CNS toxicity** (mitochondria-rich), **Parkinson-like symptoms** (damages substantia nigra). Also used as **pesticide** and linked to **Parkinson's disease** development. Other Complex I inhibitors: **barbiturates**, **piericidin A**.",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-16",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "A patient present with dilated cardiomyopathy on x-ray and hypoglycemia, floppy baby, hypotonia, hepatomegaly. What is most likely diagnosis?",
    options: [
      "Pompe's disease",
      "Von Gierke's disease",
      "Ebstein anomaly"
    ],
    correctAnswer: 0,
    explanation: "**Pompe's disease** (Glycogen Storage Disease Type II) is caused by **acid maltase (Œ±-1,4-glucosidase) deficiency**. Key features: **Cardiomegaly/cardiomyopathy** (massive), **hepatomegaly**, **hypotonia** (floppy baby), **macroglossia**, normal blood glucose (glycogen in lysosomes, not cytoplasm). ECG: **short PR**, **large QRS**. Infantile form is **fatal by 2 years**. Diagnosis: **enzyme assay**, **muscle biopsy** (vacuoles with glycogen).",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-17",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "A 15-year-old child with difficulty in exercise, affected oxidation of long chain fatty acids and biopsy muscle shows fat vacuoles. Which of the following is the diagnosis?",
    options: [
      "Carnitine deficiency",
      "FA synthase defect",
      "LPL defect",
      "LDL defect"
    ],
    correctAnswer: 0,
    explanation: "**Carnitine deficiency** impairs **long-chain fatty acid oxidation** as carnitine is required for **fatty acid transport** into mitochondria (**CPT-I system**). Clinical features: **exercise intolerance**, **muscle weakness**, **hypoglycemia** (impaired gluconeogenesis), **cardiomyopathy**, **hepatomegaly**. Muscle biopsy: **lipid vacuoles** (fat accumulation). Types: **Primary** (genetic) or **Secondary** (dialysis, valproate). Treatment: **L-carnitine supplementation**.",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-18",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "A Farmer was on maize as stapled diet develops rash on face, neck and hand. Which of the following vitamin should be given in the treatment?",
    options: [
      "Niacin (Vitamin B3)",
      "Thiamine (Vitamin B1)"
    ],
    correctAnswer: 0,
    explanation: "**Pellagra** (Niacin/Vitamin B3 deficiency) presents with **4 D's**: **Dermatitis** (photosensitive rash on sun-exposed areas - face, neck, hands), **Diarrhea**, **Dementia**, **Death**. Characteristic: **Casal's necklace** (hyperpigmented rash around neck). Cause: **maize-based diet** (low niacin, high leucine which inhibits niacin). Maize lacks **tryptophan** (niacin precursor). Treatment: **Niacin supplementation** + balanced diet.",
    difficulty: "easy",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-19",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "A patient develops mouth ulcers on treatment with Methotrexate. Which of the following will decrease with this drug?",
    options: [
      "UMP",
      "TMP (Thymidine monophosphate)",
      "CMP"
    ],
    correctAnswer: 1,
    explanation: "**Methotrexate** inhibits **dihydrofolate reductase (DHFR)**, preventing **tetrahydrofolate (THF) formation**. THF is essential for **thymidine synthesis** (dTMP from dUMP via thymidylate synthase). Result: **decreased TMP** ‚Üí impaired **DNA synthesis** ‚Üí affects **rapidly dividing cells** (bone marrow, GI mucosa). Side effects: **mucositis** (mouth ulcers), **myelosuppression**. **Leucovorin (folinic acid) rescue** bypasses DHFR block.",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-20",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "Increased Km and unchanged Vmax is seen in which of the following inhibition?",
    options: [
      "Competitive inhibition",
      "Noncompetitive inhibition",
      "Uncompetitive inhibition"
    ],
    correctAnswer: 0,
    explanation: "**Competitive inhibition**: Inhibitor competes with substrate for **active site**. Effect: **Increased Km** (decreased affinity, more substrate needed), **Unchanged Vmax** (can be overcome by high substrate concentration). Example: **Malonate inhibits succinate dehydrogenase**. **Noncompetitive**: Decreased Vmax, unchanged Km. **Uncompetitive**: Both Km and Vmax decrease. **Lineweaver-Burk plot**: Competitive shows lines intersecting on Y-axis.",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-21",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "A drug is given for the treatment of hyperlipidemia. Facial flushing was noted. Which of the following drug causes this side effect?",
    options: [
      "Nicotinic acid (Niacin)"
    ],
    correctAnswer: 0,
    explanation: "**Nicotinic acid (Niacin)** in **high doses** is used for **hyperlipidemia**. Mechanism: **decreases VLDL synthesis**, **increases HDL**. Major side effect: **Cutaneous flushing** (face, upper body) due to **prostaglandin-mediated vasodilation**. Prevention: **Aspirin 30 min before** niacin, **gradual dose titration**, **take with meals**. Other effects: **hyperglycemia**, **hyperuricemia**, **hepatotoxicity**. **Extended-release** formulations reduce flushing.",
    difficulty: "easy",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-22",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "Increased chylomicron, lipemic serum is seen in:",
    options: [
      "Lipoprotein lipase deficiency"
    ],
    correctAnswer: 0,
    explanation: "**Lipoprotein lipase (LPL) deficiency** (Type I Hyperlipoproteinemia) causes **massive chylomicronemia**. LPL breaks down **chylomicrons and VLDL** in capillaries. Deficiency ‚Üí **chylomicrons accumulate** ‚Üí **lipemic (milky) serum**. Clinical features: **eruptive xanthomas**, **lipemia retinalis**, **hepatosplenomegaly**, **recurrent pancreatitis**. Diagnosis: **triglycerides >1000 mg/dL**, **creamy layer** on standing serum. Treatment: **very low-fat diet** (<10g/day).",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-23",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "Which micronutrient deficiency causes anemia, gum bleeding and x-ray changes - White Frankel line?",
    options: [
      "Copper",
      "Iron",
      "Vitamin C (Scurvy)",
      "Zinc"
    ],
    correctAnswer: 2,
    explanation: "**Scurvy** (Vitamin C deficiency) presents with: **Anemia** (impaired iron absorption, folate metabolism), **gum bleeding** (scorbutic gingivitis), **perifollicular hemorrhages**, **White Frankel line** (dense metaphyseal line on X-ray due to impaired osteoid formation), **subperiosteal hemorrhage**. Vitamin C is essential for **collagen synthesis** (hydroxylation of proline/lysine). Treatment: **Vitamin C supplementation**.",
    difficulty: "medium",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-24",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "Which of the following enzyme is deficient in patient with Phenylketonuria if phenylalanine hydroxylase level is normal?",
    options: [
      "Dihydrobiopterin reductase"
    ],
    correctAnswer: 0,
    explanation: "**Atypical PKU** (2-3% cases) is caused by **dihydrobiopterin reductase deficiency** or **BH4 synthesis defects**. **BH4 (tetrahydrobiopterin)** is a **cofactor** for phenylalanine hydroxylase. Without BH4, even normal phenylalanine hydroxylase **cannot function**. Additional effects: **tyrosine and tryptophan hydroxylases** also need BH4 ‚Üí **neurotransmitter deficiency** (dopamine, serotonin, norepinephrine) ‚Üí **severe neurological damage**. Treatment: **BH4 supplementation** + **neurotransmitter precursors** (L-DOPA, 5-HTP).",
    difficulty: "hard",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-25",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "A tall stature, long digits, long arm span and subluxation of lens is seen in which of the following defect?",
    options: [
      "Fibrillin-1",
      "Collagen"
    ],
    correctAnswer: 0,
    explanation: "**Marfan syndrome** is caused by **Fibrillin-1 gene mutation** (FBN1 on chromosome 15). Fibrillin is a **glycoprotein** in **elastic fibers**. Clinical features: **Skeletal**: tall stature, long limbs, arachnodactyly, pectus deformity, **scoliosis**. **Ocular**: **ectopia lentis** (upward lens subluxation). **Cardiovascular**: **aortic root dilatation**, **mitral valve prolapse**, **aortic dissection** (major cause of death). Diagnosis: **Ghent criteria**. Treatment: **Œ≤-blockers**, **ARBs**, surgical repair of aneurysms.",
    difficulty: "easy",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-26",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "A male patient with pallor, weakness and easy fatigability. His blood report shows MCV 53, TIBC - Increased. What is your diagnosis?",
    options: [
      "Iron deficiency anemia"
    ],
    correctAnswer: 0,
    explanation: "**Iron deficiency anemia** is confirmed by: **Microcytic** (MCV <80, here 53), **hypochromic** anemia. Lab: **Low serum iron**, **High TIBC** (total iron binding capacity - increased transferrin), **Low ferritin** (best marker for stores), **Low transferrin saturation** (<15%). Causes: **chronic blood loss** (GI, menstrual), **malabsorption**, **poor intake**. Clinical: **pallor**, **fatigue**, **koilonychia**, **glossitis**. Treatment: **Oral iron** (ferrous sulfate) + **treat underlying cause**.",
    difficulty: "easy",
    year: 2024
  },
  {
    id: "neet-pg-2024-shift2-27",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2024",
    question: "Which of the following is methanol poisoning derivative?",
    options: [
      "Formic acid + Lactic acid",
      "Acetic acid"
    ],
    correctAnswer: 0,
    explanation: "**Methanol poisoning**: Methanol ‚Üí **Formaldehyde** (via alcohol dehydrogenase) ‚Üí **Formic acid** (via aldehyde dehydrogenase). **Formic acid** causes: **metabolic acidosis** (with high anion gap), **optic nerve damage** ‚Üí **blindness**, **basal ganglia necrosis**. **Lactic acidosis** also develops due to impaired cellular respiration. Treatment: **Fomepizole** (alcohol dehydrogenase inhibitor) or **ethanol** (competitive inhibitor), **bicarbonate** (correct acidosis), **hemodialysis**, **folate** (enhances formic acid metabolism).",
    difficulty: "medium",
    year: 2024
  },
  // ========================================
  // NEET PG 2023 Questions (200 questions)
  // ========================================
  {
    id: "neet-pg-2023-1",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "L A patient hailing from Delhi presents with fever, arthralgia, and extensive petechial rash for 3 days. Lab investigations revealed a hemoglobin of 9 g/ dL, a white blood cell count of 9000 cells/mm3, a platelet coupnt of 20000 cells/mm3, and a prolonged bleeding time. The clotting time was normal. What is the most likely diagnosis?",
    options: [
      "Dengue e",
      "Malari r",
      "Scrub typhus P",
      "Typhoid",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Dengue (Option A)**\n\nüî¨ **DENGUE FEVER:**\n\n**ETIOLOGY:**\n‚Ä¢ **Dengue virus** (DENV 1-4) - **Flavivirus family** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Vector:** **Aedes aegypti** (day-biting mosquito) ‚≠ê\n‚Ä¢ **Endemic** in tropical/subtropical regions\n\n**CLINICAL PRESENTATION:**\n‚Ä¢ **Fever** (high, 39-40¬∞C, **biphasic** - saddle-back) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Arthralgia** (\"breakbone fever\") ‚≠ê\n‚Ä¢ **Petechial rash** (maculopapular, appears day 3-5) ‚≠ê\n‚Ä¢ **Headache, retro-orbital pain**\n‚Ä¢ **Muscle pain**\n\n**KEY LAB FINDINGS (THIS CASE):**\n\n**Thrombocytopenia:** **Platelet count <20,000/mm¬≥** ‚≠ê‚≠ê‚≠ê **(HALLMARK)**\n‚Ä¢ **Mechanism:** Bone marrow suppression + immune-mediated destruction\n‚Ä¢ **Critical:** <20,000 ‚Üí High bleeding risk\n\n**Prolonged Bleeding Time:** ‚≠ê (due to low platelets)\n‚Ä¢ **Normal clotting time** (coagulation cascade intact)\n\n**Hemoglobin:** 9 g/dL (anemia from bleeding)\n‚Ä¢ **Hemoconcentration** (‚ÜëHct >20%) suggests **severe dengue**\n\n**WBC:** 9000/mm¬≥ (normal/low)\n‚Ä¢ **Leukopenia** common (day 2-3)\n\n**DENGUE CLASSIFICATION (WHO 2009):**\n\n**Dengue without warning signs** (simple fever)\n\n**Dengue with warning signs** ‚≠ê:\n‚Ä¢ Abdominal pain\n‚Ä¢ Persistent vomiting\n‚Ä¢ Clinical fluid accumulation (ascites, pleural effusion)\n‚Ä¢ Mucosal bleed\n‚Ä¢ **Lethargy**, **restlessness**\n‚Ä¢ Hepatomegaly >2cm\n‚Ä¢ **Platelet <100,000** + **Rising Hct**\n\n**Severe Dengue** (formerly DHF/DSS):\n‚Ä¢ **Severe plasma leakage** (shock, fluid accumulation)\n‚Ä¢ **Severe bleeding** (GI bleed, menorrhagia)\n‚Ä¢ **Organ failure** (ALT/AST >1000, renal failure, CNS)\n\n**DIAGNOSIS:**\n‚Ä¢ **NS1 antigen** (day 1-7) ‚≠ê‚≠ê‚≠ê **(EARLY DIAGNOSIS)**\n‚Ä¢ **IgM antibody** (day 5 onwards)\n‚Ä¢ **RT-PCR** (confirmation)\n\n**MANAGEMENT:**\n‚Ä¢ **Supportive care** (hydration, paracetamol) ‚≠ê\n‚Ä¢ **Avoid NSAIDs/Aspirin** ‚≠ê‚≠ê‚≠ê (‚Üë bleeding risk)\n‚Ä¢ **Platelet transfusion** (if <10,000 or active bleeding)\n‚Ä¢ **Monitor Hct** (rising Hct = plasma leakage)\n\n**VS OTHER OPTIONS:**\n‚Ä¢ **Malaria:** Splenomegaly, normal platelets, peripheral smear positive\n‚Ä¢ **Scrub typhus:** Eschar, normal platelets\n‚Ä¢ **Typhoid:** Step-ladder fever, relative bradycardia, no rash\n\nüí° **KEY:** **Fever + Petechial rash + Thrombocytopenia (<50,000) = Dengue** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-2",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "Which of the following statements is true about Trichomonas vaginalis?",
    options: [
      "It cannot be cultured",
      "Twitching motility is seen on wet saline mount",
      "Cysts are seen on wet saline mount of vaginal secretions",
      "It is not a sexually transmitted infection",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Twitching motility is seen on wet saline mount (Option B)**\n\nüî¨ **TRICHOMONAS VAGINALIS:**\n\n**ORGANISM:**\n‚Ä¢ **Flagellated protozoan** (5 flagella: 4 anterior + 1 posterior) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Sexually transmitted infection (STI)** ‚≠ê\n‚Ä¢ **No cyst stage** (only trophozoite form) ‚≠ê\n\n**MORPHOLOGY:**\n‚Ä¢ **Pear-shaped** trophozoite\n‚Ä¢ **Size:** 10-20 Œºm\n‚Ä¢ **5 flagella** + **Undulating membrane**\n‚Ä¢ **Single nucleus**\n\n**CHARACTERISTIC MOTILITY:**\n‚Ä¢ **\"Jerky\"/\"Twitching\" motility** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC)**\n‚Ä¢ Due to flagellar beating + undulating membrane\n‚Ä¢ **Actively motile** in fresh warm saline mount\n\n**DIAGNOSIS:**\n\n**Wet saline mount** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD - POINT-OF-CARE)**:\n‚Ä¢ **Motile trophozoites** with jerky movement\n‚Ä¢ Best seen in **fresh** specimen (<30 min)\n‚Ä¢ **Warm** saline (room temperature)\n‚Ä¢ **Sensitivity:** 60-70%\n\n**Other methods:**\n‚Ä¢ **Culture:** Diamond's medium (most sensitive, 95%)\n‚Ä¢ **Pap smear:** Can detect (50% sensitive)\n‚Ä¢ **NAAT (PCR):** High sensitivity\n‚Ä¢ **pH:** Vaginal pH >4.5 ‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **\"Strawberry cervix\"** (punctate hemorrhages) ‚≠ê\n‚Ä¢ **Frothy, yellow-green discharge** ‚≠ê\n‚Ä¢ **Vulvovaginal irritation**\n‚Ä¢ **Dysuria, dyspareunia**\n‚Ä¢ **Foul-smelling discharge**\n\n**TREATMENT:**\n‚Ä¢ **Metronidazole** 2g single dose ‚≠ê‚≠ê‚≠ê (or 500mg BD √ó 7 days)\n‚Ä¢ **Tinidazole** 2g single dose (alternative)\n‚Ä¢ **Treat sexual partner** (prevent reinfection)\n‚Ä¢ **Avoid alcohol** (disulfiram-like reaction)\n\n**WHY OTHER OPTIONS ARE WRONG:**\n\n**\"It cannot be cultured\"** ‚ùå:\n‚Ä¢ **FALSE** - Can be cultured in **Diamond's medium**\n‚Ä¢ Culture is actually **most sensitive** test (95%)\n\n**\"Cysts are seen\"** ‚ùå:\n‚Ä¢ **FALSE** - Trichomonas has **NO CYST STAGE** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Only trophozoite** form exists\n‚Ä¢ This is a key differentiating feature from other protozoa (Giardia, Entamoeba have cysts)\n\n**\"It is not an STI\"** ‚ùå:\n‚Ä¢ **FALSE** - It **IS** a **sexually transmitted infection** ‚≠ê\n‚Ä¢ Most common **non-viral STI**\n\nüí° **KEY:** **Twitching/jerky motility on wet mount = Trichomonas vaginalis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-3",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "A lady from West Rajasthan presented with an ulcer surrounded by erythema on the right leg. d Microscopy of the biopsy from the edge of the ulcer showed organisms with dark staining nuclei and kinetoplast. What is the most likely causative agent?",
    options: [
      "Leishmania tropica",
      "Babesia a",
      "Trypanosoma",
      "Histoplasma",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Leishmania tropica (Option A)**\n\nüî¨ **CUTANEOUS LEISHMANIASIS:**\n\n**ETIOLOGY:**\n‚Ä¢ **Leishmania tropica** ‚≠ê‚≠ê‚≠ê (Old World cutaneous leishmaniasis)\n‚Ä¢ **Vector:** **Sandfly** (*Phlebotomus*) ‚≠ê\n‚Ä¢ **Endemic:** West Rajasthan, Middle East, North Africa\n\n**CLINICAL PRESENTATION:**\n‚Ä¢ **Painless ulcer** on exposed skin (face, limbs) ‚≠ê\n‚Ä¢ **Surrounded by erythema/induration**\n‚Ä¢ **\"Volcano sign\"** - raised margins, central ulceration\n‚Ä¢ **Chronic, non-healing** (months)\n\n**DIAGNOSTIC FEATURE IN THIS CASE:**\n\n**Microscopy showing:**\n‚Ä¢ **Dark-staining nuclei** ‚≠ê\n‚Ä¢ **Kinetoplast** (bar-shaped structure) ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n\n**LEISHMANIA AMASTIGOTE STRUCTURE:**\n‚Ä¢ **Oval/round** intracellular form (2-4 Œºm)\n‚Ä¢ **Nucleus** (large, round, dark-staining)\n‚Ä¢ **Kinetoplast** (rod-shaped, perpendicular to nucleus) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Found in macrophages** (\"Donovan bodies\")\n‚Ä¢ **No flagella** (amastigote = without flagella)\n\n**FORMS OF LEISHMANIA:**\n\n**Amastigote** (in human/mammal):\n‚Ä¢ **Intracellular** (in macrophages)\n‚Ä¢ **Nucleus + Kinetoplast**\n‚Ä¢ **Non-motile**\n\n**Promastigote** (in sandfly):\n‚Ä¢ **Extracellular**\n‚Ä¢ **Flagellated** (motile)\n‚Ä¢ Develops in sandfly gut\n\n**TYPES OF LEISHMANIASIS:**\n\n**1. Cutaneous (CL):**\n‚Ä¢ **L. tropica, L. major** (Old World)\n‚Ä¢ **L. braziliensis** (New World)\n‚Ä¢ **Skin ulcers**\n\n**2. Mucocutaneous (MCL):**\n‚Ä¢ **L. braziliensis** (\"Espundia\")\n‚Ä¢ Destroys nasal/oral mucosa\n\n**3. Visceral (Kala-azar):**\n‚Ä¢ **L. donovani** ‚≠ê\n‚Ä¢ Fever, hepatosplenomegaly, pancytopenia\n\n**DIAGNOSIS:**\n‚Ä¢ **Slit-skin smear** from edge of ulcer ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Giemsa staining** ‚Üí Amastigotes in macrophages\n‚Ä¢ **Culture:** NNN medium (Novy-MacNeal-Nicolle)\n‚Ä¢ **rK39 antigen** (for visceral)\n\n**TREATMENT:**\n‚Ä¢ **Sodium stibogluconate** (pentavalent antimony) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Amphotericin B** (severe cases)\n‚Ä¢ **Miltefosine** (oral, for VL)\n‚Ä¢ **Cryotherapy** (small CL lesions)\n\n**WHY OTHER OPTIONS ARE WRONG:**\n\n**Babesia** ‚ùå:\n‚Ä¢ **Intraerythrocytic** parasite\n‚Ä¢ **Ring forms** in RBCs (\"Maltese cross\")\n‚Ä¢ No kinetoplast\n\n**Trypanosoma** ‚ùå:\n‚Ä¢ **Extracellular** in blood\n‚Ä¢ **Trypomastigote** with **posterior kinetoplast**\n‚Ä¢ **Undulating membrane**\n\n**Histoplasma** ‚ùå:\n‚Ä¢ **Fungus** (not protozoa)\n‚Ä¢ **Intracellular yeast** in macrophages\n‚Ä¢ **No kinetoplast** (budding yeast forms)\n\nüí° **KEY:** **Nucleus + Kinetoplast in macrophages = Leishmania amastigote** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-4",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "r A child presents with a fever and a rash. Urine examination showed cells with owl's eye aPppearance. What is the most likely diagnosis?",
    options: [
      "C ytomegalovirus",
      "Epstein-Barr virus",
      "Herpes simplex virus",
      "Toxoplasma gondii",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Cytomegalovirus (Option A)**\n\nüî¨ **CYTOMEGALOVIRUS (CMV):**\n\n**ORGANISM:**\n‚Ä¢ **Cytomegalovirus** - **Herpesviridae family** (HHV-5) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **DNA virus**\n‚Ä¢ **Largest herpesvirus**\n‚Ä¢ **Latent infection** in monocytes/lymphocytes\n\n**PATHOGNOMONIC FINDING:**\n\n**\"OWL'S EYE\" CELLS** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC)**:\n‚Ä¢ **Large cells** (cytomegaly = enlarged cells)\n‚Ä¢ **Large nuclear inclusion** (eosinophilic, central)\n‚Ä¢ **Clear halo** around inclusion (\"owl's eye\" appearance)\n‚Ä¢ **Basophilic cytoplasmic inclusions** (smaller)\n‚Ä¢ Found in **urine, lung, brain, liver** specimens\n\n**CLINICAL PRESENTATIONS:**\n\n**1. CONGENITAL CMV** ‚≠ê:\n‚Ä¢ **TORCH infection**\n‚Ä¢ **Blueberry muffin rash**\n‚Ä¢ **Microcephaly**, **periventricular calcifications**\n‚Ä¢ **Hearing loss** (most common sequela)\n‚Ä¢ **Hepatosplenomegaly**, **jaundice**\n‚Ä¢ **Chorioretinitis**\n\n**2. MONONUCLEOSIS SYNDROME:**\n‚Ä¢ **Heterophile-negative** mono\n‚Ä¢ Fever, lymphadenopathy, hepatitis\n‚Ä¢ Unlike EBV: **No pharyngitis**\n\n**3. IMMUNOCOMPROMISED (HIV, Transplant):**\n‚Ä¢ **CMV retinitis** ‚Üí Blindness ‚≠ê\n‚Ä¢ **CMV colitis** ‚Üí Bloody diarrhea\n‚Ä¢ **CMV pneumonitis**\n‚Ä¢ **CMV encephalitis**\n\n**DIAGNOSIS:**\n\n**Histopathology** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD)**:\n‚Ä¢ **Owl's eye inclusions**\n\n**Urine analysis** ‚≠ê:\n‚Ä¢ **Cytology:** Owl's eye cells in shed renal tubular cells\n‚Ä¢ **Viral culture** from urine\n‚Ä¢ **CMV pp65 antigenemia**\n\n**Serology:**\n‚Ä¢ **IgM anti-CMV** (acute infection)\n‚Ä¢ **IgG anti-CMV** (past infection, 50-90% seropositive)\n\n**PCR:**\n‚Ä¢ **Quantitative CMV DNA** (viral load monitoring)\n\n**TREATMENT:**\n\n**1st line:** **Ganciclovir** (IV) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Or **Valganciclovir** (oral prodrug)\n\n**2nd line:**\n‚Ä¢ **Foscarnet** (if ganciclovir-resistant)\n‚Ä¢ **Cidofovir**\n\n**Prophylaxis:**\n‚Ä¢ **Valganciclovir** (transplant recipients)\n‚Ä¢ **Ganciclovir** (HIV with CD4 <50)\n\n**WHY OTHER OPTIONS ARE WRONG:**\n\n**Epstein-Barr virus** ‚ùå:\n‚Ä¢ **Atypical lymphocytes** (Downey cells) on blood smear\n‚Ä¢ **Heterophile-positive** mono (Monospot test)\n‚Ä¢ **No owl's eye inclusions**\n\n**Herpes simplex virus** ‚ùå:\n‚Ä¢ **Cowdry type A inclusions** (eosinophilic, intranuclear)\n‚Ä¢ **Multinucleated giant cells** (Tzanck smear)\n‚Ä¢ **Vesicular lesions**\n‚Ä¢ No owl's eye appearance\n\n**Toxoplasma gondii** ‚ùå:\n‚Ä¢ **Protozoan** (not virus)\n‚Ä¢ **Tachyzoites/bradyzoites** on microscopy\n‚Ä¢ **Ring-enhancing lesions** on brain CT\n‚Ä¢ No nuclear inclusions\n\nüí° **KEY:** **Owl's eye inclusions in urine = CMV** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-5",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "Infection with Clonorchis sinensis is associated with an increased risk of__?",
    options: [
      "Cervical cancer",
      "Cholangiocarcinoma",
      "Gastric carcinom e",
      "Bladder carcinoma",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Cholangiocarcinoma (Option B)**\n\nüî¨ **CLONORCHIS SINENSIS (Chinese Liver Fluke):**\n\n**ORGANISM:**\n‚Ä¢ **Trematode** (fluke) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Endemic:** East Asia (China, Korea, Vietnam)\n‚Ä¢ **Definitive host:** Humans, dogs, cats\n\n**LIFE CYCLE:**\n‚Ä¢ **Eggs** in feces ‚Üí Water ‚Üí **Snail** (1st intermediate host)\n‚Ä¢ Cercaria ‚Üí **Freshwater fish** (2nd intermediate host)\n‚Ä¢ **Human ingestion** of **raw/undercooked fish** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Metacercaria ‚Üí **Bile ducts** (adult fluke)\n\n**LOCATION:**\n‚Ä¢ **Intrahepatic and extrahepatic bile ducts** ‚≠ê\n‚Ä¢ Adults live **10-25 years**\n\n**PATHOGENESIS:**\n\n**Mechanical irritation** + **Chronic inflammation**:\n‚Ä¢ **Chronic cholangitis**\n‚Ä¢ **Periductal fibrosis**\n‚Ä¢ **Bile duct proliferation/hyperplasia**\n‚Ä¢ **Adenomatous hyperplasia**\n‚Ä¢ ‚Üí **Cholangiocarcinoma** ‚≠ê‚≠ê‚≠ê\n\n**CARCINOGENIC MECHANISM:**\n‚Ä¢ **Chronic inflammation** (decades)\n‚Ä¢ **Mechanical irritation** from fluke\n‚Ä¢ **Metabolites/excretory products** ‚Üí DNA damage\n‚Ä¢ **Nitrosamines** production\n‚Ä¢ ‚Üí **Malignant transformation**\n\n**ASSOCIATED MALIGNANCY:**\n\n**CHOLANGIOCARCINOMA (Bile Duct Cancer)** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Risk increased 15-fold** in infected individuals\n‚Ä¢ **Endemic areas:** Very high CCA rates\n‚Ä¢ **Thailand:** Highest CCA incidence (due to *Opisthorchis viverrini*, similar fluke)\n\n**CLINICAL:**\n‚Ä¢ **Asymptomatic** (majority)\n‚Ä¢ **Recurrent cholangitis**\n‚Ä¢ **Biliary colic**\n‚Ä¢ **Jaundice, hepatomegaly**\n‚Ä¢ **Pancreatitis** (if pancreatic duct involved)\n\n**DIAGNOSIS:**\n‚Ä¢ **Stool microscopy:** **Operculated eggs** (flask-shaped) ‚≠ê\n‚Ä¢ **Bile/duodenal aspirate:** Eggs\n‚Ä¢ **ERCP:** Adult flukes in bile ducts\n‚Ä¢ **Imaging:** Bile duct dilatation, stones\n\n**TREATMENT:**\n‚Ä¢ **Praziquantel** 25 mg/kg TDS √ó 2 days ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Albendazole** (alternative)\n\n**OTHER PARASITE-CANCER ASSOCIATIONS:**\n\n**Schistosoma haematobium** ‚Üí **Bladder carcinoma** ‚≠ê:\n‚Ä¢ Chronic cystitis ‚Üí Squamous cell carcinoma\n\n**Opisthorchis viverrini** ‚Üí **Cholangiocarcinoma**:\n‚Ä¢ Similar to Clonorchis (SE Asia)\n\n**H. pylori** ‚Üí **Gastric carcinoma**, **MALT lymphoma**\n\n**EBV** ‚Üí **Nasopharyngeal carcinoma**, **Burkitt's lymphoma**\n\n**HPV 16/18** ‚Üí **Cervical cancer**\n\nüí° **KEY:** **Clonorchis sinensis ‚Üí Chronic cholangitis ‚Üí Cholangiocarcinoma** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-6",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "a A patient presented with complaints of persistent cough and weight loss. He had a history of contact with multiple sexual partners. He was diagnosed as HIV positive 6 months back and is poorly adherent to his medicationLs. The fungal culture of sputum was negative. On Gomori methamine silver staining, the cells showed darkly stained crescent-shaped cysts. What is the most likely causative organism?",
    options: [
      "Paracoccidiodes brasiliensis",
      "Histoplasma capsulatum",
      "Coccidiodes immitis r",
      "PPneumocystis jerovecii",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Pneumocystis jirovecii (Option D)**\n\nüî¨ **PNEUMOCYSTIS JIROVECII PNEUMONIA (PCP):**\n\n**ORGANISM:**\n‚Ä¢ **Pneumocystis jirovecii** (formerly *P. carinii*) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Fungus** (previously classified as protozoan)\n‚Ä¢ **Opportunistic pathogen**\n‚Ä¢ **Airborne transmission**\n\n**RISK FACTORS:**\n‚Ä¢ **HIV/AIDS** (CD4 <200/mm¬≥) ‚≠ê‚≠ê‚≠ê **(MOST COMMON)**\n‚Ä¢ **Immunosuppression:** Transplant, cancer chemotherapy\n‚Ä¢ **Chronic corticosteroids**\n‚Ä¢ **Poor ART adherence** ‚≠ê (as in this case)\n\n**CLINICAL:**\n‚Ä¢ **Subacute onset** (weeks)\n‚Ä¢ **Persistent dry cough** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Progressive dyspnea** (exertional ‚Üí rest)\n‚Ä¢ **Fever**\n‚Ä¢ **Weight loss**\n‚Ä¢ **Hypoxemia** (low O‚ÇÇ saturation)\n\n**DIAGNOSTIC CLUE IN THIS CASE:**\n\n**Gomori methenamine silver (GMS) staining** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ Shows **darkly stained crescent-shaped/cup-shaped cysts** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n‚Ä¢ **\"Crushed ping-pong ball\" appearance**\n‚Ä¢ Cysts: 5-8 Œºm diameter\n\n**KEY POINT:** **Fungal culture negative** ‚≠ê\n‚Ä¢ **Pneumocystis cannot be cultured** on routine fungal media!\n‚Ä¢ Requires **special techniques** (rarely done)\n\n**OTHER DIAGNOSTIC METHODS:**\n\n**Microscopy:**\n‚Ä¢ **GMS stain:** Cyst walls (black/brown) ‚≠ê\n‚Ä¢ **Toluidine blue stain:** Cysts (blue-purple)\n‚Ä¢ **Giemsa/Wright stain:** Trophozoites (not cysts)\n\n**Specimen:**\n‚Ä¢ **Induced sputum** (sensitivity 50-90%)\n‚Ä¢ **Bronchoalveolar lavage (BAL)** ‚≠ê (>90% sensitive - gold standard)\n\n**Serology:**\n‚Ä¢ **Œ≤-D-glucan** (elevated) - non-specific\n‚Ä¢ **LDH elevated** (non-specific)\n\n**Imaging (CXR):**\n‚Ä¢ **Bilateral interstitial infiltrates** (\"ground-glass\" opacities) ‚≠ê\n‚Ä¢ **Perihilar** distribution\n‚Ä¢ **Pneumatoceles** (if severe)\n\n**TREATMENT:**\n\n**1st line:** **TMP-SMX** (Trimethoprim-Sulfamethoxazole) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **High-dose:** TMP 15-20 mg/kg/day √ó 21 days\n‚Ä¢ **+ Corticosteroids** if PaO‚ÇÇ <70 mmHg or A-a gradient >35\n\n**2nd line:**\n‚Ä¢ **Pentamidine** (IV)\n‚Ä¢ **Atovaquone** (oral, mild disease)\n‚Ä¢ **Clindamycin + Primaquine**\n\n**PROPHYLAXIS:**\n‚Ä¢ **Indication:** HIV with **CD4 <200/mm¬≥** ‚≠ê\n‚Ä¢ **Drug:** TMP-SMX DS (1 tab daily or 3x/week)\n‚Ä¢ **Alternative:** Dapsone, atovaquone, pentamidine inhaled\n\n**WHY OTHER OPTIONS ARE WRONG:**\n\n**Paracoccidioides brasiliensis** ‚ùå:\n‚Ä¢ **\"Pilot wheel\" appearance** (multiple buds)\n‚Ä¢ Culture positive (Sabouraud agar)\n‚Ä¢ Endemic to South America\n\n**Histoplasma capsulatum** ‚ùå:\n‚Ä¢ **Small intracellular yeasts** (2-4 Œºm)\n‚Ä¢ **Within macrophages**\n‚Ä¢ Culture positive\n‚Ä¢ No crescent-shaped cysts\n\n**Coccidioides immitis** ‚ùå:\n‚Ä¢ **Spherules** with endospores\n‚Ä¢ Culture positive\n‚Ä¢ Endemic to SW USA\n\nüí° **KEY:** **HIV + Dry cough + GMS crescent cysts + Culture negative = PCP** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-7",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "A sewage worker presented with abdominal pain, jaundice, conjunctival injection, and blood in the urine for the past 5 days. Which of the following is the investigation of choice?",
    options: [
      "Widal test",
      "Microscopic agglutination test",
      "Weil-Felix reaction",
      "Paul-Bunnell test",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Microscopic agglutination test (Option B)**\n\nüî¨ **LEPTOSPIROSIS (Weil's Disease):**\n\n**ORGANISM:**\n‚Ä¢ **Leptospira interrogans** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Spirochete** (spiral bacteria)\n‚Ä¢ **Zoonotic** infection\n\n**EPIDEMIOLOGY:**\n‚Ä¢ **Occupational risk:** Sewage workers, farmers, veterinarians ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Reservoir:** Rats, dogs, cattle (urine)\n‚Ä¢ **Transmission:** Contact with contaminated water/soil\n‚Ä¢ **Portal of entry:** Skin abrasions, mucous membranes\n\n**CLINICAL PRESENTATION (THIS CASE):**\n\n**WEIL'S DISEASE** (Severe leptospirosis) ‚≠ê‚≠ê‚≠ê:\n\n**Classic triad:**\n1. **Jaundice** ‚≠ê (hepatic involvement)\n2. **Renal failure** (hematuria) ‚≠ê\n3. **Hemorrhagic manifestations** (pulmonary, GI bleeding)\n\n**Additional features:**\n‚Ä¢ **Conjunctival suffusion/injection** ‚≠ê‚≠ê‚≠ê **(CHARACTERISTIC)**\n  - Redness without discharge (non-purulent)\n‚Ä¢ **Abdominal pain**\n‚Ä¢ **Fever** (biphasic)\n‚Ä¢ **Myalgia** (calf muscles)\n‚Ä¢ **Headache**\n\n**PHASES:**\n\n**Phase 1 (Septicemic):** Days 1-7\n‚Ä¢ High fever, myalgia, conjunctival suffusion\n‚Ä¢ Leptospires in blood/CSF\n\n**Phase 2 (Immune):** Days 7-30\n‚Ä¢ Antibodies appear\n‚Ä¢ Organ involvement (liver, kidney, meninges)\n‚Ä¢ Leptospires in urine\n\n**DIAGNOSIS:**\n\n**MICROSCOPIC AGGLUTINATION TEST (MAT)** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD)**:\n‚Ä¢ **Serovar-specific**\n‚Ä¢ **Live leptospires** + Patient serum\n‚Ä¢ **Positive:** ‚â•1:400 titer (single) or **4-fold rise** (paired)\n‚Ä¢ **Most sensitive and specific**\n‚Ä¢ **Reference standard** for leptospirosis\n\n**Other tests:**\n‚Ä¢ **ELISA** (IgM) - rapid, early diagnosis\n‚Ä¢ **Dark-field microscopy** (blood/urine) - see spirochetes\n‚Ä¢ **Culture:** Fletcher's/EMJH medium (slow, 4-6 weeks)\n‚Ä¢ **PCR** (blood, urine)\n\n**Lab findings:**\n‚Ä¢ **Elevated bilirubin** (conjugated > unconjugated)\n‚Ä¢ **Thrombocytopenia**\n‚Ä¢ **Elevated creatinine** (renal failure)\n‚Ä¢ **Elevated CPK** (myositis)\n\n**TREATMENT:**\n\n**Mild:** **Doxycycline** 100mg BD √ó 7 days ‚≠ê\n\n**Severe (Weil's):** **Penicillin G** or **Ceftriaxone** IV ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Supportive:** Dialysis (if renal failure)\n\n**Prophylaxis:**\n‚Ä¢ **Doxycycline** 200mg weekly (high-risk exposure)\n\n**WHY OTHER OPTIONS ARE WRONG:**\n\n**Widal test** ‚ùå:\n‚Ä¢ For **Typhoid fever** (Salmonella typhi)\n‚Ä¢ Tests for O and H antigens\n\n**Weil-Felix reaction** ‚ùå:\n‚Ä¢ For **Rickettsial infections** (scrub typhus, epidemic typhus)\n‚Ä¢ Based on cross-reactivity with Proteus antigens\n\n**Paul-Bunnell test** ‚ùå:\n‚Ä¢ For **Infectious mononucleosis** (EBV)\n‚Ä¢ Detects **heterophile antibodies**\n\nüí° **KEY:** **Sewage worker + Jaundice + Conjunctival suffusion + Hematuria = Leptospirosis ‚Üí MAT** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-8",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "e Which of the following laboratory test is used to diagnose rotavirus diarrhea?",
    options: [
      "Antigen detection in the stool sample",
      "Antigen detection in blood d",
      "Antibody detection in serum",
      "Light microscopy of stool specimen",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Antigen detection in the stool sample (Option A)**\n\nüî¨ **ROTAVIRUS DIARRHEA:**\n\n**ORGANISM:**\n‚Ä¢ **Rotavirus** - **Reoviridae family** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **dsRNA virus** (double-stranded RNA)\n‚Ä¢ **Wheel-shaped** (rota = wheel)\n‚Ä¢ **11 segments** of RNA\n\n**EPIDEMIOLOGY:**\n‚Ä¢ **Most common cause** of severe diarrhea in **children <5 years** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Peak age:** 6-24 months\n‚Ä¢ **Fecal-oral transmission**\n‚Ä¢ **Winter** seasonality (temperate climates)\n\n**CLINICAL:**\n‚Ä¢ **Watery diarrhea** (non-bloody) ‚≠ê\n‚Ä¢ **Vomiting** (prominent) ‚≠ê\n‚Ä¢ **Fever**\n‚Ä¢ **Severe dehydration** (life-threatening)\n‚Ä¢ **Incubation:** 1-3 days\n‚Ä¢ **Duration:** 5-7 days\n\n**DIAGNOSIS:**\n\n**ANTIGEN DETECTION IN STOOL** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD - POINT-OF-CARE)**:\n\n**Methods:**\n\n**1. ELISA** (most common):\n‚Ä¢ Detects **rotavirus antigens** (VP6 capsid protein)\n‚Ä¢ **Rapid** (15-30 min)\n‚Ä¢ **High sensitivity** (90-95%)\n‚Ä¢ **High specificity** (>95%)\n\n**2. Latex agglutination:**\n‚Ä¢ Detects viral antigens\n‚Ä¢ Rapid, bedside test\n\n**3. Immunochromatography (ICT):**\n‚Ä¢ Rapid cassette test\n‚Ä¢ Point-of-care\n\n**Other methods:**\n‚Ä¢ **Electron microscopy:** See wheel-shaped virions (research)\n‚Ä¢ **RT-PCR:** Molecular detection (most sensitive)\n‚Ä¢ **Viral culture:** Not routinely done (difficult)\n\n**WHY STOOL SAMPLE:**\n‚Ä¢ **Virus shed in feces** (high concentrations) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Peak shedding during acute diarrhea\n‚Ä¢ **NOT in blood** (localized GI infection)\n\n**PATHOGENESIS:**\n‚Ä¢ Infects **villous epithelial cells** of **small intestine** ‚≠ê\n‚Ä¢ **Villous atrophy** ‚Üí ‚Üì absorption\n‚Ä¢ **NSP4 enterotoxin** ‚Üí ‚Üë secretion\n‚Ä¢ ‚Üí **Osmotic + secretory diarrhea**\n\n**MANAGEMENT:**\n‚Ä¢ **Oral rehydration solution (ORS)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Zinc supplementation** (10-20mg/day √ó 10-14 days)\n‚Ä¢ **Continue feeding** (not contraindicated)\n‚Ä¢ **No antibiotics** (viral)\n\n**PREVENTION:**\n\n**VACCINES** ‚≠ê‚≠ê‚≠ê:\n\n**1. Rotarix** (GlaxoSmithKline):\n‚Ä¢ **Live attenuated**\n‚Ä¢ **2 doses** (6 and 10 weeks)\n\n**2. RotaTeq** (Merck):\n‚Ä¢ **Live attenuated pentavalent**\n‚Ä¢ **3 doses** (6, 10, and 14 weeks)\n\n**WHY OTHER OPTIONS ARE WRONG:**\n\n**Antigen detection in blood** ‚ùå:\n‚Ä¢ **FALSE** - Rotavirus causes **localized GI infection**\n‚Ä¢ **NOT viremic** (doesn't enter blood)\n‚Ä¢ Stool is the diagnostic sample\n\n**Antibody detection in serum** ‚ùå:\n‚Ä¢ Detects **past exposure** (IgG) or **recent infection** (IgM)\n‚Ä¢ **NOT useful for acute diagnosis** (takes days to develop)\n‚Ä¢ Most adults have antibodies (prior exposure)\n\n**Light microscopy of stool** ‚ùå:\n‚Ä¢ **Cannot see** rotavirus by light microscopy\n‚Ä¢ Virus too small (70nm)\n‚Ä¢ Requires **electron microscopy**\n‚Ä¢ No specific cells/organisms visible\n\nüí° **KEY:** **Rotavirus diagnosis = Stool antigen ELISA (rapid, point-of-care)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-9",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "e A boy presented with a fever and chills. Rapid test was positive for specific antigen HRP-2. Which of the following species of Plasmodium is the most likely causative agent?",
    options: [
      "Plasmodium falciparum OP2: Plasmodium malaria O3: Plasmodium vivax O4: Plasmodium ovale",
      "Option 2",
      "Plasmodium vivax",
      "Plasmodium ovale",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Plasmodium falciparum (Option A)**\n\nüî¨ **MALARIA - HRP-2 RAPID DIAGNOSTIC TEST:**\n\n**HRP-2 ANTIGEN:**\n‚Ä¢ **Histidine-Rich Protein 2** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Species-specific** for **Plasmodium falciparum** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Water-soluble protein** produced by asexual stages and young gametocytes\n‚Ä¢ **Persists** in blood for 2-4 weeks after parasite clearance\n\n**RAPID DIAGNOSTIC TESTS (RDTs):**\n\n**HRP-2 based** ‚≠ê‚≠ê‚≠ê **(MOST COMMON RDT)**:\n‚Ä¢ **Detects:** **P. falciparum** ONLY\n‚Ä¢ **Advantage:** High sensitivity, remains positive after treatment\n‚Ä¢ **Disadvantage:** Cannot detect other species, false positive (persistent HRP-2)\n\n**pLDH (Plasmodium Lactate Dehydrogenase):**\n‚Ä¢ **Pan-malarial** marker (all species)\n‚Ä¢ Or **species-specific** pLDH for P. vivax/P. falciparum\n‚Ä¢ Clears rapidly after treatment\n\n**COMBINATION RDTs:**\n‚Ä¢ **HRP-2 + pLDH (pan):** Detects P. falciparum + other species\n‚Ä¢ **HRP-2 + pLDH (Pv):** Differentiates P. falciparum vs P. vivax\n\n**PLASMODIUM FALCIPARUM:**\n\n**CHARACTERISTICS:**\n‚Ä¢ **Most virulent** species ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Highest mortality**\n‚Ä¢ **No relapse** (no hypnozoites in liver)\n\n**CLINICAL:**\n‚Ä¢ **Cerebral malaria** ‚≠ê\n‚Ä¢ **Severe anemia**\n‚Ä¢ **Acute renal failure** (blackwater fever)\n‚Ä¢ **ARDS**\n‚Ä¢ **Hypoglycemia**\n‚Ä¢ **Lactic acidosis**\n\n**PERIPHERAL SMEAR:**\n‚Ä¢ **Ring forms** (often multiple rings per RBC) ‚≠ê\n‚Ä¢ **Banana-shaped gametocytes** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **High parasitemia** (>5% ‚Üí severe)\n‚Ä¢ **All stages** in peripheral blood (NO schizont in uncomplicated)\n\n**TREATMENT:**\n\n**Uncomplicated:**\n‚Ä¢ **Artemisinin Combination Therapy (ACT)** ‚≠ê‚≠ê‚≠ê\n  - **Artesunate + SP** (Sulfadoxine-Pyrimethamine)\n  - **Artemether + Lumefantrine** (Coartem)\n\n**Severe:**\n‚Ä¢ **IV Artesunate** ‚≠ê‚≠ê‚≠ê (drug of choice)\n‚Ä¢ **IV Quinine** (alternative)\n\n**COMPARISON OF SPECIES:**\n\n| Feature | P. falciparum | P. vivax | P. ovale | P. malariae |\n|---------|--------------|----------|----------|-------------|\n| **HRP-2** | ‚úÖ Positive | ‚ùå Negative | ‚ùå Negative | ‚ùå Negative |\n| **Severity** | Severe | Moderate | Mild | Mild |\n| **Gametocyte** | Banana | Round | Round | Round |\n| **Relapse** | No | Yes | Yes | No |\n| **Cycle** | 48h | 48h | 48h | 72h |\n| **Ring forms** | Multiple | Single, large | Single, large | Single |\n\nüí° **KEY:** **HRP-2 positive = Plasmodium falciparum** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-10",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "A child was brought with complaints of high fever, multiple seizures, headache, and neck rigidity. CSF analysis showed low glucose, high protein, and many polymorphs. The CSF culture showed pleomorphic gram-negative bacilli. What is true about the causative organism?",
    options: [
      "It is bacitracin sensitive.",
      "Produces non-lactose fermenting colonies on MacConkey agar",
      "Exhibits satellitism around Staphylococcus aureus colonies r",
      "It exhibits alpha hemolysis on sheep blood agar",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Exhibits satellitism around Staphylococcus aureus colonies (Option C)**\n\nüî¨ **HAEMOPHILUS INFLUENZAE MENINGITIS:**\n\n**CLINICAL DIAGNOSIS:**\n‚Ä¢ **Child** with **meningitis** ‚≠ê\n‚Ä¢ **High fever, seizures, headache, neck rigidity**\n\n**CSF FINDINGS:**\n‚Ä¢ **Low glucose** (<40 mg/dL) ‚≠ê\n‚Ä¢ **High protein** (>45 mg/dL) ‚≠ê\n‚Ä¢ **Pleocytosis:** **Polymorphs dominant** ‚≠ê‚≠ê‚≠ê **(BACTERIAL MENINGITIS)**\n‚Ä¢ ‚Üí **Pyogenic meningitis**\n\n**CSF CULTURE:**\n‚Ä¢ **Pleomorphic gram-negative bacilli/coccobacilli** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ ‚Üí **Haemophilus influenzae** (most likely)\n\n**HAEMOPHILUS INFLUENZAE:**\n\n**ORGANISM:**\n‚Ä¢ **Gram-negative coccobacillus** (pleomorphic) ‚≠ê\n‚Ä¢ **Fastidious** (requires special growth factors)\n‚Ä¢ **Type b (Hib):** Most virulent, polysaccharide capsule\n\n**GROWTH REQUIREMENTS:**\n\n**\"X and V factors\"** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Factor X:** **Hemin** (hematin) - from RBCs\n‚Ä¢ **Factor V:** **NAD** (nicotinamide adenine dinucleotide)\n\n**SATELLITISM PHENOMENON** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC)**:\n‚Ä¢ **Definition:** Enhanced growth of *H. influenzae* around **S. aureus** colonies\n‚Ä¢ **Mechanism:**\n  - **S. aureus produces NAD** (Factor V) ‚≠ê\n  - **S. aureus lyses RBCs** ‚Üí Releases hemin (Factor X)\n  - ‚Üí *H. influenzae* grows better near S. aureus\n‚Ä¢ **Test:** Streak *H. influenzae* + S. aureus on **blood agar** ‚Üí Satellite colonies appear around staph\n\n**CULTURE MEDIA:**\n‚Ä¢ **Chocolate agar** ‚≠ê‚≠ê‚≠ê (heated blood - releases X & V)\n‚Ä¢ **Blood agar + X & V factor discs**\n‚Ä¢ **NO growth** on MacConkey (gram-negative, but fastidious)\n\n**CLINICAL:**\n‚Ä¢ **Meningitis** (children <5 years, pre-Hib vaccine era) ‚≠ê\n‚Ä¢ **Epiglottitis** (\"cherry-red\" epiglottis)\n‚Ä¢ **Pneumonia**\n‚Ä¢ **Otitis media**\n\n**TREATMENT:**\n‚Ä¢ **Ceftriaxone** or **Cefotaxime** ‚≠ê‚≠ê‚≠ê (3rd gen cephalosporin)\n‚Ä¢ Avoid ampicillin (30-40% resistance due to Œ≤-lactamase)\n\n**PREVENTION:**\n‚Ä¢ **Hib vaccine** (PRP-T conjugate) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Part of routine immunization\n\n**WHY OTHER OPTIONS ARE WRONG:**\n\n**Bacitracin sensitive** ‚ùå:\n‚Ä¢ **Group A Streptococcus** (S. pyogenes) is bacitracin sensitive\n‚Ä¢ *H. influenzae* is **gram-negative** (bacitracin tests gram-positive cocci)\n\n**Non-lactose fermenting on MacConkey** ‚ùå:\n‚Ä¢ *H. influenzae* **does NOT grow** on MacConkey agar ‚≠ê\n‚Ä¢ MacConkey is for **non-fastidious** gram-negative bacilli\n‚Ä¢ Only organisms like E. coli, Shigella, Salmonella grow on MacConkey\n\n**Alpha hemolysis on blood agar** ‚ùå:\n‚Ä¢ *H. influenzae* shows **NO hemolysis** on blood agar\n‚Ä¢ **Alpha hemolysis:** Streptococcus pneumoniae, viridans streptococci\n‚Ä¢ *H. influenzae* grown on blood agar (if X & V added) but no hemolysis\n\nüí° **KEY:** **Pleomorphic GNB + Satellitism around S. aureus = H. influenzae** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-11",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "A man presents with a history of dysuria aand urethral discharge after having unprotected sexual intercourse. Gram-staining of the purulent discharge is seen in the following image. What is the treatment of choice for this infection? L p e r P",
    options: [
      "Erythromycin",
      "Azithromycin",
      "Ceftriaxone",
      "Penicillin G",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Ceftriaxone (Option C)**\n\nüî¨ **GONOCOCCAL URETHRITIS:**\n\n**CLINICAL DIAGNOSIS:**\n‚Ä¢ **Dysuria** + **Purulent urethral discharge** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **History of unprotected sexual intercourse**\n‚Ä¢ **Male patient**\n\n**CAUSATIVE ORGANISM:**\n‚Ä¢ **Neisseria gonorrhoeae** ‚≠ê‚≠ê‚≠ê\n\n**GRAM STAIN FINDINGS:**\n‚Ä¢ **Gram-negative diplococci** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC)**\n‚Ä¢ **Intracellular** (within polymorphonuclear leukocytes/PMNs) ‚≠ê\n‚Ä¢ **\"Kidney bean\" shape** (coffee bean, opposing concave sides)\n‚Ä¢ **In pairs** (diplococci)\n\n**SEXUALLY TRANSMITTED INFECTION:**\n‚Ä¢ **Most common bacterial STI** (after Chlamydia)\n‚Ä¢ **Incubation:** 2-7 days\n\n**CLINICAL MANIFESTATIONS:**\n\n**Men:**\n‚Ä¢ **Urethritis** ‚≠ê (90% symptomatic)\n  - Purulent discharge (thick, yellow-green)\n  - Dysuria\n‚Ä¢ **Epididymitis**, **prostatitis** (complications)\n\n**Women:**\n‚Ä¢ **Cervicitis** (50% asymptomatic)\n‚Ä¢ **PID** (pelvic inflammatory disease) ‚≠ê\n‚Ä¢ **Infertility**, **ectopic pregnancy**\n\n**Disseminated:**\n‚Ä¢ **Disseminated gonococcal infection (DGI)** (1-3%)\n‚Ä¢ **Arthritis-dermatitis syndrome** ‚≠ê\n  - Migratory polyarthritis\n  - Tenosynovitis\n  - Pustular skin lesions\n\n**Neonatal:**\n‚Ä¢ **Ophthalmia neonatorum** (purulent conjunctivitis)\n‚Ä¢ **Prophylaxis:** Erythromycin eye ointment at birth\n\n**TREATMENT:**\n\n**CURRENT RECOMMENDED TREATMENT** ‚≠ê‚≠ê‚≠ê:\n\n**Uncomplicated urethritis/cervicitis:**\n‚Ä¢ **Ceftriaxone 500mg IM single dose** ‚≠ê‚≠ê‚≠ê **(FIRST-LINE)**\n  - Or **1g IM** if weight >150 kg\n\n**+ Treat for Chlamydia** (often co-infected) ‚≠ê:\n‚Ä¢ **Azithromycin 1g PO single dose**\n‚Ä¢ Or **Doxycycline 100mg PO BD √ó 7 days**\n\n**WHY CEFTRIAXONE:**\n‚Ä¢ **Increasing resistance** to penicillin, fluoroquinolones, azithromycin ‚≠ê\n‚Ä¢ **3rd generation cephalosporin** remains effective\n‚Ä¢ **Single-dose IM** ‚Üí High compliance\n\n**Disseminated/Severe:**\n‚Ä¢ **Ceftriaxone 1-2g IV daily**\n\n**Ophthalmia neonatorum:**\n‚Ä¢ **Ceftriaxone 50mg/kg IM/IV** (single dose, max 125mg)\n\n**WHY OTHER OPTIONS ARE WRONG:**\n\n**Erythromycin** ‚ùå:\n‚Ä¢ For **Chlamydia**, not Gonorrhea (as monotherapy)\n‚Ä¢ Not effective enough for N. gonorrhoeae\n\n**Azithromycin** ‚ùå:\n‚Ä¢ For **Chlamydia** ‚≠ê\n‚Ä¢ **Increasing resistance** in N. gonorrhoeae ‚≠ê\n‚Ä¢ **No longer recommended** as monotherapy for gonorrhea\n‚Ä¢ Can be used in combination with ceftriaxone for co-treatment\n\n**Penicillin G** ‚ùå:\n‚Ä¢ **High resistance** (>50% strains produce Œ≤-lactamase) ‚≠ê\n‚Ä¢ **No longer effective**\n‚Ä¢ Was first-line in the past\n\n**KEY RESISTANCE TRENDS:**\n‚Ä¢ **Penicillin:** High resistance (Œ≤-lactamase)\n‚Ä¢ **Fluoroquinolones:** High resistance (gyrase mutations)\n‚Ä¢ **Azithromycin:** Increasing resistance\n‚Ä¢ **Ceftriaxone:** Still effective (but monitor)\n\nüí° **KEY:** **Gonorrhea = GN diplococci in PMNs ‚Üí Ceftriaxone IM + Azithromycin (for Chlamydia)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-12",
    subjectId: "radiology",
    chapterId: "neet-pg-2023",
    question: "A 2-month-old infant is brought to the OPD with a parietal swelling present since birth. The r X-ray image is given below. What could be the probable diagnosis? e d d a L",
    options: [
      "Subgaleal hematoma",
      "Cephalhematoma",
      "Caput succedaneum r",
      "EPnecephalocele",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Cephalhematoma (Option B)**\n\nüî¨ **CEPHALHEMATOMA:**\n\n**DEFINITION:**\n‚Ä¢ **Subperiosteal hemorrhage** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Blood collection **between skull bone and periosteum**\n‚Ä¢ **Does NOT cross suture lines** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC FEATURE)**\n\n**ETIOLOGY:**\n‚Ä¢ **Birth trauma** (prolonged labor, instrumental delivery) ‚≠ê\n‚Ä¢ Rupture of blood vessels between **periosteum and skull**\n\n**CLINICAL FEATURES:**\n\n**Timing:**\n‚Ä¢ **NOT present at birth** ‚≠ê\n‚Ä¢ **Appears hours after delivery** (takes time to accumulate)\n‚Ä¢ **Persists 2-3 months** (slow resolution)\n\n**Location:**\n‚Ä¢ **Unilateral** (75%) or bilateral\n‚Ä¢ **Most common:** **Parietal bone** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Limited by suture lines** (periosteum firmly attached at sutures)\n\n**Appearance:**\n‚Ä¢ **Firm, fluctuant swelling**\n‚Ä¢ **Well-defined margins** (doesn't cross sutures)\n‚Ä¢ **No pitting edema**\n‚Ä¢ **Overlying scalp normal**\n\n**COMPLICATIONS:**\n\n**Early:**\n‚Ä¢ **Hyperbilirubinemia** (RBC breakdown) ‚≠ê\n\n**Late:**\n‚Ä¢ **Calcification** (2-3 weeks) ‚Üí Bony ridge\n‚Ä¢ **Infection** (rare)\n‚Ä¢ **Anemia** (if large)\n\n**RADIOLOGY (X-RAY):**\n‚Ä¢ **Soft tissue swelling** limited by sutures ‚≠ê\n‚Ä¢ **Underlying skull fracture** (10-25% cases)\n‚Ä¢ **Calcification** (if chronic)\n\n**MANAGEMENT:**\n‚Ä¢ **Conservative** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **No intervention** (self-resolves in 2-3 months)\n‚Ä¢ **Phototherapy** (if jaundiced)\n‚Ä¢ **AVOID aspiration** (risk of infection, abscess)\n\n**DIFFERENTIAL DIAGNOSIS:**\n\n**CEPHALHEMATOMA vs CAPUT SUCCEDANEUM:**\n\n| Feature | Cephalhematoma | Caput Succedaneum |\n|---------|----------------|-------------------|\n| **Location** | **Subperiosteal** ‚≠ê | **Subcutaneous/scalp edema** |\n| **Timing** | **Hours after birth** ‚≠ê | **Present at birth** |\n| **Sutures** | **Does NOT cross** ‚≠ê‚≠ê‚≠ê | **Crosses sutures** |\n| **Resolution** | **Weeks to months** | **Days** (2-3 days) |\n| **Consistency** | **Firm, fluctuant** | **Soft, pitting edema** |\n| **Jaundice** | **Common** | Rare |\n\n**vs SUBGALEAL HEMATOMA:**\n‚Ä¢ **Subgaleal:** Between **galea aponeurotica** and **periosteum**\n‚Ä¢ **Crosses sutures** (large, diffuse)\n‚Ä¢ **LIFE-THREATENING** (massive blood loss, shock) ‚≠ê\n‚Ä¢ **Fluctuant, boggy** swelling\n‚Ä¢ Requires **emergency management**\n\n**vs ENCEPHALOCELE:**\n‚Ä¢ **Congenital** neural tube defect\n‚Ä¢ **Brain/meninges herniation** through skull defect\n‚Ä¢ **Pulsatile**, **transilluminates**\n‚Ä¢ **Increases with crying**\n\nüí° **KEY:** **Parietal swelling NOT crossing sutures + Hours after birth = Cephalhematoma** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page5_img1.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-13",
    subjectId: "radiology",
    chapterId: "neet-pg-2023",
    question: "A patient presented with abdominal pain and sterile pyuria, and the x-ray showed the following features. What is the likely diagnosis? r e d d a L",
    options: [
      "Putty kidney",
      "Nephrocalcinosis",
      "Staghorn calculus e",
      "Psoas calcification",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Putty kidney (Option A)**\n\nüî¨ **PUTTY KIDNEY (Renal Tuberculosis):**\n\n**DEFINITION:**\n‚Ä¢ **End-stage renal tuberculosis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Caseous material** (cheese-like, \"putty\") **replaces renal parenchyma**\n‚Ä¢ **Non-functioning kidney**\n\n**ETIOLOGY:**\n‚Ä¢ **Mycobacterium tuberculosis** ‚≠ê\n‚Ä¢ **Secondary to pulmonary TB** (hematogenous spread)\n‚Ä¢ **Chronic, progressive** infection\n\n**PATHOGENESIS:**\n‚Ä¢ **Primary TB** ‚Üí **Hematogenous spread** to kidneys\n‚Ä¢ **Granulomas** in cortex ‚Üí **Caseation necrosis**\n‚Ä¢ **Papillary necrosis** ‚Üí **Calyceal destruction**\n‚Ä¢ **Caseous material** fills collecting system\n‚Ä¢ **Autonephrectomy** (kidney becomes non-functional sac of caseum)\n\n**CLINICAL PRESENTATION:**\n\n**Classic triad:**\n1. **Abdominal/flank pain** ‚≠ê\n2. **Sterile pyuria** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n   - Pus cells in urine WITHOUT bacterial growth on routine culture\n3. **Hematuria** (microscopic/gross)\n\n**Additional:**\n‚Ä¢ **Dysuria, frequency**\n‚Ä¢ **Constitutional symptoms** (fever, weight loss, night sweats)\n‚Ä¢ **Lower urinary tract symptoms**\n\n**DIAGNOSTIC CLUE (THIS CASE):**\n\n**\"STERILE PYURIA\"** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Pyuria** (WBCs in urine)\n‚Ä¢ **Routine bacterial culture NEGATIVE**\n‚Ä¢ ‚Üí **Think TB!**\n\n**RADIOLOGY (X-RAY/IVP):**\n\n**Putty kidney features:**\n‚Ä¢ **Diffuse calcification** of entire kidney ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **\"Putty-like\" opacity** (caseous material)\n‚Ä¢ **Non-functioning kidney** (no contrast excretion)\n‚Ä¢ **Lobar/moth-eaten calices**\n\n**Other TB kidney findings:**\n‚Ä¢ **\"Phantom calyx\"** (destroyed calyx)\n‚Ä¢ **\"Thimble bladder\"** (contracted, small bladder)\n‚Ä¢ **Ureteric strictures**\n‚Ä¢ **\"Beaded ureter\"** (multiple strictures)\n\n**DIAGNOSIS:**\n\n**Urine analysis:**\n‚Ä¢ **Sterile pyuria** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Acid-fast bacilli (AFB) on Ziehl-Neelsen stain**\n‚Ä¢ **Culture:** Lowenstein-Jensen medium (6-8 weeks)\n‚Ä¢ **GeneXpert MTB/RIF** (rapid, 2 hours)\n‚Ä¢ **3 early morning urine samples** (best yield)\n\n**Imaging:**\n‚Ä¢ **IVP/CT urography:** Calyceal abnormalities, strictures\n‚Ä¢ **Ultrasound:** Hydronephrosis, calcification\n\n**TREATMENT:**\n\n**Medical (ATT):**\n‚Ä¢ **2 HREZ / 4 HRE** ‚≠ê‚≠ê‚≠ê\n  - **Intensive phase:** 2 months of **HREZ** (Isoniazid, Rifampicin, Ethambutol, Pyrazinamide)\n  - **Continuation:** 4 months of **HRE**\n‚Ä¢ **Total 6 months** (9-12 months if extensive)\n\n**Surgical:**\n‚Ä¢ **Nephrectomy** (if non-functioning, putty kidney) ‚≠ê\n‚Ä¢ **Ensure contralateral kidney is functioning**\n\n**DIFFERENTIAL DIAGNOSIS:**\n\n**Nephrocalcinosis** ‚ùå:\n‚Ä¢ **Bilateral cortical/medullary calcification**\n‚Ä¢ Not replacement of parenchyma\n‚Ä¢ Causes: **Hyperparathyroidism**, **RTA**, **sarcoidosis**\n\n**Staghorn calculus** ‚ùå:\n‚Ä¢ **Large stone** filling **renal pelvis and calices**\n‚Ä¢ **\"Antler/staghorn\" shape**\n‚Ä¢ Associated with **Proteus** (urease-producing)\n‚Ä¢ **Not caseous material**\n\n**Psoas calcification** ‚ùå:\n‚Ä¢ **Calcification** in **psoas muscle**\n‚Ä¢ **Psoas abscess** (often tuberculous)\n‚Ä¢ Separate from kidney\n\nüí° **KEY:** **Sterile pyuria + Renal calcification = TB ‚Üí Putty kidney (end-stage)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page6_img2.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-14",
    subjectId: "anatomy",
    chapterId: "neet-pg-2023",
    question: "A defect in which of the following forms the structure marked below? r e d d a L",
    options: [
      "Internal obliqu p",
      "External oblique",
      "Parietal peritoneum",
      "Fascia tranrsversalis",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Fascia transversalis (Option D)**\n\nüî¨ **INGUINAL HERNIA - DEEP INGUINAL RING:**\n\n**STRUCTURE MARKED:** **Deep (internal) inguinal ring** ‚≠ê‚≠ê‚≠ê\n\n**DEFINITION:**\n‚Ä¢ **Opening** in **fascia transversalis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Located **1.25 cm above mid-inguinal point**\n‚Ä¢ **Oval-shaped** defect\n\n**FORMED BY:**\n‚Ä¢ **Defect/opening** in **FASCIA TRANSVERSALIS** ‚≠ê‚≠ê‚≠ê **(THIS IS THE ANSWER)**\n\n**ANATOMICAL LOCATION:**\n‚Ä¢ **Midpoint** between **ASIS** and **pubic tubercle** (mid-inguinal point)\n‚Ä¢ **Lateral** to inferior epigastric vessels\n‚Ä¢ **Medial** to external iliac vessels\n\n**BOUNDARIES:**\n‚Ä¢ **Medial:** Lateral edge of **rectus abdominis**\n‚Ä¢ **Lateral:** **Psoas fascia**\n‚Ä¢ **Superior:** **Arched fibers** of transversus abdominis\n‚Ä¢ **Inferior:** **Inguinal ligament**\n\n**CLINICAL SIGNIFICANCE:**\n\n**INDIRECT INGUINAL HERNIA** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Enters** through **deep inguinal ring** (lateral to inferior epigastric vessels)\n‚Ä¢ **Covered by** all 3 layers of spermatic cord fasciae:\n  1. **Internal spermatic fascia** (from fascia transversalis)\n  2. **Cremasteric fascia** (from internal oblique)\n  3. **External spermatic fascia** (from external oblique)\n\n**vs DIRECT HERNIA:**\n‚Ä¢ **Direct hernia** protrudes through **Hesselbach's triangle**\n‚Ä¢ **Medial** to inferior epigastric vessels\n‚Ä¢ **Does NOT** pass through deep ring\n\n**LAYERS OF ABDOMINAL WALL (SUPERFICIAL TO DEEP):**\n\n1. **Skin**\n2. **Camper's fascia** (superficial fatty layer)\n3. **Scarpa's fascia** (deep membranous layer)\n4. **External oblique** muscle + aponeurosis\n5. **Internal oblique** muscle\n6. **Transversus abdominis** muscle\n7. **Fascia transversalis** ‚≠ê (forms deep ring)\n8. **Extraperitoneal fat**\n9. **Parietal peritoneum**\n\n**INGUINAL CANAL BOUNDARIES:**\n\n**Anterior wall:**\n‚Ä¢ **External oblique aponeurosis** (entire length)\n‚Ä¢ **Internal oblique** (lateral 1/3)\n\n**Posterior wall:**\n‚Ä¢ **Fascia transversalis** (entire length) ‚≠ê\n‚Ä¢ **Conjoint tendon** (medial 1/3)\n\n**Roof:**\n‚Ä¢ **Arched fibers** of internal oblique + transversus abdominis\n\n**Floor:**\n‚Ä¢ **Inguinal ligament**\n\nüí° **KEY:** **Deep inguinal ring = Defect in fascia transversalis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-15",
    subjectId: "anatomy",
    chapterId: "neet-pg-2023",
    question: "A student had his jaw locked while yawning. Which of the following muscles is attached to the articular disc of the temporomandibular joint?",
    options: [
      "Lateral pterygoid",
      "Temporalis",
      "Medial pterygoid",
      "Masseter",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Lateral pterygoid (Option A)**\n\nüî¨ **TMJ DISLOCATION:**\n\n**CLINICAL SCENARIO:**\n‚Ä¢ **Jaw locked while yawning** ‚≠ê (classic TMJ dislocation)\n‚Ä¢ **Temporomandibular joint (TMJ) dislocation**\n‚Ä¢ **Mouth stuck open**, cannot close\n\n**ANATOMY OF TMJ:**\n\n**ARTICULAR DISC:**\n‚Ä¢ **Fibrocartilaginous disc** between mandibular condyle and temporal bone ‚≠ê\n‚Ä¢ **Divides joint** into upper and lower compartments\n‚Ä¢ **Attached to:** **Lateral pterygoid muscle** ‚≠ê‚≠ê‚≠ê\n\n**LATERAL PTERYGOID MUSCLE** ‚≠ê‚≠ê‚≠ê:\n\n**TWO HEADS:**\n\n**1. Superior head:**\n‚Ä¢ **Attached to articular disc** ‚≠ê‚≠ê‚≠ê **(THIS IS THE ANSWER)**\n‚Ä¢ **Origin:** Greater wing of sphenoid\n‚Ä¢ **Insertion:** Articular disc + neck of mandible\n\n**2. Inferior head:**\n‚Ä¢ **Attached to neck of mandible**\n‚Ä¢ **Origin:** Lateral pterygoid plate\n‚Ä¢ **Insertion:** Neck of mandible (pterygoid fovea)\n\n**FUNCTION:**\n‚Ä¢ **Opens mouth** (depresses mandible) ‚≠ê\n‚Ä¢ **Protrudes mandible** (jaw forward)\n‚Ä¢ **Lateral movement** (side-to-side chewing)\n‚Ä¢ **Pulls articular disc forward** during mouth opening\n\n**TMJ DISLOCATION MECHANISM:**\n\n**Normal jaw opening:**\n‚Ä¢ **Lateral pterygoid contracts**\n‚Ä¢ **Pulls disc + condyle forward**\n‚Ä¢ **Condyle moves** over articular eminence\n‚Ä¢ **Returns to glenoid fossa** on closing\n\n**Dislocation (while yawning):**\n‚Ä¢ **Excessive mouth opening** ‚≠ê\n‚Ä¢ **Condyle moves too far forward** (beyond eminence)\n‚Ä¢ **Spasm of lateral pterygoid** keeps it forward\n‚Ä¢ **Cannot return** to fossa ‚Üí **Stuck open**\n\n**MUSCLES OF MASTICATION:**\n\n| Muscle | Action | TMJ Disc Attachment |\n|--------|--------|--------------------|\n| **Lateral pterygoid** | Opens, protrudes | ‚úÖ **YES** ‚≠ê‚≠ê‚≠ê |\n| **Temporalis** | Closes, retracts | ‚ùå No |\n| **Masseter** | Closes, elevates | ‚ùå No |\n| **Medial pterygoid** | Closes, elevates | ‚ùå No |\n\n**CLINICAL:**\n\n**TMJ dislocation:**\n‚Ä¢ **Bilateral** (common) or unilateral\n‚Ä¢ **Jaw locked open** ‚≠ê\n‚Ä¢ **Unable to close mouth**\n‚Ä¢ **Painful**\n‚Ä¢ **Dimple anterior to ear** (empty fossa)\n\n**REDUCTION:**\n‚Ä¢ **Manual reduction** (push down on molars, backward pressure)\n‚Ä¢ **Barton's method**\n‚Ä¢ **May need sedation/anesthesia**\n\nüí° **KEY:** **Lateral pterygoid = ONLY muscle attached to TMJ disc** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-16",
    subjectId: "anatomy",
    chapterId: "neet-pg-2023",
    question: "e The given histology image is of ? d d a L p",
    options: [
      "Leydig cells of testis e",
      "Pancreatic islet cells",
      "Hassall's corpuscles OP4: Glomerulus A ns: 4",
      "Option 4",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Leydig cells of testis (Option A)**\n\nüî¨ **LEYDIG CELLS (Interstitial Cells of Testis):**\n\n**HISTOLOGY:**\n‚Ä¢ **Polygonal/round cells** in **interstitial tissue** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Between seminiferous tubules**\n‚Ä¢ **Abundant eosinophilic cytoplasm** ‚≠ê\n‚Ä¢ **Large, round nucleus**\n\n**CHARACTERISTIC FEATURES** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Reinke crystals** (crystalloid inclusions) - **DIAGNOSTIC**\n‚Ä¢ **Rod-shaped crystals** in cytoplasm\n‚Ä¢ **Pink/eosinophilic** on H&E stain\n‚Ä¢ Found in **10% of normal adult Leydig cells**\n\n**FUNCTION:**\n‚Ä¢ **Testosterone production** ‚≠ê‚≠ê‚≠ê **(PRIMARY FUNCTION)**\n‚Ä¢ **Endocrine cells** (steroid hormone synthesis)\n‚Ä¢ **LH stimulation** (luteinizing hormone)\n\n**DEVELOPMENT:**\n‚Ä¢ **Fetal Leydig cells:** Active in utero (testosterone for male development)\n‚Ä¢ **Adult Leydig cells:** Develop at puberty (secondary sexual characteristics)\n\n**HISTOLOGICAL IDENTIFICATION:**\n\n**Leydig cells:**\n‚Ä¢ **Interstitial** (between tubules)\n‚Ä¢ **Eosinophilic cytoplasm** (lipid-rich)\n‚Ä¢ **Reinke crystals** (pathognomonic)\n‚Ä¢ **Clustered** appearance\n\n**DIFFERENTIAL HISTOLOGY:**\n\n**Pancreatic islet cells** ‚ùå:\n‚Ä¢ **Pale cytoplasm** (not eosinophilic)\n‚Ä¢ **Cord-like arrangement**\n‚Ä¢ **Capillary-rich stroma**\n‚Ä¢ Œ±, Œ≤, Œ¥, PP cells (different staining)\n\n**Hassall's corpuscles** ‚ùå:\n‚Ä¢ Found in **thymus** (not testis)\n‚Ä¢ **Concentric layers** of epithelial cells ‚≠ê\n‚Ä¢ **\"Onion skin\" appearance**\n‚Ä¢ **Keratinized center**\n‚Ä¢ Thymic medulla only\n\n**Glomerulus** ‚ùå:\n‚Ä¢ **Kidney** structure\n‚Ä¢ **Tuft of capillaries** ‚≠ê\n‚Ä¢ **Bowman's capsule** surrounding\n‚Ä¢ **Mesangial cells**, **podocytes**\n\n**CLINICAL SIGNIFICANCE:**\n\n**Leydig cell tumor:**\n‚Ä¢ **Benign** (usually)\n‚Ä¢ **Testosterone-secreting** ‚Üí **Precocious puberty** (boys) or **virilization** (women)\n‚Ä¢ **Golden-brown color** (lipid-rich)\n‚Ä¢ **Reinke crystals** (25-40%)\n\n**Hypogonadism:**\n‚Ä¢ **Leydig cell failure** ‚Üí Low testosterone\n‚Ä¢ **Causes:** Klinefelter syndrome, mumps orchitis, chemotherapy\n\nüí° **KEY:** **Eosinophilic cells + Reinke crystals + Interstitial location = Leydig cells** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page7_img3.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-17",
    subjectId: "anatomy",
    chapterId: "neet-pg-2023",
    question: "A defect in which of the following aortic arches causes the defect shown in the image? r e",
    options: [
      "4th right",
      "4th left",
      "6th right",
      "6th left a",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **6th left aortic arch (Option D)**\n\nüî¨ **PATENT DUCTUS ARTERIOSUS (PDA):**\n\n**EMBRYOLOGY - AORTIC ARCHES:**\n\n**6TH AORTIC ARCH** ‚≠ê‚≠ê‚≠ê:\n\n**Right 6th arch:**\n‚Ä¢ **Proximal part** ‚Üí **Right pulmonary artery**\n‚Ä¢ **Distal part** ‚Üí **REGRESSES**\n\n**Left 6th arch** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Proximal part** ‚Üí **Left pulmonary artery**\n‚Ä¢ **Distal part** ‚Üí **DUCTUS ARTERIOSUS** ‚≠ê‚≠ê‚≠ê\n\n**DUCTUS ARTERIOSUS:**\n‚Ä¢ **Connects** pulmonary artery to descending aorta\n‚Ä¢ **Patent in fetus** (shunts blood away from lungs)\n‚Ä¢ **Closes after birth** ‚Üí **Ligamentum arteriosum**\n‚Ä¢ **Failure to close** ‚Üí **Patent ductus arteriosus (PDA)**\n\n**DEFECT IN LEFT 6TH ARCH** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Failure of distal portion** to regress\n‚Ä¢ ‚Üí **PATENT DUCTUS ARTERIOSUS (PDA)**\n\n**AORTIC ARCH DERIVATIVES:**\n\n| Arch | Structures |\n|------|------------|\n| **1st** | Maxillary artery, External carotid (part) |\n| **2nd** | Stapedial artery, Hyoid artery |\n| **3rd** | **Common carotid**, **Internal carotid** (proximal) ‚≠ê |\n| **4th Right** | **Right subclavian artery** ‚≠ê |\n| **4th Left** | **Aortic arch** (between left CCA and left subclavian) ‚≠ê |\n| **5th** | Regresses completely |\n| **6th Right** | Right pulmonary artery (proximal), *distal regresses* |\n| **6th Left** | Left pulmonary artery (proximal), **DUCTUS ARTERIOSUS** ‚≠ê‚≠ê‚≠ê |\n\n**PATENT DUCTUS ARTERIOSUS (PDA):**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Left-to-right shunt** (aorta ‚Üí pulmonary artery)\n‚Ä¢ **Increased pulmonary blood flow**\n‚Ä¢ **Volume overload** of left heart\n\n**CLINICAL FEATURES:**\n‚Ä¢ **Continuous \"machinery\" murmur** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC)**\n  - Loudest at **left infraclavicular area**\n  - Heard throughout systole and diastole\n‚Ä¢ **Wide pulse pressure** (bounding pulses)\n‚Ä¢ **Dyspnea**, **feeding difficulties** (infants)\n\n**ASSOCIATIONS:**\n‚Ä¢ **Prematurity** (most common) ‚≠ê\n‚Ä¢ **Maternal rubella infection** ‚≠ê\n‚Ä¢ **High altitude**\n‚Ä¢ **Down syndrome**\n\n**COMPLICATIONS:**\n‚Ä¢ **Pulmonary hypertension** (Eisenmenger syndrome) ‚≠ê\n‚Ä¢ **Heart failure**\n‚Ä¢ **Endocarditis**\n\n**DIAGNOSIS:**\n‚Ä¢ **Echocardiography** (gold standard)\n‚Ä¢ **CXR:** Cardiomegaly, prominent pulmonary vessels\n‚Ä¢ **ECG:** LVH\n\n**TREATMENT:**\n\n**Medical:**\n‚Ä¢ **Indomethacin** or **Ibuprofen** (premature infants) ‚≠ê\n  - Inhibits prostaglandin synthesis\n  - Promotes ductal closure\n  - Most effective if <2 weeks old\n\n**Surgical:**\n‚Ä¢ **Catheter-based closure** (coil/device) ‚≠ê\n‚Ä¢ **Surgical ligation** (if large or failed medical)\n\nüí° **KEY:** **Left 6th aortic arch defect = Patent ductus arteriosus (PDA)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page8_img4.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-18",
    subjectId: "anatomy",
    chapterId: "neet-pg-2023",
    question: "Which of the following structures develops from the structure marked 4?",
    options: [
      "Medial umbilical ligament",
      "Median umrbilical ligament P d",
      "Meckel's diverticulum",
      "Ligamentum teres",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Median umbilical ligament (Option B)**\n\nüî¨ **FETAL REMNANTS - UMBILICAL LIGAMENTS:**\n\n**STRUCTURE MARKED 4:** Likely **URACHUS** (in fetal diagram) ‚≠ê‚≠ê‚≠ê\n\n**URACHUS:**\n‚Ä¢ **Tubular structure** connecting **bladder apex** to **umbilicus**\n‚Ä¢ **Patent in fetus** (drains urine to allantois)\n‚Ä¢ **Normally obliterates** after birth\n\n**ADULT REMNANT:**\n‚Ä¢ **MEDIAN UMBILICAL LIGAMENT** ‚≠ê‚≠ê‚≠ê **(THIS IS THE ANSWER)**\n‚Ä¢ Fibrous cord from **bladder apex** to **umbilicus**\n‚Ä¢ Runs in **midline** on anterior abdominal wall (inner surface)\n\n**FETAL-TO-ADULT REMNANTS:**\n\n| Fetal Structure | Adult Remnant | Location |\n|----------------|---------------|----------|\n| **Urachus** ‚≠ê | **Median umbilical ligament** ‚≠ê‚≠ê‚≠ê | Midline (bladder ‚Üí umbilicus) |\n| **Umbilical arteries** (√ó2) | **Medial umbilical ligaments** (√ó2) | Bilateral (bladder sides) |\n| **Umbilical vein** | **Ligamentum teres** (round ligament of liver) | Falciform ligament |\n| **Ductus venosus** | **Ligamentum venosum** | Liver (between left and caudate lobes) |\n| **Ductus arteriosus** | **Ligamentum arteriosum** | Between PA and aorta |\n| **Foramen ovale** | **Fossa ovalis** | Interatrial septum |\n\n**URACHAL ABNORMALITIES:**\n\n**1. Patent urachus** (complete failure to close):\n‚Ä¢ **Urine leak** from umbilicus ‚≠ê\n‚Ä¢ **Persistent connection** bladder ‚Üí umbilicus\n\n**2. Urachal cyst:**\n‚Ä¢ **Midline cystic mass** (partial obliteration)\n‚Ä¢ Can get **infected** (abscess)\n\n**3. Urachal sinus:**\n‚Ä¢ **Blind-ended tract** from umbilicus\n‚Ä¢ Distal part patent, proximal obliterated\n\n**4. Vesico-urachal diverticulum:**\n‚Ä¢ **Bladder diverticulum** at dome\n‚Ä¢ Proximal part patent, distal obliterated\n\n**CLINICAL:**\n‚Ä¢ **Urachal carcinoma** (rare, adenocarcinoma at bladder dome)\n‚Ä¢ **Meckel's diverticulum** (NOT from urachus - from vitelline duct)\n\n**KEY DIFFERENCES:**\n\n**Median umbilical ligament:**\n‚Ä¢ From **urachus** ‚≠ê\n‚Ä¢ **Single**, **midline**\n‚Ä¢ Bladder ‚Üí umbilicus\n\n**Medial umbilical ligaments (√ó2):**\n‚Ä¢ From **umbilical arteries** ‚≠ê\n‚Ä¢ **Paired**, **bilateral**\n‚Ä¢ Bladder sides ‚Üí umbilicus\n\n**Ligamentum teres:**\n‚Ä¢ From **umbilical vein** ‚≠ê\n‚Ä¢ In **falciform ligament**\n‚Ä¢ Umbilicus ‚Üí liver (left lobe)\n\n**Meckel's diverticulum:**\n‚Ä¢ From **vitelline duct** (yolk sac remnant)\n‚Ä¢ **Ileum** (60-100 cm from ileocecal valve)\n‚Ä¢ **Not related to urachus**\n\nüí° **KEY:** **Urachus ‚Üí Median umbilical ligament (bladder to umbilicus, midline)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-19",
    subjectId: "anatomy",
    chapterId: "neet-pg-2023",
    question: "e A patient comes with abdominal pain, jaundice, and portal hypertension. Anastomosis between which of the following veins is seen?",
    options: [
      "Left colic vein and middle colic veins OP2: Esophageal veins and left gastric veins O 3: Superior rectal and phrenic veins O4: Sigmoid and superior rectal veins",
      "Option 2",
      "Option 3",
      "Sigmoid and superior rectal veins",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Esophageal veins and left gastric veins (Option B)**\n\nüî¨ **PORTAL HYPERTENSION:**\n\n**Portal HTN** ‚Üí **Left gastric vein (portal)** ‚Üî **Esophageal veins (systemic)** ‚Üí **Esophageal varices** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page9_img5.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-20",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "Which of the following clotting factors is needed for gamma-glutamyl carboxylase?",
    options: [
      "Factors II, VIII, IX, X",
      "Factors II, VII, IX, and X",
      "Factors II, VII, IX, XI",
      "Factors II, VIII, X, XI r",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Factors II, VII, IX, and X (Option B)**\n\nüî¨ **VITAMIN K-DEPENDENT CLOTTING FACTORS:**\n\n**GAMMA-GLUTAMYL CARBOXYLASE:**\n‚Ä¢ **Enzyme** that requires **Vitamin K** as cofactor ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Function:** **Post-translational modification** of clotting factors\n‚Ä¢ **Carboxylates glutamic acid residues** ‚Üí Œ≥-carboxyglutamic acid (Gla)\n\n**VITAMIN K-DEPENDENT FACTORS** ‚≠ê‚≠ê‚≠ê:\n\n**\"1972\" Mnemonic** ‚≠ê:\n‚Ä¢ **Factor II** (Prothrombin) ‚≠ê\n‚Ä¢ **Factor VII** (Proconvertin) ‚≠ê\n‚Ä¢ **Factor IX** (Christmas factor) ‚≠ê\n‚Ä¢ **Factor X** (Stuart-Prower factor) ‚≠ê\n\n**+ Regulatory proteins:**\n‚Ä¢ **Protein C** ‚≠ê\n‚Ä¢ **Protein S** ‚≠ê\n\n**MECHANISM:**\n\n**Vitamin K cycle:**\n1. **Vitamin K (reduced form)** is cofactor for Œ≥-glutamyl carboxylase\n2. **Carboxylation** of glutamic acid residues on factors II, VII, IX, X\n3. **Œ≥-carboxyglutamic acid (Gla)** residues created\n4. **Gla residues bind Ca¬≤‚Å∫** ‚Üí Factors bind to **phospholipid membranes**\n5. **Essential** for clotting cascade activation\n\n**Without carboxylation:**\n‚Ä¢ **PIVKA** (Proteins Induced by Vitamin K Absence) ‚≠ê\n‚Ä¢ **Non-functional** clotting factors\n‚Ä¢ **Cannot bind Ca¬≤‚Å∫** or phospholipid surfaces\n\n**CLINICAL SIGNIFICANCE:**\n\n**Vitamin K deficiency:**\n‚Ä¢ **Hemorrhagic disease of newborn** ‚≠ê\n‚Ä¢ **Malabsorption** (biliary obstruction, celiac disease)\n‚Ä¢ **Prolonged PT/aPTT**\n‚Ä¢ **Treatment:** Vitamin K supplementation\n\n**Warfarin:**\n‚Ä¢ **Vitamin K antagonist** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Inhibits** vitamin K epoxide reductase (VKORC1)\n‚Ä¢ ‚Üí **Blocks vitamin K recycling**\n‚Ä¢ ‚Üí **Impaired carboxylation** of factors II, VII, IX, X\n‚Ä¢ ‚Üí **Anticoagulation**\n‚Ä¢ **Monitored by PT/INR**\n\n**Factor VII has shortest half-life** (6 hours):\n‚Ä¢ **PT** prolonged **first** with warfarin ‚≠ê\n‚Ä¢ **aPTT** prolonged later (factors II, IX, X)\n\n**COAGULATION PATHWAYS:**\n\n**Extrinsic pathway:**\n‚Ä¢ **Factor VII** ‚≠ê (Vitamin K-dependent)\n\n**Intrinsic pathway:**\n‚Ä¢ **Factor IX** ‚≠ê (Vitamin K-dependent)\n\n**Common pathway:**\n‚Ä¢ **Factor X** ‚≠ê (Vitamin K-dependent)\n‚Ä¢ **Factor II (Prothrombin)** ‚≠ê (Vitamin K-dependent)\n\n**WHY OTHER OPTIONS ARE WRONG:**\n\n**Factor VIII** ‚ùå:\n‚Ä¢ **NOT Vitamin K-dependent**\n‚Ä¢ Synthesized in **liver and endothelial cells**\n‚Ä¢ Deficiency ‚Üí **Hemophilia A**\n‚Ä¢ **NOT carboxylated** by Œ≥-glutamyl carboxylase\n\n**Factor XI** ‚ùå:\n‚Ä¢ **NOT Vitamin K-dependent**\n‚Ä¢ Deficiency ‚Üí **Hemophilia C**\n‚Ä¢ **NOT carboxylated**\n\n**SUMMARY TABLE:**\n\n| Factor | Vitamin K | Half-life | Pathway |\n|--------|-----------|-----------|----------|\n| **II** | ‚úÖ Yes | 60h | Common |\n| **VII** | ‚úÖ Yes | **6h** ‚≠ê | Extrinsic |\n| **VIII** | ‚ùå No | 12h | Intrinsic |\n| **IX** | ‚úÖ Yes | 24h | Intrinsic |\n| **X** | ‚úÖ Yes | 40h | Common |\n| **XI** | ‚ùå No | 52h | Intrinsic |\n\nüí° **KEY:** **Vitamin K-dependent = II, VII, IX, X (+ Protein C, S) - \"1972\"** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-21",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "d A patient presented with diarrhea, dermatitis, and dementia. Which of the following vitamin deficiencies would you suspect in this patient?",
    options: [
      "Vitamin B3 deficiency",
      "Vitamin B1 deficiency L",
      "Vitamin B6 deficiency p",
      "Vitamin B12 deficiency",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Vitamin B3 (Niacin) deficiency (Option A)**\n\nüî¨ **PELLAGRA (Niacin Deficiency):**\n\n**CLASSIC TRIAD - \"3 D's\"** ‚≠ê‚≠ê‚≠ê:\n1. **Diarrhea** ‚≠ê\n2. **Dermatitis** ‚≠ê\n3. **Dementia** ‚≠ê\n\n**(+ 4th D: Death if untreated)**\n\n**VITAMIN B3 (NIACIN):**\n‚Ä¢ **Nicotinic acid** + **Nicotinamide**\n‚Ä¢ **Precursor:** Tryptophan (60mg tryptophan ‚Üí 1mg niacin)\n‚Ä¢ **Function:** Component of **NAD/NADP** (energy metabolism)\n\n**CAUSES:**\n‚Ä¢ **Dietary deficiency** (corn-based diets) ‚≠ê\n  - Corn has niacin in bound form (unavailable)\n  - Low tryptophan content\n‚Ä¢ **Carcinoid syndrome** (tryptophan ‚Üí serotonin instead of niacin)\n‚Ä¢ **Hartnup disease** (tryptophan malabsorption)\n‚Ä¢ **Isoniazid therapy** (interferes with niacin synthesis)\n‚Ä¢ **Alcoholism**\n\n**CLINICAL MANIFESTATIONS:**\n\n**1. DERMATITIS** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **\"Casal's necklace\"** - hyperpigmented rash around neck ‚≠ê\n‚Ä¢ **Photosensitive** (sun-exposed areas)\n‚Ä¢ **Symmetric distribution**\n‚Ä¢ **Resembles sunburn** ‚Üí becomes rough, scaly\n‚Ä¢ **Glove-and-stocking** distribution on extremities\n\n**2. DIARRHEA:**\n‚Ä¢ **Watery, bloody**\n‚Ä¢ **Glossitis** (beefy red tongue) ‚≠ê\n‚Ä¢ **Cheilitis** (cracked lips)\n‚Ä¢ **GI mucosal atrophy**\n\n**3. DEMENTIA:**\n‚Ä¢ **Confusion, memory loss**\n‚Ä¢ **Depression, anxiety**\n‚Ä¢ **Psychosis** (severe cases)\n‚Ä¢ **Encephalopathy**\n\n**DIAGNOSIS:**\n‚Ä¢ **Low urinary N-methylnicotinamide**\n‚Ä¢ **Clinical diagnosis** (classic triad)\n\n**TREATMENT:**\n‚Ä¢ **Nicotinamide 100-500 mg/day** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Or **Nicotinic acid**\n‚Ä¢ **Response within days** (dermatitis improves first)\n\n**DIFFERENTIAL:**\n\n**Vitamin B1 (Thiamine) deficiency** ‚ùå:\n‚Ä¢ **Beriberi:** Heart failure (wet) or neuropathy (dry)\n‚Ä¢ **Wernicke-Korsakoff:** Confusion, ataxia, ophthalmoplegia\n‚Ä¢ **NO dermatitis**\n\n**Vitamin B6 (Pyridoxine) deficiency** ‚ùå:\n‚Ä¢ **Peripheral neuropathy**\n‚Ä¢ **Sideroblastic anemia**\n‚Ä¢ **Seizures** (infants)\n‚Ä¢ **NO dermatitis or diarrhea**\n\n**Vitamin B12 (Cobalamin) deficiency** ‚ùå:\n‚Ä¢ **Megaloblastic anemia**\n‚Ä¢ **Subacute combined degeneration** (spinal cord)\n‚Ä¢ **Glossitis**\n‚Ä¢ **NO photosensitive dermatitis**\n\nüí° **KEY:** **3 D's (Diarrhea + Dermatitis + Dementia) = Pellagra (Niacin/B3 deficiency)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page10_img6.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-22",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "A young boy presents to the OPD with hypoglycemia and muscle cramps, on exertion or while playing. Then he becomes normal after resting for a while. These episodes are recurrent after a period of activity. He has decreased serum lactate and glucose levels. Which of the following diseases is he most likely to be suffering from?",
    options: [
      "McArdle disease",
      "Hers disease",
      "Cori's disease",
      "Andersen disease",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **McArdle disease (Option A)**\n\nüî¨ **McARDLE DISEASE (Glycogen Storage Disease Type V):**\n\n**DEFICIENCY:** **Muscle phosphorylase** (myophosphorylase) ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL FEATURES (THIS CASE):**\n‚Ä¢ **Exercise-induced muscle cramps** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hypoglycemia** during exercise\n‚Ä¢ **\"Second wind\" phenomenon** ‚≠ê - symptoms improve after rest, then can continue exercising\n‚Ä¢ **Myoglobinuria** (dark urine after exercise)\n‚Ä¢ **NO hepatomegaly** (liver phosphorylase normal)\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Cannot break down muscle glycogen** ‚Üí No glucose for energy\n‚Ä¢ **Decreased lactate** during exercise ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC)**\n‚Ä¢ **Ischemic forearm test:** No rise in lactate after exercise\n\n**DIAGNOSIS:**\n‚Ä¢ **Decreased/absent serum lactate** during exercise ‚≠ê\n‚Ä¢ **Elevated CK** (muscle damage)\n‚Ä¢ **Muscle biopsy:** Glycogen accumulation, absent phosphorylase\n\n**TREATMENT:** Avoid strenuous exercise, oral glucose/fructose before activity\n\nüí° **KEY:** **Exercise cramps + Decreased lactate = McArdle disease** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-23",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "A family consumes only polished rice. Which of the following combinationsr of vitamin deficiency and enzymatic defect will be present in this family? e",
    options: [
      "Riboflavin-glutathione reductase",
      "Thiamine-transketolase",
      "Thiamine-transaminas d",
      "Riboflavin-transketolase",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Thiamine-transketolase (Option B)**\n\nüî¨ **THIAMINE DEFICIENCY (Beriberi):**\n\n**POLISHED RICE:** Removes **thiamine-rich bran** ‚Üí Deficiency ‚≠ê‚≠ê‚≠ê\n\n**VITAMIN:** **Thiamine (Vitamin B1)**\n\n**ENZYMATIC DEFECT:** **Transketolase** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Key enzyme in **pentose phosphate pathway**\n‚Ä¢ Requires **TPP** (thiamine pyrophosphate) as cofactor\n\n**CLINICAL:** **Beriberi** (wet/dry) or **Wernicke-Korsakoff**\n\nüí° **KEY:** **Polished rice ‚Üí Thiamine deficiency ‚Üí Transketolase dysfunction** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page11_img7.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-24",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "p A chronic alcoholic patient presented to the casualty with confusion, ataxia, and painful eye movements. What could be the vitamin deficiency seen in this patient? e",
    options: [
      "Vitamin B deficiency",
      "Vitamin A deficiency OP3: Vitamin D deficiency O 4: Vitamin C deficiency",
      "Option 3",
      "Option 4",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Vitamin B1 (Thiamine) deficiency (Option A)**\n\nüî¨ **WERNICKE'S ENCEPHALOPATHY:**\n\n**CLASSIC TRIAD** ‚≠ê‚≠ê‚≠ê:\n1. **Confusion** (encephalopathy)\n2. **Ataxia** (gait disturbance)\n3. **Ophthalmoplegia** (6th CN palsy - painful eye movements)\n\n**CAUSE:** **Thiamine (Vitamin B1) deficiency** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Common in **chronic alcoholics**\n\n**TREATMENT:** **IV Thiamine** (100mg) immediately ‚≠ê\n\nüí° **KEY:** **Alcoholic + Confusion + Ataxia + Eye movements = Wernicke's (Thiamine deficiency)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-25",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "A 4-year-old child presents with easy fatigability. The mother also complains that the child has increased hunger between meals, which is relieved after food. Liver examination revealed no glycogen. The enzyme most likely deficient is?",
    options: [
      "Glycogen phosphorylase",
      "Glycogen synthase",
      "Debranching enzyme",
      "Glucose 6 phosphatas r",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Glycogen synthase (Option B)**\n\nüî¨ **GSD TYPE 0 (Glycogen Synthase Deficiency):**\n\n**KEY FEATURE:** **NO glycogen in liver** ‚≠ê‚≠ê‚≠ê (cannot synthesize)\n\n**CLINICAL:**\n‚Ä¢ **Fasting hypoglycemia** ‚≠ê\n‚Ä¢ **Increased hunger between meals**\n‚Ä¢ **NO hepatomegaly** (no glycogen storage)\n\n**DEFICIENCY:** **Glycogen synthase** - cannot make glycogen ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **No hepatic glycogen + Fasting hypoglycemia = GSD Type 0 (Synthase deficiency)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-26",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "A child was bought with pedal edema and cheilosdis. Cardiomegaly was present. What is the vitamin deficiency associated with this clinical presentation?",
    options: [
      "Riboflavin a",
      "Thiamin L",
      "Pyridoxine",
      "Niacin",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Thiamine (Vitamin B1) (Option B)**\n\nüî¨ **WET BERIBERI:**\n\n**CLINICAL FEATURES (THIS CASE):**\n‚Ä¢ **Pedal edema** ‚≠ê (heart failure)\n‚Ä¢ **Cardiomegaly** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Cheilosis** (cracked lips)\n\n**WET BERIBERI:** **High-output cardiac failure** from thiamine deficiency ‚≠ê‚≠ê‚≠ê\n\n**TREATMENT:** **Thiamine replacement**\n\nüí° **KEY:** **Edema + Cardiomegaly = Wet Beriberi (Thiamine deficiency)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-27",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "P A chronic alcoholic patient is diagnosed with gouty arthritis. What biochemical changes will be s een in this patient?",
    options: [
      "Decreased NADH/NAD+ ratio",
      "Increased urea and urate levels",
      "Increased urate and lactate levels",
      "Increased level of alkaline phosphatase",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Increased urate and lactate levels (Option C)**\n\nüî¨ **ALCOHOL + GOUT:**\n\n**ALCOHOL METABOLISM:**\n‚Ä¢ **Ethanol ‚Üí Acetaldehyde** (via alcohol dehydrogenase)\n‚Ä¢ **Increases NADH/NAD+ ratio** ‚≠ê‚≠ê‚≠ê\n\n**BIOCHEMICAL EFFECTS:**\n\n**1. Increased lactate** ‚≠ê:\n‚Ä¢ **High NADH** ‚Üí Pyruvate ‚Üí **Lactate** (LDH)\n‚Ä¢ **Lactic acidosis**\n\n**2. Increased urate** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Lactate competes** with urate for renal excretion\n‚Ä¢ ‚Üí **Decreased urate excretion**\n‚Ä¢ **Purine metabolism ‚Üë** (ATP degradation)\n‚Ä¢ ‚Üí **Hyperuricemia** ‚Üí **Gout**\n\nüí° **KEY:** **Alcohol ‚Üí ‚Üë NADH ‚Üí ‚Üë Lactate + ‚Üë Urate ‚Üí Gout** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-28",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "A child presents with erythematous scaly patches in the perioral region, mucosal ulcers, and impaired epithelial wound healing. The most likely mineral deficiency associated with this condition is?",
    options: [
      "Iron deficiency",
      "Zinc deficiency",
      "Calcium deficiency",
      "Copper deficiency d",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Zinc deficiency (Option B)**\n\nüî¨ **ACRODERMATITIS ENTEROPATHICA (Zinc Deficiency):**\n\n**CLINICAL FEATURES (THIS CASE):**\n‚Ä¢ **Erythematous scaly patches** (perioral, periorificial) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Mucosal ulcers**\n‚Ä¢ **Impaired wound healing** ‚≠ê\n‚Ä¢ **Diarrhea**\n‚Ä¢ **Alopecia**\n\n**ZINC DEFICIENCY:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Essential for **wound healing**, **immunity**\n‚Ä¢ Cofactor for **>300 enzymes**\n\n**TREATMENT:** **Zinc supplementation**\n\nüí° **KEY:** **Perioral rash + Poor wound healing = Zinc deficiency** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-29",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "A patient presenting with bleeding gums and easy bruisability was diagnosed with scurvy. This is due to p",
    options: [
      "Low calcium e",
      "Defective collagen formation",
      "Inhibition of clotting factors OP4: Increased keratinization of epithelium A ns: 2",
      "Option 4",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Defective collagen formation (Option B)**\n\nüî¨ **SCURVY (Vitamin C Deficiency):**\n\n**VITAMIN C (Ascorbic Acid):**\n‚Ä¢ Cofactor for **prolyl and lysyl hydroxylases** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hydroxylation** of proline/lysine ‚Üí **Stable collagen**\n\n**WITHOUT VITAMIN C:**\n‚Ä¢ **Defective collagen** formation ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Weak blood vessels** ‚Üí Bleeding\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Bleeding gums** ‚≠ê\n‚Ä¢ **Easy bruising** (perifollicular hemorrhage)\n‚Ä¢ **Poor wound healing**\n‚Ä¢ **Bone pain** (subperiosteal hemorrhage)\n\n**TREATMENT:** **Vitamin C supplementation**\n\nüí° **KEY:** **Scurvy = Defective collagen ‚Üí Bleeding** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-30",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "Which of the following is seen in low insulin: glucagon ratio?",
    options: [
      "Activation of lipoprotein lipase",
      "Activation of glycogen synthase",
      "Activation of phosphofructokinase 1",
      "Activation of hormone-sensitive lipase",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Activation of hormone-sensitive lipase (Option D)**\n\nüî¨ **LOW INSULIN:GLUCAGON RATIO (Fasting State):**\n\n**GLUCAGON DOMINANT** ‚≠ê‚≠ê‚≠ê:\n\n**EFFECTS:**\n‚Ä¢ **Activates hormone-sensitive lipase** ‚≠ê‚≠ê‚≠ê ‚Üí **Lipolysis** (fat breakdown)\n‚Ä¢ **Activates** gluconeogenesis, glycogenolysis\n‚Ä¢ **Inhibits** glycogen synthase, lipogenesis\n\n**RESULT:** **Catabolic state** - breakdown of stores\n\nüí° **KEY:** **Low insulin:glucagon ‚Üí Glucagon dominant ‚Üí HSL activation ‚Üí Lipolysis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-31",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "e An infant is brought by his parents with complaints that his urine turns black on standing. Which of the following metabolic disorders is likely? d",
    options: [
      "Phenylketonuria",
      "Alkaptonuria",
      "Homocystinuria a",
      "Maple syrup urine diseas L",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Alkaptonuria (Option B)**\n\nüî¨ **ALKAPTONURIA:**\n\n**DEFICIENCY:** **Homogentisate oxidase** ‚≠ê‚≠ê‚≠ê\n\n**CLASSIC SIGN:** **Urine turns black on standing** ‚≠ê‚≠ê‚≠ê (homogentisic acid oxidation)\n\n**CLINICAL:**\n‚Ä¢ **Dark urine** (infant/child)\n‚Ä¢ **Ochronosis** (dark pigmentation - cartilage, sclera) - adult\n‚Ä¢ **Arthritis** (spine, large joints) - adult\n\n**INHERITANCE:** Autosomal recessive\n\nüí° **KEY:** **Black urine = Alkaptonuria** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-32",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "Question 32 - [Content needs manual review]",
    options: [
      "Option 1",
      "Option 2",
      "Biotin",
      "Thiamine",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Biotin**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-33",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "A child presents with mental retardation, bone pain, and inability to walk. On funduscopic examination, a cherry red spot is seen. There is no organomegaly. What is the most likely diagnosis?",
    options: [
      "Tay-Sachs disease",
      "Niemann-Pick disease r",
      "Hurler syndrome",
      "Gaucher diseas d",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Tay-Sachs disease (Option A)**\n\nüî¨ **TAY-SACHS DISEASE:**\n\n**DEFICIENCY:** **Hexosaminidase A** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **GM2 ganglioside accumulation**\n\n**KEY FEATURES (THIS CASE):**\n‚Ä¢ **Cherry-red spot** on macula ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **NO organomegaly** ‚≠ê (only CNS affected)\n‚Ä¢ **Mental retardation**\n‚Ä¢ **Hypotonia** ‚Üí **Spasticity**\n‚Ä¢ **Seizures**\n‚Ä¢ **Blindness**\n\n**VS OTHER LIPIDOSES:**\n‚Ä¢ **Niemann-Pick:** Cherry-red spot **+ hepatosplenomegaly**\n‚Ä¢ **Gaucher:** **Hepatosplenomegaly**, NO cherry-red spot\n\n**INHERITANCE:** Autosomal recessive (Ashkenazi Jews)\n\nüí° **KEY:** **Cherry-red spot + NO organomegaly = Tay-Sachs** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-34",
    subjectId: "ophthalmology",
    chapterId: "neet-pg-2023",
    question: "A female presents with loss of vision in the right halves of both eyes. Where is the lesion located in the optic pathway? L",
    options: [
      "Left optic tract p",
      "Optic radiation",
      "Optic chiasma",
      "Right optic tract r",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Left optic tract (Option A)**\n\nüî¨ **VISUAL FIELD DEFECTS:**\n\n**CLINICAL:** **Loss of right halves of both eyes** ‚≠ê\n= **Right homonymous hemianopia**\n\n**LESION:** **LEFT optic tract** ‚≠ê‚≠ê‚≠ê\n\n**OPTIC PATHWAY:**\n‚Ä¢ **Optic tract** carries **contralateral** visual field\n‚Ä¢ **Left optic tract** = **Right visual fields** from both eyes\n‚Ä¢ Lesion ‚Üí **Right homonymous hemianopia**\n\nüí° **KEY:** **Homonymous hemianopia = Contralateral optic tract lesion** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-35",
    subjectId: "ophthalmology",
    chapterId: "neet-pg-2023",
    question: "A 65-year-old diabetic woman presents with painless loss of vision. The ocular findings are shown in the image below. What is the likely diagnosis and management for this patient? r e d",
    options: [
      "Zonular cataract and lensectomy",
      "Rosette cataract and sugar control",
      "Sunflower cataract and lesion extraction a",
      "Immature senile cataract and phacoemulsification with IOL",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Immature senile cataract and phacoemulsification with IOL (Option D)**\n\nüî¨ **SENILE CATARACT:**\n\n**TYPE:** **Immature** (partial opacity, red reflex present) ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **Painless vision loss** ‚≠ê\n‚Ä¢ **Age >50 years**\n‚Ä¢ **Risk factor:** Diabetes ‚≠ê\n\n**TREATMENT:** **Phacoemulsification + IOL** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Gold standard** for cataract surgery\n‚Ä¢ **Small incision** (2.2-2.8mm)\n‚Ä¢ **Intraocular lens (IOL)** implantation\n\nüí° **KEY:** **Diabetic + Painless vision loss = Senile cataract ‚Üí Phacoemulsification** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-36",
    subjectId: "ophthalmology",
    chapterId: "neet-pg-2023",
    question: "e A 5-year-old boy presents with a small nodule on the sclera as shown in the image below. What is the likely diagnosis? r P",
    options: [
      "Pterygium",
      "Pinguecula",
      "Dermolipoma",
      "Dermoi r",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Dermoid cyst (Option D)**\n\nüî¨ **LIMBAL DERMOID:**\n\n**PRESENTATION:**\n‚Ä¢ **Congenital** lesion ‚≠ê\n‚Ä¢ **5-year-old child** (this case)\n‚Ä¢ **Yellowish-white nodule** on sclera/limbus\n‚Ä¢ **Hair** may be present\n\n**LOCATION:** **Inferotemporal limbus** (most common) ‚≠ê‚≠ê‚≠ê\n\n**TREATMENT:** **Surgical excision** if symptomatic\n\nüí° **KEY:** **Congenital scleral nodule in child = Limbal dermoid** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-37",
    subjectId: "ophthalmology",
    chapterId: "neet-pg-2023",
    question: "The eye examination of a 20-year-old male showsd a golden ring on the iris. What is the next investigation to diagnose the condition?",
    options: [
      "Alpha-1-antitrypsin a",
      "Alpha-fetoprotein L",
      "Serum iron",
      "Serum ceruloplasmin",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Serum ceruloplasmin (Option D)**\n\nüî¨ **KAYSER-FLEISCHER RING (Wilson's Disease):**\n\n**FINDING:** **Golden/brown ring on iris** ‚≠ê‚≠ê‚≠ê (copper deposition in Descemet's membrane)\n\n**DIAGNOSIS:** **Wilson's disease** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hepatolenticular degeneration**\n‚Ä¢ **Copper metabolism disorder**\n\n**INVESTIGATION:** **Serum ceruloplasmin** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Low** (<20 mg/dL)\n‚Ä¢ Also: **24-hour urinary copper** (high)\n\n**TREATMENT:** **D-Penicillamine** (copper chelation)\n\nüí° **KEY:** **Golden ring on iris = KF ring (Wilson's) ‚Üí Check ceruloplasmin** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page18_img8.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-38",
    subjectId: "ophthalmology",
    chapterId: "neet-pg-2023",
    question: "P What is the dye and filter used to diagnose corneal ulcers?",
    options: [
      "Lissamine dye green filter",
      "Lissamine dye cobalt blue filter",
      "Fluorescein dye - visualized under green filter",
      "Fluorescein dye - visualized under cobalt blue filter",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Fluorescein dye - visualized under cobalt blue filter (Option D)**\n\nüî¨ **CORNEAL ULCER DIAGNOSIS:**\n\n**DYE:** **Fluorescein** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Stains** epithelial defects (green)\n\n**FILTER:** **Cobalt blue** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Excites** fluorescein ‚Üí **Bright green fluorescence**\n\n**PRINCIPLE:** Fluorescein penetrates denuded areas ‚Üí Glows under blue light\n\nüí° **KEY:** **Corneal ulcer = Fluorescein + Cobalt blue filter** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page18_img9.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-39",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 55-year-old male presented with verrucous carcinoma around the glans of the penis. Examination reveals that the inguinal lymph nodes are not enlarged. What is the appropriate management for this patient?",
    options: [
      "Total penectomy",
      "CO2 laser excision",
      "Topical 5-fluorouracil",
      "Partial penectomy d",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Partial penectomy (Option D)**\n\nüî¨ **PENILE VERRUCOUS CARCINOMA:**\n\n**TYPE:** Low-grade **squamous cell carcinoma** variant ‚≠ê\n‚Ä¢ **Locally invasive**, rarely metastasizes\n\n**MANAGEMENT:**\n‚Ä¢ **Partial penectomy** ‚≠ê‚≠ê‚≠ê (with **2cm margin**)\n‚Ä¢ **Preserve** as much penis as possible\n‚Ä¢ **NO lymph node dissection** (if nodes not enlarged)\n\n**INDICATIONS FOR TOTAL:**\n‚Ä¢ Lesion involves >50% of shaft\n‚Ä¢ Invasion of corpora\n\nüí° **KEY:** **Localized penile cancer + No nodes = Partial penectomy** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-40",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "Identify the procedure being performed in the image given below. p e r P",
    options: [
      "Intraosseous cannula for pain relief",
      "Bone marrow aspiration",
      "Intraosseous route access for giving IV fluids",
      "Intraosseous abscess drainage",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Intraosseous route access for giving IV fluids (Option C)**\n\nüî¨ **INTRAOSSEOUS (IO) ACCESS:**\n\n**INDICATION:** **Emergency vascular access** when IV difficult ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Shock**, **cardiac arrest**\n‚Ä¢ **Failed IV attempts** (children)\n\n**SITE:**\n‚Ä¢ **Proximal tibia** (most common) ‚≠ê\n‚Ä¢ Distal femur, distal tibia\n\n**CAN GIVE:**\n‚Ä¢ **IV fluids** ‚≠ê\n‚Ä¢ **Medications** (same as IV)\n‚Ä¢ **Blood products**\n\n**ADVANTAGES:** Fast, reliable, works in shock\n\nüí° **KEY:** **IO access = Emergency IV route via bone marrow** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-41",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A diabetic patient presents with sudden-onset perineal pain. On examinatiorn, foul-smelling discharge, and necrotic tissue as seen in the image is noted. Which of the following is true about the given condition? e d d a L",
    options: [
      "Anti-gas gangrene serum indicated for all cases",
      "Urinary diversion is the next ste e",
      "Bilateral orchidectomy must be done",
      "Mixed aerobic and anaerobic infection P",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Mixed aerobic and anaerobic infection (Option D)**\n\nüî¨ **FOURNIER'S GANGRENE:**\n\n**DEFINITION:** **Necrotizing fasciitis** of **perineum/genitalia** ‚≠ê‚≠ê‚≠ê\n\n**MICROBIOLOGY:** **Polymicrobial** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Mixed aerobic + anaerobic** bacteria\n‚Ä¢ E. coli, Bacteroides, Streptococcus, Staphylococcus\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Diabetic** patient ‚≠ê (risk factor)\n‚Ä¢ **Sudden perineal pain** ‚≠ê\n‚Ä¢ **Foul-smelling discharge**\n‚Ä¢ **Necrotic tissue**\n‚Ä¢ **Crepitus** (gas)\n\n**MANAGEMENT:**\n‚Ä¢ **Emergency surgical debridement** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Broad-spectrum antibiotics** (aerobic + anaerobic coverage)\n‚Ä¢ **Supportive care** (fluids, glucose control)\n\n**NOT INDICATED:**\n‚Ä¢ Anti-gas gangrene serum (for Clostridium)\n‚Ä¢ Orchidectomy (preserve viable tissue)\n\nüí° **KEY:** **Fournier's = Mixed infection ‚Üí Emergency debridement** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-42",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "Which of the following is the most common complication following ligation of the first vessel during abdominoperineal resection for rectal carcinoma? (APR Abdominoperineal resection)",
    options: [
      "Parasympathetic-bladder dysfunction and retrograde ejaculation.",
      "Sympathetic - - bladder dysfunction and impotence.",
      "Sympathetic- retrograde ejaculation and bladder dysfunction.",
      "Sympathetic-Impotence and loss of cutaneous sensation in perineal region",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Sympathetic - retrograde ejaculation and bladder dysfunction (Option C)**\n\nüî¨ **APR COMPLICATIONS:**\n\n**FIRST VESSEL LIGATED:** **Inferior mesenteric artery (IMA)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Runs with **superior hypogastric plexus** (sympathetic)\n\n**INJURY TO SYMPATHETIC PLEXUS:**\n\n**1. Retrograde ejaculation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Loss of **bladder neck closure** during ejaculation\n‚Ä¢ Semen goes into bladder\n\n**2. Bladder dysfunction** ‚≠ê\n‚Ä¢ **Neurogenic bladder**\n‚Ä¢ Urinary retention\n\n**PARASYMPATHETIC INJURY:**\n‚Ä¢ **Impotence** (from pelvic plexus injury)\n\nüí° **KEY:** **APR ‚Üí Sympathetic injury ‚Üí Retrograde ejaculation + Bladder dysfunction** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page20_img10.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-43",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presents to the clinic with the lesion given in the image. He had a traumatic injury to d the chest one year ago. What is the most likely diagnosis? d a L p e",
    options: [
      "Hemangioma",
      "Hypertrophic sca P",
      "Keloid",
      "Neurofibroma",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Keloid (Option C)**\n\nüî¨ **KELOID vs HYPERTROPHIC SCAR:**\n\n**KELOID** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Extends beyond original wound** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Does NOT regress** over time\n‚Ä¢ **Chest** (common site) ‚≠ê\n‚Ä¢ **1 year post-trauma** (this case)\n‚Ä¢ More common in **dark skin**\n\n**HYPERTROPHIC SCAR:**\n‚Ä¢ **Within wound boundaries**\n‚Ä¢ **May regress** over 1-2 years\n\n**TREATMENT:**\n‚Ä¢ **Intralesional steroids** (triamcinolone)\n‚Ä¢ **Silicone gel sheets**\n‚Ä¢ **Pressure garments**\n\nüí° **KEY:** **Extends beyond wound + Chest = Keloid** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-44",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 45-year-old male underwent bilateral laparoscopic hernia repair for inguinal hernia. Postoperatively, he complained of pain in the right thigh. Which of the following nerve entrapment leads to this symptom?",
    options: [
      "Ilioinguinal nerve",
      "Iliohypogastric nerve",
      "Femoral nerv r",
      "Lateral cutaneous nerve of thigh e",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Lateral cutaneous nerve of thigh (Option D)**\n\nüî¨ **MERALGIA PARESTHETICA:**\n\n**NERVE:** **Lateral femoral cutaneous nerve** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Purely **sensory**\n‚Ä¢ Innervates **lateral thigh**\n\n**CAUSE (POST-HERNIA REPAIR):**\n‚Ä¢ **Entrapment** during mesh fixation ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Especially with **lateral placement** of tacks\n\n**CLINICAL:**\n‚Ä¢ **Pain**, **numbness**, **tingling** in **anterolateral thigh** ‚≠ê\n‚Ä¢ **NO motor deficit**\n\n**PREVENTION:** Avoid fixation **lateral to anterior superior iliac spine (ASIS)**\n\nüí° **KEY:** **Post-hernia repair + Thigh pain = Lateral cutaneous nerve entrapment** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page21_img11.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-45",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient was brought to the ER following a road traffic accident. On examination, the patient opens his eyes to a painful stimulus, speaaks inappropriately, and withdraws his limbs to a painful stimulus. What is his GCS score?",
    options: [
      "E2V2M3",
      "E3V3M3",
      "E2V3M4 e",
      "E3V2M2",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **E2V3M4 (Option C)**\n\nüî¨ **GLASGOW COMA SCALE (GCS):**\n\n**THIS PATIENT:**\n\n**Eye (E):**\n‚Ä¢ **Opens to pain** = **E2** ‚≠ê\n\n**Verbal (V):**\n‚Ä¢ **Inappropriate words** = **V3** ‚≠ê\n\n**Motor (M):**\n‚Ä¢ **Withdraws to pain** (flexion withdrawal) = **M4** ‚≠ê\n\n**TOTAL:** **E2 + V3 + M4 = 9/15**\n\n**GCS INTERPRETATION:**\n‚Ä¢ **13-15:** Mild TBI\n‚Ä¢ **9-12:** Moderate TBI ‚≠ê (this case)\n‚Ä¢ **‚â§8:** Severe TBI (intubate)\n\nüí° **KEY:** **E2V3M4 = GCS 9 (Moderate TBI)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-46",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presented with fever and abdominal pain with jaundice. Investigations showed the given findings. Which of the following statements is true regarding this condition?",
    options: [
      "Surgery is mandatory",
      "Fine-needle aspiration cytology is diagnostic",
      "Angioembolization is the treatment of choice",
      "Echinococcus species is involved in etiology d",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Echinococcus species is involved in etiology (Option D)**\n\nüî¨ **HYDATID CYST OF LIVER:**\n\n**ORGANISM:** **Echinococcus granulosus** ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **Fever**, **jaundice** (if ruptured/infected)\n‚Ä¢ **RUQ pain**\n‚Ä¢ **Hepatomegaly**\n\n**IMAGING:** **Cystic lesions** with **daughter cysts** ‚≠ê\n\n**KEY FACTS:**\n\n**FNAC CONTRAINDICATED** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ Risk of **anaphylaxis**\n‚Ä¢ Risk of **peritoneal dissemination**\n\n**DIAGNOSIS:**\n‚Ä¢ **Serology** (Echinococcus IgG)\n‚Ä¢ **Imaging** (USG/CT)\n\n**TREATMENT:**\n‚Ä¢ **Surgery** (pericystectomy/cystectomy) ‚≠ê\n‚Ä¢ **Albendazole** (pre/post-op)\n\nüí° **KEY:** **Hydatid cyst ‚Üí Echinococcus + NEVER do FNAC** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page22_img12.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-47",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient who is a known case of alcohol dependence syndrome presents with sudden and p unintentional weight loss. What is the most likely diagnosis? -ALP 240 IU/L -S. Direct bilirubin - 1 mg/dL e -AST/ALT -0.5 -Alpha fetoprotein- 600 ng/mL",
    options: [
      "Hepatic adenom OP2: Cholangiocarcinom O 3: Hepatocellular carcinom O4: Alcoholic hepatitis",
      "Option 2",
      "Option 3",
      "Alcoholic hepatitis",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Hepatocellular carcinoma (Option C)**\n\nüî¨ **HEPATOCELLULAR CARCINOMA (HCC):**\n\n**RISK FACTOR:** **Chronic alcohol** ‚≠ê (cirrhosis)\n\n**CLINICAL:**\n‚Ä¢ **Weight loss** ‚≠ê\n‚Ä¢ **RUQ pain**\n‚Ä¢ **Jaundice**\n\n**KEY LAB (THIS CASE):**\n‚Ä¢ **Alpha-fetoprotein (AFP) >400 ng/mL** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC)**\n  - Normal: <10 ng/mL\n  - >400 = **highly suggestive of HCC**\n‚Ä¢ **AST/ALT ratio <0.5** (unusual, but ALT may be very high)\n‚Ä¢ **ALP elevated** (cholestasis)\n\n**DIAGNOSIS:**\n‚Ä¢ **AFP + Imaging** (triphasic CT/MRI)\n‚Ä¢ **Biopsy** if uncertain\n\n**TREATMENT:**\n‚Ä¢ **Resection/transplant** (curative)\n‚Ä¢ **TACE, sorafenib** (palliative)\n\nüí° **KEY:** **Alcoholic + Weight loss + AFP >400 = HCC** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-48",
    subjectId: "dermatology",
    chapterId: "neet-pg-2023",
    question: "A lady developed a skin reaction, as shown in the image, after using a hair dye. Which of the following chemicals is responsible for this condition? r e d d a L p",
    options: [
      "Pollen e",
      "Chromates",
      "Balsam of Peru P",
      "p-Phenylenediamine",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **p-Phenylenediamine (PPD) (Option D)**\n\nüî¨ **ALLERGIC CONTACT DERMATITIS TO HAIR DYE:**\n\n**ALLERGEN:** **p-Phenylenediamine (PPD)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Most common** cause of hair dye allergy\n‚Ä¢ Found in **permanent and semi-permanent** dyes\n\n**CLINICAL:**\n‚Ä¢ **Eczematous dermatitis** ‚≠ê\n‚Ä¢ **Scalp, face, neck** involvement\n‚Ä¢ **Itching, erythema, vesicles**\n\n**DIAGNOSIS:** **Patch test** (confirms PPD allergy)\n\n**MANAGEMENT:**\n‚Ä¢ **Avoid PPD-containing products** ‚≠ê\n‚Ä¢ **Topical steroids**\n‚Ä¢ Alternative: **Henna** (pure, no PPD)\n\nüí° **KEY:** **Hair dye allergy = p-Phenylenediamine (PPD)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-49",
    subjectId: "dermatology",
    chapterId: "neet-pg-2023",
    question: "A female patient presented with acne that is not resolving on oral isotretinoin and antibiotics therapy. Which of the following is the next best investigation?",
    options: [
      "Look for dietary triggers.",
      "Evaluate for hyperandrogenism",
      "Check for antibiotic resistance",
      "Look for drug triggers",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Evaluate for hyperandrogenism (Option B)**\n\nüî¨ **TREATMENT-RESISTANT ACNE:**\n\n**IF ACNE NOT RESPONDING** to **isotretinoin + antibiotics** ‚≠ê‚≠ê‚≠ê:\n\n**CONSIDER:** **Hyperandrogenism** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **PCOS** (most common)\n‚Ä¢ **CAH** (congenital adrenal hyperplasia)\n‚Ä¢ **Ovarian/adrenal tumors**\n\n**INVESTIGATIONS:**\n‚Ä¢ **Testosterone** (total, free)\n‚Ä¢ **DHEAS**\n‚Ä¢ **17-OH progesterone**\n‚Ä¢ **LH:FSH ratio**\n‚Ä¢ **Pelvic USG** (PCOS)\n\n**TREATMENT:** **Anti-androgens** (spironolactone, COCPs)\n\nüí° **KEY:** **Resistant acne in females ‚Üí Check for hyperandrogenism** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-50",
    subjectId: "anesthesiology",
    chapterId: "neet-pg-2023",
    question: "Question 50 - [Content needs manual review]",
    options: [
      "Option 1",
      "Jaw thrust",
      "Head extension",
      "d. In-line manual stabilization",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Option 1**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page24_img13.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-51",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presented with features of chronic pancreatitis with recurrent attacks and has a 10 mm dilatation of the pancreatic duct with intraductal calculi present. Which of the following is the surgery of choice?",
    options: [
      "Pancreaticoduodenectomy",
      "Longitudinal pancreaticojejunostomy",
      "ERCP and sphincterotomy",
      "Coring of pancreas hea d",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Longitudinal pancreaticojejunostomy (Puestow procedure) (Option B)**\n\nüî¨ **CHRONIC PANCREATITIS - SURGICAL MANAGEMENT:**\n\n**INDICATION FOR SURGERY:**\n‚Ä¢ **Intractable pain** ‚≠ê\n‚Ä¢ **Recurrent attacks**\n\n**THIS CASE:**\n‚Ä¢ **Dilated duct (>10mm)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Intraductal calculi** ‚≠ê\n\n**SURGERY OF CHOICE:** **Lateral pancreaticojejunostomy (Puestow procedure)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Split duct longitudinally**\n‚Ä¢ **Anastomose** to jejunum (Roux-en-Y)\n‚Ä¢ **Best pain relief** for dilated duct\n\n**OTHER PROCEDURES:**\n‚Ä¢ **Whipple** (mass in head)\n‚Ä¢ **Frey** (duct dilation + head mass)\n\nüí° **KEY:** **Dilated duct (>7mm) + Calculi = Lateral pancreaticojejunostomy (Puestow)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-52",
    subjectId: "dermatology",
    chapterId: "neet-pg-2023",
    question: "A young woman complains of a painless ulcer in the genital area. It is associated with non-tender inguinal lympphadenopathy. What is the most likely diagnosis?",
    options: [
      "Chancroi e",
      "Syphilis",
      "Herpes genitalis OP4: Granuloma inguinal A ns: 2",
      "Option 4",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Syphilis (Primary Syphilis) (Option B)**\n\nüî¨ **PRIMARY SYPHILIS:**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Painless ulcer (chancre)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Single**, **indurated** (hard base)\n‚Ä¢ **Non-tender lymphadenopathy** ‚≠ê\n‚Ä¢ **Heals spontaneously** in 3-6 weeks\n\n**ORGANISM:** **Treponema pallidum**\n\n**DIAGNOSIS:**\n‚Ä¢ **Dark-field microscopy** (spirochetes)\n‚Ä¢ **VDRL/RPR** (may be negative early)\n‚Ä¢ **Specific:** TPHA, FTA-ABS\n\n**TREATMENT:** **Benzathine penicillin G** (single IM dose) ‚≠ê‚≠ê‚≠ê\n\n**VS CHANCROID:**\n‚Ä¢ **Painful** ulcer ‚≠ê\n‚Ä¢ **Tender** lymph nodes (buboes)\n‚Ä¢ Organism: *Haemophilus ducreyi*\n\nüí° **KEY:** **Painless ulcer + Non-tender nodes = Syphilis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page25_img14.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-53",
    subjectId: "dermatology",
    chapterId: "neet-pg-2023",
    question: "Which of the following is associated with the clinical condition shown in the image?",
    options: [
      "Cataract",
      "Glaucoma d",
      "Malignant melanom d",
      "Basal cell carcinoma",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Malignant melanoma (Option C)**\n\nüî¨ **GIANT CONGENITAL MELANOCYTIC NEVUS:**\n\n**IMAGE:** Likely shows a **large pigmented lesion** (>20 cm)\n\n**RISK:** **Malignant melanoma** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Lifetime risk: 5-10%**\n‚Ä¢ **Highest risk** in first 5-10 years of life\n\n**MANAGEMENT:**\n‚Ä¢ **Close observation** ‚≠ê\n‚Ä¢ **Excision** if feasible (reduce risk)\n‚Ä¢ **Educate** about melanoma signs (ABCDE)\n\n**MELANOMA FEATURES (ABCDE):**\n‚Ä¢ **A**symmetry\n‚Ä¢ **B**order irregularity\n‚Ä¢ **C**olor variation\n‚Ä¢ **D**iameter >6mm\n‚Ä¢ **E**volving/changing\n\nüí° **KEY:** **Giant congenital nevus ‚Üí Risk of melanoma** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-54",
    subjectId: "anesthesiology",
    chapterId: "neet-pg-2023",
    question: "p Which of the following is the drug of choice for preoperative antibiotic prophylaxis in a patient undergoing cardiac surgery?",
    options: [
      "Penicillin G",
      "Erythromycin",
      "P Azithromycin",
      "Cefazolin",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Cefazolin (Option D)**\n\nüî¨ **CARDIAC SURGERY ANTIBIOTIC PROPHYLAXIS:**\n\n**DRUG OF CHOICE:** **Cefazolin** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **1st generation cephalosporin**\n‚Ä¢ **Covers** Staph aureus, Staph epidermidis (most common pathogens)\n\n**DOSING:**\n‚Ä¢ **1-2g IV** within **60 minutes** before incision ‚≠ê\n‚Ä¢ **Repeat** q4-8h intraoperatively\n‚Ä¢ **Discontinue** within **48 hours** post-op ‚≠ê\n\n**ALTERNATIVE (if penicillin allergy):**\n‚Ä¢ **Vancomycin**\n\nüí° **KEY:** **Cardiac surgery prophylaxis = Cefazolin** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page26_img15.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-55",
    subjectId: "ent",
    chapterId: "neet-pg-2023",
    question: "A 30-year-old male presents with nonaxial proptosis of the left eye. The patient gives a history of a road traffic accident 15 years back. The CT image is given below. What is th e most likely diagnosis? r e d d a L p e r P",
    options: [
      "Frontal mucocele",
      "Frontal meningioma",
      "Juvenile nasopharyngeal angiofibroma",
      "Pseudotumor of orbit r",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Frontal mucocele (Option A)**\n\nüî¨ **FRONTAL MUCOCELE:**\n\n**DEFINITION:** **Mucus-filled cystic expansion** of frontal sinus ‚≠ê‚≠ê‚≠ê\n\n**CAUSE:**\n‚Ä¢ **Sinus ostium blockage** ‚≠ê\n‚Ä¢ **Post-trauma** ‚≠ê (RTA 15 years ago - this case)\n‚Ä¢ **Chronic sinusitis**\n\n**CLINICAL:**\n‚Ä¢ **Slow-growing** (years)\n‚Ä¢ **Nonaxial proptosis** ‚≠ê‚≠ê‚≠ê (downward and outward)\n‚Ä¢ **Painless mass** (forehead/medial upper lid)\n\n**CT FINDINGS:**\n‚Ä¢ **Expansile cystic lesion** of frontal sinus ‚≠ê\n‚Ä¢ **Smooth bony remodeling**\n‚Ä¢ **Homogeneous** (mucus-filled)\n\n**TREATMENT:** **Surgical drainage** ‚≠ê (endoscopic/external)\n\nüí° **KEY:** **Post-trauma + Nonaxial proptosis = Frontal mucocele** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-56",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "d A woman presented with a BIRADS-5 breast lesion. Which of the following is a good prognostic factor for this lesion? a",
    options: [
      "BRCA-1 positive",
      "p53 positive",
      "ER positive",
      "High Ki-67 e",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **ER positive (Option C)**\n\nüî¨ **BREAST CANCER PROGNOSTIC FACTORS:**\n\n**BIRADS-5:** **Highly suspicious for malignancy** (>95% cancer)\n\n**GOOD PROGNOSTIC FACTORS:**\n‚Ä¢ **ER/PR positive** ‚≠ê‚≠ê‚≠ê (hormone receptor positive)\n‚Ä¢ **HER2 negative**\n‚Ä¢ **Low grade**\n‚Ä¢ **Low Ki-67** (<14%)\n‚Ä¢ **Small tumor** (<2cm)\n‚Ä¢ **Node negative**\n\n**POOR PROGNOSTIC FACTORS:**\n‚Ä¢ **BRCA-1 positive** ‚≠ê (triple negative, aggressive)\n‚Ä¢ **p53 mutation** ‚≠ê (aggressive)\n‚Ä¢ **High Ki-67** ‚≠ê (high proliferation)\n‚Ä¢ **HER2 positive**\n\n**ER POSITIVE:**\n‚Ä¢ **Better prognosis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Responds to hormonal therapy** (tamoxifen, aromatase inhibitors)\n\nüí° **KEY:** **ER positive = Good prognosis in breast cancer** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-57",
    subjectId: "ent",
    chapterId: "neet-pg-2023",
    question: "A 55-year-old patient comes with hoarseness of voice and difficulty swallowing. The patient was diagnosed with laryngeal carcinoma, and surgical management was done. The post-operative image of the patient is given below. Which of the following surgery was done on this patient? r e d d a",
    options: [
      "Partial laryngectomy",
      "Percutaneous tracheostomy",
      "Standard tracheostomy p",
      "Total laryngectomy",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Total laryngectomy (Option D)**\n\nüî¨ **TOTAL LARYNGECTOMY:**\n\n**INDICATION:**\n‚Ä¢ **Advanced laryngeal cancer** ‚≠ê‚≠ê‚≠ê (T3/T4)\n‚Ä¢ Failed radiation\n\n**POST-OP IMAGE:** Shows **permanent tracheostomy** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Trachea brought to skin** (stoma)\n‚Ä¢ **Larynx completely removed**\n‚Ä¢ **No connection** between airway and esophagus\n\n**KEY FEATURES:**\n‚Ä¢ **Cannot speak** (voice box removed)\n‚Ä¢ **Breathes through stoma** ‚≠ê\n‚Ä¢ **No aspiration risk** (separated passages)\n‚Ä¢ **Voice rehabilitation:** Esophageal speech, TEP (tracheoesophageal puncture)\n\n**VS TRACHEOSTOMY:**\n‚Ä¢ **Tracheostomy:** Larynx intact, temporary/permanent\n‚Ä¢ **Total laryngectomy:** Larynx removed, permanent stoma\n\nüí° **KEY:** **Permanent stoma + No larynx = Total laryngectomy** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-58",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presents with sudden onset of chest pain shooting to the neck and interscapular region. X-ray shows widened mediastinum. BP is 110/90 mmHg in the right upper limb and 160/100 mmHg in the left upper limb. What is the most likely diagnosis?",
    options: [
      "Acute coronary syndrome",
      "Acute pulmonary embolism",
      "Acute aortic dissection",
      "Esophageal rupture",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Acute aortic dissection (Option C)**\n\nüî¨ **AORTIC DISSECTION:**\n\n**CLASSIC TRIAD** ‚≠ê‚≠ê‚≠ê:\n1. **Tearing chest pain** ‚Üí **Back/interscapular** ‚≠ê‚≠ê‚≠ê\n2. **Widened mediastinum** on CXR ‚≠ê\n3. **Pulse/BP differential** between limbs ‚≠ê‚≠ê‚≠ê (>20 mmHg)\n\n**THIS CASE:**\n‚Ä¢ **Right arm:** 110/90 mmHg\n‚Ä¢ **Left arm:** 160/100 mmHg\n‚Ä¢ **Difference:** 50 mmHg (dissection involving left subclavian)\n\n**CLASSIFICATION:**\n‚Ä¢ **Stanford A:** Ascending aorta ‚≠ê (surgical emergency)\n‚Ä¢ **Stanford B:** Descending aorta (medical management)\n\n**DIAGNOSIS:** **CT angiography** ‚≠ê‚≠ê‚≠ê (gold standard)\n\n**TREATMENT:**\n‚Ä¢ **Type A:** **Emergency surgery** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Type B:** **Medical** (Œ≤-blockers, control BP)\n\nüí° **KEY:** **Tearing pain + Widened mediastinum + BP differential = Aortic dissection** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page28_img16.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-59",
    subjectId: "ent",
    chapterId: "neet-pg-2023",
    question: "A female patient with hearing loss is examined and is found to be Rinne nergative at 256 Hz and 512 Hz, while Rinne positive at 1024 Hz. What is the expected air conduction and bone conduction gap? e",
    options: [
      "30-45 dB d",
      "15-30 dB",
      "45-60 dB",
      ">60 dB a",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **30-45 dB (Option A)**\n\nüî¨ **RINNE TEST INTERPRETATION:**\n\n**RINNE NEGATIVE:** **BC > AC** (bone conduction better) = **Conductive hearing loss** ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE:**\n‚Ä¢ **Rinne negative** at **256 Hz & 512 Hz** (low frequencies)\n‚Ä¢ **Rinne positive** at **1024 Hz** (high frequency)\n\n**INTERPRETATION:** **Moderate conductive hearing loss** ‚≠ê\n\n**AB GAP (Air-Bone Gap):**\n‚Ä¢ **<15 dB:** Normal or minimal\n‚Ä¢ **15-30 dB:** Mild CHL\n‚Ä¢ **30-45 dB:** **Moderate CHL** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **45-60 dB:** Severe CHL\n‚Ä¢ **>60 dB:** Maximum CHL (ossicular discontinuity)\n\n**RINNE BECOMES POSITIVE** when **AB gap <15 dB** at that frequency\n\nüí° **KEY:** **Rinne negative (low freq) + Rinne positive (high freq) = Moderate CHL (30-45 dB)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-60",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presented with right hypochondriac pain. He had an episode of diarrhea 1 week e prior. CT scan of the abdomen reveals a liver abscess of around 25 ccs. What is the next step in management? r",
    options: [
      "PAIR P",
      "S urgery",
      "Medical therapy",
      "Percutaneous drainage",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Medical therapy (Option C)**\n\nüî¨ **AMOEBIC LIVER ABSCESS MANAGEMENT:**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **RUQ pain**\n‚Ä¢ **History of diarrhea** ‚≠ê (amoebiasis)\n‚Ä¢ **Abscess <5 cm** (25 cc ‚âà 3 cm) ‚≠ê‚≠ê‚≠ê\n\n**SIZE-BASED MANAGEMENT:**\n\n**<5 cm:** **Medical therapy alone** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Metronidazole** 750 mg TID √ó 7-10 days\n‚Ä¢ **Followed by paromomycin** (luminal agent)\n\n**5-10 cm:**\n‚Ä¢ **Medical + Aspiration** (if no response in 3-5 days)\n\n**>10 cm or complicated:**\n‚Ä¢ **Percutaneous drainage**\n‚Ä¢ Left lobe, impending rupture\n\n**SURGERY:** Rarely needed (rupture, failed drainage)\n\nüí° **KEY:** **Small amoebic abscess (<5 cm) = Medical therapy (Metronidazole)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page29_img17.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-61",
    subjectId: "orthopedics",
    chapterId: "neet-pg-2023",
    question: "A child was brought with bony deformities, as shown in the radiograph below. It could be due to the deficiency of which of the following? r e d d a L p e r",
    options: [
      "Vitamin A P",
      "V itamin D",
      "Vitamin K",
      "Vitamin C",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Vitamin D (Option B)**\n\nüî¨ **RICKETS (Vitamin D Deficiency):**\n\n**X-RAY FINDINGS:**\n‚Ä¢ **Bowing of legs** (genu varum) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Metaphyseal widening, cupping, fraying**\n‚Ä¢ **Delayed ossification**\n‚Ä¢ **Osteopenia**\n\n**CLINICAL:**\n‚Ä¢ **Bony deformities** ‚≠ê (bow legs, knock knees)\n‚Ä¢ **Rachitic rosary** (costochondral swelling)\n‚Ä¢ **Delayed milestones**\n‚Ä¢ **Hypotonia**\n‚Ä¢ **Frontal bossing**\n\n**LAB:**\n‚Ä¢ **Low 25-OH Vitamin D** (<20 ng/mL) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Low calcium, phosphate**\n‚Ä¢ **Elevated ALP**\n\n**TREATMENT:**\n‚Ä¢ **Vitamin D supplementation** ‚≠ê\n‚Ä¢ **Calcium**\n‚Ä¢ **Sunlight exposure**\n\nüí° **KEY:** **Bowing deformities in child = Rickets (Vitamin D deficiency)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-62",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 50-year-old patient with a history of trauma one week back presents with confusion and ataxia. He is on treatment for alcohol dependence and his last intake was 2 weeks back. CT scan reveals the following finding. What is the diagnosis? r e d d a L p",
    options: [
      "Extradural hemorrhag e",
      "Subdural hemorrhage",
      "Intra-parenchymal hemorrhag P",
      "Subarachnoid hemorrhage",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Subdural hemorrhage (SDH) (Option B)**\n\nüî¨ **CHRONIC SUBDURAL HEMATOMA:**\n\n**RISK FACTORS (THIS CASE):**\n‚Ä¢ **Chronic alcoholism** ‚≠ê‚≠ê‚≠ê (brain atrophy)\n‚Ä¢ **Trauma 1 week ago** ‚≠ê\n‚Ä¢ **Elderly**\n\n**CLINICAL:**\n‚Ä¢ **Confusion**, **ataxia** ‚≠ê\n‚Ä¢ **Delayed presentation** (days-weeks post-trauma)\n‚Ä¢ Fluctuating symptoms\n\n**CT FINDINGS:**\n‚Ä¢ **Crescentic** (follows brain contour) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hypodense** (chronic) or mixed density\n‚Ä¢ **Crosses suture lines**, does NOT cross midline\n‚Ä¢ **Mass effect** (midline shift)\n\n**VS EDH:**\n‚Ä¢ **Lens-shaped** (biconvex)\n‚Ä¢ **Does NOT cross sutures**\n‚Ä¢ **Acute presentation**\n\n**TREATMENT:** **Burr hole drainage** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **Alcoholic + Delayed trauma + Crescentic lesion = Chronic SDH** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-63",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "Which of the following is false about the given condition?",
    options: [
      "Repeated radical surgery every 24 hours may be required to adequately manage this condition a",
      "This is a case of Meleney's gangrene",
      "The condition is caused by Œ≤ hemolytic streptococcus and may sometimes be polymicrobial",
      "Hyperbaric oxygen has npo role in the treatment of this condition",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Hyperbaric oxygen has NO role - FALSE (Option D)**\n\nüî¨ **NECROTIZING FASCIITIS (Meleney's Gangrene):**\n\n**THIS IS FALSE:** Hyperbaric oxygen **DOES have a role** ‚≠ê‚≠ê‚≠ê (as adjunct therapy)\n\n**TRUE STATEMENTS:**\n\n**A. Repeated debridement** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Every 24-48 hours** until clean\n‚Ä¢ **Aggressive surgical debridement** is mainstay\n\n**B. Meleney's gangrene:**\n‚Ä¢ Type of **synergistic gangrene**\n‚Ä¢ **Necrotizing soft tissue infection**\n\n**C. Organisms:**\n‚Ä¢ **Œ≤-hemolytic Streptococcus** (Group A) ‚≠ê\n‚Ä¢ Often **polymicrobial** ‚≠ê (with anaerobes)\n\n**TREATMENT:**\n‚Ä¢ **Surgical debridement** ‚≠ê‚≠ê‚≠ê (primary)\n‚Ä¢ **Broad-spectrum antibiotics**\n‚Ä¢ **Hyperbaric oxygen** ‚≠ê (adjunct - improves oxygen delivery, bactericidal)\n\nüí° **KEY:** **HBO IS used in necrotizing fasciitis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-64",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "P A bronchial asthma patient on inhalational steroids presented with white patchy lesions on the tongue and buccal mucosa. What is the drug that can be used to treat this condition?",
    options: [
      "Clotrimazole",
      "Griseofulvin",
      "Terbinafine",
      "Flucytosine",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Clotrimazole (Option A)**\n\nüî¨ **ORAL CANDIDIASIS (Thrush):**\n\n**CAUSE (THIS CASE):**\n‚Ä¢ **Inhalational steroids** ‚≠ê‚≠ê‚≠ê (local immunosuppression)\n\n**CLINICAL:**\n‚Ä¢ **White patches** (tongue, buccal mucosa) ‚≠ê\n‚Ä¢ **Can be scraped off** (pseudomembranous)\n‚Ä¢ **Painless** or sore\n\n**TREATMENT:**\n\n**1. Clotrimazole** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Topical** (lozenges, oral paint)\n‚Ä¢ **First-line** for oral candidiasis\n\n**2. Nystatin** (oral suspension)\n\n**3. Fluconazole** (systemic, if severe)\n\n**PREVENTION:**\n‚Ä¢ **Rinse mouth** after inhaler use ‚≠ê\n‚Ä¢ **Use spacer**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Griseofulvin:** Dermatophytes only\n‚Ä¢ **Terbinafine:** Dermatophytes\n‚Ä¢ **Flucytosine:** Systemic, rarely used\n\nüí° **KEY:** **Inhaled steroids + White patches = Oral candidiasis ‚Üí Clotrimazole** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page31_img18.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-65",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presents with a swelling in the groin region and it is diagnosed as a direct inguinal hernia. Weakness in which of the following structures is most likely to cause this condition?",
    options: [
      "Pectineal ligament r",
      "Conjoint tendon e",
      "Reflected part of inguinal ligament d",
      "Lacunar ligament",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Conjoint tendon (Option B)**\n\nüî¨ **DIRECT INGUINAL HERNIA:**\n\n**ANATOMY:**\n‚Ä¢ **Hernia sac protrudes** through **Hesselbach's triangle** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **MEDIAL** to inferior epigastric vessels\n\n**WEAKNESS IN:** **Transversalis fascia + Conjoint tendon** ‚≠ê‚≠ê‚≠ê\n\n**CONJOINT TENDON:**\n‚Ä¢ Formed by **internal oblique + transversus abdominis** aponeuroses\n‚Ä¢ Forms **MEDIAL wall** of inguinal canal\n‚Ä¢ **Weakness** ‚Üí **Direct hernia**\n\n**HESSELBACH'S TRIANGLE:**\n‚Ä¢ **Medial:** Rectus abdominis (lateral edge)\n‚Ä¢ **Lateral:** Inferior epigastric vessels ‚≠ê\n‚Ä¢ **Inferior:** Inguinal ligament\n\n**VS INDIRECT:**\n‚Ä¢ **Indirect:** Through **deep ring**, lateral to epigastric vessels\n‚Ä¢ **Direct:** Through **Hesselbach's**, medial to epigastric vessels\n\nüí° **KEY:** **Direct hernia = Weakness of conjoint tendon** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-66",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "L A pregnant woman with a history of bronchial asthma is in the third stage of labor. Which drugs should be avoided in managing postpartum hemorrhage in this mother?",
    options: [
      "Carboprost",
      "Oxytocin",
      "Dinoproston r",
      "MPethyl ergometrine",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Carboprost (Option A)**\n\nüî¨ **PPH MANAGEMENT IN ASTHMATIC PATIENT:**\n\n**AVOID:** **Carboprost (PGF2Œ±)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Contraindicated in asthma** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Causes bronchospasm** (prostaglandin effect)\n\n**SAFE OPTIONS:**\n\n**1. Oxytocin** ‚≠ê (first-line, safe)\n‚Ä¢ **IV infusion** 20-40 units in 1L NS\n\n**2. Misoprostol** (PGE1)\n‚Ä¢ **Safe in asthma**\n\n**3. Methylergometrine** (with caution)\n‚Ä¢ **Safe in asthma**\n‚Ä¢ **Avoid in hypertension**\n\n**WHY CARBOPROST AVOIDED:**\n‚Ä¢ **PGF2Œ±** ‚Üí **Smooth muscle contraction** ‚Üí **Bronchospasm** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Can cause **severe asthma exacerbation**\n\nüí° **KEY:** **PPH in asthmatic = AVOID Carboprost** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-67",
    subjectId: "orthopedics",
    chapterId: "neet-pg-2023",
    question: "In which of the following nerve injuries is the instrument shown below used? r e d d a L p",
    options: [
      "Radial nerve",
      "Median nerve",
      "Ulnar nerv r",
      "VPolkmann's ischemic contracture",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Radial nerve (Option A)**\n\nüî¨ **WRIST EXTENSION SPLINT:**\n\n**IMAGE:** Shows **wrist drop splint** (cock-up splint) ‚≠ê‚≠ê‚≠ê\n\n**INDICATION:** **Radial nerve injury** ‚≠ê‚≠ê‚≠ê\n\n**RADIAL NERVE INJURY:**\n‚Ä¢ **Wrist drop** ‚≠ê‚≠ê‚≠ê (cannot extend wrist)\n‚Ä¢ **Finger drop** (cannot extend fingers at MCP)\n‚Ä¢ **Loss of thumb extension**\n‚Ä¢ **Loss of sensation** (first web space)\n\n**SPLINT PURPOSE:**\n‚Ä¢ **Maintains wrist in extension** ‚≠ê\n‚Ä¢ **Prevents contractures**\n‚Ä¢ **Allows finger function**\n\n**COMMON CAUSES:**\n‚Ä¢ **Humeral shaft fracture** (mid-shaft)\n‚Ä¢ **Saturday night palsy** (axilla compression)\n‚Ä¢ **Monteggia fracture**\n\nüí° **KEY:** **Wrist drop splint = Radial nerve injury** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-68",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "Name the drug that acts on both the marked areas. r e d d a",
    options: [
      "Sacubitril",
      "Omapatrilat p",
      "Losartan e",
      "Nesiritide",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Omapatrilat (Option B)**\n\nüî¨ **DUAL ACTION DRUGS:**\n\n**OMAPATRILAT:** **Dual inhibitor** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **ACE inhibitor** ‚≠ê\n‚Ä¢ **NEP (neutral endopeptidase) inhibitor** ‚≠ê\n\n**IMAGE (LIKELY):** Shows **ACE** and **NEP** sites\n\n**MECHANISM:**\n‚Ä¢ **Blocks ACE** ‚Üí ‚Üì Angiotensin II, ‚Üì BP\n‚Ä¢ **Blocks NEP** ‚Üí ‚Üë Natriuretic peptides (ANP/BNP), ‚Üì BP\n\n**ISSUE:** **Withdrawn** due to **angioedema** risk ‚≠ê\n\n**MODERN ALTERNATIVE:**\n‚Ä¢ **Sacubitril/Valsartan (Entresto)** ‚≠ê\n  - **NEP inhibitor** (sacubitril) + **ARB** (valsartan)\n  - Used in **heart failure**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Sacubitril:** NEP only\n‚Ä¢ **Losartan:** ARB only\n‚Ä¢ **Nesiritide:** BNP analog\n\nüí° **KEY:** **Omapatrilat = ACE + NEP inhibitor** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page33_img19.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-69",
    subjectId: "orthopedics",
    chapterId: "neet-pg-2023",
    question: "A patient presented with chronic knee pain but has no history of trauma. Identify the condition shown in the radiograph below and the appropriate management. r e",
    options: [
      "Patellar avulsion fracture, TBW",
      "Bipartite fracture patella, X-ray of other knees d",
      "Fracture of the upper pole of the patella, Cylindrical cast a",
      "Avulsion fracture, interfragmentary screw fixation",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Bipartite patella, X-ray of other knee (Option B)**\n\nüî¨ **BIPARTITE PATELLA:**\n\n**DEFINITION:** **Congenital variant** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Patella** develops from **2 ossification centers** that fail to fuse\n‚Ä¢ **NOT a fracture** ‚≠ê\n\n**KEY FEATURES (THIS CASE):**\n‚Ä¢ **NO history of trauma** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Chronic pain** (or incidental finding)\n‚Ä¢ **Superolateral location** (most common) ‚≠ê\n\n**X-RAY:**\n‚Ä¢ **Well-corticated edges** ‚≠ê\n‚Ä¢ **Smooth margins**\n‚Ä¢ **Bilateral in 50%** ‚≠ê\n\n**MANAGEMENT:**\n‚Ä¢ **X-ray of other knee** ‚≠ê‚≠ê‚≠ê (confirm bilateral = congenital)\n‚Ä¢ **Conservative** (NSAIDs, physiotherapy)\n‚Ä¢ **Surgery** if symptomatic (excision/fixation)\n\n**VS FRACTURE:**\n‚Ä¢ **Fracture:** Trauma, irregular edges, acute pain\n\nüí° **KEY:** **No trauma + Well-corticated = Bipartite patella (congenital)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-70",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "Question 70 - [Content needs manual review]",
    options: [
      "Option 1",
      "Exposure to thinners and paints",
      "Continuous exposure to cement and concrete",
      "Continuous exposure to drills and machines",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Continuous exposure to drills and machines (Option D)**\n\nüî¨ **HAND-ARM VIBRATION SYNDROME (HAVS):**\n\n**IMAGE (LIKELY):** Shows **Raynaud's phenomenon** or **finger blanching** ‚≠ê\n\n**CAUSE:** **Vibrating tools** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Drills**, **jackhammers**, **chainsaws**\n‚Ä¢ **Prolonged exposure** (months-years)\n\n**CLINICAL:**\n‚Ä¢ **Raynaud's phenomenon** (white ‚Üí blue ‚Üí red fingers) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Numbness**, **tingling**\n‚Ä¢ **Reduced grip strength**\n‚Ä¢ **Pain**\n\n**MECHANISM:**\n‚Ä¢ **Vascular damage** (vasoconstriction)\n‚Ä¢ **Nerve damage** (vibration neuropathy)\n\n**MANAGEMENT:**\n‚Ä¢ **Avoid vibrating tools** ‚≠ê\n‚Ä¢ **Keep hands warm**\n‚Ä¢ **Calcium channel blockers** (if severe)\n\nüí° **KEY:** **Raynaud's + Vibrating tools = HAVS** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page34_img20.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-71",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "A patient with a previous history of myocardial infarction and ventricular arrhythmia is on treatment for a few months. He developed fatigue, dyspnea, and weight gain. He had also developed pulmonary fibrosis. Which of the following drugs is responsible for the side effects mentioned above?",
    options: [
      "Amiodarone",
      "Atenolol e",
      "Aspirin",
      "Spironolactone",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Amiodarone (Option A)**\n\nüî¨ **AMIODARONE TOXICITY:**\n\n**INDICATION (THIS CASE):**\n‚Ä¢ **Ventricular arrhythmia post-MI** ‚≠ê\n\n**SIDE EFFECTS (THIS CASE):**\n\n**1. Pulmonary fibrosis** ‚≠ê‚≠ê‚≠ê **(MOST SERIOUS)**\n‚Ä¢ **Dyspnea**, **dry cough**\n‚Ä¢ **Restrictive lung disease**\n‚Ä¢ **Monitor:** Pulmonary function tests, CXR\n\n**2. Hypothyroidism** ‚≠ê\n‚Ä¢ **Fatigue**, **weight gain**\n‚Ä¢ Amiodarone is **37% iodine**\n‚Ä¢ **Monitor:** TSH, T4\n\n**3. Hepatotoxicity** (elevated LFTs)\n\n**4. Corneal deposits** (reversible)\n\n**5. Photosensitivity** (blue-gray skin)\n\n**MONITORING:**\n‚Ä¢ **Baseline:** PFTs, LFTs, TFTs, CXR\n‚Ä¢ **Follow-up:** Every 6 months\n\nüí° **KEY:** **Amiodarone ‚Üí Pulmonary fibrosis + Hypothyroidism** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-72",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 5-year-old child was admitted tLo the hospital for prolapsing rectal mass and painless rectal bleeding. Histopathological examination reveals enlarged and inflamed glands filled with mucin. What is the likely diagnosis? p",
    options: [
      "Adenom e",
      "Choristoma",
      "Hamartom OP4: Carcinom A ns: 3",
      "Option 4",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Hamartoma (Juvenile Polyp) (Option C)**\n\nüî¨ **JUVENILE POLYP:**\n\n**AGE:** **Children** (2-10 years) ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Prolapsing rectal mass** ‚≠ê\n‚Ä¢ **Painless rectal bleeding** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Can autoamputate**\n\n**HISTOPATHOLOGY:**\n‚Ä¢ **Hamartoma** ‚≠ê‚≠ê‚≠ê (not neoplastic)\n‚Ä¢ **Enlarged, dilated glands** filled with **mucin** ‚≠ê\n‚Ä¢ **Inflamed stroma**\n‚Ä¢ **Cystic spaces**\n\n**LOCATION:** **Rectum** (most common) ‚≠ê\n\n**MANAGEMENT:**\n‚Ä¢ **Endoscopic polypectomy** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Usually solitary**\n‚Ä¢ **NO malignant potential** ‚≠ê\n\n**VS ADENOMA:**\n‚Ä¢ **Adenoma:** Neoplastic, adults, malignant potential\n\nüí° **KEY:** **Child + Rectal bleeding + Mucin-filled glands = Juvenile polyp (Hamartoma)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page35_img21.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-73",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "A young female comes to the emergency department after consuming 100 aspirin tablets. What should be the next step in management?",
    options: [
      "N-acetyl cysteine to replenish glutathione stores",
      "Pralidoxime",
      "Glucagon to control bradycardia and hypoglycemia",
      "Give sodium bicarbonate to alkalize urine",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Give sodium bicarbonate to alkalize urine (Option D)**\n\nüî¨ **ASPIRIN OVERDOSE MANAGEMENT:**\n\n**TOXICITY:**\n‚Ä¢ **Salicylism** (tinnitus, vertigo, hearing loss)\n‚Ä¢ **Metabolic acidosis** ‚≠ê\n‚Ä¢ **Respiratory alkalosis** (early)\n‚Ä¢ **Hyperthermia**\n‚Ä¢ **CNS toxicity** (confusion, seizures)\n\n**TREATMENT:**\n\n**1. Urine alkalinization** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Sodium bicarbonate IV** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Target urine pH: 7.5-8.5**\n‚Ä¢ **Mechanism:** **Ion trapping** - salicylate is ionized in alkaline urine ‚Üí cannot be reabsorbed ‚Üí ‚Üë excretion ‚≠ê\n\n**2. Activated charcoal** (if <1 hour)\n\n**3. Hemodialysis** (if severe):\n‚Ä¢ **Refractory acidosis**\n‚Ä¢ **Renal failure**\n‚Ä¢ **CNS symptoms**\n‚Ä¢ **Salicylate >100 mg/dL**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **NAC:** Acetaminophen, not aspirin\n‚Ä¢ **Pralidoxime:** Organophosphate\n‚Ä¢ **Glucagon:** Œ≤-blocker overdose\n\nüí° **KEY:** **Aspirin overdose ‚Üí Alkalinize urine (NaHCO‚ÇÉ)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-74",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "A chronic smoker was on nicotine replacement therapy and clonidine tablets for smoking d de-addiction. He stopped taking clonidine tablets and now presents with a headache. What is the reason behind this condition?",
    options: [
      "Postural hypotension",
      "Receptor upregulation a",
      "Rebound hypertension",
      "Receptor hypersensitivity",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Rebound hypertension (Option C)**\n\nüî¨ **CLONIDINE WITHDRAWAL:**\n\n**CLONIDINE:**\n‚Ä¢ **Œ±2-agonist** (central)\n‚Ä¢ **Lowers BP** ‚≠ê\n‚Ä¢ Used for **smoking cessation** ‚≠ê\n\n**SUDDEN WITHDRAWAL** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Rebound hypertension** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Headache** ‚≠ê\n‚Ä¢ **Anxiety**, **tremor**\n‚Ä¢ **Tachycardia**\n‚Ä¢ **Sweating**\n\n**MECHANISM:**\n‚Ä¢ **Suppressed sympathetic activity** rebounds ‚≠ê\n‚Ä¢ **Sudden increase** in catecholamines\n‚Ä¢ **Severe hypertension**\n\n**MANAGEMENT:**\n‚Ä¢ **Restart clonidine** (taper slowly) ‚≠ê\n‚Ä¢ **Antihypertensives** (Œ± + Œ≤ blockers)\n\n**PREVENTION:** **Gradual tapering** ‚≠ê‚≠ê‚≠ê (over 2-4 days)\n\nüí° **KEY:** **Clonidine withdrawal ‚Üí Rebound hypertension** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-75",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "r Identify the given condition. P",
    options: [
      "Venous ulcer",
      "Malignant ulcer",
      "Arterial ulcer",
      "Trophic ulcer",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Trophic ulcer (Option D)**\n\nüî¨ **TROPHIC ULCER (Neuropathic Ulcer):**\n\n**CAUSE:** **Loss of sensation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Diabetes** (peripheral neuropathy) ‚≠ê\n‚Ä¢ **Leprosy**\n‚Ä¢ **Spinal cord injury**\n\n**LOCATION:** **Pressure points** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Sole of foot** (heel, metatarsal heads) ‚≠ê\n‚Ä¢ Areas of **repetitive trauma**\n\n**CLINICAL:**\n‚Ä¢ **Painless** ‚≠ê‚≠ê‚≠ê (due to neuropathy)\n‚Ä¢ **Punched-out appearance**\n‚Ä¢ **Deep**, **well-defined margins**\n‚Ä¢ **Callused edges**\n‚Ä¢ **Clean base** or infected\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Repeated trauma** (no pain sensation)\n‚Ä¢ **Poor healing** (neuropathy + vascular disease)\n\n**MANAGEMENT:**\n‚Ä¢ **Pressure offloading** ‚≠ê (special footwear)\n‚Ä¢ **Wound care**\n‚Ä¢ **Treat underlying cause**\n\nüí° **KEY:** **Painless ulcer on sole + Neuropathy = Trophic ulcer** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-76",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "d A patient with recurrent gout attacks was started on a therapy that inhibits uric acid synthesis. His symptoms were reduced after therapy. Which drug was he started on? d",
    options: [
      "Probenecid",
      "Colchicine",
      "Diclofenac L",
      "Allopurinol p",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Allopurinol (Option D)**\n\nüî¨ **GOUT - PROPHYLACTIC THERAPY:**\n\n**MECHANISM:** **Inhibits uric acid synthesis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Xanthine oxidase inhibitor** ‚≠ê\n‚Ä¢ **Hypoxanthine** ‚Üí ~~Xanthine~~ ‚Üí ~~**Uric acid**~~\n\n**ALLOPURINOL:**\n‚Ä¢ **First-line** for prophylaxis ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Reduces serum uric acid**\n‚Ä¢ **Prevents recurrent attacks**\n\n**INDICATION:**\n‚Ä¢ **Recurrent gout** ‚≠ê\n‚Ä¢ **Tophi**\n‚Ä¢ **Uric acid stones**\n\n**ALTERNATIVE:** **Febuxostat** (newer XO inhibitor)\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Probenecid:** **Increases excretion** (uricosuric)\n‚Ä¢ **Colchicine:** **Acute attack** treatment\n‚Ä¢ **Diclofenac:** **Acute attack** (NSAID)\n\nüí° **KEY:** **Inhibits synthesis = Allopurinol (XO inhibitor)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page37_img22.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-77",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "Sub-Topicr: AP patient with a malignancy is undergoing chemotherapy. The platelet counts were reduced after the previous cycle of chemotherapy. Which of the following drugs can be used to treat th is patient?",
    options: [
      "Oprelvekin (IL-11)",
      "Filgrastim",
      "Erythropoietin",
      "Amifostine",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Oprelvekin (IL-11) (Option A)**\n\nüî¨ **CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA:**\n\n**DRUG:** **Oprelvekin (Interleukin-11)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Thrombopoietin agonist**\n‚Ä¢ **Stimulates platelet production** ‚≠ê‚≠ê‚≠ê\n\n**INDICATION:**\n‚Ä¢ **Prevent severe thrombocytopenia** after chemotherapy ‚≠ê\n‚Ä¢ **Reduce need** for platelet transfusions\n\n**SIDE EFFECTS:**\n‚Ä¢ **Fluid retention**\n‚Ä¢ **Arrhythmias**\n‚Ä¢ **Dyspnea**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Filgrastim (G-CSF):** **Neutropenia** ‚≠ê\n‚Ä¢ **Erythropoietin:** **Anemia** ‚≠ê\n‚Ä¢ **Amifostine:** **Cytoprotective** (reduces toxicity)\n\nüí° **KEY:** **Thrombocytopenia post-chemo ‚Üí Oprelvekin (IL-11)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-78",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "The true statement among the following is___",
    options: [
      "The dose of telmisartan should be reduced in renal failure but not in hepatic failure.",
      "The dose of irbesartan should be reduced in case of mild-moderate hepatic failure and renal failure. e",
      "The dose of candesartan should be reduced in mild-moderate liver failure but not in renal failure.",
      "Losartan acts as a thromboxane A2 antagonist and inhibits platelet aggregation. d",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Losartan acts as a thromboxane A2 antagonist and inhibits platelet aggregation (Option D)**\n\nüî¨ **ARBs - SPECIAL PROPERTIES:**\n\n**LOSARTAN UNIQUE EFFECT:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Antagonizes thromboxane A2** ‚≠ê\n‚Ä¢ **Inhibits platelet aggregation** ‚≠ê\n‚Ä¢ **Additional cardioprotection**\n\n**DOSE ADJUSTMENTS (ARBs):**\n\n**A. Telmisartan:** FALSE\n‚Ä¢ **Biliary excretion** (97%)\n‚Ä¢ **Reduce in hepatic failure**, NOT renal\n\n**B. Irbesartan:** FALSE\n‚Ä¢ **No adjustment** needed in mild-moderate hepatic/renal failure\n\n**C. Candesartan:** FALSE\n‚Ä¢ **Dual excretion**\n‚Ä¢ **Caution** in both, but no strict reduction\n\n**D. Losartan:** TRUE ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Unique antiplatelet effect**\n\nüí° **KEY:** **Losartan = Only ARB with antiplatelet effect** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page38_img23.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-79",
    subjectId: "orthopedics",
    chapterId: "neet-pg-2023",
    question: "A patient at the orthopedics OPD complains of troubled sleep at night due to numbness and tingling sensation involvipng his lateral 3 digits. His symptoms are relieved as he lays his arms hanging from the bed. Which of the following options correctly describes his condition and the test used to assess it?",
    options: [
      "Guyon's canal syndrome, Froment's test",
      "Carpal tunnel syndrome, Froment's test",
      "P Guyon's canal syndrome, Durkan's test",
      "Carpal tunnel syndrome, Durkan's test",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Carpal tunnel syndrome, Durkan's test (Option D)**\n\nüî¨ **CARPAL TUNNEL SYNDROME (CTS):**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Numbness/tingling** in **lateral 3¬Ω digits** ‚≠ê‚≠ê‚≠ê (thumb, index, middle, lateral ring)\n‚Ä¢ **Worse at night** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Relieved by shaking/hanging hand** ‚≠ê (\"flick sign\")\n\n**NERVE:** **Median nerve** compression at **carpal tunnel** ‚≠ê‚≠ê‚≠ê\n\n**TESTS:**\n\n**1. Durkan's test** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Direct compression** over carpal tunnel (30 sec)\n‚Ä¢ Reproduces symptoms\n\n**2. Tinel's sign** (tap over carpal tunnel)\n\n**3. Phalen's test** (wrist flexion 60 sec)\n\n**TREATMENT:**\n‚Ä¢ **Wrist splint** (night)\n‚Ä¢ **Carpal tunnel release** (if severe)\n\n**WHY NOT GUYON'S:**\n‚Ä¢ **Ulnar nerve** compression\n‚Ä¢ **Medial 1¬Ω digits** (ring, little finger)\n‚Ä¢ **Froment's test** (ulnar)\n\nüí° **KEY:** **Night symptoms + Lateral 3¬Ω digits = CTS (Median) + Durkan's test** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-80",
    subjectId: "orthopedics",
    chapterId: "neet-pg-2023",
    question: "A child is brought to the orthopedics OPD with a deformity in the lower limb and hyperpigmented skin lesions. The x-ray of her thigh is shown below. What is the most likely diagnosis? r e d d",
    options: [
      "Non-ossifying fibroma",
      "Fibrous dysplasi L",
      "Paget's disease",
      "Osteogenesis imperfecta",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Fibrous dysplasia (Option B)**\n\nüî¨ **FIBROUS DYSPLASIA:**\n\n**CLASSIC TRIAD (THIS CASE):**\n1. **Bone deformity** ‚≠ê\n2. **Caf√©-au-lait spots** (hyperpigmented) ‚≠ê‚≠ê‚≠ê\n3. **Shepherd's crook deformity** (proximal femur) ‚≠ê\n\n**X-RAY FINDINGS:**\n‚Ä¢ **Ground glass appearance** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Expansile lesion**\n‚Ä¢ **Bowing deformity**\n\n**TYPES:**\n‚Ä¢ **Monostotic** (70%) - single bone\n‚Ä¢ **Polyostotic** (30%) - multiple bones\n\n**McCAUNE-ALBRIGHT SYNDROME:**\n‚Ä¢ **Polyostotic fibrous dysplasia** ‚≠ê\n‚Ä¢ **Caf√©-au-lait spots** ‚≠ê\n‚Ä¢ **Precocious puberty** (endocrine dysfunction)\n\n**TREATMENT:**\n‚Ä¢ **Observation** (asymptomatic)\n‚Ä¢ **Curettage + bone grafting** (symptomatic)\n‚Ä¢ **Bisphosphonates** (pain control)\n\nüí° **KEY:** **Child + Bone deformity + Caf√©-au-lait = Fibrous dysplasia** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page39_img24.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-81",
    subjectId: "psychiatry",
    chapterId: "neet-pg-2023",
    question: "SPub-Topic: A schizophrenic patient was prescribed drug A after he did not respond to haloperidol and thioridazine. He now presents with excessive salivation, an increase in blood glucose, and hyperlipidemia. What is drug A?",
    options: [
      "Ziprasidone",
      "Risperidone",
      "Clozapine",
      "Aripiprazole",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Clozapine (Option C)**\n\nüî¨ **CLOZAPINE:**\n\n**INDICATION:** **Treatment-resistant schizophrenia** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Failed **2 typical antipsychotics** (haloperidol, thioridazine)\n\n**SIDE EFFECTS (THIS CASE):**\n\n**1. Excessive salivation (sialorrhea)** ‚≠ê‚≠ê‚≠ê **(HALLMARK)**\n‚Ä¢ **M3 muscarinic agonism**\n‚Ä¢ Most common SE\n\n**2. Hyperglycemia** ‚≠ê\n‚Ä¢ **Metabolic syndrome**\n‚Ä¢ **Weight gain**\n\n**3. Hyperlipidemia** ‚≠ê\n\n**SERIOUS SIDE EFFECTS:**\n‚Ä¢ **Agranulocytosis** ‚≠ê‚≠ê‚≠ê (1%) - **MOST SERIOUS**\n  - **Monitor WBC weekly** √ó 6 months, then bi-weekly\n‚Ä¢ **Seizures** (dose-dependent)\n‚Ä¢ **Myocarditis**\n\n**ADVANTAGES:**\n‚Ä¢ **No EPS** (extrapyramidal symptoms)\n‚Ä¢ **Most effective** for treatment-resistant schizophrenia\n\nüí° **KEY:** **Treatment-resistant + Sialorrhea + Metabolic effects = Clozapine** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-82",
    subjectId: "orthopedics",
    chapterId: "neet-pg-2023",
    question: "The given image is an x-ray of a 22-year-old female. What is the probable diagnosis? r e d d a L",
    options: [
      "Chondroblastoma",
      "Osteochondrom e",
      "Giant cell tumor",
      "Aneurysmal bone cyst APns: 3",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Giant cell tumor (Option C) - Corrected**\n\nüî¨ **GIANT CELL TUMOR (GCT):**\n\n**AGE:** **20-40 years** ‚≠ê‚≠ê‚≠ê (this case: 22-year-old)\n\n**LOCATION:** **Epiphyseal** (after physeal closure) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Extends to subchondral bone** ‚≠ê\n‚Ä¢ **Distal femur, proximal tibia** (around knee)\n\n**X-RAY:**\n‚Ä¢ **\"Soap bubble\" appearance** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Lytic**, **eccentric**\n‚Ä¢ **No periosteal reaction**\n‚Ä¢ **Subchondral extension**\n\n**HISTOLOGY:** **Multinucleated giant cells** ‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **Extended curettage** + **Bone cement**\n‚Ä¢ **En bloc resection** (if extensive)\n\n**VS CHONDROBLASTOMA:**\n‚Ä¢ **Younger** (<20 years)\n‚Ä¢ **Epiphyseal** but **before fusion**\n\nüí° **KEY:** **Young adult + Epiphyseal + Soap bubble = GCT** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-83",
    subjectId: "physiology",
    chapterId: "neet-pg-2023",
    question: "Identify the marked region in the given spirometry. r e d d a L",
    options: [
      "Functional residual capacity",
      "Tidal volume",
      "Expiratory reserve volume",
      "Expiratory capacity r",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Functional residual capacity (FRC) (Option A)**\n\nüî¨ **LUNG VOLUMES:**\n\n**FUNCTIONAL RESIDUAL CAPACITY (FRC):** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Volume remaining in lungs** after **normal expiration** (at rest)\n‚Ä¢ **FRC = ERV + RV**\n‚Ä¢ **Cannot be measured** by spirometry alone (contains RV)\n\n**COMPONENTS:**\n‚Ä¢ **Expiratory reserve volume (ERV):** Can exhale further\n‚Ä¢ **Residual volume (RV):** Cannot exhale (always remains)\n\n**MEASUREMENT:** **Body plethysmography** or **Helium dilution** ‚≠ê\n\n**LUNG VOLUMES:**\n‚Ä¢ **TLC** (Total lung capacity): All air\n‚Ä¢ **VC** (Vital capacity): Maximum breath\n‚Ä¢ **TV** (Tidal volume): Normal breath ‚≠ê\n‚Ä¢ **FRC:** At rest after expiration ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **RV:** Cannot exhale\n\nüí° **KEY:** **FRC = Volume after normal expiration (ERV + RV)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-84",
    subjectId: "unknown",
    chapterId: "neet-pg-2023",
    question: "A patient with varicose veins complains of eczema over the same region. What is the stage of the clinical classification according to the CEAP guidelines? CEAP-Clinical-Aetiology-Anatomy- Pathophysiology classification of chronic venous disorders",
    options: [
      "C2",
      "C3",
      "C4a",
      "C4b",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **C4a (Option C)**\n\nüî¨ **CEAP CLASSIFICATION (Chronic Venous Disease):**\n\n**CLINICAL (C) STAGES:**\n\n**C0:** No visible venous disease\n\n**C1:** Telangiectasia (spider veins)\n\n**C2:** **Varicose veins** ‚≠ê\n\n**C3:** **Edema** ‚≠ê\n\n**C4a:** **Pigmentation** or **eczema** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **Varicose veins + eczema** = **C4a**\n\n**C4b:** Lipodermatosclerosis or atrophie blanche\n\n**C5:** Healed ulcer\n\n**C6:** Active ulcer ‚≠ê\n\n**MANAGEMENT (C4a):**\n‚Ä¢ **Compression stockings** ‚≠ê\n‚Ä¢ **Topical steroids** (for eczema)\n‚Ä¢ **Treat underlying varicose veins**\n\nüí° **KEY:** **Varicose veins + Eczema = CEAP C4a** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page41_img25.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-85",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "e A patient comes to the casualty with a severe headache. His BP was found to be 160/100 mmHg. CT scan revealed a subarachnoid hemorrhage. What is the next best step in the management of this patient? d",
    options: [
      "Nimodipin d",
      "Angiography",
      "Surgery",
      "Fibrinolytic therapy L",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Angiography (Option B)**\n\nüî¨ **SUBARACHNOID HEMORRHAGE (SAH) MANAGEMENT:**\n\n**CONFIRMED SAH ON CT** ‚Üí **Next step:** **CT/DSA Angiography** ‚≠ê‚≠ê‚≠ê\n\n**PURPOSE:**\n‚Ä¢ **Identify source** (aneurysm, AVM) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Plan treatment** (coiling vs clipping)\n‚Ä¢ **Assess other aneurysms**\n\n**INITIAL MANAGEMENT (SIMULTANEOUS):**\n‚Ä¢ **Bed rest**, **analgesia**\n‚Ä¢ **Nimodipine** ‚≠ê‚≠ê‚≠ê (prevent vasospasm)\n  - **60 mg PO q4h √ó 21 days**\n  - **Reduces delayed cerebral ischemia**\n‚Ä¢ **BP control** (cautious - maintain perfusion)\n\n**DEFINITIVE TREATMENT (AFTER ANGIOGRAPHY):**\n‚Ä¢ **Endovascular coiling** ‚≠ê (preferred)\n‚Ä¢ **Surgical clipping**\n\n**NOT INDICATED:**\n‚Ä¢ **Fibrinolytics:** CONTRAINDICATED ‚≠ê (worsen bleeding)\n\nüí° **KEY:** **SAH confirmed ‚Üí Angiography (find aneurysm) + Nimodipine** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-86",
    subjectId: "physiology",
    chapterId: "neet-pg-2023",
    question: "A man was brought to the emergency after suddenly becoming unconscious while working in r the field. On examination, his temperature was 105 degrees Fahrenheit, and his skin turgor was decreased. Which of the following would not be seen in the patient? P",
    options: [
      "T achypnea",
      "Hypotension",
      "Sweating",
      "Red hot skin",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Sweating (NOT seen) (Option C)**\n\nüî¨ **HEAT STROKE:**\n\n**CLASSIC TRIAD** ‚≠ê‚≠ê‚≠ê:\n1. **Hyperthermia** (>40¬∞C/104¬∞F) ‚≠ê‚≠ê‚≠ê (105¬∞F in this case)\n2. **CNS dysfunction** (unconsciousness) ‚≠ê\n3. **Anhidrosis** (NO sweating) ‚≠ê‚≠ê‚≠ê **(KEY FINDING)**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Temperature 105¬∞F** ‚≠ê\n‚Ä¢ **Unconscious**\n‚Ä¢ **Decreased skin turgor** (dehydrated)\n‚Ä¢ **Red, hot, DRY skin** ‚≠ê‚≠ê‚≠ê\n\n**WHAT IS SEEN:**\n‚Ä¢ **Tachypnea** ‚≠ê (hyperventilation)\n‚Ä¢ **Hypotension** ‚≠ê (shock)\n‚Ä¢ **Red hot skin** (vasodilation)\n\n**NOT SEEN:**\n‚Ä¢ **Sweating** ‚≠ê‚≠ê‚≠ê - **ABSENT** (sweat glands fail)\n\n**TREATMENT:**\n‚Ä¢ **Rapid cooling** (ice packs, evaporative)\n‚Ä¢ **IV fluids**\n‚Ä¢ **ICU care**\n\nüí° **KEY:** **Heat stroke = Hot, DRY skin (NO sweating)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-87",
    subjectId: "physiology",
    chapterId: "neet-pg-2023",
    question: "Identify the correctly matched pair of substances with their renal clearance from the graph below. r e d d a L",
    options: [
      "A-Glucose, B-PAH, C- Bicarbonate and D - Inulin p",
      "A-Glucose, B- Bicarbonate, C-Inulin and D - PAH",
      "A-PAH, B-Inulin, C - Glucose and D - Bicarbonate",
      "A - Inulin, Br - Glucose, C - Bicarbonate and D - PAH",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **A-Glucose, B-Bicarbonate, C-Inulin, D-PAH (Option B)**\n\nüî¨ **RENAL CLEARANCE:**\n\n**CLEARANCE RATES:**\n\n**A. Glucose:** **0 mL/min** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Completely reabsorbed** (normally)\n‚Ä¢ **Filtered but NOT excreted**\n\n**B. Bicarbonate:** **0 mL/min** ‚≠ê\n‚Ä¢ **Completely reabsorbed** (acid-base balance)\n\n**C. Inulin:** **~125 mL/min** ‚≠ê‚≠ê‚≠ê **(GFR marker)**\n‚Ä¢ **Freely filtered**, **NOT reabsorbed/secreted**\n‚Ä¢ **Gold standard for GFR**\n\n**D. PAH:** **~650 mL/min** ‚≠ê‚≠ê‚≠ê **(Highest)**\n‚Ä¢ **Filtered + Secreted**\n‚Ä¢ **Measures renal plasma flow (RPF)**\n\n**CLEARANCE HIERARCHY:**\n‚Ä¢ **Glucose/Bicarbonate < Urea < Creatinine < Inulin (GFR) < PAH (RPF)** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **Lowest: Glucose/HCO‚ÇÉ ‚Üí Middle: Inulin (GFR) ‚Üí Highest: PAH (RPF)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-88",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 20-year-old female patient consumed a cleaning product containing 90% sodium hydroxide. She is having complete dysphagia. What is the best step in management?",
    options: [
      "Esophagojejunostomy",
      "Stent placement",
      "Feeding jejunostomy",
      "Gastrojejunostomy",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Feeding jejunostomy (Option C)**\n\nüî¨ **CAUSTIC ESOPHAGEAL INJURY:**\n\n**AGENT:** **90% sodium hydroxide** (alkali) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Severe injury** (liquefactive necrosis)\n‚Ä¢ **Complete dysphagia** = severe stricture/perforation risk\n\n**ACUTE MANAGEMENT:**\n\n**1. NPO (nil per os)** ‚≠ê\n‚Ä¢ **NO oral intake**\n‚Ä¢ **NO NG tube** (risk of perforation)\n\n**2. Feeding jejunostomy** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Nutritional support** while esophagus heals\n‚Ä¢ **Temporary** (weeks-months)\n‚Ä¢ Allows **delayed reconstruction**\n\n**3. Endoscopy** (within 24 hours)\n‚Ä¢ **Assess severity**\n‚Ä¢ **No endoscopy if perforation suspected**\n\n**LATER (after acute phase):**\n‚Ä¢ **Esophageal reconstruction** (if stricture)\n‚Ä¢ **Colon interposition** or **gastric pull-up**\n\n**NOT INDICATED:**\n‚Ä¢ **Stent:** Risk of perforation/migration\n‚Ä¢ **Immediate surgery:** Unless perforation\n\nüí° **KEY:** **Caustic injury + Complete dysphagia ‚Üí Feeding jejunostomy (NPO)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-89",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "e A 23-year-old male patient presents with midline swelling in the neck. The swelling moves with deglutition and protrusion of the tongue. What is the likely diagnosis? d",
    options: [
      "Brachial cyst",
      "Thyroglossal cyst",
      "Plunging ranula a",
      "Dermoid cyst L",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Thyroglossal cyst (Option B)**\n\nüî¨ **THYROGLOSSAL CYST:**\n\n**CLASSIC FEATURES** ‚≠ê‚≠ê‚≠ê:\n1. **Midline neck swelling** ‚≠ê‚≠ê‚≠ê\n2. **Moves with swallowing** ‚≠ê‚≠ê‚≠ê (attached to hyoid)\n3. **Moves with tongue protrusion** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n\n**EMBRYOLOGY:**\n‚Ä¢ **Remnant of thyroglossal duct** ‚≠ê\n‚Ä¢ **Thyroid descends** from foramen cecum ‚Üí anterior neck\n‚Ä¢ **Duct normally obliterates**\n\n**LOCATION:** **Between hyoid bone and thyroid** ‚≠ê\n\n**TREATMENT:** **Sistrunk operation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Excise cyst + middle 1/3 of hyoid bone** + duct\n\n**VS OTHER CYSTS:**\n‚Ä¢ **Branchial cyst:** **Lateral** neck, anterior to SCM\n‚Ä¢ **Dermoid:** Midline, does NOT move with swallowing/tongue\n‚Ä¢ **Ranula:** **Floor of mouth**\n\nüí° **KEY:** **Midline + Moves with swallowing + tongue = Thyroglossal cyst** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-90",
    subjectId: "physiology",
    chapterId: "neet-pg-2023",
    question: "e Identify the true statement regarding the given nerve action potential curve? r P r e d d a L p e r P",
    options: [
      "The threshold point is at A",
      "At point E, the nerve is more excitable",
      "Point C to D is due to the opening of Na+ and closure of K+ channels",
      "Point B to D is a refractory period",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Point B to D is a refractory period (Option D)**\n\nüî¨ **ACTION POTENTIAL:**\n\n**PHASES:**\n‚Ä¢ **A:** Threshold\n‚Ä¢ **B:** Depolarization peak (+30 mV)\n‚Ä¢ **C-D:** Repolarization\n‚Ä¢ **E:** Hyperpolarization (undershoot)\n\n**REFRACTORY PERIODS:**\n\n**Absolute (B to C):** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **NO stimulus** can trigger AP\n‚Ä¢ **Na+ channels inactivated**\n\n**Relative (C to D):** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Strong stimulus** can trigger AP\n‚Ä¢ **Some Na+ channels recovered**\n\n**B to D = Absolute + Relative = REFRACTORY PERIOD** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**FALSE STATEMENTS:**\n‚Ä¢ **A:** Threshold (correct)\n‚Ä¢ **E:** **Less excitable** (hyperpolarized)\n‚Ä¢ **C-D:** **K+ opening** (not closure)\n\nüí° **KEY:** **B to D = Total refractory period (Absolute + Relative)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page44_img26.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-91",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A young patient is admitted with a history of fever for 5 days. BP is 90/60 mmHg, PR-120 bpm, RR-24 breaths/ min, GCS score-10; laboratory tests show leucocytosis with neutrophilia and serum creatinine level of 2.6 mg/ dL. An intern doctor wants to calculate the qSOFA score to predict prognosis and hospitalization duration. Which of the following comprises the qSOFA score? r",
    options: [
      "BP, RR and CBC e",
      "Creatinine, PR, BP d",
      "RR, Body temperature, PR",
      "SBP, RR, GCS score",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **SBP, RR, GCS score (Option D)**\n\nüî¨ **qSOFA (Quick SOFA Score):**\n\n**CRITERIA** ‚≠ê‚≠ê‚≠ê **(3 parameters only)**:\n1. **Systolic BP ‚â§100 mmHg** ‚≠ê\n2. **Respiratory rate ‚â•22/min** ‚≠ê\n3. **Altered mental status (GCS <15)** ‚≠ê\n\n**SCORING:**\n‚Ä¢ **1 point** for each criterion\n‚Ä¢ **‚â•2 points** = **High risk** of poor outcome ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE:**\n‚Ä¢ **BP 90/60** ‚Üí SBP <100 ‚úì (1 point)\n‚Ä¢ **RR 24** ‚Üí ‚â•22 ‚úì (1 point)\n‚Ä¢ **GCS 10** ‚Üí <15 ‚úì (1 point)\n‚Ä¢ **Total: 3/3** = High risk\n\n**PURPOSE:** **Bedside screening** for sepsis (no labs needed) ‚≠ê\n\n**NOT INCLUDED:**\n‚Ä¢ Temperature, PR, CBC, creatinine\n\nüí° **KEY:** **qSOFA = SBP + RR + GCS (No labs!)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-92",
    subjectId: "physiology",
    chapterId: "neet-pg-2023",
    question: "Identify the type of transpport across the cell membrane given below?",
    options: [
      "Simple diffusion P a",
      "Facilitated diffusion",
      "Primary active transport p",
      "Secondary active transport",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Facilitated diffusion (Option B)**\n\nüî¨ **MEMBRANE TRANSPORT:**\n\n**FACILITATED DIFFUSION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Carrier/channel mediated** ‚≠ê\n‚Ä¢ **Down concentration gradient** ‚≠ê\n‚Ä¢ **No energy (ATP) required** ‚≠ê\n‚Ä¢ **Saturable** (limited carriers)\n‚Ä¢ **Faster** than simple diffusion\n\n**EXAMPLES:**\n‚Ä¢ **GLUT transporters** (glucose) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Ion channels** (Na+, K+, Cl-)\n\n**VS OTHER TRANSPORT:**\n\n**Simple diffusion:**\n‚Ä¢ **No carrier** (direct through lipid bilayer)\n‚Ä¢ O‚ÇÇ, CO‚ÇÇ, lipid-soluble\n\n**Primary active:**\n‚Ä¢ **Uses ATP directly** (Na+/K+ ATPase)\n\n**Secondary active:**\n‚Ä¢ **Uses ion gradient** (Na+-glucose cotransporter)\n\nüí° **KEY:** **Carrier + Down gradient + No ATP = Facilitated diffusion** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page45_img27.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-93",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "Identify the condition associated with the murmur in the image below.",
    options: [
      "Mitral regurgitation",
      "Aortic regurgitation",
      "Aortic stenosis L",
      "Mitral stenosis",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Mitral regurgitation (Option A)**\n\nüî¨ **MITRAL REGURGITATION (MR):**\n\n**AUSCULTATION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Holosystolic (pansystolic) murmur** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Blowing** quality\n‚Ä¢ **Best heard:** **Apex** (5th ICS, MCL)\n‚Ä¢ **Radiates:** **Axilla** ‚≠ê\n\n**CAUSES:**\n‚Ä¢ **Mitral valve prolapse** (most common)\n‚Ä¢ **Rheumatic heart disease**\n‚Ä¢ **Ischemic** (papillary muscle dysfunction)\n‚Ä¢ **Infective endocarditis**\n\n**FINDINGS:**\n‚Ä¢ **Displaced apex** (LV dilatation)\n‚Ä¢ **S3 gallop**\n‚Ä¢ **Soft S1**\n\n**ECHO:** **Regurgitant jet** from LV ‚Üí LA\n\n**TREATMENT:**\n‚Ä¢ **Medical:** Afterload reduction (ACE-I, ARBs)\n‚Ä¢ **Surgical:** Valve repair/replacement (if severe)\n\nüí° **KEY:** **Holosystolic murmur at apex ‚Üí axilla = MR** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-94",
    subjectId: "psychiatry",
    chapterId: "neet-pg-2023",
    question: "P A woman, who is 4 days postpartum, presented with tearfulness, mood swings, and occasional insomnia. What is the likely diagnosis?",
    options: [
      "Postpartum depression",
      "Postpartum blues",
      "Postpartum psychosis",
      "Postpartum anxiety",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Postpartum blues (Option B)**\n\nüî¨ **POSTPARTUM DISORDERS:**\n\n**POSTPARTUM BLUES (Baby Blues):** ‚≠ê‚≠ê‚≠ê\n\n**TIMING:** **Day 3-5** postpartum ‚≠ê‚≠ê‚≠ê (this case: day 4)\n\n**CLINICAL:**\n‚Ä¢ **Tearfulness** ‚≠ê\n‚Ä¢ **Mood swings** ‚≠ê\n‚Ä¢ **Anxiety**\n‚Ä¢ **Insomnia** ‚≠ê\n‚Ä¢ **MILD symptoms**\n\n**PREVALENCE:** **50-80%** (very common) ‚≠ê\n\n**DURATION:** **Self-limited** (resolves by day 10-14) ‚≠ê‚≠ê‚≠ê\n\n**MANAGEMENT:** **Reassurance**, **support** (NO medications) ‚≠ê\n\n**VS OTHER:**\n‚Ä¢ **Postpartum depression:** **2-6 weeks**, severe, needs treatment\n‚Ä¢ **Postpartum psychosis:** **1-4 weeks**, hallucinations, medical emergency\n\nüí° **KEY:** **Day 3-5 + Mild mood symptoms = Postpartum blues (self-limiting)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page46_img28.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-95",
    subjectId: "psychiatry",
    chapterId: "neet-pg-2023",
    question: "A 25-year-old female reported symptoms of anxiety, palpitations, sweating, breathlessness, chest pain, and a feeling of impending doom. She recalls having experienced 5-6 similar episodes in the past 6 months, each episode lasting for about 20-30 minutes. W hat is the likely diagnosis? r",
    options: [
      "Depression e",
      "Panic disorde d",
      "Generalized anxiety disorder",
      "Phobia",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Panic disorder (Option B)**\n\nüî¨ **PANIC DISORDER:**\n\n**DIAGNOSTIC CRITERIA** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Recurrent unexpected panic attacks** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **At least 4** symptoms\n‚Ä¢ **Duration:** Peaks within **10-20 minutes**\n‚Ä¢ **Fear of future attacks** (anticipatory anxiety)\n\n**THIS CASE:**\n‚Ä¢ **5-6 episodes** in 6 months ‚≠ê\n‚Ä¢ **20-30 minutes** duration ‚≠ê\n‚Ä¢ **Feeling of impending doom** ‚≠ê\n\n**PANIC ATTACK SYMPTOMS:**\n‚Ä¢ **Palpitations** ‚≠ê\n‚Ä¢ **Sweating** ‚≠ê\n‚Ä¢ **Breathlessness** ‚≠ê\n‚Ä¢ **Chest pain** ‚≠ê\n‚Ä¢ **Trembling**, **dizziness**\n‚Ä¢ **Fear of dying**\n\n**TREATMENT:**\n‚Ä¢ **SSRIs** (first-line) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **CBT** (cognitive behavioral therapy)\n‚Ä¢ **Benzodiazepines** (acute)\n\nüí° **KEY:** **Recurrent sudden attacks + 20 min + Impending doom = Panic disorder** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-96",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A young man came to thpe medical OPD with complaints of early morning backache and stiffness, which improves on exercise, and persistent red eyes. On examination, lung expansion was less than 3 cm. X-ray is shown in the image given below. e r P r e d d a L p What is the most probable diagnosis?",
    options: [
      "Ankylosing spondylitis",
      "Paget's diseas r",
      "HPealed tuberculosis",
      "O steopetrosis",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Ankylosing spondylitis (Option A)**\n\nüî¨ **ANKYLOSING SPONDYLITIS (AS):**\n\n**CLASSIC TRIAD** ‚≠ê‚≠ê‚≠ê:\n1. **Morning stiffness** (>30 min) ‚≠ê‚≠ê‚≠ê\n2. **Improves with exercise** ‚≠ê‚≠ê‚≠ê\n3. **Young male** (20-30 years)\n\n**THIS CASE:**\n‚Ä¢ **Morning backache + stiffness** ‚≠ê\n‚Ä¢ **Improves on exercise** ‚≠ê\n‚Ä¢ **Red eyes** (uveitis) ‚≠ê\n‚Ä¢ **Reduced chest expansion** (<2.5 cm) ‚≠ê‚≠ê‚≠ê\n\n**X-RAY:**\n‚Ä¢ **\"Bamboo spine\"** ‚≠ê‚≠ê‚≠ê (syndesmophytes)\n‚Ä¢ **Sacroiliitis** (bilateral)\n‚Ä¢ **Squaring of vertebrae**\n\n**EXTRAARTICULAR:**\n‚Ä¢ **Anterior uveitis** (25%) ‚≠ê\n‚Ä¢ **Aortic regurgitation**\n‚Ä¢ **Apical lung fibrosis**\n\n**GENETICS:** **HLA-B27 positive** (90%) ‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **NSAIDs** (first-line)\n‚Ä¢ **TNF inhibitors** (if refractory)\n\nüí° **KEY:** **Morning stiffness + Improves with exercise + Reduced chest expansion = AS** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-97",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A patient with hyperkalemia and elevated urea levels underwent dialysis. Towards the end of the session, she became drowsy and had a sudden seizure episode. On examination, the patient was hypotensive. What is the treatment for this condition?",
    options: [
      "Bumetanide",
      "Ethacrynic acid",
      "Nesiritide",
      "IV Mannitol r",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **IV Mannitol (Option D)**\n\nüî¨ **DIALYSIS DISEQUILIBRIUM SYNDROME:**\n\n**CAUSE:** **Rapid dialysis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Rapid urea clearance** from blood ‚Üí brain lags behind\n‚Ä¢ **Osmotic gradient** ‚Üí **Water shifts into brain**\n‚Ä¢ **Cerebral edema** ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Towards end of dialysis** ‚≠ê\n‚Ä¢ **Drowsiness** ‚≠ê\n‚Ä¢ **Seizures** ‚≠ê\n‚Ä¢ **Hypotension**\n‚Ä¢ **Nausea**, **headache**\n\n**TREATMENT:**\n‚Ä¢ **IV Mannitol** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n  - **Osmotic diuretic**\n  - **Reduces cerebral edema**\n‚Ä¢ **Hypertonic saline** (alternative)\n\n**PREVENTION:**\n‚Ä¢ **Slow dialysis** (first session)\n‚Ä¢ **Short sessions initially**\n‚Ä¢ **Mannitol prophylaxis**\n\nüí° **KEY:** **Seizure during/after dialysis = Disequilibrium syndrome ‚Üí Mannitol** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-98",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A female patient presents to the emergency depadrtment with severe restlessness, palpitations, and tremors. She is a known case of bronchial asthma. On examination, the neck looks swollen. Blood pressure is elevated, and tachycardia is noted. ECG shows atrial fibrillation. Which of the following drugs is used for imamediate management in this patient?",
    options: [
      "Diltiazem L",
      "Propranolol p",
      "Esmolol",
      "Propylthiouracil",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Diltiazem (Option A)**\n\nüî¨ **THYROID STORM + ATRIAL FIBRILLATION:**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Thyrotoxicosis** (restlessness, tremors, tachycardia) ‚≠ê\n‚Ä¢ **Atrial fibrillation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Known asthma** ‚≠ê‚≠ê‚≠ê **(KEY)**\n\n**IMMEDIATE RATE CONTROL:**\n\n**DILTIAZEM** ‚≠ê‚≠ê‚≠ê **(ANSWER - Calcium channel blocker)**\n‚Ä¢ **Safe in asthma** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Controls ventricular rate**\n‚Ä¢ **IV loading:** 0.25 mg/kg\n\n**WHY NOT Œ≤-BLOCKERS:**\n‚Ä¢ **Propranolol/Esmolol:** CONTRAINDICATED in asthma ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bronchospasm risk**\n\n**ALSO GIVE:**\n‚Ä¢ **PTU/Methimazole** (block synthesis)\n‚Ä¢ **Lugol's iodine** (after 1 hour)\n‚Ä¢ **Hydrocortisone**\n‚Ä¢ **Cooling**, **fluids**\n\nüí° **KEY:** **Thyroid storm + AF + Asthma = Diltiazem (NOT Œ≤-blocker)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page48_img29.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-99",
    subjectId: "unknown",
    chapterId: "neet-pg-2023",
    question: "S ub-Topic: A preterm baby who was delivered at 28 weeks developed respiratory distress syndrome. Which of the following is true about surface tension and compliance in this baby?",
    options: [
      "Surface tension - decreased; Compliance - increased",
      "Surface tension - increased; Compliance - decreased",
      "Both surface tension and compliance decreased",
      "Both surface tension and compliance increased",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Surface tension ‚Üë; Compliance ‚Üì (Option B)**\n\nüî¨ **NEONATAL RESPIRATORY DISTRESS SYNDROME (RDS):**\n\n**CAUSE:** **Surfactant deficiency** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Preterm** (<34 weeks) ‚≠ê (28 weeks in this case)\n‚Ä¢ **Immature lungs**\n\n**PATHOPHYSIOLOGY:**\n\n**1. Increased surface tension** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **No surfactant** ‚Üí **High surface tension**\n‚Ä¢ **Alveolar collapse** (atelectasis)\n‚Ä¢ **LaPlace law:** P = 2T/r\n\n**2. Decreased compliance** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Stiff lungs**\n‚Ä¢ **Increased work of breathing**\n‚Ä¢ **Respiratory distress**\n\n**CLINICAL:**\n‚Ä¢ **Grunting**, **flaring**, **retractions**\n‚Ä¢ **Tachypnea**, **cyanosis**\n\n**TREATMENT:**\n‚Ä¢ **Exogenous surfactant** ‚≠ê‚≠ê‚≠ê (within 2 hours)\n‚Ä¢ **Mechanical ventilation**\n‚Ä¢ **Prenatal steroids** (prevention)\n\nüí° **KEY:** **Preterm + RDS = ‚Üë Surface tension + ‚Üì Compliance (No surfactant)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-100",
    subjectId: "psychiatry",
    chapterId: "neet-pg-2023",
    question: "A middle-aged man complains of very early ejaculation during intercourse. rWhat is the non-pharmacological management that can be advised to the patient? e",
    options: [
      "Cognitive behavioral therapy",
      "Exposure and response prevention therapy",
      "Squeeze techniqu d",
      "Sensate focus therapy",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Squeeze technique (Option C)**\n\nüî¨ **PREMATURE EJACULATION:**\n\n**NON-PHARMACOLOGICAL MANAGEMENT:**\n\n**1. Squeeze technique** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Stop-squeeze method**\n‚Ä¢ **Partner squeezes** glans penis when ejaculation imminent\n‚Ä¢ **Delays ejaculation reflex**\n‚Ä¢ **Improves control** over time\n\n**2. Start-stop technique:**\n‚Ä¢ **Stop stimulation** when near ejaculation\n‚Ä¢ **Resume** after sensation subsides\n\n**3. Sensate focus therapy:**\n‚Ä¢ **Focuses** on touch, NOT performance\n‚Ä¢ **Reduces anxiety**\n\n**PHARMACOLOGICAL:**\n‚Ä¢ **SSRIs** (dapoxetine, paroxetine) - delay ejaculation\n‚Ä¢ **Topical anesthetics** (lidocaine)\n\n**WHY NOT:**\n‚Ä¢ **CBT:** For anxiety/depression\n‚Ä¢ **Exposure therapy:** For phobias/OCD\n\nüí° **KEY:** **Premature ejaculation ‚Üí Squeeze technique (behavioral)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-101",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "p A 30-year-old male is found to be positive for HBsAg and HBeAg and is diagnosed with chronic hepatitis B. The patient's viral load was 2x 100000 and SGPT is found to be doubled. e What is the appropriate management in this patient? SGPT-Serum glutamate pyruvate transaminase",
    options: [
      "Lamivudine for 30+ weeks OP2: Tenofovir for> 40 weeks O 3: Pegylated interferon for 52 weeks O4: Combined pegylated interferon with lamivudine",
      "Option 2",
      "Option 3",
      "Combined pegylated interferon with lamivudine",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Tenofovir for >40 weeks (Option B)**\n\nüî¨ **CHRONIC HEPATITIS B MANAGEMENT:**\n\n**THIS CASE - ACTIVE DISEASE:**\n‚Ä¢ **HBsAg + HBeAg positive** ‚≠ê\n‚Ä¢ **High viral load** (2√ó10‚Åµ) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Elevated ALT** (doubled) ‚≠ê\n\n**INDICATIONS FOR TREATMENT:**\n‚Ä¢ **HBeAg positive** + **HBV DNA >20,000 IU/mL** + **ALT >2√ó ULN** ‚≠ê‚≠ê‚≠ê\n\n**FIRST-LINE TREATMENT:**\n\n**1. Tenofovir** ‚≠ê‚≠ê‚≠ê **(PREFERRED)**\n‚Ä¢ **Nucleotide analog**\n‚Ä¢ **High genetic barrier** (low resistance)\n‚Ä¢ **Duration:** Indefinite (until HBeAg seroconversion + 12 months) ‚≠ê\n‚Ä¢ **Minimum:** 48 weeks\n\n**2. Entecavir** (alternative)\n\n**PEGYLATED INTERFERON:**\n‚Ä¢ **48 weeks** (finite duration)\n‚Ä¢ **Side effects** (flu-like, depression)\n‚Ä¢ Second-line\n\nüí° **KEY:** **Active CHB (HBeAg+, high VL, ‚ÜëALT) ‚Üí Tenofovir (>48 weeks)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-102",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A 25-year-old male patient complained of palpitations, sweating, and restlessness. He has a complaint of sweaty palms. Clinical findings are depicted in the image given below. r What is the diagnostic test done on this patient? e",
    options: [
      "Anti-thyroglobulin antibody d",
      "Anti-thyroid peroxidase antibody",
      "Thyroid receptor antibody",
      "Elevated ultrasensitive thyrotropin levels a",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Thyroid receptor antibody (TSH receptor antibody) (Option C)**\n\nüî¨ **GRAVES' DISEASE:**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Palpitations**, **sweating**, **restlessness** ‚≠ê\n‚Ä¢ **Sweaty palms** ‚≠ê\n‚Ä¢ **Thyrotoxicosis symptoms**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Autoantibodies** against **TSH receptor** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Stimulate** thyroid ‚Üí **Hyperthyroidism**\n\n**DIAGNOSTIC TEST:**\n‚Ä¢ **TSH receptor antibody (TRAb)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Positive in 90%** of Graves' disease\n‚Ä¢ **Stimulating antibodies**\n\n**OTHER FINDINGS:**\n‚Ä¢ **Low TSH**, **High T4/T3**\n‚Ä¢ **Diffuse goiter**\n‚Ä¢ **Exophthalmos** (if present)\n‚Ä¢ **Pretibial myxedema**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Anti-TPO/Anti-Tg:** Hashimoto's thyroiditis\n‚Ä¢ **High TSH:** Hypothyroidism\n\nüí° **KEY:** **Graves' disease ‚Üí TSH receptor antibody (TRAb)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page50_img30.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-103",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A 50-year-old HIV patient presented with a painless lesion, as shown in the image. e r P r e d d a L What is the most likely diagnosis? p",
    options: [
      "Basal cell carcinoma",
      "Kaposi sarcoma",
      "Malignant mrelanoma",
      "P Squamous cell carcinoma",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Kaposi sarcoma (Option B)**\n\nüî¨ **KAPOSI SARCOMA (KS):**\n\n**AIDS-DEFINING ILLNESS** ‚≠ê‚≠ê‚≠ê\n\n**CAUSE:** **HHV-8** (Human herpesvirus 8) ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **HIV-positive** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Painless lesions** ‚≠ê\n‚Ä¢ **Purple/violaceous plaques/nodules** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Multiple sites** (skin, oral, GI, lung)\n\n**APPEARANCE:**\n‚Ä¢ **Purple-red-brown** patches/plaques\n‚Ä¢ **Non-blanching**\n‚Ä¢ **Raised**, **vascular**\n\n**DIAGNOSIS:** **Biopsy** (spindle cells)\n\n**TREATMENT:**\n‚Ä¢ **HAART** (first-line) ‚≠ê‚≠ê‚≠ê (improves CD4, controls KS)\n‚Ä¢ **Local:** Radiation, intralesional chemo\n‚Ä¢ **Systemic:** Liposomal doxorubicin (if extensive)\n\n**TYPES:**\n‚Ä¢ **Epidemic** (AIDS-related) - most aggressive\n‚Ä¢ Classic, Endemic, Iatrogenic\n\nüí° **KEY:** **HIV + Purple painless lesions = Kaposi sarcoma (HHV-8)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-104",
    subjectId: "physiology",
    chapterId: "neet-pg-2023",
    question: "A patient came to the hospital after a road traffic accident. He had severe muscle injury, and his serum K+ level was found to be 5.5 mEq/L. What will happen to the resting membrane potential in this patient?",
    options: [
      "No change",
      "Becomes more negative",
      "Becomes more positive",
      "First becomes more positive then negative",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Becomes more positive (Depolarization) (Option C)**\n\nüî¨ **HYPERKALEMIA & MEMBRANE POTENTIAL:**\n\n**NORMAL PHYSIOLOGY:**\n‚Ä¢ **Resting membrane potential:** **-90 mV** (inside negative)\n‚Ä¢ **K+ gradient:** High inside, low outside\n‚Ä¢ **Nernst equation:** RMP ‚àù log([K+]out/[K+]in)\n\n**THIS CASE:**\n‚Ä¢ **Muscle injury** ‚Üí **K+ release** ‚≠ê\n‚Ä¢ **Serum K+ 5.5 mEq/L** (hyperkalemia) ‚≠ê\n\n**EFFECT:**\n‚Ä¢ **‚Üë Extracellular K+** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **‚Üì K+ gradient**\n‚Ä¢ **RMP becomes LESS negative** (more positive) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Example:** -90 mV ‚Üí -70 mV ‚Üí **Depolarization**\n\n**CLINICAL CONSEQUENCES:**\n‚Ä¢ **Initial:** Increased excitability\n‚Ä¢ **Severe:** Inactivation of Na+ channels ‚Üí **Weakness, arrhythmias**\n\nüí° **KEY:** **Hyperkalemia ‚Üí ‚Üë Extracellular K+ ‚Üí RMP becomes MORE POSITIVE** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-105",
    subjectId: "pediatrics",
    chapterId: "neet-pg-2023",
    question: "d A newborn presented with chest retractions, dyspnea, and lethargy. The pediatrician diagnosed the baby with respiratory distress syndrome. This occurs due to the deficiency of:",
    options: [
      "Dipalmitoyl inositol",
      "Lecithin a",
      "Sphingomyelin L",
      "Dipalmitoylphosphatidylethanolamine",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Lecithin (Dipalmitoylphosphatidylcholine - DPPC) (Option B)**\n\nüî¨ **RESPIRATORY DISTRESS SYNDROME (RDS):**\n\n**SURFACTANT COMPOSITION:**\n\n**MAIN COMPONENT:** **Dipalmitoylphosphatidylcholine (DPPC)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Also called **Lecithin** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **~80%** of surfactant lipids\n‚Ä¢ **Reduces surface tension** ‚≠ê\n\n**RDS PATHOPHYSIOLOGY:**\n‚Ä¢ **Premature birth** ‚Üí **Surfactant deficiency** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **High surface tension** ‚Üí **Alveolar collapse**\n‚Ä¢ **Respiratory distress** (retractions, dyspnea, lethargy)\n\n**FETAL LUNG MATURITY TEST:**\n‚Ä¢ **L/S ratio** (Lecithin/Sphingomyelin) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **‚â•2.0** = Mature lungs\n‚Ä¢ **<1.5** = High RDS risk\n\n**TREATMENT:**\n‚Ä¢ **Exogenous surfactant** ‚≠ê (contains DPPC)\n‚Ä¢ **Prenatal steroids** (accelerate lung maturity)\n\nüí° **KEY:** **RDS = Lecithin (DPPC) deficiency in surfactant** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-106",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "Question 106 - [Content needs manual review]",
    options: [
      "Option 1",
      "Hippocampus",
      "Cerebellum",
      "Premotor cortex",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Option 1**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page52_img31.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-107",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A 45-year-old HIV-positive male complained of persistent cough and weight loss. He has skin lesions that appear as umbilicated papules and nodules predominantly on the face, trunk, and upper extremities. Chest x-ray showed multiple bilateral nodular infiltrates. His sputum CBNAAT for tuberculosis was negative, and he has a low CD4 count. What is th e probable diagnosis? r",
    options: [
      "HIV with disseminated histoplasmosis",
      "HIV with disseminated cryptococcosis d",
      "HIV with molluscum contagiosum d",
      "HIV with tuberculosis",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **HIV with disseminated histoplasmosis (Option A)**\n\nüî¨ **DISSEMINATED HISTOPLASMOSIS IN AIDS:**\n\n**ORGANISM:** **Histoplasma capsulatum** ‚≠ê‚≠ê‚≠ê (fungus)\n\n**THIS CASE - KEY FEATURES:**\n‚Ä¢ **HIV + Low CD4** (<100) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Umbilicated papules/nodules** ‚≠ê‚≠ê‚≠ê **(CHARACTERISTIC)**\n‚Ä¢ **Face, trunk, extremities**\n‚Ä¢ **Bilateral lung nodules** ‚≠ê\n‚Ä¢ **Negative TB test**\n\n**SKIN LESIONS:**\n‚Ä¢ **Molluscum-like** (umbilicated) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **BUT:** Disseminated disease (lungs + skin)\n\n**DIAGNOSIS:**\n‚Ä¢ **Histoplasma antigen** (urine/serum) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Culture** (blood, bone marrow)\n‚Ä¢ **Biopsy:** Intracellular yeast\n\n**TREATMENT:**\n‚Ä¢ **Amphotericin B** (induction) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Itraconazole** (maintenance)\n\n**VS MOLLUSCUM:**\n‚Ä¢ **Pure molluscum:** Skin only, NO systemic disease\n\nüí° **KEY:** **AIDS + Umbilicated lesions + Lung nodules = Disseminated histoplasmosis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-108",
    subjectId: "physiology",
    chapterId: "neet-pg-2023",
    question: "p A patient met with a road traffic accident and developed a cervical spine injury. The fracture fragment had pierced the lateral aspect of the dorsal column tract. Which of the following findings is seen ein this patient?",
    options: [
      "Absence of ipsilateral lower limb proprioception r",
      "Absence of fine motor movement of fingers P",
      "Absence of ipsilateral arm proprioception",
      "Absence of contralateral lower limb proprioception",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Absence of ipsilateral arm proprioception (Option C)**\n\nüî¨ **DORSAL COLUMN ANATOMY:**\n\n**ORGANIZATION (Somatotopic):** ‚≠ê‚≠ê‚≠ê\n\n**LATERAL:** **Cuneate fasciculus** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Upper limb** (arm, trunk above T6)\n‚Ä¢ **Cervical/thoracic fibers**\n\n**MEDIAL:** **Gracile fasciculus**\n‚Ä¢ **Lower limb** (below T6)\n‚Ä¢ **Lumbar/sacral fibers**\n\n**THIS CASE:**\n‚Ä¢ **Cervical spine injury** ‚≠ê\n‚Ä¢ **LATERAL aspect damaged** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ = **Cuneate fasciculus** affected\n\n**RESULT:**\n‚Ä¢ **Loss of IPSILATERAL ARM proprioception** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ Also: vibration, fine touch (arm)\n\n**DORSAL COLUMN CARRIES:**\n‚Ä¢ **Proprioception** ‚≠ê\n‚Ä¢ **Vibration**\n‚Ä¢ **Fine touch**\n‚Ä¢ **IPSILATERAL** (crosses at medulla)\n\nüí° **KEY:** **Lateral dorsal column (cervical) = Cuneate = ARM proprioception (ipsilateral)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page53_img32.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-109",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A male patient presented to the emergency room with seizures. He has a history of fever, headache, and confusion. An MRI brain was done, and it showed inflammation involving the bitemporal lobe. What is the most likely aetiology for this presentation?",
    options: [
      "Cytomegalovirus",
      "Toxoplasma gondii",
      "Herpes simplex virus r",
      "Mycobacterium tuberculosis e",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Herpes simplex virus (HSV) (Option C)**\n\nüî¨ **HERPES SIMPLEX ENCEPHALITIS (HSE):**\n\n**MOST COMMON** sporadic viral encephalitis ‚≠ê‚≠ê‚≠ê\n\n**ORGANISM:** **HSV-1** (>95%) ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Fever**, **headache**, **confusion** ‚≠ê\n‚Ä¢ **Seizures** ‚≠ê‚≠ê‚≠ê (focal)\n‚Ä¢ **Behavioral changes**\n‚Ä¢ **Olfactory/gustatory hallucinations**\n\n**KEY IMAGING:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **MRI:** **Bitemporal lobe** involvement ‚≠ê‚≠ê‚≠ê **(CHARACTERISTIC)**\n‚Ä¢ **Hemorrhagic necrosis**\n‚Ä¢ **Medial temporal**, **inferior frontal** lobes\n\n**DIAGNOSIS:**\n‚Ä¢ **CSF PCR for HSV** ‚≠ê‚≠ê‚≠ê (gold standard)\n‚Ä¢ **CSF:** Lymphocytic pleocytosis, RBCs\n\n**TREATMENT:**\n‚Ä¢ **IV Acyclovir** ‚≠ê‚≠ê‚≠ê (10 mg/kg q8h √ó 14-21 days)\n‚Ä¢ **Start empirically** (don't wait for confirmation)\n\nüí° **KEY:** **Seizures + Confusion + Bitemporal involvement = HSV encephalitis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-110",
    subjectId: "physiology",
    chapterId: "neet-pg-2023",
    question: "Identify the true statement regarding the point marked(Red) on the myocardial action potential curve? a",
    options: [
      "Due to the opening of Na+ and closure of fast K+ channels L",
      "Due to the slow but prolonged opening of Ca2+ channels",
      "Due to the closure of Na+ and opening of the slow K+ channel",
      "Due to Na+/K+ ATPas P d",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Due to slow but prolonged opening of Ca2+ channels (Option B)**\n\nüî¨ **CARDIAC ACTION POTENTIAL (Ventricular):**\n\n**PHASE 2 - PLATEAU** ‚≠ê‚≠ê‚≠ê (marked point)\n\n**MECHANISM:**\n‚Ä¢ **Slow L-type Ca2+ channels OPEN** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Ca2+ influx** (inward current)\n‚Ä¢ **Balanced by K+ efflux**\n‚Ä¢ **Prolongs depolarization** (200-300 ms)\n\n**SIGNIFICANCE:**\n‚Ä¢ **Long refractory period** ‚≠ê\n‚Ä¢ **Prevents tetany** (unlike skeletal muscle)\n‚Ä¢ **Allows complete contraction/relaxation**\n‚Ä¢ **Ca2+ triggers contraction** (excitation-contraction coupling)\n\n**PHASES:**\n‚Ä¢ **Phase 0:** Na+ influx (rapid depolarization)\n‚Ä¢ **Phase 1:** K+ efflux (early repolarization)\n‚Ä¢ **Phase 2:** **Ca2+ influx** (plateau) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Phase 3:** K+ efflux (repolarization)\n‚Ä¢ **Phase 4:** Resting\n\nüí° **KEY:** **Plateau phase = Slow L-type Ca2+ channel opening** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-111",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A male patient presents with senLsory loss and weakness of limbs for 3 months. He also has angular stomatitis. On examination, there is loss of proprioception, vibration sensations, UMN type of lower limb weakness, and absent ankle reflex. What is the most probable diagnosis? p",
    options: [
      "Extradural cord compression e",
      "Amyotrophic lateral sclerosis",
      "Multiple sclerosis OP4: Subacute combined degeneration of cor A ns: 4",
      "Option 4",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Subacute combined degeneration of cord (Option D)**\n\nüî¨ **SUBACUTE COMBINED DEGENERATION (SCD):**\n\n**CAUSE:** **Vitamin B12 deficiency** ‚≠ê‚≠ê‚≠ê\n\n**KEY FEATURES (THIS CASE):**\n\n**1. Angular stomatitis** ‚≠ê‚≠ê‚≠ê (B12 deficiency sign)\n\n**2. COMBINED findings** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Dorsal columns:** Loss of proprioception, vibration ‚≠ê\n‚Ä¢ **Lateral corticospinal:** UMN signs (weakness, spasticity) ‚≠ê\n‚Ä¢ **Peripheral neuropathy:** Absent ankle reflex ‚≠ê\n\n**3. Subacute onset** (weeks-months)\n\n**TRIAD:**\n‚Ä¢ **Myelopathy** (UMN + dorsal column)\n‚Ä¢ **Peripheral neuropathy** (LMN)\n‚Ä¢ **Dementia** (if severe)\n\n**DIAGNOSIS:**\n‚Ä¢ **Low serum B12** (<200 pg/mL)\n‚Ä¢ **Elevated homocysteine, methylmalonic acid**\n‚Ä¢ **MRI:** T2 hyperintensity (posterior columns)\n\n**TREATMENT:** **IM Vitamin B12** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **B12 deficiency + UMN + Dorsal column + LMN = SCD** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-112",
    subjectId: "pediatrics",
    chapterId: "neet-pg-2023",
    question: "A 10-year-old child weighing 30 kg presents with a history of loose stools for 2 days. On examination, there is severe dehydration. Laboratory investigations are as follows. What is the initial management as per ISPAD guidelines? RBS 550mg/dL pH 7.01 Na+ 158mEq/L Urine glucose 3+",
    options: [
      "Manage ABC, NS 20 mL/kg and start insulin after 1 hour",
      "Manage ABC, NS 20 mL/kg along with insulin 0.1 IU/kg/h r",
      "Manage ABC, NS 10 mL/kg along with insulin 0.1 IU/kg/hr e",
      "Manage ABC, NS 10 mL/kg and start insulin after 1 hour",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Manage ABC, NS 20 mL/kg and start insulin after 1 hour (Option A)**\n\nüî¨ **DIABETIC KETOACIDOSIS (DKA) - ISPAD GUIDELINES:**\n\n**THIS CASE:**\n‚Ä¢ **RBS 550 mg/dL** (hyperglycemia)\n‚Ä¢ **pH 7.01** (severe acidosis) ‚≠ê\n‚Ä¢ **Na+ 158** (hypernatremia)\n‚Ä¢ **Severe dehydration** ‚≠ê\n\n**INITIAL MANAGEMENT (ISPAD):**\n\n**1. ABC** (Airway, Breathing, Circulation) ‚≠ê\n\n**2. FLUID RESUSCITATION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **0.9% NS 10-20 mL/kg** over 1 hour ‚≠ê\n‚Ä¢ **Repeat if needed** (max 40 mL/kg in 4 hours)\n\n**3. INSULIN:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Start AFTER 1 hour** of fluids ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **0.05-0.1 U/kg/hr** (continuous IV)\n‚Ä¢ **NO bolus** in children\n\n**WHY DELAY INSULIN:**\n‚Ä¢ **Prevent cerebral edema** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Rehydrate first**\n‚Ä¢ **Insulin shifts K+ intracellularly** (risk of hypokalemia)\n\nüí° **KEY:** **Pediatric DKA ‚Üí Fluids FIRST (1 hr), then insulin (prevent cerebral edema)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page55_img33.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-113",
    subjectId: "pediatrics",
    chapterId: "neet-pg-2023",
    question: "a Which of the following is the best sign to indicate adequate growth in an infant with a birth weight of 2.8 kg? L",
    options: [
      "Increase in length of 25 centimetres in the first year",
      "Weight gain of 300 grams per month till 1 year",
      "Anterior fontaneelle closure by 6 months of age",
      "Weight under the 75th percentile and height under the 25th percentil r",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Increase in length of 25 cm in the first year (Option A)**\n\nüî¨ **INFANT GROWTH PARAMETERS:**\n\n**LENGTH/HEIGHT:** ‚≠ê‚≠ê‚≠ê **(BEST INDICATOR)**\n‚Ä¢ **First year:** Increase by **25 cm** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Birth:** ~50 cm\n‚Ä¢ **1 year:** ~75 cm (1.5√ó birth length)\n\n**WEIGHT:**\n‚Ä¢ **Birth weight doubles** by **4-5 months**\n‚Ä¢ **Triples** by **1 year**\n‚Ä¢ **This case:** 2.8 kg ‚Üí 8.4 kg by 1 year\n‚Ä¢ **Average gain:** 25-30 g/day (first 3 months)\n\n**WHY NOT B:**\n‚Ä¢ **300 g/month** = Too low (should be ~600-700 g/month initially)\n\n**ANTERIOR FONTANELLE:**\n‚Ä¢ **Closes:** 12-18 months (NOT 6 months)\n\n**HEAD CIRCUMFERENCE:**\n‚Ä¢ Increases **12 cm** in first year\n\nüí° **KEY:** **Best growth indicator in infancy = Length increase (25 cm in first year)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-114",
    subjectId: "unknown",
    chapterId: "neet-pg-2023",
    question: "A 40-year-old female patient came with complaints of chest pain, palpitation, and shortness of breath. On examination, a mid-diastolic murmur was heard, and a prominent 'a' wave was found on JVP. What is the most likely diagnosis?",
    options: [
      "Mitral stenosis",
      "Tricuspid stenosis",
      "Mitral regurgitation",
      "Tricuspid regurgitation",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Tricuspid stenosis (Option B)**\n\nüî¨ **TRICUSPID STENOSIS:**\n\n**AUSCULTATION:**\n‚Ä¢ **Mid-diastolic murmur** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Best heard:** Lower left sternal border\n‚Ä¢ **Increases with inspiration** (Carvallo's sign) ‚≠ê\n\n**JVP FINDINGS:**\n‚Ä¢ **Prominent 'a' wave** ‚≠ê‚≠ê‚≠ê **(KEY)**\n‚Ä¢ **Slow y descent**\n\n**EXPLANATION:**\n‚Ä¢ **Stenosed tricuspid valve** ‚≠ê\n‚Ä¢ **Resistance to RA emptying**\n‚Ä¢ **Atrial contraction against stenosis** ‚Üí **Giant 'a' wave**\n\n**CAUSES:**\n‚Ä¢ **Rheumatic heart disease** (most common) ‚≠ê\n‚Ä¢ **Usually with mitral stenosis**\n‚Ä¢ Carcinoid, congenital\n\n**CLINICAL:**\n‚Ä¢ **Right heart failure** signs\n‚Ä¢ **Hepatomegaly**, **ascites**, **edema**\n\n**VS MITRAL STENOSIS:**\n‚Ä¢ **MS:** Normal JVP, opening snap\n‚Ä¢ **TS:** Prominent 'a' wave, increases with inspiration\n\nüí° **KEY:** **Mid-diastolic murmur + Prominent 'a' wave = Tricuspid stenosis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-115",
    subjectId: "pediatrics",
    chapterId: "neet-pg-2023",
    question: "e A 3-month-old baby complains of deafness, cataract, and patent ductus arteriosus. Which of the following is the most likely diagnosis? d",
    options: [
      "Congenital herpes simplex virus infection",
      "Congenital toxoplasmosis",
      "Congenital cytomegalovirus infection a",
      "Congenital rubella syndrom L",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Congenital rubella syndrome (Option D)**\n\nüî¨ **CONGENITAL RUBELLA SYNDROME (CRS):**\n\n**CLASSIC TRIAD** ‚≠ê‚≠ê‚≠ê:\n1. **Sensorineural deafness** ‚≠ê‚≠ê‚≠ê **(MOST COMMON)**\n2. **Cataracts** ‚≠ê‚≠ê‚≠ê\n3. **Patent ductus arteriosus (PDA)** ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE - ALL 3 PRESENT** ‚≠ê‚≠ê‚≠ê\n\n**OTHER FEATURES:**\n‚Ä¢ **Microcephaly**\n‚Ä¢ **Mental retardation**\n‚Ä¢ **Purpura** (blueberry muffin lesions)\n‚Ä¢ **Hepatosplenomegaly**\n\n**TIMING:**\n‚Ä¢ **First trimester** infection ‚≠ê (most severe)\n‚Ä¢ **<11 weeks:** 90% risk of defects\n\n**PREVENTION:**\n‚Ä¢ **MMR vaccine** ‚≠ê‚≠ê‚≠ê (pre-pregnancy)\n‚Ä¢ **AVOID pregnancy** for 1 month post-vaccine\n\n**VS OTHER TORCH:**\n‚Ä¢ **CMV:** Hearing loss, microcephaly (NO cataract/PDA)\n‚Ä¢ **Toxoplasma:** Chorioretinitis, hydrocephalus\n\nüí° **KEY:** **Deafness + Cataract + PDA = Congenital rubella** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-116",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "e In a village, it is observed that several farmers have crossed gait and use a stick for support to stand up and walk. Due to poor yield from farms, they consume meals containing rice and r pulses only. Supplementing their diet with which of the following vitamins could have pPrevented this?",
    options: [
      "V itamin A",
      "Vitamin D",
      "Vitamin C",
      "Vitamin B",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Vitamin B (Option D) - Likely B1/B6/B12**\n\nüî¨ **PERIPHERAL NEUROPATHY IN FARMERS:**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Crossed gait** (ataxia) ‚≠ê\n‚Ä¢ **Need stick for support** (weakness)\n‚Ä¢ **Diet:** Rice + pulses ONLY ‚≠ê (poor, monotonous)\n\n**LIKELY DIAGNOSIS:** **Peripheral neuropathy** from **B vitamin deficiency** ‚≠ê‚≠ê‚≠ê\n\n**VITAMIN B DEFICIENCIES:**\n\n**1. Vitamin B1 (Thiamine):** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Dry beriberi** (peripheral neuropathy)\n‚Ä¢ **Rice-based diet** (polished rice lacks thiamine)\n‚Ä¢ **Weakness**, **ataxia**\n\n**2. Vitamin B12:**\n‚Ä¢ **Subacute combined degeneration**\n‚Ä¢ **Ataxia** (dorsal column)\n\n**3. Vitamin B6:**\n‚Ä¢ **Peripheral neuropathy**\n\n**WHY NOT VITAMIN C:**\n‚Ä¢ **Scurvy:** Bleeding, gum disease (NOT neuropathy)\n\nüí° **KEY:** **Ataxia + Weakness + Rice diet = B vitamin deficiency (esp. B1)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-117",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "Research is being conducted to find the association between aniline dye exposure and bladder cancer in workers who have worked in the industry for >20 years. Two groups were formed: one directly involved with dye handling and the other group consisting of office clerks not directly exposed to the dye. Years of occupation were noted from records. What type of study is being performed?",
    options: [
      "Retrospective cohort study",
      "Prospective cohort study",
      "Case-control study",
      "Intervention and respons d",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Retrospective cohort study (Option A)**\n\nüî¨ **STUDY DESIGN:**\n\n**KEY FEATURES (THIS STUDY):**\n\n**1. TWO GROUPS** based on **EXPOSURE** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Exposed:** Dye handlers\n‚Ä¢ **Unexposed:** Office clerks\n\n**2. FOLLOWED OVER TIME** for outcome (bladder cancer)\n\n**3. RETROSPECTIVE** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Data from PAST records** (\"years of occupation from records\")\n‚Ä¢ **Exposure already occurred**\n‚Ä¢ **Looking back** at exposure ‚Üí outcome\n\n**COHORT STUDY CHARACTERISTICS:**\n‚Ä¢ **Start with exposure status** ‚≠ê\n‚Ä¢ **Follow for outcome**\n‚Ä¢ **Calculate:** Relative risk, incidence\n\n**VS CASE-CONTROL:**\n‚Ä¢ **Case-control:** Start with OUTCOME (cases/controls) ‚Üí look back for exposure\n\n**VS PROSPECTIVE COHORT:**\n‚Ä¢ **Prospective:** Exposure identified NOW ‚Üí follow forward\n\nüí° **KEY:** **Exposure groups + Past records ‚Üí Retrospective cohort** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-118",
    subjectId: "pediatrics",
    chapterId: "neet-pg-2023",
    question: "Chloride level in sweat is used in the diagnosis of which disease?",
    options: [
      "Phenylketonuria",
      "Cystic fibrosis",
      "Gaucher's diseas r",
      "OPsteogenesis imperfecta",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Cystic fibrosis (Option B)**\n\nüî¨ **CYSTIC FIBROSIS (CF):**\n\n**DIAGNOSTIC TEST:** **Sweat chloride test** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD)**\n\n**SWEAT CHLORIDE LEVELS:**\n‚Ä¢ **>60 mmol/L** = **Diagnostic for CF** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **40-60 mmol/L** = Borderline\n‚Ä¢ **<40 mmol/L** = Normal\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **CFTR mutation** (Cystic Fibrosis Transmembrane conductance Regulator) ‚≠ê\n‚Ä¢ **Defective Cl- channel**\n‚Ä¢ **Impaired Cl- reabsorption** from sweat\n‚Ä¢ **Thick, viscous secretions**\n\n**CLINICAL FEATURES:**\n‚Ä¢ **Recurrent lung infections** ‚≠ê\n‚Ä¢ **Pancreatic insufficiency** (steatorrhea)\n‚Ä¢ **Failure to thrive**\n‚Ä¢ **Meconium ileus** (newborn)\n‚Ä¢ **Male infertility**\n\n**TREATMENT:**\n‚Ä¢ **Chest physiotherapy**\n‚Ä¢ **Pancreatic enzymes**\n‚Ä¢ **Antibiotics** (for infections)\n‚Ä¢ **CFTR modulators** (ivacaftor)\n\nüí° **KEY:** **Sweat chloride test = Diagnostic for Cystic fibrosis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page58_img34.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-119",
    subjectId: "pediatrics",
    chapterId: "neet-pg-2023",
    question: "A child presents with fever and a rash spreading from the face, behind cheeks, and buccal mucosa to other body parts. On examination, Koplik's spot is present. What is the likely diagnosis?",
    options: [
      "Measles",
      "Rubella",
      "Varicella",
      "Mumps",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Measles (Option A)**\n\nüî¨ **MEASLES (Rubeola):**\n\n**PATHOGNOMONIC SIGN:** **Koplik's spots** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **White spots** on **buccal mucosa** (opposite molars)\n‚Ä¢ **Appear 2-3 days before rash** ‚≠ê\n‚Ä¢ **Disappear as rash appears**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Fever** ‚≠ê\n‚Ä¢ **Rash:** Face ‚Üí trunk ‚Üí extremities (cephalocaudal) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Behind ears first**\n‚Ä¢ **Koplik's spots** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC)**\n\n**3 C's:**\n‚Ä¢ **Cough**\n‚Ä¢ **Coryza** (runny nose)\n‚Ä¢ **Conjunctivitis**\n\n**COMPLICATIONS:**\n‚Ä¢ **Pneumonia** (most common)\n‚Ä¢ **Encephalitis**\n‚Ä¢ **SSPE** (subacute sclerosing panencephalitis)\n\n**PREVENTION:** **MMR vaccine** ‚≠ê‚≠ê‚≠ê\n\n**VS RUBELLA:**\n‚Ä¢ **Rubella:** Mild, no Koplik's, postauricular lymphadenopathy\n\nüí° **KEY:** **Koplik's spots = Pathognomonic for Measles** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-120",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "The blood pressure of a population was tracked from childhood to adulthood. It was observed d that those who had lower BP in childhood had low BP in adulthood, while those who had higher BP in childhood had high BP in adulthood. This can be best described as",
    options: [
      "Rule of halves",
      "Tracking of blood pressure a",
      "STEPwise approach",
      "Primordial approach",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Tracking of blood pressure (Option B)**\n\nüî¨ **TRACKING PHENOMENON:**\n\n**DEFINITION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Maintenance of relative rank** over time\n‚Ä¢ **Childhood BP status PREDICTS adult BP status** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **High in childhood ‚Üí High in adulthood**\n‚Ä¢ **Low in childhood ‚Üí Low in adulthood**\n\n**THIS CASE:** Perfect example of tracking ‚≠ê\n\n**SIGNIFICANCE:**\n‚Ä¢ **Identifies high-risk children** early\n‚Ä¢ **Early intervention** can prevent adult hypertension\n‚Ä¢ **Prevention starts in childhood**\n\n**OTHER CONCEPTS:**\n\n**Rule of halves (HTN):**\n‚Ä¢ 1/2 know they have HTN\n‚Ä¢ 1/2 of those on treatment\n‚Ä¢ 1/2 of those controlled\n\n**STEPwise approach:**\n‚Ä¢ WHO surveillance method\n\n**Primordial prevention:**\n‚Ä¢ Prevent risk factors from developing\n\nüí° **KEY:** **Childhood BP predicts adult BP = Tracking** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page59_img35.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-121",
    subjectId: "pediatrics",
    chapterId: "neet-pg-2023",
    question: "Question 121 - [Content needs manual review]",
    options: [
      "Option 1",
      "Amoxicillin",
      "Cotrimoxazole",
      "Clarithromycin",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Option 1**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-122",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "A 30-week primigravida complaints of reduced vision at night. She has been avoiding papaya, mango, and other fruits throughout her pregnancy as she thinks they could be abortifacients. It is the primary duty of which of the following workers to provide counseling and information to the patient?",
    options: [
      "ANM",
      "AWW",
      "Trained birth attendant",
      "ASHA d",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **ASHA (Accredited Social Health Activist) (Option D)**\n\nüî¨ **NIGHT BLINDNESS IN PREGNANCY:**\n\n**THIS CASE:**\n‚Ä¢ **30-week pregnant** (3rd trimester)\n‚Ä¢ **Night blindness** ‚≠ê‚≠ê‚≠ê (Vitamin A deficiency)\n‚Ä¢ **Avoiding fruits** (papaya, mango - rich in Vitamin A)\n\n**HEALTH WORKERS & ROLES:**\n\n**ASHA (Accredited Social Health Activist):** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **PRIMARY contact** between community and health system\n‚Ä¢ **Health education & counseling** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Antenatal home visits**\n‚Ä¢ **Dispels myths/misconceptions**\n‚Ä¢ **Promotes institutional delivery**\n\n**ANM (Auxiliary Nurse Midwife):**\n‚Ä¢ **Sub-center level**\n‚Ä¢ **Clinical care**, immunization\n\n**AWW (Anganwadi Worker):**\n‚Ä¢ **Nutrition** supplementation (ICDS)\n‚Ä¢ **Pre-school education**\n\n**TBA (Trained Birth Attendant):**\n‚Ä¢ **Assists in deliveries**\n\nüí° **KEY:** **ASHA = Primary health educator & counselor at community level** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-123",
    subjectId: "ent",
    chapterId: "neet-pg-2023",
    question: "Identify the structure marked in the image. p e r P",
    options: [
      "Fossa of Rosenmuller",
      "Tubal tonsil",
      "Opening of the Eustachian tube",
      "Adenoid",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Fossa of Rosenmuller (Option A)**\n\nüî¨ **FOSSA OF ROSENMULLER (Pharyngeal recess):**\n\n**ANATOMY:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Depression** in **nasopharynx** lateral wall\n‚Ä¢ **Behind** Eustachian tube opening ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Above** torus tubarius\n‚Ä¢ **Lateral pharyngeal recess**\n\n**CLINICAL SIGNIFICANCE:**\n‚Ä¢ **NASOPHARYNGEAL CARCINOMA** ‚≠ê‚≠ê‚≠ê **(NPC)**\n‚Ä¢ **Most common site** for NPC to originate\n‚Ä¢ **Blind spot** on examination (difficult to see)\n‚Ä¢ **Requires nasopharyngoscopy** for proper visualization\n\n**NASOPHARYNGEAL STRUCTURES:**\n‚Ä¢ **Adenoid** (posterior wall)\n‚Ä¢ **Torus tubarius** (elevation around Eustachian opening)\n‚Ä¢ **Eustachian tube opening** (lateral wall)\n‚Ä¢ **Fossa of Rosenmuller** (behind torus) ‚≠ê\n\n**NPC RISK FACTORS:**\n‚Ä¢ **EBV** (Epstein-Barr virus)\n‚Ä¢ **Chinese ethnicity**\n‚Ä¢ **Salted fish** consumption\n\nüí° **KEY:** **Fossa of Rosenmuller = Site of nasopharyngeal carcinoma** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-124",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "A 22-year-old female comes to the STI clinic with minimal vaginal dischargre. On speculum examination, erosions are seen on the cervix. Which of the following kit should be given to this patient? e",
    options: [
      "Green d",
      "Red",
      "Grey",
      "Yellow a",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Grey kit (Option C)**\n\nüî¨ **STI SYNDROMIC MANAGEMENT - COLOR-CODED KITS:**\n\n**THIS CASE:**\n‚Ä¢ **Minimal vaginal discharge**\n‚Ä¢ **Cervical erosions** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ = **CERVICITIS** syndrome\n\n**GREY KIT** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **For:** Cervicitis\n‚Ä¢ **Contains:**\n  - **Azithromycin 1g** (single dose) - for Chlamydia ‚≠ê\n  - **Cefixime 400mg** (single dose) - for Gonorrhea ‚≠ê\n\n**OTHER KITS:**\n\n**RED KIT:** Genital ulcer disease\n‚Ä¢ Azithromycin + Benzathine penicillin\n\n**YELLOW KIT:** Urethral discharge\n‚Ä¢ Azithromycin + Cefixime\n\n**GREEN KIT:** Vaginal discharge\n‚Ä¢ Fluconazole + Metronidazole + Azithromycin\n\n**BLUE KIT:** Lower abdominal pain (PID)\n‚Ä¢ Doxycycline + Metronidazole + Cefixime\n\nüí° **KEY:** **Cervical erosions/Cervicitis = Grey kit (Azithromycin + Cefixime)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-125",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "The years of potential life lost could be attributed to, e",
    options: [
      "Years lost to morbidity",
      "Years lost due to premature death OP3: Years lost to disability O 4: Years lost to poor quality of life",
      "Option 3",
      "Option 4",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Years lost due to premature death (Option B)**\n\nüî¨ **YEARS OF POTENTIAL LIFE LOST (YPLL):**\n\n**DEFINITION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Years lost due to PREMATURE death** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Death **before expected age** (e.g., before 65 or 75 years)\n‚Ä¢ **Mortality indicator**\n\n**CALCULATION:**\n‚Ä¢ YPLL = (Expected age) - (Age at death)\n‚Ä¢ **Example:** Death at 40, expected 75 ‚Üí YPLL = 35 years\n\n**SIGNIFICANCE:**\n‚Ä¢ **Emphasizes deaths at younger ages** ‚≠ê\n‚Ä¢ **Different from crude mortality rate**\n‚Ä¢ **Accidents/injuries** rank higher with YPLL\n\n**OTHER CONCEPTS:**\n\n**DALY (Disability-Adjusted Life Years):**\n‚Ä¢ **YLL** (Years of Life Lost) + **YLD** (Years Lost to Disability)\n‚Ä¢ **Combines mortality & morbidity** ‚≠ê\n\n**QALY (Quality-Adjusted Life Years):**\n‚Ä¢ **Accounts for quality of life**\n\nüí° **KEY:** **YPLL = Years lost due to PREMATURE death** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-126",
    subjectId: "ent",
    chapterId: "neet-pg-2023",
    question: "The instrument shown in the image is not used for which of the following? r e d",
    options: [
      "Airway toileting",
      "Upper airway examination a",
      "Acute nasopharyngeal obstruction L",
      "Prolonged mechanical ventilation",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Upper airway examination (Option B) - NOT used for this**\n\nüî¨ **TRACHEOSTOMY TUBE:**\n\n**INDICATIONS (USED FOR):**\n\n**1. Airway toileting** ‚≠ê\n‚Ä¢ Suction secretions\n‚Ä¢ Pulmonary hygiene\n\n**2. Prolonged mechanical ventilation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **>2 weeks** intubation expected\n‚Ä¢ **Less trauma** than endotracheal tube\n\n**3. Acute upper airway obstruction** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bypasses obstruction**\n‚Ä¢ Ludwig's angina, epiglottitis, trauma\n\n**NOT USED FOR:**\n‚Ä¢ **Upper airway EXAMINATION** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Tracheostomy bypasses** upper airway\n‚Ä¢ **Cannot visualize** pharynx/larynx through it\n\n**FOR UPPER AIRWAY EXAM, USE:**\n‚Ä¢ **Laryngoscopy** (direct/indirect)\n‚Ä¢ **Nasopharyngoscopy**\n‚Ä¢ **Fiberoptic endoscopy**\n\nüí° **KEY:** **Tracheostomy tube bypasses (not examines) upper airway** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-127",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "r In a 10-year-old school child, which of the following vaccines is given as a part of the school imPmunization program?",
    options: [
      "M easles vaccine",
      "Rotavirus vaccine",
      "TT/Td vaccine",
      "Hepatitis B vaccine",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **TT/Td vaccine (Tetanus Toxoid/Tetanus-diphtheria) (Option C)**\n\nüî¨ **SCHOOL IMMUNIZATION PROGRAM:**\n\n**AGE 10 YEARS:** **TT/Td vaccine** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Tetanus toxoid** booster\n‚Ä¢ Or **Td** (Tetanus + reduced diphtheria)\n\n**NATIONAL IMMUNIZATION SCHEDULE:**\n\n**SCHOOL ENTRY (5-6 years):**\n‚Ä¢ **DPT booster** (1st booster)\n‚Ä¢ **OPV booster**\n\n**10 YEARS:**\n‚Ä¢ **TT/Td** ‚≠ê‚≠ê‚≠ê\n\n**16 YEARS:**\n‚Ä¢ **Td** (2nd booster)\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Measles:** Given at 9-12 months (NOT at 10 years)\n‚Ä¢ **Rotavirus:** Given in infancy (<6 months)\n‚Ä¢ **Hepatitis B:** Birth, 6 weeks, 6 months (NOT at 10 years)\n\n**TT SCHEDULE:**\n‚Ä¢ **Total 5 doses** for lifetime protection\n‚Ä¢ **Pregnant women:** 2 doses (Td1, Td2)\n\nüí° **KEY:** **10-year school immunization = TT/Td vaccine** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-128",
    subjectId: "ent",
    chapterId: "neet-pg-2023",
    question: "A 10-year-old child presents with throat pain, fever, and ear pain. He is diagnosed with recurrent tonsillitis. Which nerve is responsible for the ear pain in this patient?",
    options: [
      "Tympanic branch of the glossopharyngeal nerve",
      "Greater auricular nerve r",
      "Auriculotemporal nerve",
      "Auricular branch of the vagus nerv d",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Tympanic branch of the glossopharyngeal nerve (CN IX) (Option A)**\n\nüî¨ **REFERRED OTALGIA (Ear pain):**\n\n**THIS CASE:**\n‚Ä¢ **Tonsillitis** (throat pain, fever) ‚≠ê\n‚Ä¢ **Ear pain** WITHOUT ear pathology ‚≠ê‚≠ê‚≠ê\n‚Ä¢ = **REFERRED pain**\n\n**MECHANISM:**\n‚Ä¢ **Glossopharyngeal nerve (CN IX)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Supplies:** Tonsils, pharynx, AND middle ear\n‚Ä¢ **Tympanic branch (Jacobson's nerve)** ‚Üí middle ear ‚≠ê\n‚Ä¢ **Tonsillar branch** ‚Üí tonsils\n‚Ä¢ **Common nerve** ‚Üí referred pain\n\n**SENSORY INNERVATION OF EAR:**\n\n**Middle ear:** CN IX (tympanic branch) ‚≠ê‚≠ê‚≠ê\n**External ear:**\n‚Ä¢ **Auriculotemporal** (CN V3) - anterior\n‚Ä¢ **Greater auricular** (C2-C3) - posterior\n‚Ä¢ **Auricular branch of vagus** (Arnold's nerve)\n\n**CAUSES OF REFERRED OTALGIA:**\n‚Ä¢ **Tonsillitis/pharyngitis** (CN IX) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **TMJ disorders** (CN V3)\n‚Ä¢ **Dental problems** (CN V3)\n‚Ä¢ **Laryngeal cancer** (CN X)\n\nüí° **KEY:** **Tonsillitis ‚Üí Referred ear pain via CN IX (same nerve supply)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page63_img36.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-129",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "Which of the following statements is true about cancer treatment according to the Colombo plan? L",
    options: [
      "Help with PET scan units for diagnosis of cance p",
      "Human resource strengthening",
      "Setting up chemotherapy units",
      "Setting up cobalt therapy units r",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Setting up cobalt therapy units (Option D)**\n\nüî¨ **COLOMBO PLAN (Cancer Control):**\n\n**FOCUS:** **Radiotherapy infrastructure** ‚≠ê‚≠ê‚≠ê\n\n**MAIN COMPONENT:**\n‚Ä¢ **Cobalt-60 therapy units** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Teletherapy** (external beam radiotherapy)\n‚Ä¢ **Cancer treatment** in developing countries\n\n**BACKGROUND:**\n‚Ä¢ **1995** - Indian initiative\n‚Ä¢ **Assist neighboring countries**\n‚Ä¢ **Sri Lanka, Bangladesh, Myanmar, etc.**\n‚Ä¢ **Provide radiotherapy** facilities\n\n**COBALT-60 UNITS:**\n‚Ä¢ **Gamma radiation** source\n‚Ä¢ **Cancer treatment** (teletherapy)\n‚Ä¢ **Cost-effective** alternative to linear accelerators\n‚Ä¢ **Simpler maintenance**\n\n**CONTRAST:**\n‚Ä¢ **NOT** for PET scans (diagnostic)\n‚Ä¢ **NOT** chemotherapy-focused\n‚Ä¢ **Primary focus:** RADIOTHERAPY ‚≠ê\n\nüí° **KEY:** **Colombo Plan = Setting up Cobalt-60 radiotherapy units** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-130",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "A poor farmer with a history of successive crop failure develops progressive spastic paraparesis, signs of upper motor neuron paralysis, and gait instability. Name the toxin responsible for this condition.",
    options: [
      "Aflatoxin",
      "Beta-oxalyl-amino-alanine",
      "Ergot alkaloids",
      "Fusarium toxin",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Beta-oxalyl-amino-alanine (BOAA) (Option B)**\n\nüî¨ **LATHYRISM:**\n\n**TOXIN:** **Beta-N-oxalyl-amino-L-alanine (BOAA)** ‚≠ê‚≠ê‚≠ê\n\n**SOURCE:** **Lathyrus sativus** (Grass pea/Khesari dal) ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Progressive spastic paraparesis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **UMN signs** (hyperreflexia, extensor plantars) ‚≠ê\n‚Ä¢ **Gait instability** (scissoring gait)\n‚Ä¢ **Lower limb weakness**\n‚Ä¢ **IRREVERSIBLE** neurological damage\n\n**CONTEXT:**\n‚Ä¢ **Poor farmers** ‚≠ê\n‚Ä¢ **Crop failure** ‚Üí Reliance on cheap Khesari dal\n‚Ä¢ **Prolonged consumption** (>3 months)\n\n**MECHANISM:**\n‚Ä¢ **Excitotoxic** to motor neurons\n‚Ä¢ **Upper motor neuron** damage (corticospinal tract)\n\n**OTHER TOXINS:**\n‚Ä¢ **Aflatoxin:** Hepatotoxic (liver cancer)\n‚Ä¢ **Ergot:** Gangrene, convulsions\n‚Ä¢ **Fusarium:** Alimentary toxic aleukia\n\nüí° **KEY:** **Lathyrism = BOAA from Khesari dal ‚Üí Spastic paraparesis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-131",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "e A young male came to the hospital with a clean-cut wound without any bleeding. The patient received a full course of tetanus vaccination 10 years ago. What is the best management for this patient? d",
    options: [
      "Human tetanus immunoglobulin and full course of vaccine",
      "Human tetanus immunoglobulin only",
      "Single-dose tetanus toxoid a",
      "Full course tetanus toxoid",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Single-dose tetanus toxoid (Option C)**\n\nüî¨ **TETANUS PROPHYLAXIS IN WOUNDS:**\n\n**THIS CASE:**\n‚Ä¢ **Clean wound** ‚≠ê (low risk)\n‚Ä¢ **Full vaccination 10 years ago** ‚≠ê‚≠ê‚≠ê\n\n**MANAGEMENT:** **Single TT booster** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**TETANUS PROPHYLAXIS GUIDE:**\n\n**CLEAN, MINOR WOUNDS:**\n‚Ä¢ **<3 primary doses:** Complete series\n‚Ä¢ **‚â•3 doses, last >10 years:** **TT booster** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **‚â•3 doses, last <10 years:** Nothing\n‚Ä¢ **NO need for TIG**\n\n**DIRTY/TETANUS-PRONE WOUNDS:**\n‚Ä¢ **<3 doses:** TT + **TIG** ‚≠ê\n‚Ä¢ **‚â•3 doses, last >5 years:** TT booster\n‚Ä¢ **‚â•3 doses, last <5 years:** Nothing\n\n**TETANUS-PRONE WOUNDS:**\n‚Ä¢ **>6 hours old**\n‚Ä¢ **>1 cm deep**\n‚Ä¢ **Contaminated** (soil, feces)\n‚Ä¢ **Devitalized tissue**\n\nüí° **KEY:** **Clean wound + Vaccinated >10 yrs ago = Single TT booster** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-132",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "e How is water collected for bacteriological examination during a disease outbreak?",
    options: [
      "Collect water from already leaking taps OP2: Before collecting, let water flow for at least 1 minut O 3: Water sample container is kept close to the tap avoid spillag O4: Collect from a gentle stream of water to avoid splashing",
      "Option 2",
      "Option 3",
      "Collect from a gentle stream of water to avoid splashing",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Collect from a gentle stream of water to avoid splashing (Option D)**\n\nüî¨ **BACTERIOLOGICAL WATER SAMPLING:**\n\n**CORRECT TECHNIQUE:**\n\n**1. Collect from gentle stream** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Avoid splashing** (prevents contamination)\n‚Ä¢ **Avoid air bubbles**\n\n**2. Let water flow 2-3 minutes FIRST** ‚≠ê\n‚Ä¢ **NOT \"at least 1 minute\"** (too short)\n‚Ä¢ **Flush stagnant water**\n‚Ä¢ **Get representative sample**\n\n**3. Use sterile bottle** ‚≠ê\n‚Ä¢ **Sodium thiosulfate** (if chlorinated)\n‚Ä¢ **Leave air space** (for mixing)\n\n**4. Transport:**\n‚Ä¢ **<6 hours** (or refrigerate)\n‚Ä¢ **Ice pack** (4¬∞C)\n\n**WRONG:**\n‚Ä¢ ‚ùå **Leaking taps** (contaminated)\n‚Ä¢ ‚ùå **Only 1 minute** flow (insufficient)\n‚Ä¢ ‚ùå **Bottle close to tap** (splash contamination)\n\n**SAMPLING SITES:**\n‚Ä¢ **Distribution system**\n‚Ä¢ **Source** (well, tank)\n‚Ä¢ **Consumer tap**\n\nüí° **KEY:** **Gentle stream to avoid splashing (prevents false contamination)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-133",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "A boys' hostel has an outbreak of fever cases with headache, followed by the development of pleomorphic rashes sparing palms and soles. What is the next best step in the management of suspected cases? VZIG-Varicella zoster immunoglobulin",
    options: [
      "Isolate for 6 days after giving acyclovir, followed by VZIG within 72 hours of exposure.",
      "Isolate for 12 days after giving acyclovir, followed by VZIG within 48 hours of exposure",
      "Isolate for 6 days r",
      "Only give VZIG",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Isolate for 6 days (Option C)**\n\nüî¨ **CHICKENPOX OUTBREAK MANAGEMENT:**\n\n**THIS CASE:**\n‚Ä¢ **Fever + headache**\n‚Ä¢ **Pleomorphic rash** ‚≠ê‚≠ê‚≠ê (macules, papules, vesicles, crusts together)\n‚Ä¢ **Spares palms & soles** ‚≠ê\n‚Ä¢ = **CHICKENPOX (Varicella)**\n\n**ISOLATION:**\n‚Ä¢ **Isolate for 6 days** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Until all lesions crust over** (usually 5-7 days)\n‚Ä¢ **Highly contagious** (airborne + contact)\n\n**VZIG (Varicella-Zoster Immunoglobulin):**\n‚Ä¢ **For HIGH-RISK exposed contacts** only ‚≠ê\n‚Ä¢ **NOT for index cases** (already infected)\n‚Ä¢ **Within 96 hours** of exposure\n‚Ä¢ **High-risk:** Immunocompromised, pregnant, neonates\n\n**ACYCLOVIR:**\n‚Ä¢ **Consider for:** Adults, immunocompromised, severe cases\n‚Ä¢ **NOT routine** for healthy children\n\n**OUTBREAK CONTROL:**\n‚Ä¢ **Isolate cases** ‚≠ê\n‚Ä¢ **Identify contacts**\n‚Ä¢ **Vaccinate susceptible contacts**\n\nüí° **KEY:** **Chickenpox cases ‚Üí Isolate for 6 days (until crusting)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-134",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A patient who is a known case of hyperteansion on multiple anti-hypertensive medications came to OPD. His ECG finding is given below. Which of the following drugs is responsible for the ECG finding? L p e r P",
    options: [
      "Prazosin",
      "Metoprolol",
      "Hydrochlorothiazide",
      "Spironolactone",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Spironolactone (Option D)**\n\nüî¨ **SPIRONOLACTONE & ECG CHANGES:**\n\n**ECG FINDING:** Likely **HYPERKALEMIA** ‚≠ê‚≠ê‚≠ê\n\n**SPIRONOLACTONE:**\n‚Ä¢ **Potassium-sparing diuretic** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Aldosterone antagonist**\n‚Ä¢ **Causes HYPERKALEMIA** ‚≠ê‚≠ê‚≠ê\n\n**HYPERKALEMIA ECG CHANGES:** (Progressive)\n1. **Peaked T waves** ‚≠ê‚≠ê‚≠ê (earliest)\n2. **Prolonged PR**\n3. **Wide QRS**\n4. **Loss of P wave**\n5. **Sine wave** (pre-arrest)\n\n**OTHER DRUGS:**\n‚Ä¢ **Prazosin:** Alpha blocker (no K+ effect)\n‚Ä¢ **Metoprolol:** Beta blocker (no K+ effect)\n‚Ä¢ **HCTZ:** Thiazide ‚Üí **HYPOKALEMIA** (opposite)\n\n**TREATMENT:**\n‚Ä¢ **Stop spironolactone** ‚≠ê\n‚Ä¢ **Calcium gluconate** (cardiac protection)\n‚Ä¢ **Insulin + glucose** (shift K+ intracellularly)\n\nüí° **KEY:** **Spironolactone ‚Üí Hyperkalemia ‚Üí Peaked T waves on ECG** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-135",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A 78-year-old woman presents with a progressive decline in daily activity. She gives a history of convulsions and visual hallucinations. She does not talk to anyone and keeps looking at the sky. Pathological examination shows the presence of Lewy bodies within the neurons. What is r the most probable diagnosis? e",
    options: [
      "Parkinson's disease",
      "Prion disease",
      "Huntington's chorea",
      "Alzheimer's diseas a",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Dementia with Lewy Bodies (DLB) - but answer is Parkinson's disease (Option A)**\n\nüî¨ **LEWY BODY DEMENTIA (DLB):**\n\n**THIS CASE - CLASSIC FEATURES:**\n‚Ä¢ **Progressive cognitive decline** ‚≠ê\n‚Ä¢ **Visual hallucinations** ‚≠ê‚≠ê‚≠ê **(CHARACTERISTIC)**\n‚Ä¢ **Fluctuating cognition** (staring at sky)\n‚Ä¢ **Lewy bodies** in neurons ‚≠ê‚≠ê‚≠ê\n\n**CORE FEATURES (2+ for diagnosis):**\n1. **Fluctuating cognition** ‚≠ê\n2. **Visual hallucinations** ‚≠ê‚≠ê‚≠ê\n3. **REM sleep behavior disorder**\n4. **Parkinsonism** (rigidity, tremor)\n\n**PATHOLOGY:**\n‚Ä¢ **Lewy bodies** (Œ±-synuclein aggregates) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Cortical distribution** (vs PD: substantia nigra)\n\n**VS PARKINSON'S:**\n‚Ä¢ **PD:** Motor >> Cognitive (dementia late)\n‚Ä¢ **DLB:** Cognitive + Motor together\n\n**VS ALZHEIMER'S:**\n‚Ä¢ **AD:** Memory loss, no hallucinations early\n‚Ä¢ **Neurofibrillary tangles** (not Lewy bodies)\n\nüí° **KEY:** **Visual hallucinations + Lewy bodies = DLB (spectrum with PD)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-136",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A patient came to the medical OPD with complaints of polyuria. He has a history of undergoing total hypophyseectomy. His Na+ levels are found to be 155 mEq/ L, urine osmolarity was 200 mOsm/L. What is the definitive management in this patient?",
    options: [
      "DDAVP for 2 weeks and then discontinu P",
      "DDAVP supplementation for lifelong",
      "Upsetting of receptors so no treatment is required",
      "Thiazides for 2 weeks",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **DDAVP supplementation for lifelong (Option B)**\n\nüî¨ **CENTRAL DIABETES INSIPIDUS (Post-hypophysectomy):**\n\n**THIS CASE:**\n‚Ä¢ **Total hypophysectomy** ‚≠ê‚≠ê‚≠ê (pituitary removed)\n‚Ä¢ **Polyuria** ‚≠ê\n‚Ä¢ **Hypernatremia** (Na+ 155 mEq/L) ‚≠ê\n‚Ä¢ **Low urine osmolality** (200 mOsm/L) ‚≠ê\n‚Ä¢ = **CENTRAL DI**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **No ADH production** ‚≠ê‚≠ê‚≠ê (pituitary removed)\n‚Ä¢ **Cannot concentrate urine**\n‚Ä¢ **Water loss** ‚Üí Hypernatremia\n\n**TREATMENT:**\n‚Ä¢ **DDAVP (Desmopressin) LIFELONG** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Synthetic ADH analog**\n‚Ä¢ **Cannot recover** (no pituitary)\n‚Ä¢ **Intranasal or oral**\n\n**MONITORING:**\n‚Ä¢ **Serum sodium**\n‚Ä¢ **Urine output**\n‚Ä¢ **Avoid overtreatment** (hyponatremia)\n\n**WHY NOT OTHERS:**\n‚Ä¢ **2 weeks only:** Inadequate (permanent DI)\n‚Ä¢ **Thiazides:** For nephrogenic DI (not central)\n\nüí° **KEY:** **Post-hypophysectomy DI = Lifelong DDAVP** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-137",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A 65-year-old chronic smoker came to the medicine outpatient department with complaints of upper chest discomfort and drooping of an eyelid. He also complained of pain radiating to the upper arm and a tingling sensation in the 4th and 5th digits of his left hand. The chest X-ray is given below. r e d d a L p Which of the folleowing is the most likely diagnosis?",
    options: [
      "Pancoast tumou r",
      "Upper lobe pneumoni P",
      "Superior vena cava obstruction",
      "Aspergilloma",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Pancoast tumor (Superior sulcus tumor) (Option A)**\n\nüî¨ **PANCOAST TUMOR (SYNDROME):**\n\n**LOCATION:** **Lung apex** (superior sulcus) ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE - CLASSIC FEATURES:**\n‚Ä¢ **Chronic smoker** ‚≠ê\n‚Ä¢ **Horner's syndrome** (drooping eyelid) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Shoulder/chest pain** (T1 involvement) ‚≠ê\n‚Ä¢ **C8-T1 symptoms** (4th & 5th digit tingling) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Upper lobe mass** on CXR\n\n**PANCOAST SYNDROME (Triad):**\n1. **Horner's syndrome** ‚≠ê‚≠ê‚≠ê (ptosis, miosis, anhidrosis)\n   - **Sympathetic chain** invasion\n2. **Shoulder/arm pain** ‚≠ê\n   - **Brachial plexus** (C8-T1) invasion\n3. **Upper lobe mass**\n\n**DIAGNOSIS:**\n‚Ä¢ **CT/MRI** chest\n‚Ä¢ **Biopsy** (usually NSCLC - squamous/adenocarcinoma)\n\n**TREATMENT:**\n‚Ä¢ **Neoadjuvant chemoradiation** ‚≠ê\n‚Ä¢ **Surgical resection** (if resectable)\n\nüí° **KEY:** **Lung apex mass + Horner's + C8-T1 involvement = Pancoast tumor** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-138",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A chronic alcoholic patient presents with acute pain and swelling of the left great toe. There is no history of trauma. Synovial fluid analysis shows raised leukocytes. Lab investigations show normal serum uric acid levels. What is the most likely diagnosis?",
    options: [
      "Pseudogout",
      "Acute gout",
      "Reactive arthritis",
      "Septic arthritis r",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Acute gout (Option B)**\n\nüî¨ **ACUTE GOUT:**\n\n**THIS CASE:**\n‚Ä¢ **Chronic alcoholic** ‚≠ê\n‚Ä¢ **Acute pain/swelling** of **1st MTP** (great toe) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **No trauma**\n‚Ä¢ **NORMAL serum uric acid** ‚≠ê‚≠ê‚≠ê **(KEY POINT)**\n\n**IMPORTANT:** **Serum uric acid CAN BE NORMAL during acute attack** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **~30% of acute gout** has normal uric acid\n‚Ä¢ **During attack:** Uric acid precipitates in joint\n‚Ä¢ **Serum level drops** temporarily\n\n**DIAGNOSIS:**\n‚Ä¢ **Synovial fluid analysis** ‚≠ê‚≠ê‚≠ê (GOLD STANDARD)\n‚Ä¢ **Needle-shaped negatively birefringent crystals** (under polarized light)\n‚Ä¢ **Monosodium urate crystals**\n\n**RISK FACTORS:**\n‚Ä¢ **Alcohol** ‚≠ê (especially beer)\n‚Ä¢ **High purine diet**\n‚Ä¢ **Diuretics**\n\n**TREATMENT:**\n‚Ä¢ **NSAIDs** (indomethacin) ‚≠ê\n‚Ä¢ **Colchicine**\n‚Ä¢ **Corticosteroids**\n\nüí° **KEY:** **Normal uric acid does NOT exclude acute gout** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page68_img37.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-139",
    subjectId: "psychiatry",
    chapterId: "neet-pg-2023",
    question: "d A chronic alcoholic is brought to the emergency department with confusion, ataxia, and painful eye movements. The 6th cranial nerve is also involved. What is the likely diagnosis?",
    options: [
      "Wernicke's encephalopathy",
      "Korsakoff psychosis L",
      "Delirium tremens p",
      "De Clerambault syndrome",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Wernicke's encephalopathy (Option A)**\n\nüî¨ **WERNICKE'S ENCEPHALOPATHY:**\n\n**CAUSE:** **Thiamine (Vitamin B1) deficiency** ‚≠ê‚≠ê‚≠ê\n\n**CLASSIC TRIAD:** ‚≠ê‚≠ê‚≠ê\n1. **Confusion** (altered mental status) ‚≠ê\n2. **Ataxia** (gait instability) ‚≠ê\n3. **Ophthalmoplegia** (eye movement abnormalities) ‚≠ê\n\n**THIS CASE - ALL 3 PRESENT + CN VI involvement** ‚≠ê‚≠ê‚≠ê\n\n**EYE FINDINGS:**\n‚Ä¢ **CN VI palsy** (abducens) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Horizontal nystagmus** (most common)\n‚Ä¢ **Conjugate gaze palsy**\n\n**CONTEXT:**\n‚Ä¢ **Chronic alcoholic** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Malnutrition** ‚Üí Thiamine deficiency\n\n**TREATMENT:**\n‚Ä¢ **IV Thiamine** (100-500 mg) ‚≠ê‚≠ê‚≠ê **(URGENT)**\n‚Ä¢ **BEFORE glucose** (glucose can worsen)\n\n**PROGNOSIS:**\n‚Ä¢ **Reversible** if treated early ‚≠ê\n‚Ä¢ **Untreated** ‚Üí Korsakoff syndrome (irreversible memory loss)\n\nüí° **KEY:** **Alcoholic + Confusion + Ataxia + Ophthalmoplegia = Wernicke's** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-140",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 mg/dL. The plasma therapeutic range is 1 mg/dL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?",
    options: [
      "40 hours",
      "80 hours",
      "120 hours",
      "140-180 hours",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **80 hours (Option B)**\n\nüî¨ **DIGOXIN TOXICITY - RESUMPTION CALCULATION:**\n\n**GIVEN:**\n‚Ä¢ **Current level:** 4 mg/dL ‚≠ê\n‚Ä¢ **Therapeutic level:** 1 mg/dL ‚≠ê\n‚Ä¢ **Half-life:** 40 hours ‚≠ê\n‚Ä¢ **Need to reduce:** 4 ‚Üí 1 mg/dL (4-fold reduction)\n\n**HALF-LIFE CALCULATION:**\n\n**After 1 half-life (40 hrs):** 4 ‚Üí 2 mg/dL\n**After 2 half-lives (80 hrs):** 2 ‚Üí 1 mg/dL ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**FORMULA:**\n‚Ä¢ **Number of half-lives** = log‚ÇÇ(Current/Target)\n‚Ä¢ log‚ÇÇ(4/1) = log‚ÇÇ(4) = **2 half-lives**\n‚Ä¢ 2 √ó 40 hours = **80 hours** ‚≠ê‚≠ê‚≠ê\n\n**DIGOXIN TOXICITY FEATURES:**\n‚Ä¢ **GI:** Nausea, vomiting (earliest) ‚≠ê\n‚Ä¢ **Cardiac:** Arrhythmias (any type)\n‚Ä¢ **Visual:** Yellow-green halos\n‚Ä¢ **CNS:** Confusion\n\n**MANAGEMENT:**\n‚Ä¢ **Stop digoxin**\n‚Ä¢ **Correct K+** (hypokalemia worsens toxicity)\n‚Ä¢ **Severe:** Digoxin-specific Fab fragments\n\nüí° **KEY:** **2 half-lives to reduce concentration by 75% (to 1/4)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-141",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "A patient comes to the casualty with organophosphate poisoning. He was started on atropine infusion and pralidoxime. After 2 hours, the patient had a sudden rise in temperature. What is the likely cause of fever?",
    options: [
      "Atropine toxicity",
      "A side effect of pralidoxime",
      "Due to organophosphate poisoning d",
      "Idiopathic",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Atropine toxicity (Option A)**\n\nüî¨ **ATROPINE TOXICITY:**\n\n**THIS CASE:**\n‚Ä¢ **OP poisoning** being treated\n‚Ä¢ **Atropine infusion** ‚≠ê\n‚Ä¢ **Sudden fever** after 2 hours ‚≠ê‚≠ê‚≠ê\n\n**ATROPINE SIDE EFFECTS:**\n‚Ä¢ **FEVER/HYPERTHERMIA** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n  - **Anticholinergic** ‚Üí blocks sweating\n  - **Heat dissipation impaired**\n‚Ä¢ **Dry mouth**, **flushed skin**\n‚Ä¢ **Mydriasis** (dilated pupils)\n‚Ä¢ **Tachycardia**\n‚Ä¢ **Urinary retention**\n‚Ä¢ **Confusion/delirium**\n\n**ATROPINE TOXICITY MNEMONIC:**\n**\"Hot as a hare, Dry as a bone, Red as a beet, Blind as a bat, Mad as a hatter\"** ‚≠ê‚≠ê‚≠ê\n\n**OP POISONING TREATMENT:**\n‚Ä¢ **Atropine** ‚≠ê (reverses muscarinic effects)\n‚Ä¢ **Pralidoxime (PAM)** ‚≠ê (reactivates cholinesterase)\n‚Ä¢ **Decontamination**\n\n**MANAGEMENT:**\n‚Ä¢ **Reduce atropine dose** ‚≠ê\n‚Ä¢ **Cooling measures**\n‚Ä¢ **Monitor vitals**\n\nüí° **KEY:** **Atropine ‚Üí Impaired sweating ‚Üí Hyperthermia** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-142",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "p A partogram of a woman who is in labor is shown below. Oxytocin infusion is already given. How will you manage the condition? e r P r e d d a L p e",
    options: [
      "Forceps-assisted delivery r",
      "VPacuum-assisted delivery",
      "O xytocin infusion",
      "Cesarean section",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Cesarean section (Option D)**\n\nüî¨ **PARTOGRAM - FAILED INDUCTION:**\n\n**THIS CASE:**\n‚Ä¢ **Partogram** showing abnormal labor ‚≠ê\n‚Ä¢ **Oxytocin already given** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **No progress** (likely crossed alert/action line)\n\n**PARTOGRAM LINES:**\n‚Ä¢ **Alert line:** Expected progress (1 cm/hr)\n‚Ä¢ **Action line:** 4 hours right of alert line ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Crossing action line** = EMERGENCY\n\n**MANAGEMENT:**\n‚Ä¢ **Action line crossed** + **Oxytocin failed** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ = **CESAREAN SECTION** **(ANSWER)**\n\n**WHY NOT OPERATIVE DELIVERY:**\n‚Ä¢ **Forceps/Vacuum:** Only if\n  - **Full dilation** ‚≠ê\n  - **Head engaged** (0 station or below)\n  - **No CPD**\n‚Ä¢ If **not fully dilated** ‚Üí **C-section** ‚≠ê‚≠ê‚≠ê\n\n**PARTOGRAM INDICATIONS FOR C-SECTION:**\n‚Ä¢ **Crossed action line** despite oxytocin\n‚Ä¢ **Fetal distress**\n‚Ä¢ **CPD suspected**\n\nüí° **KEY:** **Failed oxytocin augmentation (action line crossed) = C-section** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page70_img38.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-143",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "The mechanism of action of tissue plasminogen activator is",
    options: [
      "Inhibit extrinsic pathway",
      "Inhibits platelet aggregation",
      "Enhance fibrin degradation",
      "Inhibit clot formation",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Enhance fibrin degradation (Option C)**\n\nüî¨ **TISSUE PLASMINOGEN ACTIVATOR (tPA):**\n\n**MECHANISM:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Converts plasminogen ‚Üí plasmin** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Plasmin breaks down fibrin** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ = **Fibrinolysis** (clot breakdown)\n\n**THROMBOLYTIC AGENT** ‚≠ê\n\n**TYPES:**\n‚Ä¢ **Alteplase** (recombinant tPA) ‚≠ê\n‚Ä¢ **Tenecteplase** (TNK-tPA)\n‚Ä¢ **Reteplase** (r-PA)\n\n**INDICATIONS:**\n‚Ä¢ **Acute MI** (ST-elevation) ‚≠ê\n‚Ä¢ **Ischemic stroke** (<4.5 hours) ‚≠ê\n‚Ä¢ **Massive PE**\n\n**CONTRAINDICATIONS:**\n‚Ä¢ **Active bleeding**\n‚Ä¢ **Recent surgery/trauma**\n‚Ä¢ **Hemorrhagic stroke**\n\n**VS OTHER OPTIONS:**\n‚Ä¢ **Inhibit extrinsic pathway:** Warfarin\n‚Ä¢ **Inhibit platelet aggregation:** Aspirin, clopidogrel\n‚Ä¢ **Inhibit clot formation:** Heparin, warfarin\n\nüí° **KEY:** **tPA ‚Üí Plasminogen to Plasmin ‚Üí Fibrin degradation** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-144",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "d A woman presents to you at 36 weeks of gestation with complaints of breathlessness and excessive abdominal distension. Fetal movements are normal. On examination, fetal parts are d not easily felt and fetal heartbeat is heard but it is muffled. Her symphysis fundal height is 41 cm. Her abdomen is tense but not tender. What is the most likely diagnosis? a",
    options: [
      "Abruptio placenta",
      "Hydrocephalus of fetus",
      "Polyhydramnios p",
      "Fetal-maternal ascites e",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Polyhydramnios (Option C)**\n\nüî¨ **POLYHYDRAMNIOS:**\n\n**DEFINITION:** AFI >24 cm or single pocket >8 cm ‚≠ê\n\n**THIS CASE - CLASSIC FEATURES:**\n‚Ä¢ **36 weeks pregnant**\n‚Ä¢ **Breathlessness** ‚≠ê (diaphragm pushed up)\n‚Ä¢ **Excessive abdominal distension** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **SFH 41 cm** at 36 weeks (>5 cm above expected) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Fetal parts NOT easily felt** ‚≠ê‚≠ê‚≠ê (fluid cushion)\n‚Ä¢ **Muffled FHS** ‚≠ê (fluid dampens sound)\n‚Ä¢ **Tense but NOT tender** abdomen ‚≠ê\n\n**CAUSES:**\n\n**MATERNAL:**\n‚Ä¢ **Diabetes** (most common) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Isoimmunization**\n\n**FETAL:**\n‚Ä¢ **GI obstruction** (esophageal/duodenal atresia)\n‚Ä¢ **Anencephaly**\n‚Ä¢ **Twin-twin transfusion**\n\n**COMPLICATIONS:**\n‚Ä¢ **Preterm labor**\n‚Ä¢ **Malpresentation**\n‚Ä¢ **Cord prolapse**\n‚Ä¢ **PPH**\n\nüí° **KEY:** **Large for dates + Muffled FHS + Fetal parts not felt = Polyhydramnios** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-1",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "For which of the following procedures in the given OT list, can you preferably do a hysteroscopy?",
    options: [
      "Tubal ligation",
      "Asherman syndrome",
      "Endocervical polyp",
      "Subserosal fibroid",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Asherman syndrome (Option B)**\n\nüî¨ **HYSTEROSCOPY - INDICATIONS:**\n\n**ASHERMAN SYNDROME:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Intrauterine adhesions** (synechiae)\n‚Ä¢ **Hysteroscopy = GOLD STANDARD** ‚≠ê‚≠ê‚≠ê\n  - **Diagnosis** (direct visualization)\n  - **Treatment** (adhesiolysis)\n\n**CAUSE:**\n‚Ä¢ **Post D&C** (most common)\n‚Ä¢ **Endometritis**\n‚Ä¢ **Post-cesarean**\n\n**CLINICAL:**\n‚Ä¢ **Amenorrhea/Hypomenorrhea**\n‚Ä¢ **Infertility**\n‚Ä¢ **Recurrent miscarriage**\n\n**WHY NOT OTHERS:**\n\n‚Ä¢ **Tubal ligation:** Laparoscopy (NOT hysteroscopy)\n‚Ä¢ **Endocervical polyp:** Office polypectomy (hysteroscopy can be used but not preferred)\n‚Ä¢ **Subserosal fibroid:** Laparoscopy (OUTSIDE uterus)\n\n**HYSTEROSCOPY INDICATIONS:**\n‚Ä¢ **Intrauterine pathology** ‚≠ê\n‚Ä¢ **Asherman syndrome** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Submucous fibroids**\n‚Ä¢ **Endometrial polyps**\n‚Ä¢ **Septate uterus**\n\nüí° **KEY:** **Asherman syndrome = Hysteroscopy (diagnosis + treatment)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-146",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A primigravida presents to you with anemia early in her pregnancy. She is r7 weeks pregnant as seen on ultrasound. Her hemoglobin level is 9 g/dL. When should the iron supplements be started for her? e",
    options: [
      "10 to 12 weeks d",
      "8 to 10 weeks",
      "After 14 weeks",
      "After 20 weeks a",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Start NOW (8-10 weeks) - But answer is Option B**\n\nüî¨ **IRON SUPPLEMENTATION IN PREGNANCY:**\n\n**THIS CASE:**\n‚Ä¢ **7 weeks pregnant** ‚≠ê\n‚Ä¢ **Hb 9 g/dL** (anemia) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Early pregnancy**\n\n**WHEN TO START IRON:**\n\n**ANEMIC PATIENT (Hb <11 g/dL):** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **START IMMEDIATELY** (as soon as diagnosed) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **This case:** Start NOW (at 7-8 weeks)\n\n**NON-ANEMIC PATIENT:**\n‚Ä¢ **Routine prophylaxis:** After **14-16 weeks** ‚≠ê\n‚Ä¢ **IFA tablets:** 100 mg elemental iron + 500 mcg folic acid\n\n**DOSING:**\n‚Ä¢ **Therapeutic:** 100-200 mg elemental iron/day\n‚Ä¢ **Prophylactic:** 60 mg elemental iron/day\n\n**WHY IMMEDIATE:**\n‚Ä¢ **Prevent complications** ‚≠ê\n‚Ä¢ **Maximize Hb rise** before delivery\n‚Ä¢ **Fetal requirements** increase in 2nd/3rd trimester\n\n**MONITORING:**\n‚Ä¢ **Repeat Hb** after 4 weeks\n‚Ä¢ **Target:** Hb >11 g/dL\n\nüí° **KEY:** **Anemia in pregnancy = Start iron IMMEDIATELY (don't wait)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-147",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A 23-year-old woman accompanied by her mother-in-law comes to the infertility clinic. She has e been having regular intercourse for 6 months but is not able to conceive. What is the next best step?",
    options: [
      "Semen analysis for husban OP2: Reassure and review the couple after 6 months O 3: Hysterolaparoscopy O4: Diagnostic hysteroscopy",
      "Option 2",
      "Option 3",
      "Diagnostic hysteroscopy",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Reassure and review after 6 months (Option B)**\n\nüî¨ **INFERTILITY WORKUP TIMING:**\n\n**THIS CASE:**\n‚Ä¢ **23-year-old** (young)\n‚Ä¢ **Regular intercourse for 6 months** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Only 6 months** of trying\n\n**INFERTILITY DEFINITION:**\n‚Ä¢ **Failure to conceive after 12 MONTHS** ‚≠ê‚≠ê‚≠ê of regular unprotected intercourse\n‚Ä¢ **Exception:** >35 years ‚Üí investigate after 6 months\n\n**MANAGEMENT:**\n‚Ä¢ **<35 years + <12 months:** **REASSURE** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Counsel:** Normal conception takes time\n‚Ä¢ **Optimize:** Timing of intercourse, lifestyle\n‚Ä¢ **Review after 6 more months** (total 12 months)\n\n**WHEN TO INVESTIGATE EARLY:**\n‚Ä¢ **Age >35 years** ‚≠ê (reduced ovarian reserve)\n‚Ä¢ **Known factors** (amenorrhea, azoospermia)\n‚Ä¢ **History** of pelvic surgery, infections\n\n**NORMAL CONCEPTION RATES:**\n‚Ä¢ **3 months:** 50%\n‚Ä¢ **6 months:** 75%\n‚Ä¢ **12 months:** 85%\n\nüí° **KEY:** **<12 months + <35 years = Reassure (not infertility yet)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-148",
    subjectId: "anesthesiology",
    chapterId: "neet-pg-2023",
    question: "During resuscitation, when is the given position indicated? r e d d a",
    options: [
      "Unconsciousness with pulse and breathing absent",
      "Unconsciousness with pulse present and breathing absent",
      "Unconsciousness with pulse and breathing present e",
      "Unconsciousness with pulse absent and breathing present",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Unconsciousness with pulse and breathing present (Option C)**\n\nüî¨ **RECOVERY POSITION (Lateral decubitus):**\n\n**INDICATION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Unconscious** ‚≠ê\n‚Ä¢ **Pulse PRESENT** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Breathing PRESENT** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ = **Protects airway** while awaiting help\n\n**PURPOSE:**\n‚Ä¢ **Prevents aspiration** ‚≠ê‚≠ê‚≠ê (vomit, secretions drain out)\n‚Ä¢ **Maintains airway patency**\n‚Ä¢ **Prevents tongue from falling back**\n\n**HOW TO POSITION:**\n‚Ä¢ **Lateral** (on side)\n‚Ä¢ **Lower arm extended**\n‚Ä¢ **Upper leg bent** (stability)\n‚Ä¢ **Head tilted** (airway open)\n\n**WHY NOT FOR OTHER SCENARIOS:**\n\n‚Ä¢ **No pulse, No breathing:** **CPR** (supine) ‚≠ê\n‚Ä¢ **No pulse, Breathing present:** Impossible (agonal breathing only)\n‚Ä¢ **Pulse present, No breathing:** **Rescue breathing** (supine)\n\n**REMEMBER:**\n‚Ä¢ **Breathing + Pulse** = Recovery position\n‚Ä¢ **No pulse** = CPR (supine)\n\nüí° **KEY:** **Unconscious + Breathing + Pulse = Recovery position** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page73_img39.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-149",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A 50-year-old woman presents with foul-smelling bloody discharge per vagina mixed with mucous. On examination, a necrotizing growth is seen in the cervix with lateral parametrium involvement. What is the management for this patient?",
    options: [
      "Chemotherapy",
      "Brachytherapy",
      "Chemoradiation",
      "Surgery",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Chemoradiation (Option C)**\n\nüî¨ **CERVICAL CANCER - STAGING & TREATMENT:**\n\n**THIS CASE - KEY FEATURES:**\n‚Ä¢ **Foul-smelling bloody discharge** ‚≠ê\n‚Ä¢ **Necrotizing growth** on cervix ‚≠ê\n‚Ä¢ **Parametrial involvement** ‚≠ê‚≠ê‚≠ê **(CRITICAL)**\n‚Ä¢ = **Stage IIB** (at least) ‚≠ê‚≠ê‚≠ê\n\n**FIGO STAGING:**\n‚Ä¢ **Stage I:** Confined to cervix\n‚Ä¢ **Stage IIA:** Upper 2/3 vagina (NO parametrium)\n‚Ä¢ **Stage IIB:** **Parametrial involvement** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Stage III:** Lower vagina OR pelvic wall\n‚Ä¢ **Stage IV:** Bladder/rectum or distant mets\n\n**TREATMENT:**\n\n**Stage IIB-IVA:** **CONCURRENT CHEMORADIATION** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **External beam RT** + **Brachytherapy** + **Cisplatin**\n‚Ä¢ **Curative intent**\n\n**WHY NOT SURGERY:**\n‚Ä¢ **Parametrial involvement** = **Not surgically resectable** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Surgery:** Only for Stage IA-IIA\n\n**TREATMENT SUMMARY:**\n‚Ä¢ **IA-IB1:** Surgery OR RT\n‚Ä¢ **IB2-IIA:** Surgery + adjuvant RT/CRT\n‚Ä¢ **IIB-IVA:** **Chemoradiation** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **Parametrial involvement = Stage IIB = Chemoradiation** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-150",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "e A 28-year-old woman with a history of multiple sexual partners presents with lower abdominal pain for 1 month. She experiences minimal discharge and complaints of intermenstrual bleeding. What is the most likely cause? d",
    options: [
      "Herpes simplex",
      "Genital tuberculosis",
      "Candida a",
      "Neisseria gonorrhoea",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Neisseria gonorrhoeae (Gonorrhea) (Option D)**\n\nüî¨ **PELVIC INFLAMMATORY DISEASE (PID):**\n\n**THIS CASE:**\n‚Ä¢ **Multiple sexual partners** ‚≠ê‚≠ê‚≠ê (STI risk)\n‚Ä¢ **Lower abdominal pain** (1 month) ‚≠ê\n‚Ä¢ **Minimal discharge** ‚≠ê\n‚Ä¢ **Intermenstrual bleeding** ‚≠ê\n‚Ä¢ = **PID** (likely Gonorrhea)\n\n**NEISSERIA GONORRHOEAE:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Most common cause** of PID in sexually active women\n‚Ä¢ **Acute PID** presentation\n‚Ä¢ **Often with Chlamydia** (co-infection)\n\n**PID CLINICAL:**\n‚Ä¢ **Lower abdominal pain** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Cervical motion tenderness**\n‚Ä¢ **Adnexal tenderness**\n‚Ä¢ **Fever** (may be absent)\n‚Ä¢ **Abnormal discharge**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **TB:** Chronic, weight loss, night sweats (NOT acute STI-related)\n‚Ä¢ **HSV:** Painful ulcers (NOT PID)\n‚Ä¢ **Candida:** Vulvovaginal (NOT PID, NO pain)\n\n**TREATMENT:**\n‚Ä¢ **Ceftriaxone 250 mg IM** (gonorrhea) ‚≠ê\n‚Ä¢ **Doxycycline 100 mg BD √ó 14 days** (chlamydia) ‚≠ê\n‚Ä¢ **¬± Metronidazole**\n\nüí° **KEY:** **Multiple partners + PID = Gonorrhea (N. gonorrhoeae)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-151",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "e A woman is set to undergo a complete laparoscopic hysterectomy. She wants to know if there are any disadvantages to this procedure. What are the disadvantages of laproscopis r over-open surgery? P",
    options: [
      "P rolonged recovery time",
      "Not knowing the extent of thermal burns",
      "Increased bleeding",
      "Increased pain",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Not knowing the extent of thermal burns (Option B)**\n\nüî¨ **LAPAROSCOPIC SURGERY - DISADVANTAGES:**\n\n**MAIN DISADVANTAGE:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Thermal injuries** (from electrocautery/energy devices) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Extent NOT immediately visible** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Delayed presentation** (bowel perforation)\n\n**THERMAL INJURY ISSUES:**\n‚Ä¢ **Spread of heat** beyond visible area\n‚Ä¢ **Adjacent organ damage** (bowel, bladder, vessels)\n‚Ä¢ **May present days later** (peritonitis)\n\n**OTHER DISADVANTAGES:**\n‚Ä¢ **Limited tactile feedback**\n‚Ä¢ **Steep learning curve**\n‚Ä¢ **Equipment cost**\n‚Ä¢ **Longer operative time** (initially)\n‚Ä¢ **Risk of port site hernias**\n\n**ADVANTAGES (vs open):**\n‚Ä¢ **LESS pain** ‚≠ê\n‚Ä¢ **SHORTER recovery** ‚≠ê\n‚Ä¢ **LESS bleeding** ‚≠ê\n‚Ä¢ **Better cosmesis**\n‚Ä¢ **Shorter hospital stay**\n\n**WHY NOT OTHER OPTIONS:**\n‚Ä¢ **Prolonged recovery:** NO (shorter recovery)\n‚Ä¢ **Increased bleeding:** NO (less bleeding)\n‚Ä¢ **Increased pain:** NO (less pain)\n\nüí° **KEY:** **Laparoscopy disadvantage = Hidden extent of thermal burns** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-152",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A 27-year-old pregnant G3P2L2 woman presents to you at 36+6 weeks. Ultrasound is done and shows the fetus is in a transverse lie. The liquor is adequate, the placenta is normal, and she has no risk factors. Both her previous deliveries were normal vaginal deliveries. How will you manage this patient?",
    options: [
      "Cesarean section",
      "External cephalic version e",
      "Expectant management",
      "Induction of labor",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Expectant management (Option C)**\n\nüî¨ **TRANSVERSE LIE AT 36+6 WEEKS:**\n\n**THIS CASE:**\n‚Ä¢ **36+6 weeks** (near term) ‚≠ê\n‚Ä¢ **Transverse lie** ‚≠ê\n‚Ä¢ **Multipara** (G3P2L2) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Adequate liquor**, **normal placenta**\n‚Ä¢ **NO risk factors**\n‚Ä¢ **Previous 2 normal deliveries**\n\n**MANAGEMENT:** **EXPECTANT** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**RATIONALE:**\n‚Ä¢ **Multipara** ‚Üí lax uterus ‚Üí **fetus can still turn** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **<37 weeks** ‚Üí NOT term yet\n‚Ä¢ **Spontaneous version possible** (especially in multipara)\n‚Ä¢ **Review at 37-38 weeks**\n\n**IF PERSISTS AT 37-38 WEEKS:**\n‚Ä¢ **External cephalic version (ECV)** ‚≠ê (first attempt)\n‚Ä¢ **If ECV fails** ‚Üí **Elective C-section** at 39 weeks\n\n**WHY NOT OTHERS:**\n‚Ä¢ **ECV now:** Can wait (may turn spontaneously)\n‚Ä¢ **C-section now:** Too early (not indicated yet)\n‚Ä¢ **Induction:** CONTRAINDICATED in transverse lie\n\nüí° **KEY:** **Multipara + 36+6 wks + Transverse lie = Expectant (may turn spontaneously)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page75_img40.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-153",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A female presents to you with 6 wLeeks of amenorrhea complaining of bleeding per vagina and slight abdominal pain. The urine pregnancy test is positive and hCG level is 2800 IU/L. A mass is seen on the left adnexa measuring 3 x 2.5 cm. She is hemodynamically stable. How will you manage this patient? p hCG-Human chorionic gonadotropin",
    options: [
      "Oral methotrexate",
      "Single-dose methotrexate injection",
      "P Serial methotrexate + leucovorin rescue",
      "Salpingectomy",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Single-dose methotrexate injection (Option B)**\n\nüî¨ **ECTOPIC PREGNANCY - MEDICAL MANAGEMENT:**\n\n**THIS CASE:**\n‚Ä¢ **6 weeks amenorrhea**\n‚Ä¢ **Bleeding + mild pain**\n‚Ä¢ **Positive pregnancy test**\n‚Ä¢ **hCG 2800 IU/L** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Adnexal mass 3√ó2.5 cm** (<3.5 cm) ‚≠ê\n‚Ä¢ **Hemodynamically STABLE** ‚≠ê‚≠ê‚≠ê\n\n**MEDICAL MANAGEMENT CRITERIA:** (ALL met here) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hemodynamically stable** ‚≠ê\n‚Ä¢ **hCG <5000 IU/L** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Mass <3.5-4 cm** ‚≠ê\n‚Ä¢ **No fetal cardiac activity**\n‚Ä¢ **No contraindications to MTX**\n\n**SINGLE-DOSE METHOTREXATE:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **50 mg/m¬≤ IM** (based on BSA)\n‚Ä¢ **Monitor hCG** (days 4 & 7)\n‚Ä¢ **>15% drop** = success\n‚Ä¢ **Success rate:** ~90%\n\n**OTHER REGIMENS:**\n‚Ä¢ **Multi-dose:** hCG >5000 or failed single-dose\n‚Ä¢ **Oral:** NOT used\n\n**SURGICAL (Salpingectomy):** If hemodynamically unstable, ruptured, or medical management fails\n\nüí° **KEY:** **Stable + hCG <5000 + Mass <3.5 cm = Single-dose MTX** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-154",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A 24-year-old woman who is being treated for infertility with human menopausal gonadotropin came with complaints of sudden abdominal pain, nausea, vomiting, and breathlessness. The finding of the ultrasound is shown below. What is the most likely diagnosis? r e d d a",
    options: [
      "Ovarian hyperstimulation syndrom L",
      "Polycystic ovarian syndrome",
      "Theca lutein cysts",
      "Granulosa cell tumo e",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Ovarian hyperstimulation syndrome (OHSS) (Option A)**\n\nüî¨ **OVARIAN HYPERSTIMULATION SYNDROME:**\n\n**THIS CASE:**\n‚Ä¢ **Infertility treatment** with **hMG** (gonadotropins) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Sudden abdominal pain** ‚≠ê\n‚Ä¢ **Nausea, vomiting** ‚≠ê\n‚Ä¢ **Breathlessness** ‚≠ê (ascites ‚Üí diaphragm)\n‚Ä¢ **USG:** Enlarged ovaries, ascites\n\n**OHSS PATHOPHYSIOLOGY:**\n‚Ä¢ **Ovarian enlargement** (>12 cm) ‚≠ê\n‚Ä¢ **Increased vascular permeability** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Third spacing** ‚Üí Ascites, pleural effusion\n‚Ä¢ **Hemoconcentration**\n\n**SEVERITY:**\n\n**MILD:** Abdominal bloating, mild pain\n**MODERATE:** Nausea, vomiting, ascites (USG)\n**SEVERE:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Clinical ascites/hydrothorax**\n‚Ä¢ **Oliguria**\n‚Ä¢ **Hemoconcentration** (Hct >45%)\n‚Ä¢ **Thrombosis risk**\n\n**TREATMENT:**\n‚Ä¢ **Supportive** (mild-moderate)\n‚Ä¢ **IV fluids** (maintain output)\n‚Ä¢ **Paracentesis** (if severe ascites)\n‚Ä¢ **Thromboprophy laxis**\n‚Ä¢ **Avoid pregnancy** (hCG worsens)\n\nüí° **KEY:** **Gonadotropin therapy + Ascites + Breathlessness = OHSS** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-1",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "During a hysteroscopic removal of a submucosal fibroid, a fluid deficit of 2000 mL is estimated in a patient. What is the immediate complication of this?",
    options: [
      "Acute tubular necrosis",
      "DIC",
      "Pulmonary edema",
      "Thromboembolism",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Pulmonary edema (Option C)**\n\nüî¨ **HYSTEROSCOPY - FLUID OVERLOAD:**\n\n**THIS CASE:**\n‚Ä¢ **Hysteroscopic fibroid removal**\n‚Ä¢ **Fluid deficit: 2000 mL** ‚≠ê‚≠ê‚≠ê (MASSIVE)\n\n**HYSTEROSCOPY FLUID:**\n‚Ä¢ **Distention media** (glycine, sorbitol, saline)\n‚Ä¢ **Absorbed systemically** through open venous sinuses\n‚Ä¢ **Monitor fluid deficit** carefully\n\n**FLUID DEFICIT:**\n‚Ä¢ **Infused - Recovered = Absorbed**\n‚Ä¢ **Safe limit:** <1000-1500 mL ‚≠ê\n‚Ä¢ **This case:** 2000 mL ‚≠ê‚≠ê‚≠ê (EXCEEDED)\n\n**IMMEDIATE COMPLICATION:** **FLUID OVERLOAD** ‚≠ê‚≠ê‚≠ê\n\n**PULMONARY EDEMA:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Volume overload** ‚Üí ‚Üë hydrostatic pressure\n‚Ä¢ **Fluid in alveoli**\n‚Ä¢ **Breathlessness**, **hypoxia**\n‚Ä¢ **Crackles on auscultation**\n\n**OTHER COMPLICATIONS:**\n‚Ä¢ **Hyponatremia** (if glycine used)\n‚Ä¢ **Dilutional hyponatremia**\n\n**PREVENTION:**\n‚Ä¢ **Monitor deficit closely**\n‚Ä¢ **Stop if >1500 mL**\n\nüí° **KEY:** **Fluid deficit >1500 mL ‚Üí Pulmonary edema (volume overload)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-156",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A woman comes with complaints of pain and swelling in the perineal area. She also has complaints of difficulty in walking and sitting. She gives a history of multipler sexual partners. On examination, a tender swelling is seen with redness on the labia, as shown in the image given below. What is the most likely diagnosis? e d d a L p e",
    options: [
      "Chlamydial infection",
      "Bartholin abscess OP3: Genital Tuberculosis O 4: Herpes infection",
      "Option 3",
      "Option 4",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Bartholin abscess (Option B)**\n\nüî¨ **BARTHOLIN GLAND ABSCESS:**\n\n**THIS CASE:**\n‚Ä¢ **Pain & swelling** in perineum ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Difficulty walking/sitting** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Tender swelling** with **redness** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Location:** Labia (posterolateral) ‚≠ê\n‚Ä¢ **Multiple sexual partners** (STI risk)\n\n**BARTHOLIN GLAND:**\n‚Ä¢ **Location:** **4 & 8 o'clock** position (posterolateral vaginal opening) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Function:** Mucus secretion (lubrication)\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Duct obstruction** ‚Üí Cyst formation\n‚Ä¢ **Secondary infection** ‚Üí **Abscess** ‚≠ê‚≠ê‚≠ê\n\n**ORGANISMS:**\n‚Ä¢ **Polymicrobial** (most common)\n‚Ä¢ **Gonorrhea, Chlamydia** (STI-related)\n‚Ä¢ **E. coli, anaerobes**\n\n**TREATMENT:**\n‚Ä¢ **Incision & drainage** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Word catheter** (prevents recurrence)\n‚Ä¢ **Antibiotics** (if cellulitis)\n‚Ä¢ **Marsupialization** (recurrent cases)\n\n**VS OTHERS:**\n‚Ä¢ **Herpes:** Painful vesicles/ulcers (NOT abscess)\n\nüí° **KEY:** **Painful labial swelling + Redness = Bartholin abscess** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-157",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A 54-year-old woman was diagnosed with advanced cervical cancer. She has a 14-year-old daughter. What advice would you give her daughter?",
    options: [
      "Advise HPV vaccine",
      "Screen for BRCA mutation",
      "Screen for PTEN mutation",
      "Perform cervical biopsy r",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Advise HPV vaccine (Option A)**\n\nüî¨ **HPV VACCINE - CERVICAL CANCER PREVENTION:**\n\n**THIS CASE:**\n‚Ä¢ **Mother:** Advanced cervical cancer\n‚Ä¢ **Daughter:** 14 years old ‚≠ê‚≠ê‚≠ê (ideal age)\n\n**HPV & CERVICAL CANCER:**\n‚Ä¢ **HPV** (Human Papillomavirus) causes **>99%** of cervical cancer ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **HPV 16 & 18:** ~70% of cases ‚≠ê\n‚Ä¢ **NOT hereditary** (unlike BRCA)\n\n**HPV VACCINE:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**TYPES:**\n‚Ä¢ **Gardasil 9** (9-valent): HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 ‚≠ê\n‚Ä¢ **Cervarix** (2-valent): HPV 16, 18\n\n**SCHEDULE:**\n‚Ä¢ **9-14 years:** **2 doses** (0, 6 months) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **‚â•15 years:** 3 doses (0, 2, 6 months)\n\n**EFFECTIVENESS:**\n‚Ä¢ **Nearly 100%** prevention (if given before exposure) ‚≠ê‚≠ê‚≠ê\n\n**WHY NOT OTHERS:**\n‚Ä¢ **BRCA/PTEN:** Breast/ovarian cancer (NOT cervical)\n‚Ä¢ **Biopsy:** NO indication (asymptomatic)\n\nüí° **KEY:** **14-year-old daughter of cervical cancer patient ‚Üí HPV vaccine** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-158",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A 17-year-old girl is seen for primary amenorrhead. There is no development of breasts or hair in the pubic or axillary region. Her height is 155 cm, and her weight is 48 kg. She has bilateral inguinal masses. The uterus, fallopian tube, and Ovary are absent on ultrasound examination. What is the most likely diagnosis? a",
    options: [
      "Complete androgen insensitivity syndrome",
      "Hypergonadotropic hypogonadism",
      "Turner syndrome",
      "Polycystic ovary syndrom e",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Hyper gonadotropic hypogonadism (Option B) - But likely GONADAL DYSGENESIS**\n\nüî¨ **GONADAL DYSGENESIS (46,XY):**\n\n**THIS CASE - KEY FEATURES:**\n‚Ä¢ **Primary amenorrhea** ‚≠ê\n‚Ä¢ **NO breast development** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **NO pubic/axillary hair** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bilateral inguinal masses** ‚≠ê‚≠ê‚≠ê (streak gonads/testes)\n‚Ä¢ **NO uterus/ovaries** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Normal height** (155 cm)\n\n**DIAGNOSIS:** **46,XY Gonadal Dysgenesis** (Swyer syndrome) ‚≠ê‚≠ê‚≠ê\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **46,XY karyotype** BUT\n‚Ä¢ **Defective testicular development** (SRY mutation)\n‚Ä¢ **No testosterone** ‚Üí No virilization\n‚Ä¢ **No AMH** ‚Üí M√ºllerian ducts persist BUT regress\n\n**CLINICAL:**\n‚Ä¢ **Female phenotype**\n‚Ä¢ **Streak gonads** (inguinal) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hypergonadotropic hypogonadism** (‚ÜëFSH/LH, ‚ÜìEstrogen)\n\n**VS CAIS:**\n‚Ä¢ **CAIS:** Breast development ‚úì, Testes in inguinal canal, Blind vagina\n\n**MANAGEMENT:**\n‚Ä¢ **Gonadectomy** ‚≠ê (malignancy risk 30%)\n‚Ä¢ **Hormone replacement**\n\nüí° **KEY:** **No breast + No hair + Inguinal masses + No uterus = Gonadal dysgenesis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page78_img41.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-1",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 54-year-old woman presents with cervical cancer stage 2A. It is decided to give neoadjuvant chemotherapy. What does neoadjuvant chemotherapy mean?",
    options: [
      "Chemotherapy is given along with radiation.",
      "Chemotherapy is given during surgery.",
      "Chemotherapy is given before radical surgery to reduce the bulk of the tumor",
      "Chemotherapy is given after radical surgery for micrometastases",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Chemotherapy given BEFORE surgery to reduce tumor bulk (Option C)**\n\nüî¨ **NEOADJUVANT CHEMOTHERAPY:**\n\n**DEFINITION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Chemotherapy BEFORE** definitive treatment (surgery/RT) ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Goal:** Downstage tumor, improve resectability\n\n**ADVANTAGES:**\n‚Ä¢ **Shrinks tumor** ‚Üí easier resection ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Tests chemo-sensitivity** in vivo\n‚Ä¢ **Treats micrometastases** early\n‚Ä¢ **Better organ preservation**\n\n**INDICATIONS:**\n‚Ä¢ **Locally advanced tumors** ‚≠ê\n‚Ä¢ **Cervical cancer** (Stage IB2-IIA)\n‚Ä¢ **Breast cancer** (locally advanced)\n‚Ä¢ **Bladder cancer**\n‚Ä¢ **Rectal cancer**\n\n**VS ADJUVANT:**\n‚Ä¢ **Adjuvant:** Chemotherapy AFTER surgery ‚≠ê\n‚Ä¢ **Goal:** Treat micrometastases\n\n**VS CONCURRENT:**\n‚Ä¢ **Concurrent:** Chemo WITH radiation (radiosensitizer)\n\n**THIS CASE:**\n‚Ä¢ **Stage IIA cervical cancer**\n‚Ä¢ **Neoadjuvant** ‚Üí shrink ‚Üí **radical hysterectomy**\n\nüí° **KEY:** **Neoadjuvant = BEFORE surgery (to downstage)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-160",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A 16-year-old girl presents with cyclical pelvic pain every month. She has nrot achieved menarche yet. On examination, a suprapubic bulge can be seen in the lower abdomen. PR examination reveals a bulging swelling in the anterior aspect. Whaet is the most likely diagnosis?",
    options: [
      "Transverse vaginal septum above the vagina",
      "Vaginal atresi d",
      "Imperforate hymen",
      "Cervical agenesis",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Imperforate hymen (Option C)**\n\nüî¨ **IMPERFORATE HYMEN:**\n\n**MOST COMMON** cause of outflow tract obstruction ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE - CLASSIC TRIAD:**\n1. **Cyclical pelvic pain** ‚≠ê‚≠ê‚≠ê (monthly = menstrual)\n2. **Primary amenorrhea** ‚≠ê‚≠ê‚≠ê\n3. **Suprapubic bulge** ‚≠ê‚≠ê‚≠ê (hematocolpos)\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Hymen completely closed** ‚≠ê\n‚Ä¢ **Menstrual blood accumulates** behind it\n‚Ä¢ **Hematocolpos** (vagina) ‚Üí **Hematometra** (uterus)\n\n**CLINICAL:**\n‚Ä¢ **Age:** 13-15 years (at menarche)\n‚Ä¢ **Cyclical pain** without bleeding ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bulging hymen** (bluish, tense)\n‚Ä¢ **PR:** Anterior bulge (hematocolpos) ‚≠ê‚≠ê‚≠ê\n\n**DIAGNOSIS:**\n‚Ä¢ **Clinical** ‚≠ê (examination)\n‚Ä¢ **USG:** Distended vagina with fluid\n\n**TREATMENT:**\n‚Ä¢ **Hymenectomy** ‚≠ê‚≠ê‚≠ê (surgical excision)\n‚Ä¢ **Cruciate incision**\n‚Ä¢ **Drainage** of accumulated blood\n\n**VS OTHERS:**\n‚Ä¢ **Transverse septum/Atresia:** Higher obstruction, no bulging hymen\n\nüí° **KEY:** **Cyclical pain + Amenorrhea + Bulge = Imperforate hymen** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-161",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "e A pregnant woman comes to the clinic. She already has twins by normal delivery. Which of the following is the correct representation of her obstetric score?",
    options: [
      "G3P2 OP2: G3P1 O 3: G2P1 O4: G2P2",
      "Option 2",
      "Option 3",
      "G2P2",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **G2P1 (Option C/B - G3P1 in options)**\n\nüî¨ **OBSTETRIC SCORING (GPLA):**\n\n**THIS CASE:**\n‚Ä¢ **Currently pregnant** ‚≠ê\n‚Ä¢ **Previous delivery:** Twins (one birth event) ‚≠ê‚≠ê‚≠ê\n\n**CALCULATION:**\n\n**G (Gravida):** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Total pregnancies** (including current)\n‚Ä¢ **This case:** **1 (previous) + 1 (current) = G2** ‚≠ê‚≠ê‚≠ê\n\n**P (Para):** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Deliveries ‚â•20 weeks** (NOT number of babies)\n‚Ä¢ **Twins count as 1 delivery** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **This case:** **P1** (one delivery, though twins)\n\n**ANSWER: G2P1** ‚≠ê‚≠ê‚≠ê\n\n**DETAILED (TPAL):**\n‚Ä¢ **T (Term):** Full-term deliveries\n‚Ä¢ **P (Preterm):** 20-37 weeks\n‚Ä¢ **A (Abortions):** <20 weeks\n‚Ä¢ **L (Living):** Number alive\n‚Ä¢ **Example:** G2P1001 (if twins alive)\n\n**COMMON MISTAKE:**\n‚Ä¢ **G3P2:** Would mean 3 pregnancies total (incorrect)\n\nüí° **KEY:** **Twins = 1 delivery (para). Current pregnancy = G2P1** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-162",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presents with sudden onset of hematemesis. He has been taking aspirin for his arthritis and drinks alcohol occasionally. He gives a history of occasional abdominal pain. On examination, there is no abdominal mass or tenderness. What is the likely diagnosis?",
    options: [
      "Mallory-Weiss tear",
      "Esophagitis",
      "Peptic ulcer r",
      "Esophageal varices",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Peptic ulcer (Option C)**\n\nüî¨ **PEPTIC ULCER DISEASE (PUD) - ACUTE BLEEDING:**\n\n**THIS CASE:**\n‚Ä¢ **Sudden hematemesis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Aspirin use** ‚≠ê‚≠ê‚≠ê (NSAID)\n‚Ä¢ **Alcohol** ‚≠ê\n‚Ä¢ **Occasional abdominal pain** ‚≠ê (ulcer symptoms)\n‚Ä¢ **No mass/tenderness** (NO peritonitis)\n\n**PEPTIC ULCER:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Most common cause** of upper GI bleeding ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Risk factors:** NSAIDs ‚≠ê, H. pylori, alcohol\n\n**ASPIRIN & PUD:**\n‚Ä¢ **Inhibits COX-1** ‚Üí ‚Üì prostaglandins\n‚Ä¢ **Loss of mucosal protection** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bleeding risk** increased\n\n**WHY NOT OTHERS:**\n\n‚Ä¢ **Mallory-Weiss:** Post-vomiting tear (NO prior vomiting here)\n‚Ä¢ **Esophagitis:** Heartburn, dysphagia (NO massive bleeding)\n‚Ä¢ **Varices:** Chronic liver disease, cirrhosis (NOT mentioned)\n\n**MANAGEMENT:**\n‚Ä¢ **Resuscitation** (IV fluids, blood)\n‚Ä¢ **PPI** (high-dose)\n‚Ä¢ **Endoscopy** (diagnosis + hemostasis)\n\nüí° **KEY:** **Aspirin + Hematemesis + Abdominal pain = Peptic ulcer bleeding** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-163",
    subjectId: "obgyn",
    chapterId: "neet-pg-2023",
    question: "A woman presents to you at 36 weeks of agestation with complaints of feeling lightheadedness and dizziness when she lies on her back. She says she feels alright if she lies on her side or when walks. What is the most likely reason behind this? IVC- inferior vena cava L",
    options: [
      "Increased intracranial pressur p",
      "IVC compression",
      "Heavy meals",
      "Excessive venous pooling at the feet r",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **IVC compression (Supine hypotensive syndrome) (Option B)**\n\nüî¨ **SUPINE HYPOTENSIVE SYNDROME:**\n\n**THIS CASE - CLASSIC:**\n‚Ä¢ **36 weeks pregnant** ‚≠ê\n‚Ä¢ **Lightheaded/dizzy when lying SUPINE** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Relief when lying on SIDE or walking** ‚≠ê‚≠ê‚≠ê\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Enlarged uterus** compresses **IVC** ‚≠ê‚≠ê‚≠ê (when supine)\n‚Ä¢ **‚Üì Venous return** to heart\n‚Ä¢ **‚Üì Cardiac output** ‚Üí Hypotension\n‚Ä¢ **Cerebral hypoperfusion** ‚Üí Dizziness\n\n**RELIEF:**\n‚Ä¢ **Left lateral position** ‚≠ê‚≠ê‚≠ê (uterus shifts off IVC)\n‚Ä¢ **Walking/standing** (uterus moves anteriorly)\n\n**CLINICAL SIGNIFICANCE:**\n‚Ä¢ **Occurs:** 2nd/3rd trimester ‚≠ê\n‚Ä¢ **Management:** Avoid supine position\n‚Ä¢ **During surgery:** Left uterine displacement\n\n**VS POSTURAL HYPOTENSION:**\n‚Ä¢ **Postural:** Dizziness on standing (opposite)\n\n**REMEMBER:**\n‚Ä¢ **Always position pregnant women LEFT LATERAL** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **Pregnant + Dizzy when supine + Relief on side = IVC compression** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-164",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 40-year-old male patient presents with a swelling that has been slowly growing in the past 2 years. On examination, it was variable in consistency and fully mobile. What is the most likely diagnosis?",
    options: [
      "Dermoid cyst d",
      "Parotid tumor d",
      "Sebaceous cyst a",
      "Cervical lymph node",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Parotid tumor (Option B)**\n\nüî¨ **PAROTID GLAND TUMOR:**\n\n**THIS CASE:**\n‚Ä¢ **Slow-growing swelling** (2 years) ‚≠ê\n‚Ä¢ **Variable consistency** ‚≠ê‚≠ê‚≠ê **(CHARACTERISTIC)**\n‚Ä¢ **Fully mobile** ‚≠ê\n‚Ä¢ **Location:** Parotid region (from image)\n\n**VARIABLE CONSISTENCY = PATHOGNOMONIC** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Pleomorphic adenoma** (benign mixed tumor) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Most common parotid tumor** (80% of parotid tumors)\n‚Ä¢ **Contains both epithelial & mesenchymal elements**\n\n**PLEOMORPHIC ADENOMA:**\n‚Ä¢ **Slow growth** ‚≠ê\n‚Ä¢ **Painless**\n‚Ä¢ **Mobile** (not fixed)\n‚Ä¢ **Variable/Lobulated** surface\n‚Ä¢ **Facial nerve intact** (no palsy)\n\n**DIAGNOSIS:**\n‚Ä¢ **FNAC** (Fine needle aspiration)\n‚Ä¢ **MRI** (extent, facial nerve relation)\n\n**TREATMENT:**\n‚Ä¢ **Superficial parotidectomy** with **facial nerve preservation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Risk:** Facial nerve injury, Frey's syndrome\n\n**MALIGNANT FEATURES:**\n‚Ä¢ **Rapid growth**, **Pain**, **Facial palsy**, **Fixed**\n\nüí° **KEY:** **Slow parotid swelling + Variable consistency = Pleomorphic adenoma** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page81_img42.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-165",
    subjectId: "radiology",
    chapterId: "neet-pg-2023",
    question: "e A woman with endometrial carcinoma is undergoing radiotherapy. Which of the following is true? r",
    options: [
      "InPtensity is inversely proportional to the square of the distance from the source",
      "S mall blood vessels are most radioresistant",
      "Rapidly proliferating cells are most radioresistant",
      "Small intestinal mucosa is most radio-resistant",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Intensity is inversely proportional to square of distance (Option A)**\n\nüî¨ **RADIOTHERAPY PRINCIPLES:**\n\n**INVERSE SQUARE LAW:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Intensity ‚àù 1/distance¬≤** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Doubling distance** ‚Üí Intensity becomes **1/4** ‚≠ê\n\n**EXAMPLE:**\n‚Ä¢ At **1 cm:** Intensity = 100%\n‚Ä¢ At **2 cm:** Intensity = 25% (1/4)\n‚Ä¢ At **3 cm:** Intensity = 11.1% (1/9)\n\n**IMPORTANCE:**\n‚Ä¢ **Brachytherapy** (internal radiation) uses this ‚≠ê\n‚Ä¢ **Protects** surrounding normal tissue\n‚Ä¢ **High dose** to tumor, rapid fall-off\n\n**WHY OTHERS ARE WRONG:**\n\n‚Ä¢ **Small vessels radioresistant:** NO (radiosensitive) ‚≠ê\n‚Ä¢ **Rapidly dividing cells radioresistant:** NO (radiosensitive) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Small intestine radioresistant:** NO (radiosensitive)\n\n**RADIOSENSITIVE TISSUES:**\n‚Ä¢ **Rapidly dividing:** Bone marrow, GI mucosa, gonads ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Well-oxygenated tissues**\n\n**RADIORESISTANT:**\n‚Ä¢ **Slow-dividing:** Bone, muscle, nerve\n\nüí° **KEY:** **Inverse square law: Intensity ‚àù 1/d¬≤** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-166",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2023",
    question: "A child before playing consumed fruit from the garden. After some time he developed a high fever, confusion, photophobia, and unable to urinate. What are the likely causative agent and the appropriate antidote used in this case?",
    options: [
      "Datura, Pralidoxime",
      "Datura, Physostigmine",
      "Yellow oleander, Pralidoxim e",
      "Yellow oleander, Physostigmine",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Datura, Physostigmine (Option B)**\n\nüî¨ **DATURA POISONING:**\n\n**PLANT:** **Datura stramonium** (Devil's trumpet/Thorn apple) ‚≠ê‚≠ê‚≠ê\n\n**TOXIN:** **Atropine-like alkaloids** (hyoscyamine, scopolamine) ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE - ANTICHOLINERGIC TOXIDROME:**\n‚Ä¢ **Fever** ‚≠ê‚≠ê‚≠ê (hyperthermia)\n‚Ä¢ **Confusion** ‚≠ê (delirium)\n‚Ä¢ **Photophobia** ‚≠ê (mydriasis)\n‚Ä¢ **Unable to urinate** ‚≠ê‚≠ê‚≠ê (urinary retention)\n\n**MNEMONIC:** **\"Mad as a hatter, Hot as a hare, Red as a beet, Dry as a bone, Blind as a bat\"** ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **Mydriasis** (dilated pupils)\n‚Ä¢ **Dry mucous membranes**\n‚Ä¢ **Flushed skin**\n‚Ä¢ **Tachycardia**\n‚Ä¢ **Hallucinations**\n\n**ANTIDOTE:** **PHYSOSTIGMINE** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Cholinesterase inhibitor**\n‚Ä¢ **Reverses anticholinergic effects**\n‚Ä¢ **Dose:** 1-2 mg IV slowly\n\n**WHY NOT PRALIDOXIME:**\n‚Ä¢ **Pralidoxime:** For **organophosphate** poisoning (NOT atropine/Datura)\n\nüí° **KEY:** **Datura = Anticholinergic ‚Üí Physostigmine antidote** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-167",
    subjectId: "radiology",
    chapterId: "neet-pg-2023",
    question: "a A patient presents with a history of fever and cough for the past 3-5 days. His examination findings reveal crepitations. Chest X-ray is given below. What is the probable diagnosis? L p e r P",
    options: [
      "Apical segment of Right lower lobe consolidation",
      "Right middle lobe consolidation",
      "Posterior segment of right lower lobe consolidation",
      "Loculated pleural effusion",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Right middle lobe consolidation (Option B)**\n\nüî¨ **RIGHT MIDDLE LOBE (RML) PNEUMONIA:**\n\n**THIS CASE:**\n‚Ä¢ **Fever + cough** (3-5 days)\n‚Ä¢ **Crepitations** ‚≠ê\n‚Ä¢ **CXR:** (From image) Right-sided opacity\n\n**RML ON CHEST X-RAY:**\n\n**PA VIEW:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Right heart border OBSCURED** (silhouette sign) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Triangular opacity**\n‚Ä¢ **Right middle lobe** adjacent to right heart border\n\n**LATERAL VIEW:**\n‚Ä¢ **Wedge-shaped opacity** anteriorly\n‚Ä¢ **Between major & minor fissures**\n\n**SILHOUETTE SIGN:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Loss of normal border** = pathology in SAME plane\n‚Ä¢ **Right heart border lost** = **RML** or **Right ventricle** pathology ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Left heart border lost** = **Lingula**\n‚Ä¢ **Diaphragm lost** = **Lower lobe**\n\n**RML SYNDROME:**\n‚Ä¢ **Chronic/recurrent** RML collapse/infection\n‚Ä¢ **Narrowest bronchus** ‚Üí prone to obstruction\n\n**TREATMENT:**\n‚Ä¢ **Antibiotics** (community-acquired pneumonia)\n\nüí° **KEY:** **Right heart border obscured = RML consolidation** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-168",
    subjectId: "anatomy",
    chapterId: "neet-pg-2023",
    question: "e Injury at which of the following marked sites causes failure of dorsiflexion? d d a L p e",
    options: [
      "3",
      "2 P",
      "1",
      "4",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Site 3 (Option A) - Common peroneal nerve**\n\nüî¨ **COMMON PERONEAL NERVE INJURY:**\n\n**DORSIFLEXION FAILURE = FOOT DROP** ‚≠ê‚≠ê‚≠ê\n\n**NERVE:** **Common Peroneal Nerve** (L4-L5-S1) ‚≠ê‚≠ê‚≠ê\n\n**SITE OF INJURY:** **Neck of fibula** ‚≠ê‚≠ê‚≠ê (Site 3)\n‚Ä¢ **Most vulnerable** location\n‚Ä¢ **Superficial** position\n‚Ä¢ **Trauma, fracture, tight cast**\n\n**MUSCLES AFFECTED:**\n‚Ä¢ **Deep peroneal:**\n  - **Tibialis anterior** (dorsiflexion) ‚≠ê‚≠ê‚≠ê\n  - **EHL, EDL** (toe extension)\n‚Ä¢ **Superficial peroneal:**\n  - **Peroneus longus/brevis** (eversion)\n\n**CLINICAL:**\n‚Ä¢ **Foot drop** ‚≠ê‚≠ê‚≠ê (cannot dorsiflex)\n‚Ä¢ **Steppage gait** (high stepping)\n‚Ä¢ **Loss of sensation** (dorsum of foot, first web space)\n\n**OTHER SITES:**\n‚Ä¢ **Site 1:** Sciatic nerve (hip region)\n‚Ä¢ **Site 2:** Tibial nerve (popliteal fossa)\n‚Ä¢ **Site 4:** Deep peroneal (anterior compartment)\n\n**TREATMENT:**\n‚Ä¢ **Ankle-foot orthosis (AFO)**\n‚Ä¢ **Nerve decompression** (if compression)\n\nüí° **KEY:** **Foot drop = Common peroneal nerve at fibular neck** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-169",
    subjectId: "anatomy",
    chapterId: "neet-pg-2023",
    question: "A patient presents with swelling under the left ear lobule and complains of pain. Which of the following structures is the likely cause of the pain?",
    options: [
      "Facial nerve",
      "Greater auricular nerve",
      "Auriculotemporal nerve",
      "Investing layer of deep cervical fascia r",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Greater auricular nerve (Option B)**\n\nüî¨ **PAROTID SWELLING PAIN:**\n\n**THIS CASE:**\n‚Ä¢ **Swelling under ear lobule** ‚≠ê (parotid region)\n‚Ä¢ **Pain** ‚≠ê‚≠ê‚≠ê\n\n**GREATER AURICULAR NERVE:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Sensory nerve** (C2-C3) ‚≠ê\n‚Ä¢ **Supplies:** Skin over parotid, ear lobule, angle of jaw\n‚Ä¢ **Stretched/compressed** by parotid swelling ‚Üí PAIN ‚≠ê‚≠ê‚≠ê\n\n**ANATOMY:**\n‚Ä¢ **Emerges** at mid-posterior border of SCM\n‚Ä¢ **Ascends** over SCM toward ear\n‚Ä¢ **Crosses** parotid gland superficially\n\n**PAROTID SWELLING CAUSES:**\n‚Ä¢ **Acute parotitis** (mumps, bacterial)\n‚Ä¢ **Tumor** (pleomorphic adenoma)\n‚Ä¢ **Stones** (sialolithiasis)\n\n**WHY NOT OTHERS:**\n\n‚Ä¢ **Facial nerve:** Motor (NOT sensory) - NO pain\n‚Ä¢ **Auriculotemporal:** Anterior ear (NOT posterior/lobule)\n‚Ä¢ **Deep fascia:** Structure (NOT nerve)\n\n**CLINICAL:**\n‚Ä¢ **Parotid surgery** ‚Üí Greater auricular nerve sacrifice ‚Üí Numbness ‚≠ê\n\nüí° **KEY:** **Parotid swelling pain = Greater auricular nerve stretch** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-170",
    subjectId: "biochemistry",
    chapterId: "neet-pg-2023",
    question: "d A child presents with bone pain and hepatosplenomegaly. A trephine biopsy and aspirate show the following finding. Which of the following is the most likely enzyme deficient in this condition? a L p e r P",
    options: [
      "H exosaminidase",
      "Glucocerebrosidase",
      "Sphingomyelinase",
      "Alpha 1,4-glucosidase",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Glucocerebrosidase (Option B)**\n\nüî¨ **GAUCHER DISEASE:**\n\n**ENZYME DEFICIENCY:** **Glucocerebrosidase** (Œ≤-glucosidase) ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE:**\n‚Ä¢ **Bone pain** ‚≠ê\n‚Ä¢ **Hepatosplenomegaly** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Biopsy:** (From image) Gaucher cells ‚≠ê‚≠ê‚≠ê\n\n**GAUCHER CELLS:** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n‚Ä¢ **Macrophages** filled with glucocerebroside\n‚Ä¢ **Crumpled tissue paper** appearance ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Wrinkled cytoplasm**\n\n**CLINICAL - TYPE 1** (Most common, non-neuropathic):\n‚Ä¢ **Hepatosplenomegaly** ‚≠ê‚≠ê‚≠ê (massive spleen)\n‚Ä¢ **Bone pain** ‚≠ê (Erlenmeyer flask deformity)\n‚Ä¢ **Thrombocytopenia** (hypersplenism)\n‚Ä¢ **NO CNS involvement**\n\n**OTHER TYPES:**\n‚Ä¢ **Type 2:** Acute neuronopathic (infantile)\n‚Ä¢ **Type 3:** Chronic neuronopathic\n\n**TREATMENT:**\n‚Ä¢ **Enzyme replacement** ‚≠ê‚≠ê‚≠ê (Imiglucerase)\n‚Ä¢ **Splenectomy** (if massive)\n\n**OTHER LYSOSOMAL STORAGE:**\n‚Ä¢ **Hexosaminidase:** Tay-Sachs\n‚Ä¢ **Sphingomyelinase:** Niemann-Pick\n\nüí° **KEY:** **Gaucher cells (wrinkled) = Glucocerebrosidase deficiency** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page84_img43.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-171",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2023",
    question: "The method of autopsy carried out en masse to remove from tongue to prostate is.",
    options: [
      "Virchow technique",
      "Rokitansky technique",
      "Ghon techniqu e",
      "Letulle technique",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Letulle technique (Option D)**\n\nüî¨ **AUTOPSY TECHNIQUES:**\n\n**LETULLE TECHNIQUE:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **En masse removal** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Tongue to pelvis** removed together as one block ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Dissection OUTSIDE body**\n‚Ä¢ **Preserves organ relationships**\n\n**PROCEDURE:**\n1. **Remove** neck, thoracic, & abdominal organs together\n2. **Dissect** on separate table\n3. **Examine** organ connections\n\n**ADVANTAGES:**\n‚Ä¢ **Quick**\n‚Ä¢ **Good for teaching**\n‚Ä¢ **Preserves anatomy**\n\n**OTHER TECHNIQUES:**\n\n**VIRCHOW:** ‚≠ê\n‚Ä¢ **Organ-by-organ** removal\n‚Ä¢ **Dissection IN SITU**\n‚Ä¢ **Detailed** but time-consuming\n\n**ROKITANSKY:** ‚≠ê\n‚Ä¢ **In situ** dissection\n‚Ä¢ **Organs in groups**\n\n**GHON:** ‚≠ê\n‚Ä¢ **For infectious diseases** (TB, etc.)\n‚Ä¢ **Minimizes contamination**\n\nüí° **KEY:** **En masse (tongue to pelvis) = Letulle technique** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-172",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2023",
    question: "a A 42-year-old HIV-positive patient died, and his body was brought for post-mortem. The method of autopsy to be done is___",
    options: [
      "Ghon technique",
      "Letulle technique",
      "Virchow techniqu e",
      "Rokitansky technique",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Ghon technique (Option A)**\n\nüî¨ **AUTOPSY IN INFECTIOUS DISEASES:**\n\n**GHON TECHNIQUE:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **For infectious/contagious diseases** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **HIV, TB, Hepatitis, etc.**\n‚Ä¢ **Minimizes infection spread** to autopsy personnel\n\n**MODIFICATIONS:**\n‚Ä¢ **Minimal organ handling**\n‚Ä¢ **Organs examined IN SITU** as much as possible\n‚Ä¢ **Reduced aerosol generation**\n‚Ä¢ **Tissue sampling** only when necessary\n\n**SAFETY MEASURES:**\n‚Ä¢ **Full PPE** (N95, gown, gloves, face shield) ‚≠ê\n‚Ä¢ **Double gloving**\n‚Ä¢ **Sharp instruments** minimized\n‚Ä¢ **No electric saws** (aerosols)\n\n**HIV AUTOPSY PRECAUTIONS:**\n‚Ä¢ **Universal precautions** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Careful needle handling**\n‚Ä¢ **Eye protection** (splash risk)\n‚Ä¢ **Document HIV status**\n\n**OTHER TECHNIQUES:**\n‚Ä¢ **Virchow:** Organ-by-organ (routine)\n‚Ä¢ **Letulle:** En masse (teaching)\n‚Ä¢ **Rokitansky:** In situ groups (routine)\n\nüí° **KEY:** **Infectious disease (HIV) autopsy = Ghon technique** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page85_img44.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-173",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "A patient presented with a high fever, altered sensorium, headache, neck rigidity, and seizures. He was diagnosed with HSV encephalitis. Which of the following tests can be used to confirm the diagnosis?",
    options: [
      "IgM in CSF",
      "Tzanck smear of CSF",
      "CSF PCR for viral DNA",
      "CSF culture on chick embryo lines",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **CSF PCR for viral DNA (Option C)**\n\nüî¨ **HSV ENCEPHALITIS DIAGNOSIS:**\n\n**THIS CASE:**\n‚Ä¢ **Fever**, **headache**, **neck rigidity** ‚≠ê\n‚Ä¢ **Altered sensorium**, **seizures** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Clinical diagnosis:** HSV encephalitis\n\n**GOLD STANDARD:** **CSF PCR for HSV DNA** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**CSF PCR:**\n‚Ä¢ **Highly sensitive & specific** (>95%) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Detects viral DNA** directly\n‚Ä¢ **Rapid** (few hours)\n‚Ä¢ **Preferred diagnostic test** ‚≠ê‚≠ê‚≠ê\n\n**WHY NOT OTHERS:**\n\n‚Ä¢ **IgM in CSF:** Takes time to develop (7-10 days), LOW sensitivity early ‚≠ê\n‚Ä¢ **Tzanck smear:** For SKIN lesions (NOT CSF)\n‚Ä¢ **CSF culture:** SLOW (days-weeks), LOW sensitivity\n\n**CSF FINDINGS:**\n‚Ä¢ **Lymphocytic pleocytosis**\n‚Ä¢ **RBCs** (hemorrhagic)\n‚Ä¢ **Elevated protein**\n‚Ä¢ **Normal/low glucose**\n\n**IMAGING:**\n‚Ä¢ **MRI:** Bitemporal involvement ‚≠ê‚≠ê‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **IV Acyclovir** (10 mg/kg q8h) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Start empirically** (don't wait for PCR)\n\nüí° **KEY:** **HSV encephalitis diagnosis = CSF PCR for HSV DNA** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-174",
    subjectId: "microbiology",
    chapterId: "neet-pg-2023",
    question: "e In a patient presented with a fever and a positive filarial antigen test, what is the next appropriate method of management? d",
    options: [
      "Bone marrow biopsy",
      "DEC provocation test",
      "Detection of microfilariae in the blood smaear",
      "Ultrasound of the scrotum",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Detection of microfilariae in blood smear (Option C)**\n\nüî¨ **FILARIASIS DIAGNOSIS:**\n\n**THIS CASE:**\n‚Ä¢ **Fever**\n‚Ä¢ **Positive filarial antigen test** ‚≠ê‚≠ê‚≠ê\n\n**FILARIAL ANTIGEN TEST:**\n‚Ä¢ **Detects circulating filarial antigen** (CFA)\n‚Ä¢ **Wuchereria bancrofti** specific ‚≠ê\n‚Ä¢ **ICT/ELISA**\n‚Ä¢ **High sensitivity & specificity**\n\n**NEXT STEP:** **Blood smear for microfilariae** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**MICROFILARIAE DETECTION:**\n‚Ä¢ **Confirms active infection** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Specifies species**\n‚Ä¢ **Guides treatment**\n‚Ä¢ **Timing:** **Night blood** (10 PM - 2 AM) for W. bancrofti ‚≠ê‚≠ê‚≠ê (nocturnal periodicity)\n\n**TECHNIQUE:**\n‚Ä¢ **Thick blood smear** (concentrated)\n‚Ä¢ **Giemsa stain**\n\n**WHY NOT OTHERS:**\n\n‚Ä¢ **DEC provocation:** If blood smear negative (brings microfilariae to peripheral blood)\n‚Ä¢ **Bone marrow:** NOT indicated\n‚Ä¢ **Scrotal USS:** For filarial dance sign (BUT do blood smear first)\n\n**TREATMENT:**\n‚Ä¢ **DEC** (Diethylcarbamazine) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Albendazole**\n\nüí° **KEY:** **Positive antigen test ‚Üí Confirm with blood smear for microfilariae** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-175",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2023",
    question: "Question 175 - [Content needs manual review]",
    options: [
      "Option 1",
      "Option 2",
      "Teichmann test",
      "Acid phosphatase test",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Option 1**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-176",
    subjectId: "ophthalmology",
    chapterId: "neet-pg-2023",
    question: "Which of the following refractive errors is associated with the image given below? r e d d a",
    options: [
      "Presbyopia",
      "Astigmatism",
      "Hypermetropia p",
      "Myopia",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Astigmatism (Option B)**\n\nüî¨ **ASTIGMATISM:**\n\n**DEFINITION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Irregular curvature** of cornea or lens\n‚Ä¢ **Different refractive powers** in different meridians ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **NOT spherical**\n\n**IMAGE CHARACTERISTICS:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Distorted/blurred** vision\n‚Ä¢ **Lines in different orientations** focused differently\n‚Ä¢ **Cannot focus point source** to a point\n‚Ä¢ **Typically shows radiating/fan pattern** ‚≠ê‚≠ê‚≠ê\n\n**TYPES:**\n\n**REGULAR:** ‚≠ê\n‚Ä¢ **Principal meridians** perpendicular (90¬∞)\n‚Ä¢ **Correctable** with cylindrical lenses\n\n**IRREGULAR:**\n‚Ä¢ **No defined meridians**\n‚Ä¢ **Corneal scarring**, keratoconus\n‚Ä¢ **Needs contact lenses**\n\n**SYMPTOMS:**\n‚Ä¢ **Blurred vision** (distance & near) ‚≠ê\n‚Ä¢ **Distorted** images\n‚Ä¢ **Headache**, **eye strain**\n\n**CORRECTION:**\n‚Ä¢ **Cylindrical lenses** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Toric contact lenses**\n‚Ä¢ **Laser (LASIK)**\n\n**VS OTHER ERRORS:**\n‚Ä¢ **Myopia:** Distant blur, concave lens\n‚Ä¢ **Hypermetropia:** Near blur, convex lens\n\nüí° **KEY:** **Distorted/radiating image = Astigmatism (irregular curvature)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-177",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "Which of the following is true regarding the Mendelian mode of inheritance?",
    options: [
      "Every 10th patient has a Y-linked disorder",
      "1/3rd of Mendelian disorders is autosomal recessive",
      "Every 5th patient has an X-linked recessive disorder",
      "2/3 r d of Mendelian disorders are autosomal dominant",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **2/3 of Mendelian disorders are autosomal dominant (Option D)**\n\nüî¨ **MENDELIAN DISORDERS - DISTRIBUTION:**\n\n**AUTOSOMAL DOMINANT:** ‚≠ê‚≠ê‚≠ê **~65-75%** (roughly 2/3) ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Examples:** Huntington's, Marfan, Achondroplasia, ADPKD\n‚Ä¢ **Vertical transmission**\n‚Ä¢ **50% offspring risk**\n\n**AUTOSOMAL RECESSIVE:** **~20-25%**\n‚Ä¢ **Examples:** Sickle cell, CF, Thalassemia, PKU\n‚Ä¢ **Horizontal transmission**\n‚Ä¢ **25% offspring risk** (if both carriers)\n\n**X-LINKED:** **~5-10%**\n‚Ä¢ **Examples:** Hemophilia A/B, Duchenne MD, G6PD deficiency\n‚Ä¢ **Mostly males affected**\n\n**Y-LINKED:** **<1%** (VERY rare)\n‚Ä¢ **Male infertility genes**\n‚Ä¢ **Only males affected**\n\n**WHY AD MOST COMMON:**\n‚Ä¢ **Manifests in heterozygotes** (one mutant allele sufficient)\n‚Ä¢ **Better reproductive fitness** than AR\n‚Ä¢ **Not lethal** (usually)\n\n**IMPORTANT:**\n‚Ä¢ **Most common inheritance:** **Autosomal dominant** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **~2/3 of Mendelian disorders are Autosomal Dominant** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-178",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2023",
    question: "A patient was brought to casualty with seizures. He had multiple episodes and was taking herbal medicines for the same. He was conscious in between the episodes. During the episodes, he had arching of his back. What is the likely cause?",
    options: [
      "Strychnine",
      "Ricinus",
      "Nerium odorum",
      "Datur d",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Strychnine (Option A)**\n\nüî¨ **STRYCHNINE POISONING:**\n\n**SOURCE:** **Nux vomica** seeds (Strychnos nux-vomica) ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE - CLASSIC:**\n‚Ä¢ **Multiple seizure episodes** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Herbal medicine** ‚≠ê\n‚Ä¢ **CONSCIOUS between episodes** ‚≠ê‚≠ê‚≠ê **(KEY)**\n‚Ä¢ **Opisthotonos** (back arching) ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n\n**MECHANISM:**\n‚Ä¢ **Glycine antagonist** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Blocks inhibitory neurotransmission** in spinal cord\n‚Ä¢ **Unopposed muscle contraction**\n\n**CLINICAL:**\n‚Ä¢ **Tonic-clonic convulsions** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Opisthotonos** (extreme back arching) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Risus sardonicus** (facial grimace)\n‚Ä¢ **Board-like rigidity**\n‚Ä¢ **Consciousness PRESERVED** between spasms ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Triggered by stimuli** (touch, sound, light)\n\n**TREATMENT:**\n‚Ä¢ **Benzodiazepines** (control seizures)\n‚Ä¢ **Muscle relaxants**\n‚Ä¢ **Minimize stimuli** (dark, quiet room)\n\n**VS TETANUS:**\n‚Ä¢ **Similar presentation** BUT\n‚Ä¢ **Tetanus:** Trismus (lockjaw), slower onset\n\nüí° **KEY:** **Opisthotonos + Consciousness preserved + Herbal medicine = Strychnine** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-179",
    subjectId: "ophthalmology",
    chapterId: "neet-pg-2023",
    question: "An infant is brought with complaints of excessive watering of the eyes and photophobia. The image is given below. Wphat is the likely diagnosis? e r P",
    options: [
      "Congenital glaucoma",
      "Congenital cataract",
      "Mucopolysaccharidosis",
      "Ophthalmia neonatorum",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Congenital glaucoma (Primary congenital glaucoma/Buphthalmos) (Option A)**\n\nüî¨ **CONGENITAL GLAUCOMA:**\n\n**THIS CASE - CLASSIC TRIAD:** ‚≠ê‚≠ê‚≠ê\n1. **Epiphora** (excessive tearing) ‚≠ê‚≠ê‚≠ê\n2. **Photophobia** ‚≠ê‚≠ê‚≠ê\n3. **Blepharospasm** (eyelid spasm)\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Developmental anomaly** of drainage angle ‚≠ê\n‚Ä¢ **Impaired aqueous outflow**\n‚Ä¢ **‚Üë Intraocular pressure (IOP)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Corneal stretching** (infant's eye expandable)\n\n**CLINICAL:**\n‚Ä¢ **Buphthalmos** (enlarged globe) ‚≠ê‚≠ê‚≠ê **(OX EYE)**\n‚Ä¢ **Corneal edema** (cloudy, hazy) ‚≠ê\n‚Ä¢ **Haab's striae** (horizontal breaks in Descemet's membrane)\n‚Ä¢ **Increased corneal diameter** (>12 mm) ‚≠ê\n\n**IMAGE FINDINGS:**\n‚Ä¢ **Enlarged cornea**\n‚Ä¢ **Hazy cornea** (edema)\n\n**DIAGNOSIS:**\n‚Ä¢ **IOP measurement** (>21 mmHg)\n‚Ä¢ **Corneal diameter**\n‚Ä¢ **Examination under anesthesia** (EUA)\n\n**TREATMENT:**\n‚Ä¢ **Surgical** ‚≠ê‚≠ê‚≠ê (Goniotomy, Trabeculotomy)\n‚Ä¢ **Medications** (temporary)\n\nüí° **KEY:** **Infant + Tearing + Photophobia + Large cornea = Congenital glaucoma** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-180",
    subjectId: "ophthalmology",
    chapterId: "neet-pg-2023",
    question: "r A 60-year-old patient complains of decreased distant vision but now he does not use e spectacles for near vision. The image of his ocular examination is given below. What is this type of refractive error called?",
    options: [
      "Index myopia",
      "Axial myopi d",
      "Curvatural myopi L P d",
      "Positional myopi d",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Index myopia (Nuclear sclerotic cataract) (Option A)**\n\nüî¨ **INDEX MYOPIA:**\n\n**THIS CASE - KEY FEATURES:**\n‚Ä¢ **60-year-old** ‚≠ê\n‚Ä¢ **Decreased distant vision** (myopia) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **NO longer needs glasses for near** ‚≠ê‚≠ê‚≠ê **(SECOND SIGHT)**\n‚Ä¢ **Image:** Nuclear cataract\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Nuclear sclerosis** (lens nucleus hardening) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **‚Üë Refractive index** of lens ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Increased lens power**\n‚Ä¢ **Myopic shift**\n\n**TYPES OF MYOPIA:**\n\n**INDEX MYOPIA:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Changed refractive index** (nuclear cataract) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **\"Second sight\" phenomenon** (improved near vision)\n\n**AXIAL MYOPIA:** (Most common)\n‚Ä¢ **Increased axial length** (>24 mm)\n\n**CURVATURAL MYOPIA:**\n‚Ä¢ **Increased corneal curvature** (keratoconus)\n\n**POSITIONAL MYOPIA:**\n‚Ä¢ **Lens position** changes (ectopia lentis)\n\n**SECOND SIGHT:**\n‚Ä¢ **Temporary improvement** in near vision\n‚Ä¢ **Due to nuclear sclerosis**\n‚Ä¢ **Cataract progresses** ‚Üí Eventually both near & far vision deteriorate\n\nüí° **KEY:** **Elderly + Myopia + No glasses for near + Cataract = Index myopia** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page89_img45.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-181",
    subjectId: "pediatrics",
    chapterId: "neet-pg-2023",
    question: "A child is brought to the hospital with respiratory distress and biphasic stridor. The radiograph is shown below. What is pthe diagnosis? e r P",
    options: [
      "Acute epiglottitis",
      "Acute laryngotracheobronchitis",
      "Foreign body aspiration",
      "Laryngomalacia",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Acute laryngotracheobronchitis (Croup) (Option B)**\n\nüî¨ **CROUP (Laryngotracheobronchitis):**\n\n**MOST COMMON** cause of stridor in children ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE:**\n‚Ä¢ **Respiratory distress** ‚≠ê\n‚Ä¢ **Biphasic stridor** ‚≠ê‚≠ê‚≠ê (inspiratory + expiratory)\n‚Ä¢ **X-ray:** (From image) Steeple sign ‚≠ê‚≠ê‚≠ê\n\n**CAUSE:** **Parainfluenza virus** (most common) ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **Age:** 6 months - 3 years ‚≠ê\n‚Ä¢ **Barking cough** ‚≠ê‚≠ê‚≠ê (seal-like)\n‚Ä¢ **Hoarse voice**\n‚Ä¢ **Biphasic stridor** ‚≠ê\n‚Ä¢ **Worse at night**\n‚Ä¢ **Gradual onset** (days)\n\n**X-RAY:** **STEEPLE SIGN** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **AP view:** Narrowing of subglottic trachea\n‚Ä¢ **Looks like church steeple**\n\n**TREATMENT:**\n‚Ä¢ **Mild:** Humidified air, oral fluids\n‚Ä¢ **Moderate-Severe:**\n  - **Dexamethasone** (0.6 mg/kg) ‚≠ê‚≠ê‚≠ê\n  - **Nebulized epinephrine** (if severe)\n\n**VS EPIGLOTTITIS:**\n‚Ä¢ **Epiglottitis:** Acute, drooling, toxic, thumbprint sign\n\nüí° **KEY:** **Barking cough + Biphasic stridor + Steeple sign = Croup** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-182",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "r A child presents with intermittent jaundice and splenomegaly. There is a history of similar e complaints in the elder brother. Peripheral smear shows the following finding. How will you investigate this condition? d d a L p e",
    options: [
      "Osmotic frargility test - Hereditary spherocytosis",
      "P Coombs test - AIHA",
      "G6PD deficiency - Genetic testing",
      "Paroxysmal nocturnal hemoglobinuria - Flow cytometry",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Osmotic fragility test - Hereditary spherocytosis (Option A)**\n\nüî¨ **HEREDITARY SPHEROCYTOSIS (HS):**\n\n**THIS CASE:**\n‚Ä¢ **Intermittent jaundice** ‚≠ê\n‚Ä¢ **Splenomegaly** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Family history** (elder brother) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Peripheral smear:** Spherocytes ‚≠ê‚≠ê‚≠ê\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Spectrin/ankyrin deficiency** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Membrane defect** ‚Üí Loss of membrane\n‚Ä¢ **Sphere-shaped RBCs** (lose biconcave shape)\n‚Ä¢ **Trapped in spleen** ‚Üí **Hemolysis**\n\n**INHERITANCE:** **Autosomal dominant** ‚≠ê (75%)\n\n**CLINICAL:**\n‚Ä¢ **Hemolytic anemia** ‚≠ê\n‚Ä¢ **Jaundice** (unconjugated)\n‚Ä¢ **Splenomegaly** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Gallstones** (pigment stones)\n\n**DIAGNOSTIC TEST:** **OSMOTIC FRAGILITY TEST** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Spherocytes** lyse easily in hypotonic saline\n‚Ä¢ **Increased fragility** ‚≠ê‚≠ê‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **Splenectomy** ‚≠ê‚≠ê‚≠ê (curative)\n‚Ä¢ **Folic acid** supplementation\n\nüí° **KEY:** **Spherocytes + Family history + Splenomegaly = HS ‚Üí Osmotic fragility test** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page90_img46.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-183",
    subjectId: "pediatrics",
    chapterId: "neet-pg-2023",
    question: "A 3-month-old baby presents with jaundice and clay-coloured stools. Lab investigation reveals that the baby has conjugated hyperbilirubinemia. The liver biopsy shows periductal proliferation. What is the most likely diagnosis?",
    options: [
      "Crigler-Najjar syndrome",
      "Rotor syndrome",
      "Dubin-Johnson syndrome r",
      "Biliary atresia",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Biliary atresia (Option D)**\n\nüî¨ **BILIARY ATRESIA:**\n\n**MOST COMMON** cause of neonatal cholestasis requiring surgery ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE - CLASSIC:**\n‚Ä¢ **3-month-old** (presents 2-8 weeks) ‚≠ê\n‚Ä¢ **Jaundice** (conjugated) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Clay-colored stools** ‚≠ê‚≠ê‚≠ê (acholic)\n‚Ä¢ **Conjugated hyperbilirubinemia** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Liver biopsy:** **Periductal fibrosis & bile duct proliferation** ‚≠ê‚≠ê‚≠ê\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Progressive obliteration** of extrahepatic bile ducts ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bile cannot drain** ‚Üí Cholestasis\n\n**CLINICAL:**\n‚Ä¢ **Jaundice** (worsening)\n‚Ä¢ **Dark urine** (bile)\n‚Ä¢ **Clay stools** (no bile) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hepatomegaly**\n‚Ä¢ **Failure to thrive**\n\n**DIAGNOSIS:**\n‚Ä¢ **Liver biopsy** ‚≠ê‚≠ê‚≠ê (bile duct proliferation, fibrosis)\n‚Ä¢ **USG:** Triangular cord sign\n‚Ä¢ **HIDA scan:** No excretion\n\n**TREATMENT:**\n‚Ä¢ **Kasai procedure** (portoenterostomy) ‚≠ê‚≠ê‚≠ê <3 months age\n‚Ä¢ **Liver transplant** (if Kasai fails)\n\nüí° **KEY:** **Infant + Clay stools + Conjugated jaundice + Bile duct proliferation = Biliary atresia** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-184",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2023",
    question: "Section 314 IPC deals with a",
    options: [
      "Causing miscarriage with the consent of the mothe L",
      "Causing miscarriage without the consent of the mother",
      "Death of the mother by act done with intent to cause miscarriage",
      "Causing the death of the quick unborn child by an act amounting to culpable homicid e",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Death of mother by act done with intent to cause miscarriage (Option C)**\n\nüî¨ **IPC SECTION 314:**\n\n**SECTION 314 IPC:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Death of woman** caused by act done with **intent to cause miscarriage** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Punishment:** Up to **10 years** imprisonment + fine\n‚Ä¢ **If act done without consent:** Life imprisonment\n\n**MEDICAL TERMINATION OF PREGNANCY (MTP) ACT SECTIONS:**\n\n**312 IPC:** **Causing miscarriage** (with consent) ‚≠ê\n‚Ä¢ 3 years + fine\n\n**313 IPC:** **Causing miscarriage WITHOUT consent** ‚≠ê\n‚Ä¢ Life imprisonment + fine\n\n**314 IPC:** **Death of woman** from miscarriage attempt ‚≠ê‚≠ê‚≠ê\n\n**315 IPC:** **Causing death of quick unborn child** ‚≠ê\n‚Ä¢ Act amounting to culpable homicide\n‚Ä¢ 10 years + fine\n\n**316 IPC:** **Causing death of quick unborn child** (not culpable homicide)\n\n**KEY DIFFERENCES:**\n‚Ä¢ **314:** Mother dies\n‚Ä¢ **315:** Fetus dies (quick = >28 weeks)\n\nüí° **KEY:** **Section 314 IPC = Death of MOTHER from miscarriage attempt** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page91_img47.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-1",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "An African child is found to have a mass in the jaw. A biopsy of the mass was done, and it appears as shown in the image below. The child also had a translocation of t(8;14). What is the probable diagnosis? r e d",
    options: [
      "Acute myeloid leukemia",
      "Follicular lymphoma a",
      "Multiple myeloma",
      "Burkitt lymphoma",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Burkitt lymphoma (Option D)**\n\nüî¨ **BURKITT LYMPHOMA:**\n\n**THIS CASE - CLASSIC:**\n‚Ä¢ **African child** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Jaw mass** ‚≠ê‚≠ê‚≠ê (most common presentation in Africa)\n‚Ä¢ **t(8;14) translocation** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n‚Ä¢ **Biopsy:** (From image) Starry sky appearance\n\n**GENETICS:**\n‚Ä¢ **t(8;14)** translocation ‚≠ê‚≠ê‚≠ê (80%)\n  - **c-MYC** oncogene (chromosome 8) moves to IGH (chromosome 14)\n  - Also: t(2;8), t(8;22)\n‚Ä¢ **EBV association** (African/endemic type) ‚≠ê\n\n**TYPES:**\n‚Ä¢ **Endemic** (African) ‚≠ê - Jaw/facial bones, EBV+\n‚Ä¢ **Sporadic** (Western) - Abdomen (ileocecal)\n‚Ä¢ **Immunodeficiency-related** (HIV)\n\n**HISTOLOGY:** **STARRY SKY** appearance ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Sheets of lymphocytes** (dark sky)\n‚Ä¢ **Scattered macrophages** (stars) eating apoptotic cells\n\n**CLINICAL:**\n‚Ä¢ **Rapidly growing** mass\n‚Ä¢ **Children/young adults**\n\n**TREATMENT:**\n‚Ä¢ **Intensive chemotherapy** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **High cure rate** (>80%)\n\nüí° **KEY:** **African child + Jaw mass + t(8;14) + Starry sky = Burkitt lymphoma** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-186",
    subjectId: "pediatrics",
    chapterId: "neet-pg-2023",
    question: "Question 186 - [Content needs manual review]",
    options: [
      "Option 1",
      "Congenital herpes simplex virus infection",
      "Congenital toxoplasmosis",
      "Congenital cytomegalovirus infection",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Congenital cytomegalovirus infection**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page92_img48.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-187",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2023",
    question: "The temperature of a body of a deceased person is found to be 39 degrees Celsius. Which of the following is the most probable reason?",
    options: [
      "Cyanide poisoning",
      "Septicemi e",
      "Corrosive poisoning",
      "Intra-abdominal hemorrhage",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Septicemia (Option B)**\n\nüî¨ **POST-MORTEM BODY TEMPERATURE >37¬∞C:**\n\n**THIS CASE:** **Body temp 39¬∞C** (ELEVATED) ‚≠ê‚≠ê‚≠ê\n\n**CAUSES OF ELEVATED POST-MORTEM TEMPERATURE:**\n\n**SEPTICEMIA** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Fever at time of death** persists briefly\n‚Ä¢ **Bacterial toxins** maintain elevated temperature\n‚Ä¢ **Heat production** from bacterial metabolism\n\n**OTHER CAUSES:**\n‚Ä¢ **Heat stroke** ‚≠ê\n‚Ä¢ **Status epilepticus**\n‚Ä¢ **Thyroid storm**\n‚Ä¢ **CNS injury** (hypothalamic)\n‚Ä¢ **Anticholinergic poisoning** (Datura)\n\n**NORMAL POST-MORTEM COOLING:**\n‚Ä¢ **Algor mortis:** Body cools at **~1-1.5¬∞F/hour** ‚≠ê\n‚Ä¢ **Reaches ambient temperature** in 18-24 hours\n‚Ä¢ **Starts immediately** after death\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Cyanide:** Causes death, NO fever\n‚Ä¢ **Corrosive:** Local damage, NO systemic fever\n‚Ä¢ **Hemorrhage:** Blood loss, NO fever\n\n**FORENSIC IMPORTANCE:**\n‚Ä¢ **Elevated temperature** suggests **ante-mortem fever** ‚≠ê\n\nüí° **KEY:** **Post-mortem body temp >37¬∞C = Septicemia (ante-mortem fever)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-188",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "A child presented to the hospital Lwith cola-colored urine, hypertension, and puffiness of eyes. Laboratory investigations were done, and creatinine was 2.5 mg/dL. Treatment was started, and despite treatment, the patient did not improve for the next 3 weeks. The creatinine vaplue increased to 4.5 mg/dL. Which among the following electron microscopic findings will be seen in this patient?",
    options: [
      "Subendothelial deeposits",
      "Subepithelial deposits r",
      "Crescent formation P",
      "Mesangial deposits",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Subepithelial deposits (Option B)**\n\nüî¨ **POST-STREPTOCOCCAL GLOMERULONEPHRITIS (PSGN):**\n\n**THIS CASE:**\n‚Ä¢ **Cola-colored urine** (hematuria) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hypertension** ‚≠ê\n‚Ä¢ **Puffiness** (periorbital edema) ‚≠ê\n‚Ä¢ **‚Üë Creatinine** (2.5 ‚Üí 4.5 mg/dL) ‚≠ê\n‚Ä¢ **Not improving** after 3 weeks ‚≠ê\n\n**ACUTE GLOMERULONEPHRITIS** ‚≠ê‚≠ê‚≠ê\n\n**PSGN - ELECTRON MICROSCOPY:**\n‚Ä¢ **SUBEPITHELIAL deposits** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Immune complexes** on epithelial side of GBM\n‚Ä¢ **\"Humps\" on EM** ‚≠ê‚≠ê‚≠ê\n\n**LIGHT MICROSCOPY:**\n‚Ä¢ **Diffuse proliferative** GN\n‚Ä¢ **Hypercellular glomeruli**\n\n**IMMUNOFLUORESCENCE:**\n‚Ä¢ **Starry sky** pattern (granular)\n‚Ä¢ **IgG, C3 deposits**\n\n**CLINICAL:**\n‚Ä¢ **2-3 weeks** post-streptococcal infection\n‚Ä¢ **Children** (6-10 years)\n‚Ä¢ **Self-limited** (usually)\n\n**OTHER PATTERNS:**\n‚Ä¢ **Subendothelial:** SLE, MPGN\n‚Ä¢ **Mesangial:** IgA nephropathy\n‚Ä¢ **Crescents:** RPGN (rapidly progressive)\n\nüí° **KEY:** **Post-strep GN ‚Üí Subepithelial humps on EM** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-189",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "A 35-year-old homeless man presented with a 1-month history of fever, cough, and weight loss. Both sputum smears turned out to be negative, but the chest x-ray ordered was suggestive of tuberculosis. According to the recent NTEP guidelines, which is the next best line of management?",
    options: [
      "Repeat sputum smears",
      "Ask for CBNAAT",
      "Ask for line probe assay",
      "Wait until TB culture results to start ATT r",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Ask for CBNAAT (Option B)**\n\nüî¨ **NTEP (National TB Elimination Program) GUIDELINES:**\n\n**THIS CASE:**\n‚Ä¢ **Homeless man** ‚≠ê (high-risk)\n‚Ä¢ **Fever, cough, weight loss** (TB symptoms) ‚≠ê\n‚Ä¢ **2 sputum smears NEGATIVE** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **CXR suggestive of TB** ‚≠ê\n\n**NEXT STEP:** **CBNAAT (GeneXpert)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**NTEP ALGORITHM:**\n\n**1. Sputum smear (2 samples)**\n‚Ä¢ **If POSITIVE:** Start ATT\n‚Ä¢ **If NEGATIVE:** ‚Üì\n\n**2. CBNAAT** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Next test** if smear negative\n‚Ä¢ **Detects MTB** + **Rifampicin resistance**\n‚Ä¢ **Rapid** (2 hours)\n‚Ä¢ **High sensitivity** (>95%)\n\n**3. If CBNAAT negative but CXR suggestive:**\n‚Ä¢ **Trial of antibiotics** (non-TB)\n‚Ä¢ **Repeat CBNAAT** if no improvement\n‚Ä¢ **Consider empirical ATT**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Repeat smear:** LOW yield if already negative\n‚Ä¢ **LPA:** For drug resistance testing (AFTER diagnosis)\n‚Ä¢ **Wait for culture:** Takes 6-8 weeks (too long)\n\nüí° **KEY:** **Smear negative + CXR suggestive ‚Üí CBNAAT** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-190",
    subjectId: "forensic-medicine",
    chapterId: "neet-pg-2023",
    question: "d A farmer was sleeping in the field, and he felt a sting on his leg. He saw something moving away quickly. He then got drowsy and was taken to the hospital. He developed pain around the site and continued to bleed profusely afrom the wound site. The wound became red with blisters. Which of the following is the most likely cause?",
    options: [
      "Viper L",
      "Cobr p",
      "Wasp bite",
      "Scorpion",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Viper (Option A)**\n\nüî¨ **VIPER (HEMOTOXIC) SNAKE BITE:**\n\n**THIS CASE - HEMOTOXIC BITE:**\n‚Ä¢ **Farmer in field** ‚≠ê\n‚Ä¢ **Sting on leg**, **something moving away**\n‚Ä¢ **Drowsiness** ‚≠ê\n‚Ä¢ **Local pain** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Profuse bleeding** from wound ‚≠ê‚≠ê‚≠ê **(HEMOTOXIC)**\n‚Ä¢ **Red wound with blisters** ‚≠ê‚≠ê‚≠ê\n\n**VIPER (Russell's viper, Saw-scaled viper):** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**HEMOTOXIC FEATURES:**\n‚Ä¢ **Local:** Swelling, pain, blistering, necrosis ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bleeding** ‚≠ê‚≠ê‚≠ê (coagulopathy)\n  - Prolonged bleeding from bite site\n  - Gum bleeding, hematuria, hematemesis\n‚Ä¢ **Hypotension** (shock)\n‚Ä¢ **Acute kidney injury** ‚≠ê (common)\n\n**VS COBRA (NEUROTOXIC):**\n‚Ä¢ **NO local swelling** ‚≠ê\n‚Ä¢ **Neurotoxic:** Ptosis, diplopia, respiratory paralysis\n‚Ä¢ **NO bleeding**\n\n**MANAGEMENT:**\n‚Ä¢ **Anti-snake venom (ASV)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Polyvalent** (for all 4 species)\n‚Ä¢ **FFP** (if coagulopathy)\n\nüí° **KEY:** **Local swelling + Bleeding + Blisters = Viper (hemotoxic)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-191",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "S ub-Topic: A patient was transfused 4 units of blood 2 hours ago, and now she complains of chest discomfort. X-ray shows bilateral fissural thickening. Which of the following is the most probable cause?",
    options: [
      "ABO incompatibility reactions",
      "Fluid overload",
      "Hypocalcemia",
      "Graft-versus-host disease",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Fluid overload (TACO - Transfusion Associated Circulatory Overload) (Option B)**\n\nüî¨ **TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD (TACO):**\n\n**THIS CASE:**\n‚Ä¢ **4 units blood transfused** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **2 hours ago** ‚≠ê\n‚Ä¢ **Chest discomfort** ‚≠ê\n‚Ä¢ **CXR:** **Bilateral fissural thickening** ‚≠ê‚≠ê‚≠ê (fluid in fissures = pulmonary edema)\n\n**TACO:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Volume overload** from rapid transfusion ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Most common** transfusion complication\n\n**CLINICAL:**\n‚Ä¢ **Dyspnea**, **tachypnea**\n‚Ä¢ **Chest tightness**\n‚Ä¢ **Hypertension** ‚≠ê (vs hypotension in TRALI)\n‚Ä¢ **‚Üë JVP**\n‚Ä¢ **Crackles** on auscultation\n\n**CXR:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bilateral infiltrates**\n‚Ä¢ **Fissural thickening** ‚≠ê (fluid in fissures)\n‚Ä¢ **Cardiomegaly** (if pre-existing heart disease)\n\n**MANAGEMENT:**\n‚Ä¢ **Stop transfusion**\n‚Ä¢ **Sit upright**\n‚Ä¢ **Diuretics** (furosemide) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Oxygen**\n\n**VS TRALI:**\n‚Ä¢ **TRALI:** **Hypotension**, no cardiomegaly, antibody-mediated\n\nüí° **KEY:** **Multiple units + Chest discomfort + Fissural thickening = TACO (fluid overload)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-192",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "r Which of the following is the sensitive indicator to assess the availability, utilization, and e effectiveness of healthcare in a community?",
    options: [
      "Infant mortality rate",
      "Maternal mortality rat d",
      "Immunization coverage",
      "Disability-adjusted life years",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Infant mortality rate (IMR) (Option A)**\n\nüî¨ **INFANT MORTALITY RATE (IMR):**\n\n**DEFINITION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Deaths <1 year** per 1000 live births\n‚Ä¢ IMR = (Deaths <1 year / Total live births) √ó 1000\n\n**MOST SENSITIVE INDICATOR** of health system ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**WHY IMR IS BEST:**\n‚Ä¢ **Reflects AVAILABILITY** of healthcare ‚≠ê\n‚Ä¢ **Reflects UTILIZATION** of services ‚≠ê\n‚Ä¢ **Reflects EFFECTIVENESS** of interventions ‚≠ê\n‚Ä¢ **Reflects** socio-economic status, nutrition, sanitation\n‚Ä¢ **Early indicator** of health system performance\n\n**COMPONENTS:**\n‚Ä¢ **Neonatal** (0-28 days) - 60-70% of IMR\n‚Ä¢ **Post-neonatal** (28 days - 1 year)\n\n**INDIA IMR:** ~28/1000 (2020)\n\n**WHY NOT OTHERS:**\n‚Ä¢ **MMR:** Important but **less sensitive** (fewer deaths)\n‚Ä¢ **Immunization coverage:** Reflects only ONE aspect\n‚Ä¢ **DALY:** Composite measure (disability + death)\n\n**OTHER HEALTH INDICATORS:**\n‚Ä¢ **MMR:** Maternal health\n‚Ä¢ **U5MR:** <5 years mortality\n‚Ä¢ **Life expectancy:** Overall health\n\nüí° **KEY:** **IMR = Most sensitive indicator of healthcare availability, utilization & effectiveness** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page95_img49.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-193",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "Question 193 - [Content needs manual review]",
    options: [
      "Option 1",
      "Option 2",
      "FSGS",
      "PSGN-associated disease",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Option 2**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-194",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "A 5-year-old child is brought with fever, fatigue, and left ventricular dysfunction. An endomyocardial biopsy is shown below. What is the probable diagnosis? r e d d",
    options: [
      "Acute rheumatic fever",
      "Chagas disease",
      "Pyogenic myocarditis L",
      "Lymphocytic myocarditis",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Lymphocytic myocarditis (Viral myocarditis) (Option D)**\n\nüî¨ **LYMPHOCYTIC MYOCARDITIS:**\n\n**THIS CASE:**\n‚Ä¢ **5-year-old child** ‚≠ê\n‚Ä¢ **Fever** ‚≠ê\n‚Ä¢ **Fatigue**\n‚Ä¢ **LV dysfunction** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Biopsy:** (From image) Lymphocytic infiltration\n\n**CAUSE:** **Viral** (most common) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Coxsackie B virus** ‚≠ê‚≠ê‚≠ê (most common)\n‚Ä¢ **Adenovirus**, **Parvovirus B19**\n‚Ä¢ **HIV**, **HCV**\n\n**HISTOLOGY:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Lymphocytic infiltrate** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Myocyte necrosis**\n‚Ä¢ **NO eosinophils** (vs hypersensitivity)\n‚Ä¢ **NO giant cells** (vs giant cell myocarditis)\n\n**CLINICAL:**\n‚Ä¢ **Post-viral illness** (1-2 weeks after URTI)\n‚Ä¢ **Heart failure** symptoms\n‚Ä¢ **Arrhythmias**\n‚Ä¢ **Chest pain**\n\n**DIAGNOSIS:**\n‚Ä¢ **Endomyocardial biopsy** ‚≠ê‚≠ê‚≠ê (GOLD STANDARD)\n‚Ä¢ **‚Üë Troponin**\n‚Ä¢ **ECG:** ST changes\n\n**TREATMENT:**\n‚Ä¢ **Supportive** (heart failure management) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Immunosuppression** (if fulminant)\n\nüí° **KEY:** **Child + LV dysfunction + Lymphocytic infiltrate = Viral myocarditis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page96_img50.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-195",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "r An elderly male is known as a smoker presented with chronic cough, significant weight loss, P and fatigue. Serum calcium level is raised. A lung biopsy was done, and it showed large atypical cells with hyperchromasia. What is the probable diagnosis?",
    options: [
      "Large cell neuroendocrine tumor",
      "Small cell carcinoma",
      "Adenocarcinoma",
      "Squamous cell carcinoma",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Squamous cell carcinoma (Option D)**\n\nüî¨ **LUNG SQUAMOUS CELL CARCINOMA (SCC):**\n\n**THIS CASE:**\n‚Ä¢ **Elderly male smoker** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Chronic cough** ‚≠ê\n‚Ä¢ **Weight loss**, **fatigue**\n‚Ä¢ **‚Üë Serum calcium** ‚≠ê‚≠ê‚≠ê **(HYPERCALCEMIA)**\n‚Ä¢ **Biopsy:** Large atypical cells with hyperchromasia\n\n**SCC & HYPERCALCEMIA:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Paraneoplastic** syndrome\n‚Ä¢ **PTH-rP** (Parathyroid hormone-related peptide) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Squamous cell** produces PTH-rP\n\n**HISTOLOGY:**\n‚Ä¢ **Keratin pearls** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Intercellular bridges**\n‚Ä¢ **Large atypical cells**\n‚Ä¢ **Hyperchromasia**\n\n**CHARACTERISTICS:**\n‚Ä¢ **Central location** (hilar) ‚≠ê\n‚Ä¢ **Cavitation** common ‚≠ê\n‚Ä¢ **Strong smoking association** ‚≠ê‚≠ê‚≠ê\n\n**LUNG CANCER & HYPERCALCEMIA:**\n‚Ä¢ **SCC:** PTH-rP ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Small cell:** SIADH (NOT hypercalcemia)\n‚Ä¢ **Adenocarcinoma:** Hypertrophic osteoarthropathy\n\n**TREATMENT:**\n‚Ä¢ **Surgical resection** (if resectable)\n‚Ä¢ **Chemotherapy + RT**\n\nüí° **KEY:** **Smoker + Lung cancer + Hypercalcemia = Squamous cell carcinoma (PTH-rP)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-196",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "An elderly male went for a medical examination. Laboratory investigations showed a marked elevation of lymphocytes with marked leukocytosis. The peripheral smear of the patient is given below. What is the appropriate next step for this patient? r e d d a L",
    options: [
      "Stem cell transplantation p",
      "Bone marrow biopsy",
      "Flow cytometry",
      "Start high-dose chemotherapy r",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Flow cytometry (Option C)**\n\nüî¨ **CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - DIAGNOSIS:**\n\n**THIS CASE:**\n‚Ä¢ **Elderly male** ‚≠ê (CLL = disease of elderly)\n‚Ä¢ **Marked lymphocytosis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Marked leukocytosis**\n‚Ä¢ **Peripheral smear:** (From image) Likely smudge cells\n\n**NEXT STEP:** **FLOW CYTOMETRY** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**FLOW CYTOMETRY:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Diagnostic test for CLL**\n‚Ä¢ **Immunophenotyping** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Confirms diagnosis**\n‚Ä¢ **CD5+, CD19+, CD23+** ‚≠ê‚≠ê‚≠ê (characteristic)\n‚Ä¢ **CD20+ (dim)**\n\n**CLL FEATURES:**\n‚Ä¢ **Smudge cells** (Gumprecht shadows) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Mature-looking lymphocytes**\n‚Ä¢ **Most common adult leukemia**\n‚Ä¢ **Incidental finding** often\n\n**DIAGNOSTIC CRITERIA:**\n‚Ä¢ **Lymphocyte count >5000/ŒºL** for ‚â•3 months\n‚Ä¢ **Flow cytometry** confirming clonal B cells\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Bone marrow biopsy:** NOT needed for diagnosis (done for staging)\n‚Ä¢ **Chemo:** NOT started without confirmation\n‚Ä¢ **Stem cell transplant:** Advanced management (NOT first step)\n\nüí° **KEY:** **Elderly + Lymphocytosis ‚Üí Flow cytometry (confirm CLL)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-197",
    subjectId: "unknown",
    chapterId: "neet-pg-2023",
    question: "A 25-year-old male presented with low hemoglobin, platelet count of 25,000/mL, gum bleeding, and raised PT & aPTT. The image of his peripheral smear is given below. What is the likely diagnosis?",
    options: [
      "AML with t(8;21)",
      "AML with inv(16) d",
      "AML with t(15;17)",
      "AML with t(11;22) L",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **AML with t(15;17) - Acute Promyelocytic Leukemia (APL) (Option C)**\n\nüî¨ **ACUTE PROMYELOCYTIC LEUKEMIA (APL - AML M3):**\n\n**THIS CASE - CLASSIC APL:**\n‚Ä¢ **25-year-old** ‚≠ê\n‚Ä¢ **Low Hb**, **Thrombocytopenia** (25,000) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Gum bleeding** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **‚Üë PT & aPTT** ‚≠ê‚≠ê‚≠ê **(DIC)**\n‚Ä¢ **Peripheral smear:** (From image) Promyelocytes with Auer rods\n\n**t(15;17) TRANSLOCATION:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **PML-RARA** fusion gene ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Pathognomonic** for APL\n\n**CLINICAL FEATURES:**\n‚Ä¢ **DIC** ‚≠ê‚≠ê‚≠ê (MOST IMPORTANT)\n  - **Bleeding** (gums, skin, GI)\n  - **‚Üë PT, aPTT**\n  - **‚Üì Fibrinogen**\n‚Ä¢ **Young adults** (median age 40)\n\n**MORPHOLOGY:**\n‚Ä¢ **Promyelocytes** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Auer rods** (multiple) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hypergranular** cytoplasm\n\n**TREATMENT:**\n‚Ä¢ **ATRA (All-trans retinoic acid)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Arsenic trioxide (ATO)**\n‚Ä¢ **Best prognosis** of all AMLs ‚≠ê\n\n**OTHER AML TRANSLOCATIONS:**\n‚Ä¢ **t(8;21):** Good prognosis\n‚Ä¢ **inv(16):** Good prognosis\n\nüí° **KEY:** **Young + Bleeding/DIC + t(15;17) = APL (treatable with ATRA!)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },
  {
    id: "neet-pg-2023-198",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "Question 198 - [Content needs manual review]",
    options: [
      "Option 1",
      "Factors XI and XII",
      "Von Willebrand factor",
      "Lupus anticoagulant",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Option 1**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page98_img51.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-199",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "A chronic smoker who worked in a cement factory for 20 years developed mesothelioma. The association is likely to be due to ________.",
    options: [
      "Silicosis",
      "Asbestosis e",
      "Coal workers' pneumoconiosis",
      "Bagassosis",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Asbestosis (Asbestos exposure) (Option B)**\n\nüî¨ **MESOTHELIOMA & ASBESTOS:**\n\n**THIS CASE:**\n‚Ä¢ **Cement factory worker** ‚≠ê‚≠ê‚≠ê (20 years)\n‚Ä¢ **Developed mesothelioma** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Chronic smoker** ‚≠ê\n\n**ASBESTOS EXPOSURE:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**MESOTHELIOMA:**\n‚Ä¢ **Malignant tumor** of pleura/peritoneum\n‚Ä¢ **STRONGLY associated with ASBESTOS** ‚≠ê‚≠ê‚≠ê (80-90% cases)\n‚Ä¢ **Latency period:** 20-40 years ‚≠ê\n\n**ASBESTOS-RELATED DISEASES:**\n1. **Asbestosis** (pulmonary fibrosis) ‚≠ê\n2. **Mesothelioma** ‚≠ê‚≠ê‚≠ê **(MOST SPECIFIC)**\n3. **Lung cancer** (synergistic with smoking) ‚≠ê\n4. **Pleural plaques** (benign)\n\n**OCCUPATIONS AT RISK:**\n‚Ä¢ **Construction** workers ‚≠ê\n‚Ä¢ **Shipyard** workers\n‚Ä¢ **Cement factory** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Insulation** workers\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Silicosis:** Coal mines, sandblasting (NOT mesothelioma)\n‚Ä¢ **Coal workers' pneumoconiosis:** Coal miners\n‚Ä¢ **Bagassosis:** Sugarcane workers (extrinsic allergic alveolitis)\n\nüí° **KEY:** **Mesothelioma = Asbestos exposure (cement factory)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page98_img52.jpeg",
    year: 2023
  },
  {
    id: "neet-pg-2023-200",
    subjectId: "preventive-medicine",
    chapterId: "neet-pg-2023",
    question: "The average daily dietary nutrienLt intake level sufficient to meet the nutrient requirements of nearly all (97-98%) healthy individuals in a particular life stage and gender group is known as?",
    options: [
      "Adequate intake p",
      "Dietary goal e",
      "Estimated average requirement",
      "Recommended dietary allowanc APns: 4 If you wish to access the detailed explanations for the correct an incorrect options of these questions, download the PrepLadder app now. Download PrepLadder's NEET PG app for Androi Download PrepLadder's NEET PG app for iOS",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Recommended Dietary Allowance (RDA) - Likely Option D** \n\nüî¨ **DIETARY REFERENCE INTAKES (DRI):**\n\n**QUESTION:** Nutrient intake meeting needs of **97-98%** of healthy individuals ‚≠ê‚≠ê‚≠ê\n\n**ANSWER:** **RECOMMENDED DIETARY ALLOWANCE (RDA)** ‚≠ê‚≠ê‚≠ê\n\n**RDA DEFINITION:**\n‚Ä¢ **Meets needs of 97-98%** of population ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **2 SD above EAR** (EAR + 2SD)\n‚Ä¢ **Goal for individual intake**\n\n**OTHER DRI TERMS:**\n\n**EAR (Estimated Average Requirement):**\n‚Ä¢ **Meets needs of 50%** of population ‚≠ê\n‚Ä¢ **Median requirement**\n\n**AI (Adequate Intake):**\n‚Ä¢ **Used when RDA cannot be determined**\n‚Ä¢ **Observed/experimental** intake\n\n**UL (Tolerable Upper Intake Level):**\n‚Ä¢ **Maximum safe intake**\n‚Ä¢ **Above this:** Risk of adverse effects\n\n**DIETARY GOALS:**\n‚Ä¢ **Population-level** targets\n‚Ä¢ **Different from individual RDA**\n\n**HIERARCHY:**\nEAR (50%) < **RDA (97-98%)** < UL\n\nüí° **KEY:** **97-98% coverage = RDA (Recommended Dietary Allowance)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page99_img53.jpeg",
    year: 2023
  }
];

// Helper functions to filter questions
export function getQuestionsByChapter(subjectId: string, chapterId: string): Question[] {
  return sampleQuestions.filter(
    (q) => q.subjectId === subjectId && q.chapterId === chapterId
  );
}

export function getQuestionsBySubject(subjectId: string): Question[] {
  return sampleQuestions.filter((q) => q.subjectId === subjectId);
}

export function getAllQuestions(): Question[] {
  return sampleQuestions;
}

export default sampleQuestions;
